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Abstract  
The predicted costs and savings of integrated preventive chemotherapy (IPCT) for the Neglected 
Tropical Diseases (NTDs) have been proposed by a number of prior studies. The principle aims of the 
research presented in this thesis were to determine the cost, effectiveness and sustainability of the 
Ugandan integrated NTD Control Programme (NTDCP). 
Annual programme costs were prospectively and retrospectively collected at all levels of programme 
implementation in twelve districts over three years. Overall cost per person treated for IPCT were, 
financial (excluding purchased drugs) US$0.17; economic (excluding purchased and donated) US$0.65 
and full economic cost per person (including value of all drugs) US$12.06. When costs of the NTDCP 
were compared to the combined costs of the pre-integration stand-alone (SA) control programmes in 
Uganda, cost savings of 54% to 72% were achieved. The IPCT was also effective with over 43 million 
treatments delivered and 2,444,714 disability-adjusted life years (DALYs) averted; and highly cost-
effective at an estimated economic cost of US$16.50 per NTD case averted and US$10.19 per DALY 
averted.  
Using a novel approach to measure community drug distributors (CDDs) involvement in IPCT; pictorial 
diaries collected prospective data on their time allocation. On average 2.5 working weeks were spent on 
NTDCP activities per year by a CDD. This meant a significant reduction in time available for subsistence 
and income generating engagements. With each incremental drug delivery required over a mass IPCT 
campaign i.e. the number of times a CDD delivered a NTD drug package to communities, economic costs 
increased. Moreover, as CDDs took more time to complete NTDCP activities their programme coverage 
performance decreased. Motivation for the programme was acknowledged as low and CDDs felt 
undervalued. Finally the applications and implications of the thesis results are discussed with regards to 
programme effectiveness and sustainability and in the context of NTD control and elimination.   
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Chapter 1. Background 
 
 
A Renewed Focus  
The beginning of the new millennium brought a dramatic increase in international efforts supporting the 
improvement of health to those living in poverty [1-3]. The attention was predominantly focused on the 
“big three” diseases of malaria, HIV/AIDS and tuberculosis (TB), with initiatives such as the Global Fund 
to Fight AIDS, TB and Malaria, US President’s Emergency Plan for AIDS Relief (PEPFAR) and Roll Back 
Malaria [4-6]. These three diseases alone are accountable for a global burden of 166 million disability-
adjusted life years (DALYs) and 5 million lives lost annually [7,8]. Many of the tropical diseases that cause 
less mortality, collectively 534,000 deaths per year [7], are termed ‘other’ in the sixth Millennium 
Development Goal (MDGs) (http://www.un.org/millenniumgoals). As a consequence of the focused 
attention on the big three, these ‘other’ diseases were largely ignored and received less funding despite 
causing chronic morbidity and subsequently 56.6 million DALYs lost per year [7,9-11].  
 
The term ‘Neglected Tropical Diseases’ (NTDs) was created to describe a sub-set of the common chronic 
infectious ‘other’ diseases which were overlooked. The 17 core diseases are macro (helminthic) and 
micro (bacterial, protista and viral) infections that affect the poorest populations, largely in sub-Saharan 
Africa, and include schistosomiasis, three of the soil-transmitted helminth infections (ascariasis, 
hookworm infection and trichuriasis), lymphatic filariasis, onchocerciasis, dracunculiasis, Chagas’ 
disease, human African trypanosomiasis, leishmaniasis, Buruli ulcer, leprosy and trachoma [7,10,12]. 
Fortunately, for those living in poverty with these chronic conditions, recognition of the importance of 
the NTDs and their significant contribution to the global burden of diseases gained momentum towards 
the end of the last decade [13-15]. With over a billion individuals infected with NTDs worldwide [16], 
drug donations, funding and coordinated opportunities were created and strengthened for the ‘tool 
ready’ diseases, those that could be targeted with mass preventive chemotherapy and transmission 
control (PCT) campaigns [13,17,18], and those which required innovative and intensified disease 
management (IDM) [11]. Table 1.1 summarises the seven PCTs NTDs that are relevant to this thesis and 
a fuller description of each follows within the chapter. As the IDM diseases will not be covered in this 
thesis, no detailed description is given, however in summary these are diseases for which cost-effective 
control tools do not exist and where large-scale use of tools is limited [11]. These diseases include Buruli 
Page | 17  
 
ulcer, Chagas disease, human African trypanosomiasis, leishmaniasis (cutaneous, mucocutaneous and 
visceral), leprosy and yaws. Innovative work is essential to improve diagnostic methods and provide 
safer medicines for administration under shorter treatment regimens [11]. 
 
The London Declaration 
In January 2012 the momentum for the fight against these chronic disabling and disfiguring diseases was 
accelerated with the London Declaration on NTDs [19-22]. Donors and endemic country governments, 
private sector leaders, pharmaceutical companies and multilateral organizations made a unique 
commitment for a close partnership to control or eliminate ten NTDs by 2020, in alignment with World 
Health Organization (WHO) targets and the 2020 Roadmap on NTDs [23]. The roadmap is a guide to the 
implementation of policies and strategies to combat each of the NTDs and the extraordinary 
commitments towards these by the partners are summarized in Table 1.2. Essentially these shared 
responsibilities build and expand upon decades of work in controlling these diseases with additional and 
increased drug supply, increased funding for drug delivery and implementation programmes and 
amplified research and development (R&D) for new treatments [22].  
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oo
ds
tr
ea
m
. 
Th
ey
 
m
at
ur
e 
as
 t
he
y 
m
ig
ra
te
 t
hr
ou
gh
 
th
e 
bo
dy
 
un
til
 
th
ey
 
re
ac
h 
m
es
en
te
ric
 
ve
in
s 
an
d 
ve
sic
al
 
pl
ex
us
 w
he
re
 th
e 
fe
m
al
es
 p
ro
du
ce
 
eg
gs
.  
   
U
rin
e 
fil
tr
at
io
n 
or
 
Ka
to
 K
at
z f
ae
ca
l 
sm
ea
r t
o 
co
un
t 
eg
gs
 b
y 
m
ic
ro
sc
op
y 
 
 An
tib
od
y 
ba
se
d 
as
sa
ys
 
 An
tig
en
 d
et
ec
tio
n 
te
st
s 
Bl
oo
d 
in
 
st
oo
l/u
rin
e 
 In
te
st
in
al
 
sc
hi
st
os
om
ia
sis
;
as
ci
te
s a
nd
 
se
ve
re
 li
ve
r 
co
m
pl
ic
at
io
ns
  
 Ur
og
en
ita
l 
sc
hi
st
os
om
ia
sis
; 
bl
ad
de
r a
nd
 
ur
et
hr
al
 fi
br
os
is 
an
d 
bl
ad
de
r 
ca
nc
er
 
 An
ae
m
ia
, 
pa
rt
ic
ul
ar
ly
 in
 
ch
ild
re
n 
an
d 
w
om
en
 
En
de
m
ic
 in
 7
8 
co
un
tr
ie
s w
ith
 6
52
 
m
ill
io
n 
pe
op
le
 a
t r
isk
 o
f i
nf
ec
tio
n 
[2
4]
 
 Es
tim
at
ed
 th
at
 2
37
 m
ill
io
n 
pe
op
le
 
ar
e 
in
fe
ct
ed
 w
ith
 sc
hi
st
os
om
ia
sis
 
w
or
ld
w
id
e 
w
ith
 9
0%
 o
f t
he
 d
ise
as
e 
bu
rd
en
 in
 S
ub
-S
ah
ar
an
 A
fr
ic
a 
an
d 
w
ith
 e
nd
em
ic
ity
 in
 E
gy
pt
, C
hi
na
, L
at
in
 
Am
er
ic
a 
an
d 
So
ut
h 
Ea
st
 A
sia
 [2
4]
 
 Sc
hi
st
os
om
ia
sis
 h
as
 fo
ca
l 
ep
id
em
io
lo
gy
 a
nd
 o
ve
rd
isp
er
se
d 
po
pu
la
tio
n 
di
st
rib
ut
io
n,
  
 In
fe
ct
io
n 
ra
te
s a
re
 h
ig
he
r i
n 
ch
ild
re
n 
th
an
 in
 a
du
lts
. 
 
Pa
ge
 | 
19
  
 Ho
ok
w
or
m
  
(S
TH
) 
Ag
en
t 
An
cy
lo
st
om
a 
du
od
en
al
e 
an
d 
N
ec
at
or
 a
m
er
ic
an
us
 
(h
oo
kw
or
m
s)
  
Pe
ne
tr
at
io
n 
of
 sk
in
 b
y 
in
fe
ct
iv
e 
la
rv
ae
 in
 so
il 
Eg
gs
 in
 fa
ec
es
 a
re
 d
ep
os
ite
d 
in
to
 
th
e 
so
il 
an
d 
ha
tc
h 
un
de
r 
fa
vo
ur
ab
le
 c
on
di
tio
ns
 o
f m
oi
st
ur
e 
an
d 
te
m
pe
ra
tu
re
. T
he
 la
rv
ae
 
de
ve
lo
p 
an
d 
th
en
 in
fe
ct
 a
 h
um
an
 
w
he
re
 th
ey
 m
ig
ra
te
 th
ro
ug
h 
th
e 
sy
st
em
 to
 b
e 
sw
al
lo
w
ed
. T
he
y 
ev
en
tu
al
ly
 a
tt
ac
h 
to
 th
e 
w
al
l o
f 
th
e 
sm
al
l i
nt
es
tin
e 
an
d 
pr
od
uc
e 
eg
gs
 
M
ic
ro
sc
op
y 
de
te
ct
io
n 
of
 e
gg
s 
in
 K
at
o 
Ka
tz
 fa
ec
al
 
sm
ea
rs
 
  
Iro
n 
de
fic
ie
nc
y 
an
ae
m
ia
 
 M
al
nu
tr
iti
on
 
w
hi
ch
 le
ad
s t
o 
re
ta
rd
at
io
n 
in
 
gr
ow
th
 a
nd
 th
e 
de
ve
lo
pm
en
t o
f 
ch
ild
re
n 
in
cl
ud
in
g 
co
gn
iti
ve
 
de
ve
lo
pm
en
t. 
 
Es
tim
at
ed
 7
40
 m
ill
io
n 
pe
op
le
 
in
fe
ct
ed
 in
 th
e 
de
ve
lo
pi
ng
 n
at
io
ns
 o
f 
th
e 
tr
op
ic
s [
25
] 
 U
p 
to
 4
4 
m
ill
io
n 
pr
eg
na
nt
 w
om
en
 
ar
e 
es
tim
at
ed
 to
 b
e 
in
fe
ct
ed
 w
ith
 
ho
ok
w
or
m
 [2
5]
 
 Hi
gh
 in
te
ns
ity
 in
fe
c t
io
ns
 a
re
 fo
un
d 
m
os
t c
om
m
on
ly
 in
 c
hi
ld
re
n 
an
d 
th
e 
el
de
rly
 
 
As
ca
ria
si
s 
 
(S
TH
) 
Ag
en
t 
As
ca
ris
 lu
m
br
ic
oi
de
s 
(r
ou
nd
w
or
m
) 
 In
ge
st
io
n 
of
 in
fe
ct
iv
e 
eg
gs
 
Eg
gs
 
re
ac
h 
so
il 
in
 
fa
ec
es
 
th
en
 
un
de
rg
o 
de
ve
lo
pm
en
t 
in
 
fa
vo
ur
ab
le
 
co
nd
iti
on
s.
 
In
ge
st
ed
 
eg
gs
 h
at
ch
 i
n 
th
e 
in
te
st
in
e 
an
d 
de
ve
lo
p 
as
 t
he
y 
m
ig
ra
te
 t
hr
ou
gh
 
th
e 
bo
dy
 v
ia
 th
e 
lu
ng
s.
 M
at
ur
at
io
n 
oc
cu
rs
 
in
 
th
e 
sm
al
l 
in
te
st
in
e 
w
he
re
 th
ey
 m
at
e 
an
d 
 
pr
od
uc
e 
eg
gs
 
 
 M
ic
ro
sc
op
y 
de
te
ct
io
n 
of
 e
gg
s 
in
 K
at
o 
Ka
tz
 fa
ec
al
 
sm
ea
rs
 
 Id
en
tif
ic
at
io
n 
of
 
w
or
m
s p
as
se
d 
in
 
st
oo
l 
 In
fe
ct
io
n 
is 
of
te
n 
as
ym
pt
om
at
ic
 
 M
al
nu
tr
iti
on
, 
 Vi
ta
m
in
 A
 
de
fic
ie
nc
y 
 
1.
5 
bi
lli
on
 p
eo
pl
e 
in
fe
ct
ed
, 
ap
pr
ox
im
at
el
y 
25
%
 o
f t
he
 w
or
ld
’s
 p
op
ul
at
io
n 
an
nu
al
ly
 [2
5]
 
 Th
e 
m
os
t c
om
m
on
 h
um
an
 h
el
m
in
th
ic
 
in
fe
ct
io
n 
w
ith
 w
or
ld
w
id
e 
di
st
rib
ut
io
n,
 m
ai
nl
y 
af
fe
ct
s c
hi
ld
re
n 
 Hi
gh
es
t p
re
va
le
nc
e 
in
 tr
op
ic
al
 a
nd
 
su
bt
ro
pi
ca
l r
eg
io
ns
, a
nd
 a
re
as
 w
ith
 
in
ad
eq
ua
te
 sa
ni
ta
tio
n 
Tr
ic
hu
ria
si
s 
 
(S
TH
) 
Ag
en
t 
Tr
ic
hu
ris
 tr
ic
hi
ur
a 
(w
hi
pw
or
m
) 
 In
ge
st
io
n 
of
 in
fe
ct
iv
e 
eg
gs
 
Eg
gs
 p
as
se
d 
in
 fa
ec
es
 a
nd
 b
ec
om
e 
in
fe
ct
iv
e 
af
te
r 
10
-1
4 
da
ys
 in
 w
ar
m
 
m
oi
st
 
so
il.
 
In
ge
st
ed
 
eg
gs
 
ha
tc
h 
la
rv
ae
 a
nd
 a
tt
ac
h 
to
 th
e 
m
uc
os
a 
in
 
th
e 
co
lo
n.
 T
he
re
 t
he
y 
de
ve
lo
p 
to
 
m
at
ur
e 
w
or
m
s 
an
d 
be
gi
n 
pr
od
uc
in
g 
eg
gs
 
 
M
ic
ro
sc
op
y 
de
te
ct
io
n 
of
 e
gg
s 
in
 K
at
o 
Ka
tz
 fa
ec
al
 
sm
ea
rs
 
 
In
fe
ct
io
n 
is 
of
te
n 
as
ym
pt
om
at
ic
 
 Re
ct
al
 p
ro
la
ps
e 
 An
ae
m
ia
 a
nd
 
gr
ow
th
 
re
ta
rd
at
io
n  
Es
tim
at
ed
 th
at
 8
00
 m
ill
io
n 
pe
op
le
 
ar
e 
in
fe
ct
ed
 w
or
ld
w
id
e 
[2
5]
 
 Th
ird
 m
os
t c
om
m
on
 h
el
m
in
th
 
in
fe
ct
io
n 
of
 h
um
an
s,
 m
ai
nl
y 
af
fe
ct
s 
ch
ild
re
n 
[2
5]
 
 W
or
ld
w
id
e 
di
st
rib
ut
io
n 
w
ith
 
in
fe
ct
io
ns
 m
or
e 
fr
eq
ue
nt
 in
 tr
op
ic
al
 
ar
ea
s w
ith
 tr
op
ic
al
 w
ea
th
er
 a
nd
 p
oo
r 
sa
ni
ta
tio
n  
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 On
ch
oc
er
ci
as
is
 
Ag
en
t 
O
nc
ho
ce
rc
a 
vo
lv
ul
us
 
 Bl
ac
k 
Fl
y 
Ve
ct
or
 
Si
m
ul
iu
m
 sp
p 
Bi
te
 o
f i
nf
ec
te
d 
fe
m
al
e 
bl
ac
k 
fly
 
M
ic
ro
fil
ar
ia
e 
(m
f),
 in
ge
st
ed
 b
y 
th
e 
bl
ac
k 
fly
 
du
rin
g 
a 
bl
oo
d 
m
ea
l, 
de
ve
lo
p 
in
to
 i
nf
ec
tiv
e 
la
rv
ae
 a
nd
 
en
te
r 
hu
m
an
 d
ur
in
g 
fe
ed
in
g.
 T
he
 
la
rv
ae
 
fo
rm
 
no
du
le
s 
in
 
th
e 
su
bc
ut
an
eo
us
 t
iss
ue
 a
nd
 m
at
ur
e 
to
 a
du
lt 
w
or
m
s.
 A
ft
er
 m
at
in
g,
 t
he
 
fe
m
al
e 
ad
ul
t 
w
or
m
 
re
le
as
es
 
m
ic
ro
fil
ar
ia
e 
w
hi
ch
 
w
he
n 
di
e 
ca
us
e 
a 
va
rie
ty
 o
f c
on
di
tio
ns
  
M
ic
ro
sc
op
ic
 
ex
am
in
at
io
n 
of
 
m
ic
ro
fil
ar
ia
e 
in
 
sk
in
 b
io
ps
y 
 N
od
ul
e 
pa
lp
at
io
n 
&
 sk
in
 d
ise
as
e 
cl
as
sif
ic
at
io
n 
 En
zy
m
e-
lin
ke
d 
im
m
un
os
or
be
nt
 
as
sa
y 
(E
LI
SA
) a
nd
 
po
ly
m
er
as
e 
ch
ai
n 
re
ac
tio
n 
(P
CR
) 
Bl
in
dn
es
s  
 Sk
in
 ra
sh
es
, 
le
sio
ns
  
In
te
ns
e 
itc
hi
ng
 
&
 sk
in
 
de
pi
gm
en
ta
tio
n 
  
O
nc
ho
ce
rc
ia
sis
 is
 th
e 
w
or
ld
’s
 se
co
nd
 
le
ad
in
g 
in
fe
ct
io
us
 c
au
se
 o
f b
lin
dn
es
s.
 
[2
4]
 
 Ap
pr
ox
im
at
el
y 
17
.7
 m
ill
io
n 
in
di
vi
du
al
s a
re
 in
fe
ct
ed
 w
ith
 O
. 
vo
lv
ul
us
 o
f w
hi
ch
 2
68
,0
00
 a
re
 b
lin
d 
as
 a
 re
su
lt 
of
 th
e 
di
se
as
e 
[2
6]
.  
 O
ve
r 9
9%
 o
f t
he
 in
fe
ct
ed
 p
eo
pl
e 
liv
e 
in
 su
b-
Sa
ha
ra
n 
Af
ric
a.
 
 
Ly
m
ph
at
ic
 
Fi
la
ria
si
s 
Ag
en
t 
W
uc
he
re
ria
 
ba
nc
ro
fti
;M
an
so
ne
lla
 
pe
rs
ta
ns
;  
Br
ug
ia
 m
al
ay
i; 
 
B.
tim
or
i 
  M
os
qu
ito
 V
ec
to
r  
Ae
de
s s
pp
;  
Cu
le
x 
sp
p;
  
An
op
he
le
s s
pp
; 
M
an
so
ni
a 
sp
p 
By
 b
ite
 o
f a
  m
os
qu
ito
 h
ar
bo
ur
in
g 
in
fe
ct
iv
e 
la
rv
ae
 
Th
e 
m
f e
m
er
ge
 fr
om
 th
e 
m
os
qu
ito
 
an
d 
en
te
r 
th
e 
pu
nc
tu
re
d 
sk
in
 t
o 
re
ac
h 
th
e 
bl
oo
d 
an
d 
ly
m
ph
at
ic
 
sy
st
em
s.
 T
he
re
 t
he
y 
de
ve
lo
p 
in
to
 
ad
ul
ts
, 
m
at
e 
an
d 
pr
od
uc
e 
m
f 
w
hi
ch
 a
re
 t
he
n 
pi
ck
ed
 u
p 
by
 a
 
m
os
qu
ito
 
du
rin
g 
a 
bl
oo
d 
m
ea
l 
w
he
re
 
th
ey
 
de
ve
lo
p 
in
to
 
th
e 
in
fe
ct
iv
e 
m
f s
ta
ge
 
M
f i
n 
ni
gh
t b
lo
od
 
sa
m
pl
es
;  
 C l
in
ic
al
 
as
se
ss
m
en
t; 
 Im
m
un
oc
hr
om
at
o
gr
ap
hi
c 
te
st
s 
(IC
T)
 
ca
rd
s w
hi
ch
 te
st
 
fo
r a
nt
ib
od
ie
s 
 
Ly
m
ph
oe
de
m
a 
 El
ep
ha
nt
ia
sis
 
 Ch
yl
ur
ia
 
 Hy
dr
oc
el
e 
1.
39
 b
ill
io
n 
pe
op
le
 (2
0%
 o
f t
he
 
w
or
ld
’s
 p
op
ul
at
io
n)
 a
re
 a
t r
isk
 o
f 
ac
qu
iri
ng
 in
fe
ct
io
n 
an
d 
re
qu
ire
 P
CT
 
[2
4]
 
 O
ve
r 1
20
 m
ill
io
n 
pe
op
le
 in
 8
3 
co
un
tr
ie
s a
re
 in
fe
ct
ed
 a
nd
 4
0 
m
ill
io
n 
in
ca
pa
ci
ta
te
d 
or
 d
isf
ig
ur
ed
 b
y 
th
e 
di
se
as
e 
[2
7]
  
 Ap
pr
ox
im
at
el
y 
on
e 
th
ird
 o
f t
ho
se
 a
t 
ris
k 
liv
e 
in
 In
di
a,
 o
ne
 th
ird
 in
 A
fr
ic
a 
an
d 
th
e 
re
m
ai
nd
er
 in
 A
sia
, t
he
 P
ac
ifi
c 
an
d 
th
e 
Am
er
ic
as
 [2
4]
 
 M
os
t i
nf
ec
tio
ns
 a
re
 a
cq
ui
re
d 
in
 
ch
ild
ho
od
, w
ith
 a
 lo
ng
 p
er
io
d 
of
 
su
bc
lin
ic
al
 d
ise
as
e 
th
at
 p
ro
gr
es
se
s t
o 
cl
in
ic
al
 m
an
ife
st
at
io
ns
 in
 a
du
lts
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 Tr
ac
ho
m
a 
 
Ag
en
t 
Ch
la
m
yd
ia
 
tr
ac
ho
m
at
is 
 M
ec
ha
ni
ca
l v
ec
to
r 
M
us
a 
so
rb
en
s 
Hi
pp
el
at
es
 
Ba
ct
er
ia
 
tr
an
sm
itt
ed
 
by
 
di
re
ct
 
sp
re
ad
 o
f i
nf
ec
te
d 
oc
ul
ar
 m
at
er
ia
l 
fr
om
 o
ne
 p
er
so
n 
to
 a
no
th
er
 b
y 
co
m
m
on
 h
ou
se
 f
lie
s 
an
d 
th
ro
ug
h 
co
nt
am
in
at
ed
 fi
ng
er
s a
nd
 fo
m
ite
s.
 
 
O
cu
la
r 
ex
am
in
at
io
n 
to
 
lo
ok
 fo
r a
ct
iv
e 
in
fe
ct
io
n,
 tr
ic
hi
as
is 
an
d 
bl
in
dn
es
s 
 M
ic
ro
sc
op
y 
of
 
co
nj
un
ct
iv
al
 
sc
ra
pi
ng
s 
 An
tig
en
 d
et
ec
tio
n 
by
 P
CR
 
 di
re
ct
  f
lu
or
es
ce
nt
 
an
tib
od
y 
te
st
 
Bl
in
dn
es
s 
Le
ad
in
g 
ca
us
e 
of
 p
re
ve
nt
ab
le
 
bl
in
dn
es
s i
n 
th
e 
de
ve
lo
pi
ng
 w
or
ld
. 
Re
sp
on
sib
le
 fo
r 1
.2
 m
ill
io
n 
ca
se
s o
f 
bl
in
dn
es
s [
24
] 
 Es
tim
at
ed
 th
at
 2
1 
m
ill
io
n 
pe
op
le
 in
 
53
 c
ou
nt
rie
s, 
m
ai
nl
y 
in
 A
fr
ic
a,
 A
sia
, 
M
id
dl
e 
Ea
st
, L
at
in
 A
m
er
ic
a 
an
d 
Au
st
ra
lia
 h
av
e 
ac
tiv
e 
tr
ac
ho
m
a 
w
ith
 
7.
2 
m
ill
io
n 
in
fe
ct
ed
 in
di
vi
du
al
s 
re
qu
iri
ng
 c
or
re
ct
iv
e 
su
rg
er
y 
[2
4]
 
 In
 e
nd
em
ic
 a
re
as
, t
he
 d
ist
rib
ut
io
n 
of
 
di
se
as
e 
is 
he
te
ro
ge
ne
ou
s 
 Tr
ac
ho
m
a 
in
fe
ct
io
n 
is 
m
os
t c
om
m
on
 
in
 c
hi
ld
re
n 
es
pe
ci
al
ly
 th
os
e 
<5
 y
ea
rs
 
bu
t m
or
bi
di
ty
 e
m
er
ge
s i
n 
ad
ul
ts
 
Ta
bl
e 
1.
1:
 T
he
 se
ve
n 
pr
ev
en
tiv
e 
ch
em
ot
he
ra
py
 (P
CT
) N
eg
le
ct
ed
 T
ro
pi
ca
l D
ise
as
es
 (N
TD
s)
 
 
 
Lo
nd
on
 D
ec
la
ra
ti
on
 C
om
m
it
m
en
t 
Pa
rt
ne
rs
 
D
is
ea
se
s 
Su
st
ai
ni
ng
, E
xp
an
di
ng
 a
nd
 E
xt
en
di
ng
 D
ru
g 
Su
pp
ly
 
 
 
Al
l 
co
m
pa
ni
es
 w
ith
 N
TD
 d
ru
g 
do
na
tio
n 
pr
og
ra
m
s 
pl
ed
ge
d 
to
 s
us
ta
in
 o
r 
ex
te
nd
 t
he
ir 
pr
og
ra
m
m
es
 to
 th
e 
en
d 
of
 th
e 
de
ca
de
, a
nd
 s
om
e 
pl
ed
ge
d 
to
 in
cr
ea
se
 th
ei
r c
om
m
itm
en
ts
. 
Th
es
e 
co
m
m
itm
en
ts
 in
cl
ud
e 
th
e 
fo
llo
w
in
g  
x 
12
0 
m
ill
io
n 
do
na
te
d 
Di
et
hy
lc
ar
ba
m
az
in
e 
(D
EC
) t
ab
le
ts
 
x 
do
ub
le
d 
ni
fu
rit
im
ox
 fo
r C
ha
ga
s d
ise
as
e 
x 
do
na
tio
n 
of
 A
m
Bi
so
m
e 
fo
r v
isc
er
al
 le
ish
m
an
ia
sis
 
x 
ex
te
nd
ed
 a
nd
 in
cr
ea
se
d 
al
be
nd
az
ol
e 
(A
LB
) a
nd
 m
eb
en
da
zo
le
 (M
EB
) d
on
at
io
ns
 
x 
te
n-
fo
ld
 in
cr
ea
se
 in
 p
ra
ziq
ua
nt
el
 (P
ZQ
) d
on
at
io
n 
x 
co
nt
in
ue
d 
co
m
m
itm
en
t o
f m
ul
ti-
dr
ug
 th
er
ap
y 
fo
r l
ep
ro
sy
 
x 
co
nt
in
ue
d 
do
na
tio
n 
of
 a
zit
hr
om
yc
in
 (Z
IT
) 
x 
ex
te
nd
ed
 d
on
at
io
n 
of
 e
flo
rn
ith
in
e,
 m
el
ar
so
pr
ol
 a
nd
 p
en
ta
m
id
in
e 
fo
r 
sle
ep
in
g 
sic
kn
es
s 
 
Sa
no
fi,
 E
isa
i a
nd
 t
he
 B
ill
 &
 M
el
in
da
 
Ga
te
s 
Fo
un
da
tio
n,
 
W
HO
, 
Ba
ye
r, 
Gi
le
ad
, G
la
xo
Sm
ith
Kl
in
e,
 Jo
hn
so
n 
&
 
Jo
hn
so
n,
 M
SD
 
Ly
m
ph
at
ic
 fi
la
ria
sis
 
Ch
ag
as
 D
ise
as
e 
Vi
sc
er
al
 le
ish
m
an
ia
sis
 
So
il 
Tr
an
sm
itt
ed
 H
el
m
in
th
s 
O
nc
ho
ce
rc
ia
sis
 
Sc
hi
st
os
om
ia
sis
 
Le
pr
os
y 
Tr
ac
ho
m
a 
Af
ric
an
 tr
yp
an
os
om
ia
sis
 
Ac
ce
le
ra
tin
g 
R&
D 
fo
r N
ew
 T
re
at
m
en
ts
 
 
 
Pr
od
uc
t d
ev
el
op
m
en
t p
ar
tn
er
sh
ip
s u
nd
er
 th
e 
co
or
di
na
tio
n 
of
 D
ru
gs
 fo
r N
eg
le
ct
ed
 D
ise
as
es
 
in
iti
at
iv
e 
(D
N
Di
) a
re
 u
nd
er
w
ay
 to
 d
ev
el
op
 n
ew
 d
ru
gs
 to
 tr
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The Neglected Tropical Diseases 
Schistosomiasis 
Aetiology 
Schistosomiasis (Trematoda: Schistosomatidae) is a water-borne trematode infection which can lead to 
chronic disease, such as, bladder and ureteral fibrosis and bladder cancer in urogenital schistosomiasis 
and, ascites and severe liver complications in intestinal schistosomiasis. Eggs produced by the adult 
female in the human host are released in either stool or urine. When in fresh water, miracidia larvae 
hatch from the eggs and enter molluscan intermediate hosts. The cercariae larvae are shed from the 
snails into water as a response to light, then penetrate the skin of a human host where they migrate to 
the lungs and finally develop into adult worms. The adult worms settle in pairs in the blood vessels of 
the bladder in the urogenital form (Schistosoma haematobium), or the hepatic portal system in the 
intestinal form (S. intercalatum, S. japonicum, S. mansoni, S. mekongi, S. guineensis). It is the eggs which 
get trapped in the tissues on leaving the human body that are the cause of much of the schistosomiasis 
related internal damage and subsequent morbidity in the bladder and liver.  
 
Epidemiology 
Schistosomiasis is one of the most common parasitic diseases, endemic in 76 countries with 652 million 
people at risk of infection [28]. It is estimated that 203 million people are infected with schistosomiasis 
worldwide, with more than 90% of the disease burden in sub-Saharan Africa [29]. In other regions, 
human disease caused by schistosomiasis has been successfully controlled or eliminated [30,31]. Among 
human parasitic diseases, schistosomiasis ranks second behind malaria in terms of social-economic and 
public health importance in tropical regions [29]. Chronic intestinal schistosomiasis results in severe 
organ pathology such as hepatosplenomegaly, periportal liver fibrosis and portal hypertension which 
progress from abdominal pain and bloody diarrhoea. Urogenital schistosomiasis leads to haematuria, 
dysuria, hydronephrosis and calcification of the bladder and increases the risk of those infected to HIV 
infection [32]. These morbidities contribute to, amongst others, anaemia, growth stunting and cognitive 
impairment in infected individuals [33-35]. Globally, schistosomiasis alone is estimated to cause about 
300,000 deaths per year, although this is thought to be a significant underestimate [33], because the 
schistosomiasis-related deaths are rarely stated as such in hospital records and death certificates. It is 
the schistosomiasis-related chronic consequences i.e. liver fibrosis and hematemesis, which are given as 
reasons for death instead with no connection made to underlying health status. 
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Diagnosis and Control 
The early symptomatic stages of S. mansoni infection such as bloody stool, diarrhoea, abdominal pain 
and discomforts can also be associated with other infections and are non-specific indicators of infection 
[36]. The presence and number of eggs per gram of faeces using the Kato Katz technique for S. mansoni 
[37] or per volume of urine through urine filtration for S. haematobium [38], are the most widely utilised 
indirect measures of infection. These methods are used because egg load is positively correlated with 
underlying adult worm burden [39,40] and severity of disease [41]. However, there is often considerable 
intra-individual variability in counts as eggs are not homogenously distributed throughout a faecal or 
urine specimen [38,42] or shed in the same volumes each day [43,44]. The diagnostic performance of 
these methods increases with the number of consecutive days over which samples are taken. The late 
stages of chronic schistosomiasis infection such as ascites and bleeding from gastro-oesophageal varices 
are also unreliable indicators because they are seen in a relatively small number of infected individuals. 
These clinical pathologies can be detected using ultrasonography [35,45,46]. This technique is sensitive 
and precise for measuring changes in periportal fibrosis and other clinical morbidities following 
treatment in individuals [47-50]. 
 
Schistosomiasis control aims to reduce the transmission of parasites and reduce the level of infection in 
individuals, to minimise the pathological effects. The predominant intervention for control is annual 
treatment with one dose of PZQ (at 40mg/kg) where number of tablets received is determined by a dose 
pole [51]. Annual treatment should be supported by improved access to safe water, adequate sanitation 
and, where feasible, snail control [29,36,52]. Mass chemotherapy campaigns with PZQ are targeted at 
school-age children (SAC), as they harbour the heaviest worm burden in a population, and to reach at 
least 75% therapeutic coverage of SAC at risk of infection [53]. WHO also recommends that those at 
high-risk, for example fishermen and women who frequently visit contaminated water sources, should 
also be targeted for mass treatment [53]. 
 
Soil-Transmitted Helminths 
Aetiology 
The Soil Transmitted Helminths (STH) are a group of 16 species of parasitic nematodes. The four most 
prevalent species worldwide are: Ascaris lumbricoides (roundworm), Trichuris trichiura (whipworm), 
Ancylostoma duodenale and Necator americanus (hookworms). The STH eggs are deposited in the 
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faeces and then into the environment. These eggs can be ingested through contaminated food or 
through dirty hands. In contrast, hookworm eggs hatch into larvae while in the soil and the infective 
larvae penetrate through the feet, pass through blood vessels and join the digestive system. The eggs / 
larvae mature into adult worms in the intestines of the human host where they produce eggs and the 
life cycle is repeated.  The morbidity caused by these infections is dependent primarily on the intensity 
of infection and manifests itself in a different manner for each disease. The overall effects of the STH are 
detrimental to health, growth, and the development of children. 
 
Epidemiology 
Soil-transmitted helminthiasis affects more than 2 billion people worldwide with more than 300 million 
suffering from chronic debilitating morbidity [25,54-56]. The chronic morbidity caused by these 
infections results in, for instance, impaired growth and cognitive development in children and work 
output in adults. The morbidities are a consequence of the relationships between hookworm and 
anaemia, ascariasis and growth stunting, and trichuriasis and decreased school performance [57-62]. 
Internationally these outcomes are measured in terms of DALYs. The combined DALYs of schistosomiasis 
and STH infections are 43.5 million, second only to TB (46.5 million) and well ahead of malaria (35.7 
million) and measles (34.1 million)  [63,64]. Mortality caused by each of the STH, when combined, have 
been estimated to range between 12,000 about 135,000 annual deaths [65]. SAC (5 to 14 years of age) 
are most at-risk of infection for ascariasis and trichuriasis, however, hookworm prevalence and intensity 
are highest in 30 to 44 year olds and older because it is thought that they can either evade or suppress 
host immune responses [56,66]. The effects of STH infection are of particular importance in pregnant 
women due to the impact of nutritional deficiencies and anaemia on the unborn child [67].  
 
Diagnosis and Control 
STH diagnosis is commonly through the same as method used for S. mansoni infection, which is through 
the number of eggs per gram of faeces using direct smear and the Kato Katz technique. The major aim of 
control activities is morbidity control through treatment of at-risk populations to reduce the intensity of 
infection and protect infected individuals from morbidity [11]. Encouraging healthy behaviour such as, 
hand washing and using latrines, and the provision of safe water are other important control measures 
for STH control [68]. Treatment is either with a single tablet of ALB (400mg) or MEB (500mg). ALB can be 
safely co-administered with ivermectin (IVM) for the treatment of lymphatic filariasis and ALB or MEB 
can be safely co-administered with PZQ for the treatment of schistosomiasis. Mass treatment should be 
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delivered once or twice a year depending on the underlying endemicity with therapeutic coverage of 
75% and above in SAC [53]. 
 
Onchocerciasis 
Aetiology  
Onchocerciasis (Secernentea: Onchocercidae), also known as river blindness, is characterized by skin 
lesions and severe visual impairment and blindness. It is a parasitic disease caused by the helminths 
Onchocerca volvulus and is transmitted by small blackflies of the Genus Simulium, which breed in rapidly 
flowing rivers and streams. During a blood meal the mf, a larval stage of O. volvulus, are ingested by the 
blackfly where they undergo development in the thoracic muscles of the fly. Following development the 
mf are transmitted back to a human host through the infected bite of the black fly. The mf then migrate 
to the subcutaneous tissue where they mature into adult worms in visible nodules. When maturation 
has been achieved the adult worms, which have a life span of 8-15 years, mate and release up to 1000 
new mf a day. The mf then migrate to the skin and eyes and cause inflammatory tissue reactions when 
they die resulting in subsequent morbidity such as eye lesions and onchocercal skin disease (severe 
itching, dermatitis and de-pigmentation).  
 
Epidemiology 
Onchocerciasis is the world’s second leading infectious cause of blindness after trachoma. The disease is 
endemic in 37 countries globally; 30 are in sub-Saharan Africa, six in Central and Southern America and 
also The Yemen [11]. Approximately 42 million individuals are estimated to be infected with O. volvulus 
of which there are 13.1 million cases of severe itching, 385,000 cases of blindness as a result of the 
disease, and 944,000 are visually impaired [69]. Severe itching alone is estimated to account for 60% of 
the disease burden due to the social and physical consequences of onchocercal dermatitis [70-73]. The 
age-intensity profiles of O. volvulus differ under different endemic situations however, men in their late 
teens and early twenties and older women appear to harbour heavier intensities [74]. Nevertheless 
early signs and symptoms are frequently common among children [75].   
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Diagnosis and Control 
The gold standard test for the diagnosis of onchocerciasis remains the skin snip biopsy. Two skin snips 
using a 2mm Holth corneoscleral punch, or by elevating a small cone of skin (3 mm in diameter) with a 
needle and shaving it off with a scalpel, are taken from the iliac crests from each individual and 
incubated for 24 hours in isotonic saline in microtitration plates. O. volvulus mf are then counted 
microscopically [76]. Due to the perceived and genuine discomfort caused by skin snipping other clinical 
diagnostic methods such as nodule palpation [77] and skin manifestations due to onchocerciasis can be 
assessed using a standardised tool with the infected individual [78].There is strong evidence for an 
association between microfilarial load and onchocercal dermatitis where treatment with IVM reduces 
microfilarial load and the prevalence of onchocercal dermatitis [71,78-80].  
 
Mass treatment for onchocerciasis is with IVM, which reduces the occurrence of blindness and the 
occurrence and severity of skin symptoms [81,82]. The IVM kills the mf but does not kill the 
macrofilariae which are the adult worms. However, an annual single dose of IVM (at 150μg/kg), also 
measured by a dose pole, does result in a significant decrease in mf load and reduces the fecundity in 
female adult worms [83,84]. Insecticide spraying of blackfly breeding sites is another successful, yet 
expensive and long-term, control intervention for onchocerciasis as seen by the Onchocerciasis Control 
Programme in West Africa [75]. In some selected foci in the Americas and Africa the disease is being 
eliminated by 85% therapeutic coverage of the population at-risk every six months and with health 
education [85,86]. The six endemic countries which, along with international partners form The 
Onchocerciasis Elimination Program for the Americas (OEPA), have established effective national 
programmes reaching a target 500,000 at-risk population. These countries have eliminated eye lesions 
attributable to onchocerciasis in 9 of the 13 foci targeted [11].  
 
Lymphatic Filariasis 
Aetiology 
Lymphatic Filariasis, also referred to as elephantiasis, is a disease characterized by the invasion of the 
human blood and lymphatic systems by filarial nematodes (Secernentea: Onchocercidae). The filarial 
nematodes, of the species Wuchereria bancrofti, Brugia malayi and B. timori are transmitted by the 
intermediate host, the mosquito Anopheles gambiae and An. funestus [87]. Mf are taken up from the 
peripheral blood by the mosquito whilst it feeds on a human. Following approximately 15 days of 
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developmental changes in the mosquito’s thorax muscles, the mf infect or re-infect a human during a 
mosquito blood meal. Once in the human the mf reach the lymphatic system and within a lymphatic 
node develop into an adult. Adult worms living in the lymphatic system cause acute adenolymphangitis 
inflammatory attacks (ADL) followed by dilation of the lymph vessels and lymphatic insufficiency. 
Consequently, there is impaired drainage and circulation of lymph in the body and weaker resistance to 
invading organisms which leads to lymphoedema and eventually elephantiasis. 
 
Epidemiology 
Approximately 1.2 billion people (20% of the world’s population) are at risk of acquiring infection of 
lymphatic filariasis with an estimated 120 million people in over 80 countries already infected and 40 
million incapacitated or disfigured by the disease [88]. Lymphatic filariasis is now recognized as a major 
source of morbidity and physical disability [89,90] being ranked by the WHO as the second major cause 
of permanent and long term disability worldwide [89]. It is also closely associated with conditions of 
extreme poverty, considerable psycho-social burden and can be responsible for sexual dysfunction 
[91,92]. Commonly there is a higher prevalence of mf in males than in women and an increasing 
prevalence with age [87,93].  
 
Diagnosis and Control 
Diagnosis is through finding the presence of mf in the blood. This is performed by thick blood smear, 
counting chamber or filtration of venepuncture blood from night-time samples which is during peak 
microfilarial output or ICT cards [94]. The latter test detects monoclonal antibodies and can be used 
during the daytime, however, it does not measure density of infection. In addition to measuring the 
prevalence and intensity of mf infections, to indicate level of lymphatic filariasis infection, the WHO 
recommends that the prevalence of the clinical manifestations, lymphoedema and hydrocele, are also 
measured [89]. There are associations between the prevalence of both of these morbidities and 
prevalence and intensity of microfilariaemia [95,96]. Lymphoedema and hydrocele prevalence increase 
with age, and with increasing severity there are effects on the individual’s productivity at home and at 
the work place with many even having to change their role at work or having to completely stop [97-99]. 
Their reduced earning capacity has an effect on diverse issues such as personal relationships and the 
economic status of their household and the community where they reside [91,92,97]. There is a large 
body of evidence that demonstrates lymphoedema and hydrocele prevalence and severity decrease 
following mass treatment with antifilarial drugs [100,101]. 
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 Lymphatic filariasis control aims to decrease the number of mf in the human host through mass 
treatment of at-risk populations with ALB plus either IVM or DEC and through reduction in the number 
of infective mosquito bites by using insecticide treated bednets. Annual mass chemotherapy with a 
single annual dose of ALB (400mg) and IVM (at 150 - 200μg/kg) or DEC (6mg/kg) at ≥ 80% therapeutic 
coverage of at-risk populations for four to six years will interrupt transmission of lymphatic filariasis in 
many settings [89].  
 
Trachoma 
Aetiology  
Trachoma is an infectious disease which the leading cause of preventable blindness in the developing 
world. The people at risk of blindness live in dry rural areas with poor environmental sanitation, 
inadequate water supply and tend to be of low socio-economic status. Trachoma is caused by Chlamydia 
trachomatis (Chlamydiae: Chlamydiaceae), a bacterium transmitted by direct spread of infected ocular 
material from one person to another. The spread of trachoma is by common house flies (Musca 
sorbens), and through contaminated fingers and fomites. Transmission can also occur by sharing clothes, 
towels or overcrowded sleeping quarters and is therefore passed among family members in households 
that are in close proximity. After years of repeated infection, the inside of the eyelid becomes so 
severely scarred that it inverts and the lashes rub on the eyeball causing corneal scarring.  
 
Epidemiology 
Trachoma is the leading cause of preventable blindness globally, being responsible for 1.3 million cases 
of blindness (3.6% of global blindness) [102]. It has been estimated by WHO that 84 million people in 57 
countries, mainly in Africa, Asia, Middle East, Latin America and Australia have active trachoma [103]. Of 
these, 7.6 million require corrective surgery. The WHO has graded trachoma into five main categories 
[104]. These are: Trachomatous Inflammation Follicular (TF); Trachomatous Inflammation Intense (TI); 
Trachoma Scarring (TS); Trachomatous Trichiasis (TT) and Corneal Opacity (CO). TF and TI are the grades 
of active trachoma and are more common in children who act as reservoirs for infection. Re-infections 
perpetuate severe tarsal conjunctival inflammation leading to scarring and trichiasis. Trichiasis (in-
turning of eye lashes) leads to constant rubbing of the eyelashes on the cornea, causing corneal 
ulceration which heals leaving behind a scar leading to CO. CO over the pupil in turn leads to substantial 
visual loss and this usually occurs in mid to late adulthood. Blinding trachoma (grades TT and CO) is 
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more common in females than males and this is attributed to the role of women as caretakers of 
children who are the main reservoirs of infection [105]. The age distribution of different manifestations 
of trachoma depends on the endemicity levels. In hyperendemic areas, active disease is most common 
in pre-school children where prevalences as high as 60-90% have been reported [105]. The prevalence of 
active trachoma decreases with increasing age [106,107]. In areas where trachoma has been endemic 
for a long time, conjunctival scars also increase with age [108].  
 
Diagnosis and Control 
Diagnosis of trachoma is through clinical examination for the presence of trachoma infection in each 
age. Trachoma infection can be assessed using a simple grading scale [104]. Prevalence of the two 
grades of active trachoma TF and TI are used to define where a control programme should be 
implemented [109-111]. There is evidence, however, that active trachoma does not correctly identify 
ocular chlamydial infection due to the time lapse between infection and the clinical appearance of active 
disease and again following a reduction in infection and the disappearance in clinical disease 
[106,112,113]. A dipstick assay for rapid diagnosis of infection prevalence is currently being developed 
[114]. 
 
The ‘SAFE’ strategy (Surgery for trichiasis, distribution of Antibiotics, Facial cleanliness and 
Environmental improvements) is recommended for the comprehensive and effective control of 
trachoma [115]. Surgery can be carried out by ophthalmic surgeons or nurses [116] and uptake is better 
in the communities than at a health unit or hospital [117]. Antibiotics for the mass treatment of 
trachoma to infected and at-risk populations are a single oral dose of ZIT (20mg/kg, with a maximum 
dose of 1g) and for children under six months, the application twice a day of 1% tetracycline eye 
ointment for six weeks [118]. A therapeutic coverage of 80% over at least three years where baseline 
prevalence of TF in 1 to 9 year olds is 10 percent or greater is the minimum threshold for mass 
treatment of an endemic district [118]. Face-washing aims to interrupt transmission by removing 
infected ocular secretions [119]. Environmental improvement also aims to break transmission by 
reducing the breeding sites (exposed faeces) of the mechanical vector Musca sorbens [119]. To achieve 
the elimination of blinding trachoma it is imperative that each of the four components be addressed 
within a control programme [120,121]. 
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Global Burden of NTDs  
It has been estimated that collectively the seven PCT NTDs contribute to approximately 52.1 million 
DALYs lost annually in the world, which is an estimated 3.4% of the global burden of disease and injuries 
[16,122]. This, however, is debated as a considerable underestimate as the contribution of 
schistosomiasis to the DALYs alone could be up to 15 times greater than previously thought [123-125]. 
The reason for the undervaluing is due to the exclusion in DALY calculations of the effects of subtle 
morbidity, caused by early and light infections, which although they are, largely, asymptomatic can 
contribute significantly to an individual’s health [123,126]. The DALY estimates in the original Global 
Burden of Disease (GBD) study in 1996 [127] were derived from disability weight valuations that were 
calculated through the Person Trade Off process by panels of “nonexpert, highly educated participants”. 
It should be noted here that the DALY disability scale is inverted so that 1 is death and 0 is equal to 
perfect health and thus disability weights are fractions on this scale which reflect the severity of disease, 
the closer the fraction is to 1 indicates an increased severity of disease [127]. The specific disability 
weights for the NTDs, in both the original and the 2004 GBD study were weighted to give an average 
representation of all levels of infection i.e. mild, moderate and severe, nevertheless they were 
disaggregated from their associated morbidities such as anaemia, ADL and cognitive and growth 
impairments and thus are underestimations of the disability caused by the NTDs. What is most 
important to take into consideration about these NTDs, in terms of global burden of disease, is that each 
of them has chronic complications from morbidity that leads to reduced productivity caused by reduced 
physical and cognitive function and, ultimately, to a decreased capacity for wage-earning [72,90,98,128-
132]. 
 
Two recent studies using empirical evidence and including associated morbidities, have reassessed the 
disability weights for Schistosoma japonicum and have shown that in comparison to the disability weight 
of 0.005–0.006 assigned to every schistosome species in the GBD study, more accurate estimates are an 
overall disability weight of 0.19,  with age-specific weights ranging from 0.095 among 5 – 14 years and 
0.246 among those aged > 60 years [133]; and an overall disability weight of 0.132, with age-specific 
weights of 0.098 for children and 0.186 for adults [134]. King [124,135,136] suggests that a more 
realistic range for a schistosomiasis disability weight range is from 0.02 to 0.25. Both the studies 
mentioned used different methods in calculating the disability weights, where Jia et al. [133] collected 
infection prevalence and health-related quality of life data whilst Finklestein et al. [134] used infection 
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prevalence data from existing literature to develop a decision tree model. What both studies 
acknowledge but unfortunately lacked, as do the GBD study estimates, was the importance of 
incorporating co-morbidities due to polyparasitism in their analysis. Polyparasitism is the norm in 
communities affected by the NTDs [137-140]. Further empirical research into the disability weights for 
each individual NTD, whilst at the same time incorporating co-morbidities due to potential polyparasitic 
interactions and co-factors, is therefore imperative. Such investigations will not only result in better 
estimates for DALYs lost to the NTDs and thus a more accurate estimate of  economic burden, but 
should also help to reprioritise the NTDs in the global forum.   
 
Control programmes for NTDs 
History of control programmes for NTDs 
Since the 1970’s control programmes and alliances for NTDs, in particular the PCT diseases, have 
focused on individual diseases, such as the West African Onchocerciasis Control Programme, the Global 
Elimination of Blinding Trachoma by 2020 (GET2020), the Global Alliance to Eliminate Lymphatic 
Filariasis (GAELF) [103,141,142]. These stand-alone (SA) control programmes have typically been carried 
out at the national or regional level by Ministries of Health supported by public-private partnerships and 
non-governmental organisations (NGOs). Through the monitoring and evaluation of infection and 
disease indicators and programme processes, these SA initiatives have shown significant progress 
towards reaching aims of  elimination (lymphatic filariasis), eradication (Guinea worm), and/or the 
control of morbidity (schistosomiasis, onchocerciasis, trachoma) [27,35,109,143]. Not only have these 
initiatives achieved the desired health impact, latterly through sustained mass treatment coverage, but 
because they are extremely affordable. Their affordability is due to the safe and effective drugs to treat 
them being either donated or relatively inexpensive. A multi-country study of the cost per treatment 
using the Community Directed Treatment with IVM (CDTI) strategy showed an average economic cost of 
$0.74 per person treated for onchocerciasis in Nigeria, Uganda and Cameroon [144]. A further seven 
country study assessing the costs of IVM and ALB for the elimination of lymphatic filariasis estimated 
economic costs of $0.48 to $6.97 per person treated which varied due to year of programme 
implementation, use of volunteers and the size of the population treated [145]. Control efforts for 
schistosomiasis and the STH, when treated together and as individual programmes, have also been 
shown to be extremely affordable with cost per-person treatments ranging between $0.03 and $0.58 
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[146-151].  
 
Historically each programme has, by virtue of being autonomously coordinated at both national and 
global levels, rarely incorporated involvement of the other SA programmes that may be operating in the 
same region or treating the same high risk communities. Yet, due to the overlapping distributions of 
many of the NTDs, it is indeed often the same poverty-stricken, poly-parasitized populations that are 
targeted under each programme. The consequences of such overlap are that each programme has little 
or no awareness of other programme activities and aims. Thereby, problems and inefficiencies occur 
such as unnecessary treatments, for example, of ALB, duplication of efforts by mobile teams or 
community distributors, and disengagement of the afflicted populations with decreasing coverage and 
compliance for each programme individually [10].  
 
Integrated Control of Neglected Tropical Diseases 
As discussed earlier, since 2006 there has been an increase in attention received by the NTDs at the 
international level. A good percentage of the response was assigned to how efforts of programmes 
tackling the NTDs could be better coordinated and co-implemented at the international, regional and 
national level [53].  Subsequently, several philanthropic and multilateral agencies pledged to support 
this integration of NTD control and elimination, in particular the Bill and Melinda Gates Foundation, 
Geneva Global, the USAID with an initial commitment of US$100 million for their Neglected Tropical 
Disease Control Program in 2006 [152]. These commitments were followed later by declarations from 
both the US and UK governments of US$350 million and GBP£50 million respectively in 2008 [153]. This 
push for the integration of NTD control and elimination programmes was focused on the seven NTDs, 
which aim for control of morbidity and transmission interruption through presumptive PCT  (see Table 
1.1). The seven NTDs are ‘tool’ ready in that they require only four different safe, effective and available 
drugs for their treatment, these are; IVM, ALB/MEB, PZQ and ZIT as illustrated in Table 1.3. Therefore, in 
theory, programmes should be integrated so that individuals with single, and especially those with 
multiple infections, will receive the necessary treatments for their infections at the appropriate times, 
frequencies and dosages that maximise impact, minimise side-effects, and optimise the use of resources 
in constrained settings.   
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NTD Goal PCT Drug(s) as Major Control Intervention 
Current Control 
Programmes Drug Donors 
Lymphatic 
Filariasis 
Elimination as a public 
health problem and the 
interruption of 
transmission 
(WHA 50.29) 
 
 DEC 
 
or 
IVM and ALB 
 
GAELF 
Sanofi, Eisai and 
the Bill & 
Melinda Gates 
Foundation  
 
Merck and Co. 
GlaxoSmithKline 
Schistosomiasis 
Elimination as a public 
health problem 
(WHA 65.19) 
PZQ 
Schistosomiasis 
Control Initiative 
(SCI) 
 
The Schistosomiasis 
Control Program (The 
Carter Centre) 
MedPharm 
(limited)  
 
Merck Serono 
STH  
Sustainable control 
activities and access to 
essential drugs in 
endemic areas for 
treatment of clinical 
cases and high risk 
groups such as women 
and children. (WHA 
54.19) 
ALB 
 
MEB 
SCI 
 
GAELF 
 
Children Without 
Worms (CWW) 
GlaxoSmithKline  
 
Johnson 
&Johnson  
Onchocerciasis 
Elimination as a public 
health problem 
(WHA 47.32) 
IVM 
African Programme for 
Onchocerciasis Control 
(APOC) 
 
River Blindness 
Programme (The 
Carter Centre) 
Merck and Co. 
Trachoma  
Elimination of blinding 
trachoma as a blinding 
disease 
(WHO 51.11) 
ZIT 
International 
Trachoma Initiative 
(ITI) 
Pfizer 
Table 1.3: International control and elimination goals for each of the PCT NTDs     
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The Concept of Integration  
Integration in the context of healthcare can have a broad range of meanings and these depend on 
whether it is approached from a disease control perspective or from the viewpoint of the health system 
[154]. A disease control programme focuses on one or multiple diseases, whereby specialist health staff 
are expected to act on empirical evidence to provide population based interventions which aim to 
achieve wide programme coverage and have an impact on the frequency and severity of disease [155]. 
In contrast, a basic healthcare system focuses on patients, whereby multi-skilled health workers act on a 
mix of evidence, patients’ preferences and circumstantial constraints to provide individuals with 
healthcare that will enable them to carry on their life lives [155]. Table 1.4 gives a description of the 
potential interpretations of integration and provides them as examples of vertical and horizontal 
approaches to healthcare [156]. Both vertical and horizontal approaches provide opportunities for 
integration and are not necessarily mutually exclusive [157,158]. Instead, and to quote Criel et al. [155] 
“when we talk about integration, the issue is not integrating (or not) programmes in their totality; the 
issue is integrating or not (some) activities of a programme”. 
Disease control perspective:  
(i) “Integration” means the creation of packages of healthcare which will be delivered vertically through campaigns 
or other channels 
Health systems perspective:  
(ii) “Integration” can be defined as a horizontal approach where healthcare interventions are delivered as part of 
routine services, through:  
(a) Integrated care – whereby one unit i.e. a health centre, provides individuals and communities 
with preventive, health promotion and curative services 
(b) Integrated health service delivery systems – whereby all health services (health centres, referral 
hospitals, etc.) are coordinated to achieve shared objectives 
(c) Integration of disease programmes into the general health services – whereby specific disease 
programmes provide the general health services staff with the resources to carry out, in full or in 
part, programme activities  
Table 1.4: Definitions of integration in the context of healthcare 
Source: Adapted from [154,155,157] 
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Integration in Operation 
When referring to the integration of the PCT NTD control and elimination programmes it is the model 
described in Table 1.4 definition (i) that has been used theoretically and practically [158-161]. There are, 
however, examples of SA programmes for NTDs which have been successfully integrated into existing 
health services as described in (ii) (c) [162-164]. Arguments for the current vertical application of 
integrated PCT (IPCT) for the control and elimination of NTDs centre around the promise of ‘rapid-
impact packages’ and ‘best buys in public health’ which indicate time-limited investments and high 
impact through immediate and equitable coverage [157]. Whereas, achieving control and especially 
elimination with IPCT as the main intervention for the NTDs through a horizontal approach could mean a 
slow achievement of programme goals in an already overburdened health system, a loss of focus and 
the risk of specialised tasks being delegated to non-specialists [155,157]. The implications of IPCT being 
fully integrated into the health services will be discussed in full in Chapter 6.  
It is important to determine what the impetus is for integration i.e. why do healthcare services and 
programmes not run in parallel to one another with each attaining their own goals? From any of the 
healthcare perspectives the main drivers for integration would be to: achieve efficiencies in delivery; 
increase effectiveness; enhance health benefits; and optimise the use of limited resources that could 
permit more individuals being reached [14,165]. It has been widely suggested that, from an economic 
perspective, the integration of multiple disease control programmes for NTDs under one umbrella 
intervention will achieve cost-savings [7,166,167]. The cost-savings would be a consequence of the 
combination and reduction of resources to achieve increased therapeutic coverage, number of 
treatments delivered, and to ultimately attain economies of scope and scale [168]. A further economic 
benefit of integration will be through improving health in the targeted individuals and population and 
thus improved school performance and worker productivity [56,168].  
 
Grépin and Reich [165] suggest, within their conceptual integration framework, that cost savings and 
benefits achieved by integration will be dependent on at what level it is being targeted. For example, 
and in the perspective of current integrated efforts for NTDs: 
Global Integration among the international health organisations and public-private partnerships in 
terms of organisation, policy or activity, e.g. The London Declaration Scorecard 
(http://www.unitingtocombatntds.org/content/promises-to-progress) has been developed by 
multiple global and national partners for NTDs. It is a set of joint indicators to evaluate the progress 
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of single and multi-disease programmes to accomplish control and elimination goals.  
National Integration among the national and/or regional disease-specific programmes within the 
Ministry of Health (MoH) and other ministries, NGOs and other national stakeholders in terms of 
organisation, policy or activity, e.g. the joint operational planning between disease-specific 
programmes with regard to the timing and sequencing of the drug supply chain and delivery to the 
local level [14,161]. 
 
Local (district, school, community) Integration among the local level disease-specific programme 
implementers and the drug distributors, in terms of organisation, policy or activity, e.g. a community 
drug distributor (CDD) who has previously been involved in each separate disease-specific 
programme will now be responsible for multi-disease distributions which should, in theory, reduce 
the time they need to dedicate on trainings, community mobilisation and treatment [161,165]. 
 
The extent to which integration occurs can also vary across each level and this too can have an effect on 
overall programme and economic benefits. To illustrate the extent, or degree, to which integration can 
occur Grépin and Reich [165] put forward three categories for integration to which I have added a 
fourth: 
(a) Coordination: The exchange of communication and information between disease-specific 
programmes for the purpose of simplifying the implementation of each programme. For example, 
programmes at the national level working together to develop an annual work-plan and budget for 
implementation.  
(b) Collaboration: In addition to increased coordination, the disease-specific programmes could scale-up 
the sharing of personnel or resources. For example, multiple programmes can jointly purchase 
equipment or train technicians that could then be used by all of the programmes  
(c) Consolidation: The replacement of parts, or an entire programme, by a new effort or programme. 
For example, annual multi-diseases training workshops instead of the national level conducting multiple 
single disease training workshops at the local level. 
 (d) Co-implementation: The implementation of specific programme activities, which have been 
consolidated, being shared by each disease-specific programme. For example, multi-disease training 
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workshops carried out by the schistosomiasis specialists in the northern region of a country whilst the 
onchocerciasis specialists simultaneously conduct the same training in the southern region and the 
trachoma specialists in the eastern region.  
In this thesis the reality of integration is within the context of NTD control in Uganda, which fits the 
model of a package of already existing PCT interventions which are delivered simultaneously and 
vertically through mass treatment campaigns to targeted populations. The IPCT strategy in Uganda is a 
consequence of integration at the global and national levels and involves all four categories of 
integration – coordination, collaboration, consolidation and co-implementation at each level of 
implementation i.e. at the national, district, health centre, school and community levels which are 
described more fully in the forthcoming sections. 
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Uganda 
Uganda’s transition from prior SA control programmes to current integrated efforts for the control of 
NTDs is the focus of the research described within this thesis. The following sections will describe 
Uganda as a country and also provide details of its history of NTD control as context to the subsequent 
chapters.  
 
History 
What is now the Republic of Uganda in Eastern Africa has experienced two human migrations which still 
influence society today. The first brought Bantu speaking populations to the centre and the south of the 
country in 1200 A.D. carrying with them agricultural practices which displaced the hunter-gatherer 
peoples [169]. The second around 1500 A.D. brought the Nilotic peoples south from Sudan to the north 
of the country where they practiced herding for a living and had a reputation for being cattle rustlers, 
and still do [170]. The mid-19th century brought the arrival of Arab traders and European explorers and 
relationships were formed with the Bugandan kingdom [171]. Uganda became a British protectorate in 
1894 and after 68 years under semi-autonomous rule, independence was re-gained in 1962 [172]. Until 
1986, when Yoweri Museveni and the National Resistance Army took power, Uganda was marred first by 
the rule of Milton Obote and then, following a military coup in 1971, by the despot Idi Amin [172]. Since 
the reign of President Museveni, Uganda has been relatively stable and peaceful with the exception of 
the occupation of several districts in the northern Acholi region by the Lord’s Resistance Army (LRA) 
rebels [173]. 
 
Government 
The country is administered by the central government based in Kampala and a presidential system. 
Continued decentralization has resulted in power being devolved to 112 districts spread across four 
administrative regions: North, Eastern, Central, and Western, which are made up of 184 counties, 1260 
sub-counties and 7,138 parishes and 66,036 villages (unpublished data, Uganda MoH Master Plan for 
the control NTDs (2011-15). 
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Geography and Climate 
Uganda is in East Africa, situated between latitudes 4⁰12’N and 1⁰29’S and longitudes 29⁰34’ and 35⁰0’E. 
It is a land-locked country bordered by Kenya to the east, Tanzania and Rwanda to the south, the 
Democratic Republic of Congo to the west and Sudan to the north. The country sits at an average 
altitude of 1,100 metres and covers 240,000 square kilometres of which 18% is open water and swamps 
and 12% is forest reserves and game parks. Lake Victoria, the third largest lake in the world, makes up 
most of the open water area and is shared by Kenya and Tanzania. Uganda has tropical rain forest in the 
south and savannah woodlands and semi-desert vegetation in the north. Temperatures range between 
17°C and 32°C. The central, west and southwest receive most of the rainfall between March and May 
with a national average annual rainfall of 1400mm.  
 
Demography and Social Structure 
The population of Uganda is projected to be 31.8 million for 2012 with a growth rate of 3.2%. 
Approximately 88% of the population live in rural areas and 49% of the population are male. The 
population composition is similar to other sub-Saharan countries in Africa with approximately 51.6% 
under 15 years of age and 21.3% below the age of 5 years of which 19.3% are between 6 – 59 months 
and 2% between 0 – 6 months [174]. The net primary school enrolment rate in financial year 2006/7 was 
84% in approximately 14,728 primary schools [175].  
There are 13 major tribes in Uganda which make up 80% of the population resulting in diverse cultural 
beliefs, practices and over 50 different spoken languages. In rural areas, communities are organized 
along the kinship/clan systems socially and culturally. In these communities, there is obvious male 
dominance over women. This dominance influences marriage decisions and property ownership 
including land. As a result of this male dominance, the man makes the ultimate decisions about the 
majority of issues including health-seeking behaviour. In the kinship arrangement, the younger 
generation take responsibility for the health of the older generations in addition to the protection of 
mothers and children.  
 
Economy 
Agriculture is the most important economic sector, employing over 80% of the workforce and 
contributing about 90% of the country’s exports. It also contributes to 50% of the Gross Domestic 
Page | 42  
 
Product (GDP) and 40% of government revenue. Uganda has substantial natural resources, including 
fertile soils, regular rainfall, and sizable mineral deposits of copper and cobalt. Coffee accounts for the 
bulk of export revenues but other important cash crops are tea, cotton, sugar cane and tobacco. A 
variety of food crops including potatoes, chickpeas, bananas, maize, millet, groundnuts, cassava and rice 
are cultivated in quantities sufficient to render Uganda self-sufficient in food supplies. Uganda has a GDP 
of US$16.81 billion which per capita is US$487 and a Gross National Income (GNI) per capita of US$510 
(2011, World Bank). A quarter (24.5%) of the population live below the national poverty line (2009, 
World Bank) and Uganda is ranked 143 out of 169 on the UN Human Development Index (2010, United 
Nations Development Programme) approximately 68% of the rural population have access to an 
improved water source (2010, World Bank).  
 
Health 
Health Financing  
The sources of healthcare expenditures include three primary sources. External sources account for 
29%, followed by the central government budget through conditional as well as unconditional grants to 
districts and local government (34%) and households through insurance and out of pocket contributions 
(38%) [176]. The proportion of health spending within the Government of Uganda budget (i.e. excluding 
project support) increased from 7.6% in financial year 2000/01 to 10.3% in 2004/05 translating into 
$8.30 per capita spending by government and donors. This, however, is only a small part of the 
estimated $28 per capita health expenditure for 2004/05, the rest of which comes from the private 
sector, external support and patient out of pocket spending. The amount needed to adequately fund the 
implementation of the Uganda Minimal Health Care Package is estimated at $30-40 per capita and will 
need an increase on the health budget to at least 15% over the next years. Government resources for 
health are overwhelmed by the major killers malaria, HIV/AIDS and TB and there is virtually no money 
for government support of the NTDs (unpublished data, Uganda MoH Master Plan for NTDs 2011-15). 
 
Health Services 
The MoH is now in its third Health Sector Strategic Plan (HSSP) which guides health sector investments 
led by the Ministry, medium term planning and scaling up of critical health interventions. The HSSP is 
developed in line with both the National Development Plan and is an operationalisation of the National 
Health Policy (2010, HSSPP III, Uganda MoH). The four priorities of the HSSP III are Sexual and 
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Reproductive Health, Child Health, Health Education and the Control and Prevention of Communicable 
Diseases (HIV/AIDS, Malaria and TB). The HSSP ensures the streamlining of health services, illustrated in 
Figure 1.1, which are decentralized to the district level (level V) where primary strategic and budgetary 
decisions are made by District Health Office and District Health Management Teams. Each district is 
divided into health sub-districts (level IV). At this level is a hospital equipped with laboratory facilities, an 
operating theatre and other specialised services. Below it is a level III facility, which is commonly based 
at the sub-county, followed by a level II health facility at parish level. While almost all sub-counties have 
health facilities, a significant number of parishes have none. The lowest health facilities which are being 
rolled out as a phased approach, 75% of districts but only 31% have trained CDDs in all villages [177], are 
linked with family and community members through Village Health Teams (VHT) at the village level. The 
VHT is responsible for identifying the community’s health needs and taking appropriate control 
measures, selecting village members to be trained as community health workers, and serving as the link 
between the community and the health providers. Three-quarters of the population (72%) live within 
five kilometres of a health facility (public or private), yet utilisation is limited due to poor infrastructure, 
inadequate supplies of medicines and other health supplies and the shortage and low motivation of 
human resource. The private health system comprises of Private-not-for-Profit Organisations, Private 
Healthcare Practitioners and traditional and complementary medicine practitioners. Unlike government 
facilities, the private health sector charge user fees which further limits the access to care (2010, HSSP 
III, MoH Uganda). 
 
Health Indicators 
Uganda has made substantial efforts towards achieving many of the MDG targets, especially for Goals 1, 
3, 6, 7 and 8, which are respectively to: eradicate extreme poverty; promote gender equality and 
empower women; combat HIV/AIDS, malaria and other diseases; ensure environmental sustainability; 
and develop a global partnership for development. Examples of those that are on track are, the halving 
of the proportion of people below the national poverty line which was 56% in 1992/3 and 23% in 
2009/10 [178]; ratios of girls to boys in primary was 0.93 in 2000 but had achieved the target of 1.00 by 
2009; the proportion of the population with advanced HIV infection with access to antiretroviral drugs 
had reached 54% in 2009 towards a target of 80% [178]. Achieving universal primary education, Goal 2, 
requires greater effort to encourage children to complete primary as the current completion rate stands 
at only 52%, only half of the target (100%). Progress has been slow, and has even reversed in some cases  
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Figure 1.1: An illustration of the different levels of Health Services within Uganda superimposed with the 
corresponding implementation levels of the NTDCP and the key actors in the programme at each level. 
Abbreviations in full: DHO - District Health Officer, DVCO - District Vector Control Officer, DEO - District Education 
Officer 
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towards Goals 4 and 5, which are to reduce child mortality, and to improve maternal health, 
respectively. For instance, the infant mortality rate (under 1 year) has decreased from 106 (1990) to 63 
(2010) per 1,000 live births but has a target of 31 per 1,000 live births for 2015; the under-5 years 
mortality rate, which has a 2015 target of 56 per 1,000 live births had only reduced from 175 (1990) to 
99 (2010) per 1,000 live births in 10 years (2012, United Nations Children’s Fund (UNICEF)). 
 
The ratio of medical doctors to population ranges from 1:12,500 to 1:50,000 and for nurses to 
population is 1:500 [179]. Life expectancy at birth is 54 years (2010, World Bank) and the fertility rate is 
an estimated seven children per woman (HSSP III, MoH Uganda).  
 
 
  
Page | 46  
 
NTDs in Uganda 
The following text outlines the epidemiology of the seven NTDs targeted for IPCT in Uganda and gives a 
history of the control measures that were implemented as SA programmes in the country prior to the 
inception of the integrated NTD Control Programme (NTDCP). Table 1.5 provides a timeline for the 
programmes for NTD control in Uganda and in the context of global NTD alliances. Following on an 
overview is given of the NTDCP in Uganda which brought each MoH SA programme together to be co-
implemented under one secretariat.  
 
Epidemiology and Control of NTDs in Uganda (1993 – 2007) 
Schistosomiasis, STH and the National Bilharzia and Worm Control Programme  
Epidemiology: Schistosomiasis, predominantly caused by S. mansoni, was identified as early as the 
middle of the last century in north-western Uganda [180,181]. More recent studies carried out between 
1988 and 2002 by the Vector Control Division (VCD) reported S. mansoni to be prevalent in at least 38 
districts, with S. haematobium occurring in just five of the former 56 districts in Uganda [182]. The 
overall estimate was, four million people infected and almost 17 million at risk of schistosomiasis 
infection in Uganda [183]. Both intensity and prevalence of infection were estimated through faecal egg 
counts and urine filtration techniques. The highest intensities of infection were found in populations 
that had regular contact with the large water bodies e.g. Lakes Victoria, Kyoga, Albert and the Albert 
Nile. In these locations the prevalence of infection ranged from 60 to 100% [182]. In such heavily 
infected areas, many people were acquiring infections at a young age and either suffering early severe 
disease which would lead to premature death, or they experienced severe complications as a result of 
chronic disease. If caught early enough, the disease had the potential to be reversed with appropriate 
treatment of infected individuals. Of the STH in Uganda, hookworm is the most widespread; it is 
homogenously distributed throughout the country exceeding 60% prevalence in 85% of the schools 
surveyed [184,185]. 
 
In contrast Ascaris lumbricoides and Trichuris trichiura are concentrated in south-western Uganda where 
the prevalence can be as high as 89% [185,186]. The spatial distributions of the STH in Uganda are 
heavily influenced by climatic factors, especially temperature and rainfall [186]. Given the large overlap 
in distribution of schistosomiasis and STH in Uganda, it is predicted that every child in the country is 
either infected with one or more of these helminth species or is at risk of infection [183]. 
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Intervention: In 1992 the MoH drafted a national schistosomiasis control plan which, following a 
reduction in the cost of PZQ and the availability of funds, was finally realised in 2003 with the official 
launch of the National Bilharzia and Intestinal Worm Control Programme (BWCP). The programme was 
financially and technically supported by SCI with a Bill and Melinda Gates Foundation grant. The aim of 
the programme was to reach at least 75% of the school-age population and high-risk communities with 
mass treatment of PZQ and ALB for the STH, to reduce and prevent morbidity. The programme was 
managed through the VCD of the MoH with district activities managed by the District Health Team 
specifically by the District Vector Control officer (DVCO), with supervisors at the health-centre level and 
school teachers distributing drugs in schools and CDDs in the communities [183]. Full details of 
programme management are described by Kabatereine et al. [183,187] and Fleming et al. [188]. 
Between 2003 and 2007, five annual mass treatment campaigns were held under the BWCP reaching 9.5 
million individuals and achieving between 74.9% and 88% programme coverage [160]. Crucially, the 
programme was also having a significant impact on reducing the prevalence and intensity of S. mansoni 
and STH [50,189]; and reducing anaemia, as a result of increased haemoglobin (Hb) levels, in individuals 
with S. mansoni and hookworm infection post-treatment [160,190].  
 
 
Onchocerciasis and the National Onchocerciasis Control Programme 
Epidemiology: In Uganda the use of Rapid Epidemiological Mapping of Onchocerciasis identified that 
onchocerciasis was endemic in 18 of the former 56 districts [191,192]. The REMO maps indicate that 
onchocerciasis was highly endemic in the West Nile region, along Lake Albert and in selected foci around 
Mount Elgon in the east and in the southwest of the country. In these areas prevalence of infection, 
measured by nodule prevalence, ranged from 10% to almost 100%. Two million people were estimated 
to be at risk of acquiring the infection with approximately 1.45 million harbouring onchocerciasis 
infections [80,192]  
 
Intervention: Implementation of the National Onchocerciasis Control Programme (NOCP) began in 1991, 
initially with funding from the River Blindness Foundation and from 1996 with funds from the Carter 
Centre’s Global 2000 River Blindness Programme. Annual mass treatment with IVM was supplemented 
by vector control of Simulium neavei in isolated foci from 1995 [80]. APOC, a multinational disease 
control programme with the goal to support annual mass IVM via a CDTI strategy, was formed in 1995 
[193,194] and first gave funding support to the Ugandan NOCP in 1997. The success of the CDTI strategy 
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for onchocerciasis strategy has been reported [195]. Katabarwa  et al. have extensively assessed the use 
of this strategy in Uganda and give a full description of how it is applied in communities [194,196]. In 
summary, the CDTI strategy is an approach whereby community members are collectively involved in all 
stages of the planning cycle from design to implementing and monitoring. Other partners such as non-
governmental development organisations (NGDOs) provided material and technical support, when and 
where appropriate, but do not dominate the process. In Uganda the NOCP, based at the VCD, had 
financial and technical support provided through APOC and the NDGOs, Sightsavers and the Carter 
Centre.  
 
A programme review in 1997 showed that the target of 90% programmer coverage of the eligible 
population was reached in 43% to 51% of the communities [193]. In 2004, Ndyomugyenyi et al. [80] 
reported that the programme had been highly successful in reducing the burden of onchocerciasis, 
onchocercal dermatitis had reduced from 34% to 2.9% and mf carriers from 88% to 7.5% in selected 
populations. Interruption of transmission and disease elimination in selected foci in Uganda has also 
been achieved with annual IVM and ground larviciding [197] and through bi-annual CDTI and expanded 
geographic coverage [86].  
 
Lymphatic Filariasis and the Programme to Eliminate Lymphatic Filariasis 
Epidemiology: The first publication on lymphatic filariasis in Uganda was by Burkitt in 1951 [198]. 
However, the first baseline epidemiological investigations on lymphatic filariasis were conducted, by the 
VCD, in 1998. The surveys were conducted in areas of northern and eastern Uganda where lymphatic 
filariasis was repeatedly reported as a major health problem [87]. Three communities were surveyed in 
the districts of Lira (Alebtong area), Soroti (Lwala area) and Katakwi (Obalanga area) and lymphatic 
filariasis was found to be highly endemic in these areas. In these three areas the prevalence of 
hydrocoele in adult males aged > 20 years, were 28%, 7% and 17% and limb elephantiasis in adults were 
9%, 4% and 4% respectively. The prevalence of circulating filarial antigens (CFA) in the same study was 
high, ranging from 18% to 30% in the general population. The prevalence of microfilaraemia of W. 
bancrofti was also found to be high in night blood samples, with a range of 9% to 21%. 
 
The geographical distribution of lymphatic filariasis in Uganda was subsequently assessed to plan control 
and elimination targets [199]. A country-wide survey was conducted in 2001-2 among SAC at 76 
locations. At each site the children were checked for W. bancrofti CFA using a rapid ICT. The survey 
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showed that W. bancrofti infections were concentrated in a large focus covering most of the districts in 
the east, north of Lake Kyoga and in the northern part of the Albert Nile basin. A smaller focus was 
found in Bundibugyo district bordering the Democratic Republic of the Congo. Further analysis, based on 
population data from 2002, indicated that more than 10 million people lived in areas where CFA 
positivity was ≥ 1% [199]. If an infection rate (CFA or mf) of ≥ 1% is found then the whole district will be 
treated.  
 
Intervention: The Programme to Eliminate Lymphatic Filariasis (PELF) in Uganda was supported by the 
WHO and the GAELF with the aim of eliminating lymphatic filariasis through MDA with donated IVM and 
ALB in communities. The first MDA for lymphatic filariasis was carried out in 2002 in the adjacent 
districts of Katakwi and Lira, with a further three districts being added in 2004 during the second mass 
treatment campaign and reaching approximately 2.9 million. In 2005 the programme scaled up to 
include another five districts. Further scale-up plans to include more districts failed due to insufficient 
funds and insecurity in the target districts, treating an estimated 4.9 million individuals in communities 
and schools. Mass treatment was carried out by teachers in schools and by CDDs in the communities 
where they would distribute door to door in the community or from a central location.  
 
Trachoma and the National Trachoma Task Force 
Epidemiology: Prior to prevalence studies funded through the Uganda NTDCP from 2007 onwards there 
were little data on trachoma distribution in the country. Nevertheless, trachoma was known to be 
endemic in 24 districts (of the original 56) where approximately 700,000 children below the age of 10 
years had active disease and an estimated 7 million people were thought to be at risk of infection. It was 
also estimated that overall, 47,000 people in Uganda were blind from various forms of trachoma. In 
Matheniko sub-county of Moroto District, using the McCallam’s classification, stage I trachoma 
prevalence was 3.6% and stage II was 27% in children 0-9 years old [200]. In similar age groups active 
trachoma (TF) was shown to range from 14% to 38% [201] and  blinding trachoma (TT) from 3.7% to 
11.8% [200] in districts across the country. In 2005 - 2006 seven districts were surveyed, with support 
from Sightsavers, using the WHO standard methodology. Results indicated prevalence of active and non-
active trachoma in all the surveyed districts, >20% and >4% respectively which were above the threshold 
set by WHO for massive antibiotic distribution, with three being classified as hyperendemic (TF>65%). 
[202]. Since 2007 baseline surveys have been conducted in 18 suspected endemic districts. Out of these 
districts 16 were found to have prevalence of TF above 10% which has qualified them for donated 
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Zithromax (azithromycin) from Pfizer, to be mass distributed in conjunction with the SAFE strategy (S. 
Bubikire, MoH, pers comm 2012).  
 
Intervention: Prior to 2007, there was no national trachoma control programme in Uganda. The 
presence of trachoma in Uganda was documented through surveys and routine data from district 
reports. The management of trachoma activities was by individual eye care organizations in their areas 
of operation. The Uganda National Prevention of Blindness Committee in conjunction with the MoH, 
with members from Sightsavers and the Lions Club, set up a National Trachoma Task Force (NTTF) to 
spearhead trachoma control and coordinate the various efforts towards elimination of trachoma. The 
aim was to expand the already existing small-scale trachoma control efforts using the WHO 
recommended SAFE strategy. 
 
 
Integrated Control of NTDs in Uganda (2007 – present) 
Ugandan NTD Control Programme 
Uganda was chosen by the USAID NTD Control Program as one of their five ‘fast-track’ countries in 2006 
[13,14]. The NTD Control Program was initiated when the U.S. Congress authorised funds for the 
“integrated control of NTDs” as a result of heavy lobbying by several key academics and international 
organisations [14]. Linehan et al. [14] state the aims of the five-year programme: 
1) to support and empower national governments to develop integrated NTD control programmes 
embedded, where possible, within existing service delivery platforms and to lead these programs in 
scaling-up activities to full national level;  
2) to provide technical assistance for planning, budgeting, reporting, and complying with 
international standards and guidelines to improve programme integration;  
3) to promote cost-efficiency, improved integration strategies, and effective advocacy; and  
4) to assure national ownership, continued commitment, and resource mobilization for sustained 
support for NTD control. 
Following a tender process, the Research Triangle International (RTI) was selected as the prime 
contractor to manage and coordinate the sub-grantees initially the SCI and the ITI, who were to 
collaborate in supporting the governments in Uganda, Niger, Burkina Faso, Mali and Ghana to integrate 
their existing SA disease control programmes for NTDs [203]. The number of partner NGOs and 
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implementing agencies to support the in-country efforts later grew with increasing numbers of countries 
being targeted for support.  
 
As previously described Uganda is endemic for all of the seven NTDs that are included for integrated PCT 
(IPCT) under the USAID program and the majority of the country is in endemic for two or more NTDs 
with overlapping distributions. The current MoH Master Plan for the control NTDs 2011-15 (unpublished 
data, 2012) describes the STH infections as being the most widespread of the NTDs in Uganda. It states 
that the STH are endemic in all 112 districts with approximately 33.2 million, of a national population of 
33.4 million, at risk of infection and goes on to report that; lymphatic filariasis is the second most widely 
spread infection in Uganda with 50% of the country’s districts endemic and an estimated 14.5 million at 
risk of infection; approximately 10.8 million children and adults are at-risk of trachoma infection in 35 of 
the country’s districts; schistosomiasis is endemic in 63 districts and 5.2 million are at-risk of infection; 
and lastly, onchocerciasis  is endemic in 37 of the 112 districts with approximately 4.2 million individuals 
at-risk.  
 
The Ugandan MoH’s NTDCP was launched in July 2007. Prior to this date there were the successful SA 
national control programmes described in detail above but which, in summary, focused on annual 
chemotherapy for onchocerciasis, schistosomiasis and the STH and an intermittent lymphatic filariasis 
programme (Table 1.5) Although trachoma control activities were being carried out, for example, water 
and sanitation and trichiasis surgeries, these were not widespread and no chemotherapy was being 
implemented.   
 
Central (National) Level: The Uganda NTDCP is managed at the central level by the MoH’s VCD, part of 
the Community Health Department, in Kampala (Figure 1.1) with financial and technical support from 
RTI. As well as being the prime contractor for the USAID funding, in Uganda RTI was the selected 
implementing partner and NTD control was added to its existing in-country portfolio which included 
indoor residual spraying for mosquitoes, school health and reading programmes and improving 
HIV/AIDS services. RTI employed a Country Programme Manager for the NTDCP as well as two support 
Accountants, a Logistician, a Monitoring and Evaluation manager and a Secretary. The NTDCP staff were 
originally located in the RTI Country Offices then, following several renovations, the team moved into 
the VCD compound. The NTDCP Country Programme Manager was part of, and collaborated with, the 
NTD Secretariat which comprised of each MoH NTD SA Programme Manager i.e. for the BWCP, NOCP, 
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PELF and NTTF, and usually one additional member of each of their teams and was headed by the 
Assistant Commissioner of the Vector Control at the central MoH. The role of the NTD Secretariat was to 
liaise with all the NTD stakeholders within the MoH, other government departments, the District Health 
Offices, partner NGOs, implementing agencies and other partners such as WHO and UNICEF, with the 
specific responsibilities: 
 
 National advocacy and capacity building 
 Planning and implementation of all IPCT activities (Appendix Ia) with the NTDCP Country 
Programme Manager Coordinator 
 Planning and implementation of Monitoring and Evaluation will all relevant partners 
 Management of MoH personnel  
 Development of guidelines and tools for IPCT activities  
 Preparation and submission of drug donation applications for the each treatment round 
 Supervision of all national and district IPCT activities 
 In partnership with the NTDCP Country Programme Manager preparation of: (i) semi-annual 
NTDCP reports which review implementation activities, programme coverage, drug summaries, 
financial expenditure and monitoring and evaluation analysis and results; (ii) annual work and 
budgets 
 
The NTDCP Country Programme Manager coordinated all the IPCT activities and held the overall 
responsibility of communication between all partners. The roles of NTDCP Country Programme 
Manager, with his support personnel, were: 
 Liaison with all partner institutions i.e. MoH, RTI, SCI, WHO, the Carter Centre and others 
 Management of the NTD support personnel  
 Procurement of drugs, supplies and coordination of logistics in liaison with the NTD Secretariat 
 Timely disbursement of funds and as budgeted 
 In partnership with the NTD Secretariat, participation in the planning, implementation, and 
monitoring and evaluation of the programme. 
 Responsible for the development, finalisation and dissemination of the (i) semi-annual NTDCP 
reports which reviews implementation activities, programme coverage, drug summaries, 
financial expenditure and monitoring and evaluation analysis and results; (ii) annual work and 
budget 
 
 
District Level: Uganda has a decentralised health system and therefore the NTDCP worked directly with 
each of the District Health Offices to plan and budget for their control programme activities (Figure 1.1). 
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The District played a central role in the NTDCP for which it served as the anchor for sustainable planning 
and implementation. The District Health Office typically assigned the following staff to NTDCP activities: 
District Health Officer (DHO), DVCO, District Education Officer (DEO), District Inspector of Schools, 
District Community Development Officer and heads of health sub-districts, for which they were 
responsible for:  
 
 Coordination of district planning, advocacy, mobilisation and health education, activities 
 Management and disbursement of NTDCP funds sent to district 
 Training of supervisors and teachers and supervision of CDD training 
 Coordinating the receiving and distribution of drugs from the NTDCP Country Programme 
Manager 
 Supervision of drug distribution in schools and communities 
 Receiving reports from, and providing feedback to, the communities, schools and health 
facilities within the District 
 Compilation of district reports and forwarding to the NTD Secretariat 
 Pooling of additional resources to support IPCT implementation  
 
Community Level: In each district, the responsibility for the programme activities was cascaded to 
implementing teams at the health sub-district, sub-county, parish, community and school levels, (see 
Figure 1.1). Staff involved in NTDCP activities at the health centres (HC) levels II and III e.g. In-charge of 
HC or Health Assistants, maintained and strengthened the links and support provided to local schools 
and communities. HC II and III were the base for these Supervisors who carried out the following 
responsibilities:  
 
 Community mobilisation and sensitisation 
 Training the CDDs 
 Health education and promotion to enhance compliance and coverage 
 Support to teachers and CDDS in the treatment of SAC and communities 
 Accountability of drugs and returning unused drugs to the District Health Office 
 Provision of treatment reports to the District Health Office 
 Epidemiological surveillance 
 Participation in pharmacovigilance and treatment of Serious Adverse Events  
 
The school was main centre for the treatment of enrolled SAC. The head teacher and all the NTDCP 
trained teachers managed implementation at their school and were responsible for: 
 Community mobilization and sensitization through Parent Teacher Association and School 
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Management Committees.  
 Health education and promotion of personal and environmental hygiene 
 Treatment of enrolled SAC, according to eligibility, with IPCT drug package (Table 1.6) 
 Accountability of drug use and returning unused drugs to their Supervisor 
 Compilation of treatment and drug accountability reports and provide these data to the 
Supervisor 
 Monitor for any post-treatment side-effects and referrals to HC 
 
NTDCP activities in the community were coordinated by the Supervisors in collaboration with the CDDs 
as part of the VHT. The Supervisors ensured that the activities were carried out according to the 
programme requirements. In addition, a nominated individual (often the Local Council Chairman at 
parish level), known as the Parish Supervisor, presided over the VHT and liaised with the Supervisors and 
the local schools. The CDDs had the following responsibilities:  
 Widespread community mobilization and sensitization  
 Registration of all residents in the community 
 Selection of the distribution method and/or distribution points within the community 
 Collection of drugs from the nearest health unit 
 Proper storage of the drugs 
 Treatment of the community members, according to eligibility, with IPCT drug package (Table 
1.6) 
 Monitoring for any post-treatment side-effects and referrals to HC 
 Compilation of treatment and drug accountability reports and provision of these data to the 
Supervisor 
 Returning drug balances and registers to the nearest health facility after MDA  
 
Ugandan NTDCP Activities 
The activities required to implement the Ugandan NTDCP and to what level they were integrated 
between the previously SA disease-specific programmes are described in Appendix Ia. In addition, Figure 
1.1 gives an illustration of each NTDCP implementation level in the backdrop of the overall Health 
Services in Uganda.   
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Of the 81 districts that were originally to be targeted by the programme, the first rounds of treatment 
were completed in 28 districts in November 2007 to January 2008 and 19 districts in May to June 2008. 
Scale-up continued through 2008/9 (61 districts), 2009/10 (72 districts) and 2010/11 (83 districts). The 
map below (Figure 1.2) shows the end of strategy for IPCT. The strategy is based on the mapping of 
disease distributions and illustrates the package of PCT drugs required, based on the WHO Algorithm for 
PCT [53] (see Appendix Ib), for each targeted district when full scale-up of treatment has been reached 
by the Ugandan NTDCP.  
 
 
  
Page | 58  
 
 
Figure 1.2: Districts targeted for IPCT by the Uganda NTDCP by drug package**  
Map retrieved from http://ntd.rti.org on 18 September 2012 
* Treatment drug names in full; PZQ = praziquantel for schistosomiasis; IVM = ivermectin for lymphatic filariasis 
and onchocerciasis; ALB/MEB = albendazole or mebendazole for STH and lymphatic filariasis; Zithro/Tetra = 
azithromycin and/or tetracycline for trachoma) 
** The maps are based on information provided to the USAID NTD Control Program and changes from ongoing 
work may apply. The boundaries are approximate. Boundaries are meant to represent programme activity and are 
not necessarily true political boundaries.  
Uganda 
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Non-NTDCP control activities in Uganda for the NTDs 
In addition to the NTDCP there were several control activities carried out in Uganda that go beyond the 
scope of the programme and were implemented by programmes and organisations which have a long 
history of partnering with the VCD. In summary: 
APOC: continued support of REMO to refine maps in some onchocerciasis endemic foci. APOC and WHO 
also provided additional funds for advocacy in districts for sustainability, operational research and 
support supervision, in particular Pader and Kitgum districts1, where cases of blindness due to 
onchocerciasis were reported.     
CWW: donated approximately six million tablets of MEB to be used during Child Days Plus and for 
routine deworming in 51 districts.  
Child Days Plus strategy: a package of health interventions aimed to combat child and maternal health 
and including, vitamin A supplementation, deworming of one to 14 year olds and immunisations 
amongst others. The Child Health Days were initiated in 1998 as partnership between MoH, WHO and 
UNICEF for vitamin A supplementation and polio immunizations. They were renamed Child Days Plus 
(CDP) in 2004 when schistosomiasis control was added to the package and in 2008 all NTDCP were 
scheduled to be co-implemented in the CDP months of April and November thereafter.   
SCI: support the BWCP to conduct treatment for schistosomiasis in schools in districts which fall below 
the prevalence threshold (≤ 20%) for which the NTDCP implements mass treatment. In addition they 
have continued conducting operational research on NTDs and their control in Uganda.   
Sightsavers: were involved in the SAFE strategy elimination of blinding trachoma in Uganda. They 
continued to support TT surgeries and health education in many trachoma endemic districts in eastern, 
northern and western regions. They contributed towards advocacy, Information, Education and 
Communication (IEC) campaigns and MDA in hyper and mesoendemic communities.  
The Carter Centre: In districts where the Carter Centre onchocerciasis elimination activities were being 
rolled out and the NTDCP was also in operation, treatment by each programme was rolled out 
separately, but resources were combined to conduct joint training, health education and community 
mobilisation. The rationale for this was that the Carter Centre with VCD had made significant progress 
towards elimination of onchocerciasis in several foci with a combined strategy of biannual treatment 
and vector control such as ground larviciding. Integrated NTDCP registers were being used in these 
                                                          
1Pader and Kitgum districts were occupied by the Lord’s Resistance Army rebels up until 2007 and had not previously been 
treated for NTDs under a mass treatment programme.  
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areas. The Carter Centre provided additional funds for advocacy workshops in Pader and Kitgum1 
districts.     
UNICEF: was a major source of funds and materials for CDP. During 2011 they provided funds for 
Vitamin A supplementation, microplanning, training and support supervision, IEC campaign including 
posters, talk shows, jingles, radio spots and tools for CDP implementation.  
World Food Programme: supported school feeding programmes in eight districts and supplemented 
ALB to these districts to cover requirements for at least one or both of the semi-annual treatments.  
World Vision: In 2011 World Vision were expected to provide MEB to districts which were not fully 
covered by NTDCP or other partners.    
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Study Districts  
The following are descriptions of the thirteen originally selected study districts from where I collected 
data for inclusion in this thesis. 
 
Buliisa district 
Separated from Masindi district in 2006, Buliisa is in the western region of Uganda where it borders the 
Democratic Republic of Congo separated only by Lake Albert. It lies at an altitude of 621 to 1158 meters 
above sea level in a savannah climatic zone. The 2010 population projection2  was 80,783of which the 
majority belong to the Banyoro tribe and speak Runyoro. The main economic activities are food crops 
(maize, millet, beans), cash crops (tobacco, coffee, cotton) and fishing. There are two sub-counties in the 
district and between them there are seven HC II, one HC III and one HC IV serving the district.  
 
Busia district 
Busia district was created in 1997 and lies on the Eastern border of Uganda neighbouring the Republic of 
Kenya and on the shores of Lake Victoria. Rainfall is relatively high at the shore but declines inland. The 
2010 population projection2 was 278,191 of which the majority are of the Basamia and speak Lusamia-
Lugwe. The main economic activities are food crops (maize, cassava, rice), cash crops (ginger, cotton, 
sunflower) and industries include oil milling, cotton ginning and flour milling. There are 10 sub-counties 
in the district and between them there are 16 HC II, eight HC III and two HC IV and one hospital (HC V) 
serving the district.  
 
Dokolo district 
Until 2006 Dokolo district was a county of Lira district. It lies in the northern region of the country and 
experiences moderate rainfall accompanied with high temperatures. The 2010 population projection2 
was 176,284 of which the majority are the Langi people who speak Luo and Lango. The main economic 
activities are food crops (cassava, millet, maize), and vegetables (tomatoes, onions, cabbage) and the 
main industries include oil and grain milling, cotton ginning and milk processing. There are five sub-
counties in the district and between them there are 10 HC II, four HC III and one HC IV serving the 
district.  
 
                                                          
22002 national census 
Page | 62  
 
Kamuli district 
In 1974, Kamuli was part of the North Busoga Province and became its own district in 1980. It is part of 
the eastern region of Uganda and lies at an altitude of 914 to 1,101 meters above sea level with heavy 
rainfall and moderate temperatures. Vegetation in the district is woodland, thickets and bushes. The 
2010 population projection2 was 600,233 of which the majority speak Lusoga but are made up on many 
different tribes including the Basoga, Bakenyi and Iteso. The main economic activities are food crops 
(soya beans, maize and sorghum), cash crops (cotton, coffee and sugar cane) and industries include brick 
making and maize milling. There are 18 sub-counties in the district and between them there are 52 HC II, 
14 HC III and three HC IV and two hospitals (HC V) serving the district.  
 
Katakwi district 
Katakwi district was created in 1997 and lies in the north-east of Uganda on the northern plateau. It is 
characterised by extensive flat plains with grassland savannah with low rainfall. The 2010 population 
projection2 was 163,000 of which the majority are of the Iteso, Bakenyi and Acholi tribes with the main 
language being Ateso. The main economic activities are food crops (millet, sorghum, groundnuts), cash 
crop (cotton) and industries include flour milling, cotton ginning and woodwork. There are nine sub-
counties in the district and between them there are 13 HC II, seven HC III and one HC IV serving the 
district.  
 
Kibaale district 
Kibaale district was traditionally part of the Bunyoro Kingdom until the abolition of kingdoms in 1967 
and was later separated from Hoima district in 1991. It lies on the western edge of Uganda and at the 
south-eastern tip of Lake Albert. The land is savannah and receives moderately low rainfall and high 
temperatures. The 2010 population projection2 was 586,400 of which the majority are of the Banyoro 
and the Batooro with both respective languages spoken. The main economic activities are food crops 
(rice, maize and sweet potato), cash crops (coffee, cotton, tea and tobacco). There are 19 sub-counties 
in the district and between them there are 25 HC II, 22 HC III, six HC IV and one hospital (HC V) serving 
the district.  
 
Kitgum district 
Originally part of Acholi district, Kitgum district was created in 1980 and lies on the Northern border of 
Uganda neighbouring the Republic of South Sudan. It lies at an altitude of between 351 to 1,341 meters 
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above sea level and frequently experiences temperatures of over 25⁰C. The 2010 population projection 
was 364,7002 of which the majority are of the Acholi and speak Luo and Acholi. The main economic 
activities are food crops (millet, sorghum, maize), cash crops (cotton, sugar cane and sesame) and cattle 
keeping. Industries include grain milling and cotton ginning. There are 18 sub-counties in the district and 
between them there are 21 HC II, 16 HC III, three HC IV and two hospitals (HC V) serving the district.  
 
Kotido district 
Kotido is part of the Karamoja region of the country in the north-east and was created in 1980. It lies 
between 1,219 and 1,524 meters above sea level with arid land resulting from very high temperatures (> 
30⁰C) and minimal rainfall. The 2010 population projection2 was 188,100 of which the majority are of 
the Karamojong and speak Ng’akarimojong. The main economic activities are cattle rearing under 
pastoralism and food crops (sorghum, maize, millet). Industry tends to be grain milling. There are six 
sub-counties in the district and between them there are 11 HC II, seven HCIII and one HC IV serving the 
district.  
 
Kyenjojo district 
Kyenjojo district in the Western region of the country was carved out of Kabarole district in 2000. It lies 
at an approximate altitude of 1,585 and 3,962 meters above sea level and is subject to moderate rainfall 
and temperatures (19⁰C). The predominant languages in the district are Rutooro and Rukiga which are 
spoken by the estimated 20,000 population (2010 projection2). Agriculture is the main economic activity, 
particularly food crops (sweet potatoes, maize and bananas), cash crops (coffee and tea) and fruits and 
vegetables (pineapples and tomatoes). There are two counties in the district comprised of 13 sub-
counties and one town council which are served by 11 HC II, 13 HC III and three HC IV.  
 
Mayuge district 
Mayuge district was formerly part of Iganga district and was annexed in 2000. It is part of the Busoga 
Kingdom in eastern Uganda and lies along the shore of Lake Victoria. Both rainfall and temperatures are 
high resulting in thick tropical rain forest. The 2010 population projection2 was 407,300 of which the 
majority are Basoga and speak Lusoga. Fishing is the largest economic activity in the district but food 
and cash crops are also undertaken in addition to coffee processing, brick making and the milling of rice 
and cotton. The population are served by 16 HC II, three HC III, two HC IV with the nearest government 
hospital HC V being located in neighbouring Iganga district. 
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Namutumba district 
Namutumba district was created in 2006 from Iganga district. Rainfall is relatively high, temperatures 
are warm and the vegetation is in places swampy and in others tropical rain forest. The 2010 population 
projection2 was 198,586 of which the majority are of the Busoga and speak Lusoga. The main economic 
activities are food crops (sorghum, rice, bananas). There are six sub-counties in the district and between 
them there are 29 HC II, five HC III and one HC IV serving the district.  
 
Pallisa district 
Formerly part of Tororo, Pallisa district was created in 1991 and lies on the eastern region of Uganda. It 
experiences a moderate equatorial climate and lies at 1,097 to 1,219 meters above sea level. The 2010 
population projection2 was 487,100 of which the majority are Bagwere and Iteso and speak Lugwere and 
Ateso. The main economic activities are food crops (millet, cassava, rice), cash crop (cotton) and 
industries include manufacturing of food products, beverages and textiles. There are 13 sub-counties in 
the district and between them there are 17 HC II, 22 HC III, two HCIV and two hospitals (HC V) serving 
the district.  
 
Yumbe district 
Yumbe district was created in 2000 from Arua district and lies in the far north-western corner of Uganda 
neighbouring the Republic of South Sudan. It experiences high temperatures and a moderate equatorial 
climate. The 2010 population projection2 was 423,100 of which there are a variety of tribes (Alur, 
Lugubara, Kakwa and Madi) which speak their respective languages. The main economic activities are 
food crops (beans, maize, cassava), cash crop (tobacco) and industries include craft making, tobacco 
curing and small-scale brick-making. There are eight sub-counties in the district and between them there 
are 12 HC II, eight HC III and one HC IV and one hospital (HC V) serving the district.  
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Chapter 2. Thesis Outline 
 
Aims and Objectives  
The aim of this thesis was to evaluate the new integrated health intervention strategy for the control of 
NTDs in Uganda and the cost, effectiveness and sustainability, in terms of community level participation, 
of the programme were determined.  
The specific objectives were to: 
 Provide a background for past and present global control and elimination efforts towards the 
NTDs and to describe Uganda, its infrastructure, its history in NTD control and to introduce its 
current strategy of integrated NTD control. 
 Estimate the annual overall programme financial and economic costs, costs per person treated, 
and intra-country variation of the integrated NTDCP and determine what influenced these costs 
and the effects of scaling up. 
 Define the key cost drivers in determining cost savings between SA and IPCT, the differences in 
cost per person treated between these strategies and to elucidate whether efficiencies are 
achieved by changing from SA to IPCT for NTD control. 
 Calculate DALYs averted and determine the incremental cost-effectiveness ratio (ICER) between 
SA and integrated strategies in terms of cost per DALY averted.  
 Create a novel approach to collect prospective data on daily activities of the CDDs involved in 
the Ugandan NTDCP. 
 Determine the role, the work burden and performance of the CDD in integrated NTD control, 
including how involvement in the NTDCP activities had an effect on their time and livelihoods 
and assigning values to this time. 
 Discuss the implications of the findings with respect to NTD control and elimination, the 
limitations of the work presented and how further suggested work. 
 
The results produced will provide implementation and policy guidelines for current and future 
integrated disease control strategies in Uganda, sub-Saharan Africa as a whole and indeed with potential 
uptake of lessons learned in the international NTD arena and beyond to other integrated strategies for 
improving health.  
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All ideas presented within this thesis were formulated by the candidate under the guidance of Professor 
Joanne Webster (Imperial College London), Dr Kristian Schultz Hansen (London School of Hygiene and 
Tropical Medicine) and Dr Fred Matovu (Makerere University, Kampala). I declare that the work 
conducted and presented in this thesis is that of my own except where I have acknowledged the work of 
others when relevant. In summary: 
Chapter 1: The literature review and all background information searches were conducted solely by the 
candidate. 
Chapter 3: The study was conceived and designed by the candidate. The literature review was 
performed by the candidate. The development of the study costing tools was done by partners at Emory 
University, Atlanta and the Taskforce for Global Health, Atlanta as well as the candidate and colleagues 
at SCI, as part of a wider multi-country study assessing the costs of integrated NTD packages. The data 
collection was conducted primarily by the candidate with some assistance from Dr Fred Matovu, 
Makerere University Kampala (MUK). All data entry, data management, statistical analysis and 
interpretation were conducted solely by the candidate and to which her supervisors provided comments 
on the candidate’s drafts in the writing up process.  
Chapter 4: The study was conceived and designed and the literature reviewed by the candidate. The 
cost data for the NTDCP was that described and used in Chapter 3. The collection of cost data for the 
BWCP in Uganda was designed by Dr Simon Brooker, London School of Hygiene and Tropical Medicine 
and the actual data collected by the candidate, Dr Brooker and Dr Narcis Kabatereine, VCD, Uganda. The 
data were entered and managed by the candidate and for the purposes of this thesis the dataset was 
reanalysed and interpreted by the candidate. The collection of cost data for the PELF in Uganda was 
designed, collected, entered, managed, analysed and interpreted by the candidate. The cost data for the 
NOCP in Uganda was designed, collected, entered and managed by Dr Deborah McFarland and Nicholas 
Menzies, Emory University. The original dataset was reanalysed and interpreted by the candidate for 
this study. 
The epidemiological health impact study, for which data were used to calculate DALYs in this chapter, 
was conceived by the candidate and who led the design with input from colleagues from the SCI and the 
Department of Infectious Disease Epidemiology, Imperial College London, most specifically Professor 
Joanne Webster, Dr Tom Churcher and Dr Maria-Gloria Basáñez and for the sample size calculations Dr 
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Artemis Koukounari, Professor Christl Donnelly and Professor Webster. The tools for data collection 
were designed by the candidate and the data collection was conducted by the candidate with Dr Edridah 
M Tukahebwa and a team of technicians from VCD, Uganda. Data were entered at VCD, managed by the 
candidate and then statistically analysed first by Dr Ben Styles, biostatistician at SCI and then by his 
replacement Dr Sarah Knowles. The data analysis was interpreted by the candidate. 
 The statistical analysis of the cost data and calculation of DALYs in the chapter were conducted and 
interpreted by the candidate and the writing up was carried out by the candidate with comments on 
drafts of the chapter by her supervisors. Dr Charles King (Case Western Reserve University, Ohio) 
reviewed and provided comments on the DALY calculations.  
Chapter 5: The study was conceived and designed and the literature reviewed by the candidate. The 
pictorial diaries were designed by the candidate with assistance from two artists in Uganda and Dr Fred 
Matovu. The tools for semi-structured interviews and guides for the focus group discussions (FGDs) 
were developed by the candidate with comments from Dr Matovu and, following pre-testing, from the 
four research assistants from MUK, Joan Gabula, Nicholas Muhofa, Tinah Nassali and Geoffrey Orijabo, 
whom also assisted the candidate in conducting the data collection. The data were entered by data 
entry staff at VCD, and by the candidate, and all data were managed, statistically analysed and 
interpreted by the candidate. The writing up of the results was performed by the candidate with input 
from her supervisors. 
Chapter 6: The final discussion chapter was developed and written solely by the candidate and reviewed 
by her supervisors.  
 
All work presented in this thesis was funded by a Bill and Melinda Gates Foundation grant to the SCI to 
evaluate integrated NTD control in four sub-Saharan African countries.  
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Chapter 3. Costing of the NTDCP in Uganda: is 
integrated preventive chemotherapy really as 
affordable as US$0.50 per person? 
 
 
Abstract  
Background: The predicted costs and savings of IPCT programmes for NTDs, over that achieved by SA 
programmes, has been proposed by a number of prior studies but rarely assessed. Here, using empirical 
data gathered from the Ugandan integrated NTDCP from its inception and first three years, we evaluate, 
the (i) annual overall programme financial and economic costs, (ii) costs per person treated, (iii) and 
intra-country variation. 
 
Methodology/Principal Findings: To obtain annual (i – iii) costs, a combination of prospective and 
retrospective data were collected at central, district and community levels of programme 
implementation in twelve districts. Over the programme years a total of 6,571,222 individuals received 
IPCT through the NTDCP. Overall cost per person treated for any combination of NTD were, financial 
(excluding purchased drugs) US$0.17 (US$0.06 – US$0.70); economic (excluding purchased and donated 
drugs) US$0.65 (US$0.22 – US$2.58) and full economic cost per person (including value of all drugs) 
US$12.06 (US$0.58 - US$30.97). Financial cost per person treated by district was highly sensitive to total 
number of individuals treated (Spearman’s rho: -0.82, p<0.001). This correlation was not observed for 
economic or full economic cost per person treated. As the number of drug deliveries borne by a drug 
distributor over a MDA campaign increased the financial cost per person decreased (p=0.02), however 
the converse was observed with full economic cost per person treated, which increased with the 
number of deliveries (p<0.001). This was attributable to the increasing amount of human resources 
required with increased number of treatment deliveries by a drug distributor. 
 
Conclusions: The current analysis is the first to document the cost of an integrated NTD control 
programme using all four PCT drugs and seven PCT diseases. It reports on the existence of economies 
and diseconomies of scale and the intra-country variation in financial and economic costs and cost per 
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person treated. Although a programme may be deemed affordable and cost <US$0.50 per person 
treated annually it must also be achieving its ultimate purpose, in the case of the NTDs to treat above 75 
percent of all eligible populations to control or eliminate the disease. This study highlights that when the 
number of treatment deliveries carried out during and MDA campaign is increased, the economic costs 
are greater and ultimate therapeutic coverage is not attained. This is suggestive of diseconomies of 
scope, whereby adding more treatments to the community distribution system results in less efficient 
treatment.  
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Introduction  
Recent public health strategy developments for the control of NTDs have aimed to minimise 
inefficiencies, and improve the overall health of those treated, by creating health packages which 
integrate the control efforts between the SA programmes for NTD control [13,14,161]. An integrated 
strategy for control has been supported by the WHO [11,53,204], donor and multilateral organisations 
[13,14,20,205,206]. The seven NTDs which are ‘tool ready’ for large-scale control efforts 
(schistosomiasis, lymphatic filariasis, ascariasis, hookworm infection, trichuriasis, onchocerciasis and 
trachoma), can be treated using as few as four safe, effective, available and largely donated drugs, that 
of PZQ, IVM, ALB and ZIT. Integrated strategies use the MDA of the four drugs as a PCT intervention in 
the control of these seven NTDs. Therefore, in theory, integrated programmes are coordinated whereby 
individuals with single, and especially those with multiple infections, will receive the necessary 
treatments at the appropriate times, frequencies and dose that maximise health impact, minimise side-
effects, and optimises the use of resources in constrained settings.   
 
Taking into account the low costs for treating the NTDs [144-146,149,150]; the long-term commitment 
from pharmaceutical companies to provide donated drugs; the synergising of delivery approaches; and 
the contribution of time by community ‘volunteers’ [168], it was previously projected that integrated 
NTD programmes in sub-Saharan Africa could be delivered between US$0.46 – US$0.79 per person 
treated [10,166,207]. In addition emphatic international advocacy and fundraising campaigns have been 
promoting integrated treatment of NTDs for ‘50 cents’ (US$) or 50p (GBP£) for example End7 
(www.End7.org) and the ‘50p Life Change Appeal’ (http://www.50pence.org). Recent published 
literature has shown that cost-analysis on the co-implementation of ALB and DEC over one programme 
year in Haiti had an average of US$0.64 economic cost per person when including drugs and US$0.42 
per person when excluding them [208]. A second study, carried out in Nigeria over a two year period 
which assessed the change in costs prior to and during integration, reported a US$0.10 financial delivery 
cost per person for triple drug administration (TDA) of IVM, ALB and PZQ [209].  
 
The current study was conducted in Uganda where the MoH’s NTDCP to treat the seven PCT diseases 
was launched in December 2007 with financial support from the USAID NTD Control Program. The 
majority of the country is in endemic for two or more NTDs with overlapping distributions. Prior to 2007 
there were established and successful national control programmes which focused on annual 
chemotherapy for onchocerciasis, schistosomiasis and the STH and an intermittent lymphatic filariasis 
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programme which have been described in Chapter 1. Although trachoma control activities were being 
carried out, for example, improved water and sanitation and trichiasis surgeries these were not 
widespread and no MDA was being implemented [210]. The study reported is unique because it covers 
the first three annual treatment rounds of the integrated control programme for the seven PCT NTDs in 
Uganda, and the different packages rolled out dependent on the underlying endemicity. This study will 
increase the empirical evidence of integrated programme costs and demonstrate the affordability of the 
strategy. The specific aims of this study were to determine (i) the overall financial and economic annual 
costs of running the integrated NTDCP (ii) the average costs per person treated, (iii) intra-country 
variation in costs, with further cost-analysis on (iv) the main determinants of average costs and  (v) the 
effects of scaling up on costs and cost per person. Finally this study hoped to determine whether in 
reality an integrated programme for NTD control could cost as little as US$0.50 per person and would 
thus be affordable for governments to choose when allocating their scarce resources and for donors as 
they choose between competing health interventions.  
 
Materials and Methods 
Study Sites and Treatment History 
The MoH in Uganda estimates that there approximately 14.5 million individuals infected with two or 
more of the seven PCT NTDs in Uganda. The district is the main implementing unit of the Ugandan 
NTDCP and thus a key source of programme cost data. Stratified sampling of districts was carried out 
based on factors believed to be influential on costs, for instance those that would vary across districts, 
these were: the number of drug delivery rounds borne by a drug distributor in order to distribute the 
drugs in an NTD package (the different combinations of IVM, ALB, PZQ and ZIT to be distributed in a 
district) during the MDA period and; the distance of the district centre from Kampala, specifically 
whether a journey delivering items to the district centre would require an overnight stay or not by 
central level staff. Thirteen districts, out of 47 districts that were originally planned for treatment in the 
first year, were randomly selected to participate in the study (Figure 3.1). In the strata that required 3 
deliveries there were four districts randomly selected, for 2 deliveries five districts were randomly  
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Figure 3.1: The thirteen study districts showing number of drug delivery rounds borne by a drug distributor during 
an MDA campaign in each (as known at time of district selection), under the integrated NTDCP in Uganda. 
 
In each district, above 88% of the population live in rural, subsistence agriculture settings and 
population size ranged from 80,753 to 586,400 (population projection for 2010 from 2002 national 
census). Each of these districts varied in epidemiological characteristics and endemicity of the seven PCT 
diseases (Table 3.1), hence the different drug packages required. Nevertheless, all had prevalence of 
disease above the threshold for mass treatment, according to WHO guidelines [53]. During the study 
one district, Buliisa, was excluded from the study as is discussed in the Results section. 
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District Population* 
Distance 
from 
Kampala 
(km) 
Endemic PCT 
Diseases ** 
>MDA threshold 
SA 
Treatment 
Pre-2007† 
IPCT†† Drug 
Packageⱡ  
Buliisa 80,783 284 
Oncho,  
SCH, STH,  
Trachoma 
Yes 
Yes 
No 
PZQ+ALB; IVM 
Busia 278,191 208 SCH, STH Yes PZQ+ALB 
Dokolo 176,284 408 
LF, STH 
SCH 
Trachoma 
Yes 
Yes 
No 
IVM+ALB; PZQ 
Kamuli 600,233 138 
LF, STH 
SCH 
Trachoma 
Yes 
Yes 
No 
IVM+ALB; PZQ; ZIT 
Katakwi 163,000 410 LF, STH Yes IVM+ALB 
Kibaale 586,400 224 Oncho SCH, STH 
Yes 
Yes PZQ+ALB; IVM 
Kitgum 364,700 453 
LF, STH 
Oncho 
SCH 
Trachoma 
No 
No 
No 
No 
IVM+ALB; PZQ; ZIT 
Kotido 188,100 711 LF, STH Trachoma 
Yes 
No IVM+ALB; ZIT 
Kyenjojo 468,100 250 Oncho STH 
Yes 
No IVM 
Mayuge 416,089 146 
LF, STH 
SCH 
Trachoma 
No, Yes 
Yes 
No 
IVM+ALB; PZQ; ZIT 
Namutumba 198,586 152 LF, STH Trachoma 
No 
No IVM+ALB; ZIT 
Pallisa 487,100 301 LF, STH No IVM+ALB 
Yumbe 423,100 593 
LF, STH 
SCH 
Oncho 
Trachoma 
No, Yes 
Yes 
Yes 
No 
IVM+ALB; PZQ; ZIT 
Table 3.1: Description of study districts, endemic NTDs, treatment history and IPCT drug package 
*Population projection for 2010 from 2002 national census  
**Disease names in full; Oncho = Onchocerciasis, SCH = Schistosomiasis, STH = Soil Transmitted Helminthiasis, LF = 
Lymphatic Filariasis 
†at least one year of SA MDA received 
††Treatment drug names in full; PZQ = praziquantel for schistosomiasis; IVM = ivermectin for lymphatic filariasis 
and onchocerciasis; ALB = albendazole for soil-transmitted helminthiasis and lymphatic filariasis; ZIT = azithromycin 
for trachoma 
ⱡIPCT drug package rolled out in NTDCP Year One (Oct 2006 – Sept 2007) and Year Two (Oct 2007 – Sept 2008) 
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All districts had received at least one round of MDA as a SA programme, prior to 2007, for at least one of 
the PCT diseases, except for Kitgum district (Table 3.1). Kitgum district, in the Northern Region was one  
 of three Acholi districts that were occupied by the Lords Resistance Army rebels for approximately 20 
years until 2006. Travel to the districts carried high risks and the population largely lived in internally 
displaced peoples camps, thus no SA control programmes were functioning in the region. Under IPCT 
the same drugs and dose (details of dose can be found in this chapter in section (5) under ‘Costing’) 
were applied to those given during the SA programmes but where diseases which used the same drugs 
overlapped i.e. lymphatic filariasis and onchocerciasis, only one delivery or round of treatment with IVM 
was given. Where lymphatic filariasis and schistosomiasis distributions overlapped, ALB for the 
treatment of the STH was only given with the IVM. There had been no previous mass treatment for 
trachoma control in Uganda, however the disease was treated during the integrated strategy with ZIT. 
 
Control Programme  
The Ugandan NTDCP was implemented in 2007 through RTI International in collaboration with the VCD 
of the MoH in Kampala, with the aim to provide anthelmintic and antibiotic treatment to schools and 
communities at risk of morbidity due to the seven endemic PCT diseases. As described more fully in 
Appendix Ia, the programme comprised of the following activities:  
(i) central programme running and administration,  
(ii) advocacy about the NTDs and the NTDCP treatment activities and successes,  
(iii) prevalence mapping and assessment of the NTDs,  
(iv) health education and mobilisation in schools and the community,  
(v) cascaded training of district officials, health-workers supervisors, teachers and CDDs.  
(vi) registration of eligible population in communities and schools,  
(vii) delivery and mass distribution of drugs through community-based and school-based 
systems in targeted areas,  
(viii) data management and programme/therapeutic coverage reporting,  
(ix) monitoring and evaluation of the programme and  
(x) planning and budgeting of the programme for subsequent years.  
 
Treatment in schools was carried out by teachers and in communities by CDDs. The RTI Country 
Programme Manager for the NTDCP, the MoH NTD Secretariat and VCD headquarters staff had overall 
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responsibility for the programme and regularly visited districts to monitor progress. Implementation of 
the programme at the district level was undertaken by District Health Office but specifically the DVCOs 
or in newly appointed districts, where such a post often has not been created, an NTD focal point person 
was involved.  
 
To advocate for political engagement and increase awareness, an initial stakeholders workshop was held 
in Kampala in November 2006, followed by a series of workshops held in each district before 
programme activities began in October and November 2007. The programme was officially launched by 
the MoH in December 2007. Mass treatment began in October 2007, taking place in 28 districts 
targeting 5,704,589 people. Subsequently, two mass treatment campaigns were held a year to coincide 
with the national Child Days Plus strategy. In each district, training workshops provided health worker 
supervisors, teachers and CDDs with a basic understanding of each NTD endemic in the district and how 
to complete record forms, measure individuals using the appropriate dose poles and to safely 
administer tablets. The design of training and number of participants varied between districts. Health 
education messages were delivered through posters, booklets and radio. All IEC material was translated 
into several main local languages. Imported drugs were cleared at Entebbe airport by the Uganda 
National Medical Stores, who then, initially, transported them to VCD headquarters for distribution. In 
2008, due to the volume of drugs and to reduce the risk of theft or damage, the drugs were distributed 
directly from, and by, the Uganda National Medical Stores to the district medical stores. Drug 
registration and treatment included compiling community census information and school enrolment 
data to determine the target population and drug needs. The number of tablets provided to each 
community and school was calculated on the basis of treatment registers completed by CDDs and head 
teachers. The drugs were delivered to each health unit by the DVCOs and were then collected by CDDs 
and an NTD trained teacher from schools before each treatment round. Depending on the treatment 
package in a district, drugs were delivered in separate rounds. For example, in a district where lymphatic 
filariasis, STH and schistosomiasis are endemic the treatment package would be IVM, ALB and PZQ and 
the treatment rounds of the package would be IVM and ALB given simultaneously, followed two weeks 
later by PZQ, therefore two delivery rounds. Treatment was administered in communities by the CDDs 
and in schools by the teachers, under the supervision of the head teachers and community health 
workers and in some localities by district and/or national staff. Distribution in schools was done by class, 
whereas, within communities CDDs distributed from a central point (health unit, school, trading centre), 
carried the drugs door-to-door or used a combination of both, first treating from a central point and 
Page | 77  
 
then ‘mopping up’ those not treated on the register by going door-to-door. The distribution mechanism 
used by the CDDs was dependent on what platform for MDA they had historically used i.e. that of door 
to door for treatment of lymphatic filariasis, or from a central place for schistosomiasis, or in what the 
District Health Office advised and thus it varied from district to district. The platform was always that of 
community-based treatment rather than a community-directed treatment, except for those districts 
where The Carter Centre, in conjunction with the National Onchocerciasis Control Programme, was 
conducting biannual treatment for onchocerciasis where it used CDTI. This study does not include the 
CDTI districts. The tablets were administered, following WHO guidelines (WHO, 2006) to individuals on 
the basis of height, using locally made height poles. All unused tablets were recovered by DVCOs who 
also compiled a report of all treatment activities. 
 
Costing 
(1) Perspective and time horizon 
The study adopted a societal perspective including the costs from both the provider and the costs 
incurred by the community in drug delivery. Household costs of accessing treatment were deemed to be 
negligible, as children were treated in their own schools and adults were either treated at home or in a 
central locality within the community. The cost analyses in this study were originally aimed to cover 
three years of integrated NTD treatment using the financial year of the NTDCP which is October 1st to 
September 30th and thus: 
- Year One (Y1)  Oct 2006 – Sept 2007;  
- Year Two (Y2) Oct 2007 – Sept 2008;  
- Year Three (Y3) Oct 2008 – Sept 2009;  
- Year Four (Y4) Oct 2009 – Sept 2010 was then added for six of the selected districts because 
remaining funds allowed for the additional data collection.  
As very few control activities occurred under the programme during Y1 (programme inception was 
delayed until July 2007 and no NTD activities were implemented in districts until Y2), data were available 
from the central level only for that year.  
 
(2) Cost Disaggregation 
The main programme inputs i.e. the items that are necessary to produce the expected outputs and 
outcomes of the programme were:  
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(i) Capital costs – Costs for buildings, vehicles and equipment that have a life expectancy of more 
than one year. 
(ii) Salaries – Recurrent costs associated with paying salaries to employed personnel, including 
any supplements, emoluments, insurance or other benefits of employment. 
(iii) Transport – Recurrent costs associated with vehicular transport, namely fuelling, insurance, 
maintenance, repairs, road taxes or fees and rentals costs if any vehicles were rented.  
(iv) Supplies – Recurrent costs associated with supplies used for NTDCP activities and general 
office running, namely stationery, photocopying, IEC materials, refreshments, office supplies, 
equipment hire/maintenance/repair, telephone, internet and other communication costs. 
(v) Per diems – Specific per diems and extra allowances paid by the NTDCP for carrying out specific 
programmatic activities. 
(vi) Overheads – Recurrent indirect costs associated with the NTDCP administration and 
maintaining the work environment, namely utility charges, cleaning services, security guards, 
transport and other ancillary personnel.  
(vii) Time – The time allocated to the NTDCP by key personnel was collected prospectively and 
retrospectively by cost centre. For all government staff e.g. MoH Programme Managers, 
district personnel and teachers the value of time was based on the salary input data collected. 
For the CDDs their ‘volunteer time’ was valued separately.  
(viii) Intervention drugs – The specific intervention drugs, both purchased and donated that were 
needed to carry out IPCT. 
These pre-defined inputs were allocated to one or more of the 10 defined Cost Centres which represent 
the main programmatic activities which are listed and described in Appendix Ia. 
 
(3) Collection of central, district and community costs 
Data collection was both retrospective and prospective and used pre-tested questionnaires developed 
by partners at Emory University and the Taskforce for Global Health, Atlanta and SCI, as part of a wider 
multi-country study assessing the costs of integrated NTD packages (see Appendix II for each costing 
tool used for data collection).  
 
Central costs: At the central level retrospective cost data on all the Inputs and by Cost Centre were 
collected once annually from accountancy records and programme documentation (Appendix II, pages 3 
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to 8). All NTD Secretariat members and NTDCP staff were interviewed annually to capture their time 
spent on NTDCP activities (Appendix II, pages 13 to 14).  
 
District costs: At the district level retrospective cost data on all the Inputs and by Cost Centre were 
collected once annually from accountancy records and programme documentation (Appendix II, pages 3 
to 8). Prospective cost data collection was carried out by focal NTD personnel in the districts e.g. the 
DVCO or NTD Focal Person, keeping monthly work logs (Appendix II, page 10). A sample of non-routine 
district personnel for example, those individuals who have limited involvement in the NTDCP on an 
everyday or weekly basis, but whose involvement is critical to the project e.g. the DHO, DEO, were 
interviewed annually using a personnel questionnaire (Appendix II, pages 13 to 14). 
 
Community costs: Activities took place and resources were consumed at levels below the district 
including sub-county and health unit. To ensure no data were missed at the lower implementation 
levels, an average of two to four health units were sampled in each selected district each year and 
interviews were held with the NTDCP Sub-county Supervisors based at those health units (Appendix II, 
pages 13 to 14) and approximately ten CDDs and teachers to collect retrospective data on programme 
involvement (Appendix II, pages 15 to 16). The main focus of the questionnaire was the time spent on 
the NTDCP and volunteer work-time of the CDDs, but data on community contributions and benefits to 
the community were also collected and are reported in Chapter 4. In addition to these retrospective 
questionnaires, a further study was carried out to investigate prospectively and thus, more accurately, 
the role and time of the CDD in the NTDCP for Y3 (08/09) of the programme using daily pictorial diaries. 
This study was carried out in four of the thirteen cost districts and will also be covered in Chapter 5. 
 
To ensure validity of the collected data at each of the levels, the data from sub-district level were 
triangulated with data from the district level and central level. A similar process of triangulation 
between the central and district level data to ensure all resource consumption was captured accurately 
was carried out.  
 
(4) Shared costs 
As central, district and sub-district resources are often shared by more than one health programme the 
data collected enabled costs to be apportioned accordingly to the NTDCP. The work logs and 
questionnaires performed at each of these levels (described in section (3)) included the ten specific Cost 
Page | 80  
 
Centre activities performed annually for the NTDCP and assessed the amount of time spent on each of 
these activities, whether any per diem was received, transport used and whether there was any out-of-
pocket expense incurred by those involved in programme implementation (Appendix II, pages 15 to 16). 
From these data the average number of days per activity was calculated for each level of staff. For the 
sampled questionnaire data this average number of days worked was then allocated to all members of 
MoH, Ministry of Education (MoE) staff or community volunteers at each level who were recorded as 
being involved in the NTDCP. For each level of staff or volunteers, the time was then converted into 
money by using the daily average salary, appropriate to the national Ugandan salary scale, and 
multiplied by the average number of days worked in that district and per activity (see Table 3.4 in 
Results).  
 
The vehicles used by the NTDCP were valued (described below in section (5)) and a percentage of their 
overall use (100%) was allocated to the NTDCP based on the information provided by the central level 
personnel in their interviews and the district personnel in their worklogs and interviews. For building 
and office space at the VCD headquarters the building that was shared with various non-PCT NTD or 
vector control programmes was assumed that 33% of the building costs were attributable to the NTDCP. 
For the refurbished building 100% of the costs were attributable to the NTDCP. These percentage 
allocations were based on the average amount of time spent annually by the relevant central level 
personnel on the NTDCP captured during the retrospective interviews. 
 
(5) Valuation of resource use  
Both financial and economic costs were estimated. Financial costs represent cash expenditure paid for 
the implementation of the intervention on an annual basis as funded by the RTI International NTD 
Control Program. Economic costs refer to all contributions including those that are not paid for, for 
example, the opportunity cost of using existing MoH and MoE staff and drug distributors as well as 
annuitized capital costs, and donated drugs. Opportunity costs for staff were calculated from salary 
costs, based on Ugandan public service pay scales for 2010/11 and the CDD time was assigned a 
monetary value equivalent to the Uganda casual labour wage [211]. Capital costs were annuitized over 
the useful life of each item using a discount rate of 3%, following standard practice [212]. Such 
annuitization enables an equivalent annual cost to be estimated and reflects the value-in-use of capital 
items, rather than reflecting when the item was purchased. The financial cost of a new building at VCD 
used to store drugs and other equipment and to house some of the programme officers was estimated 
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on the basis of the cost of constructing and furnishing the building (US$87,000), a second building was 
estimated on the cost of refurbishment (US$50,000), both were annuitized using an estimated useful life 
of 30 years. From 2002 onwards, fifteen vehicles were purchased by the SA programmes prior to 
integration and all of the fleet were used for various NTDCP activities. The costs of these vehicles were 
annuitized over a useful life of 7.5 years and it was assumed that 30% of costs were attributable to 
NTDCP activities. The remaining 70% of annuitized costs were used prior to the NTDCP. Computer 
equipment and telephones were also purchased for the NTDCP and each of the control programme 
managers of which 100% was allocated to the programme and a 3 year useful life. Annuitized capital 
costs were allocated equally across the study districts.  
 
PZQ tablets were purchased by RTI International on behalf of all of their NTD supported programmes at 
a unit price of US$0.073 per 600mg tablet. Assuming 2.5 tablets per individual treated, the drug cost per 
person treated for schistosomiasis was US$0.18. ALB tablets (400mg), one per individual for the 
treatment of STH, were purchased at a unit price of US$0.023, including cost, insurance and freight (CIF). 
ALB was also donated for use in lymphatic filariasis endemic areas by GlaxoSmithKline for which the 
market value was at US$0.045 plus US$0.0016 for shipping per 400mg tablet (M. Bradly, 
GlaxoSmithKline, pers. comm). The market value per 3mg tablet of IVM, donated by Merck & Co., for 
distribution in lymphatic filariasis and onchocerciasis endemic areas, was US$1.50 plus US$0.018 
insurance and freight (Y. Sodhalon, Mectizan Donation Program, pers. comm) and at approximately 3 
tablets per person a dose would cost US$4.60. Donated ZIT tablets (250mg), the antibiotic used as part 
of trachoma SAFE strategy for trachoma control, were valued at US$7.70, US$8.48, US$8.91 and 
US$9.26 per tablet for the years 2007-10 respectively (D. Haddad, ITI, pers. comm), with an average dose 
of 3.4 tablets. For children under five years ZIT syrup is given and a bottle, which can be used to treat 
approximately four children was valued at US$32.58, US$35.92, US$37.72 and US$39.23 for the years 
2007-10 respectively. The Uganda National Medical Stores cleared the imported drugs and transported 
them to VCD headquarters in Kampala at a cost of 5% of the drug price for purchased PZQ and ALB. The 
importation of the ZIT also incurred some charges which have been included. There is a lack of published 
data on the wastage of these drugs in national control programmes, so a wastage rate of 1% was 
assumed [208,213]. The CIF was paid in foreign currency (US$). All other costs were paid in Uganda 
Shillings (USh) and converted to US dollars using official exchange rates, based on average yearly 
exchange rate: 1 US$ = 1770.72 USh in 2006/7, 1697.15 USh in 2007/8, 2,002.51 USh in 2008/9 and 
2,060.42 in 2009/10 (http://www.oanda.com/convert/classic). Monetary costs were adjusted for 
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inflation over time using the GDP implicit price deflator and expressed in US$ 2010 prices (IMF, 2008 
http://www.imf.org/external/pubs/ft/weo/2008/01/weodata/index.aspx).  
 
(6) Allocation of central level costs to individual districts  
For each study district the annual costs for the Inputs and Cost Centres were captured using the 
methods described above. In addition the annual central level costs, also described above, required 
allocation to each individual district to allow for the calculation of cost per person on an annual and 
district by district basis. This allocation was done by totalling the annual financial and economic central 
level costs for each Input in each of the Cost Centres and then dividing each total by the total number of 
districts treated under the NTDCP in that year. The proportion of each of the annual central level costs 
was then allocated to each of the study districts under the appropriate Cost Centre and Input and was 
entered into a District Costs Table which was completed for each study district for each programme year 
(Appendix III, page 2). 
 
Cost Analysis 
District annual and average costs were disaggregated by Inputs and Cost Centres, as described above, 
and reported by financial and economic costs. The cost profile of the financial and economic costs, that 
is, the percentage of a particular input or Cost Centre attributable to the total cost, were calculated. As 
there were no treatments in Y1 (2006/7) the financial and economic costs were allocated across the 
subsequent three programme years proportionally to the number of people treated. The primary 
outcome measure of cost per person treated was calculated as the annual programme costs / the 
annual number of people treated. The reasons for this outcome measure were: (i) the NTDCP and the 
implementing and donor agency partners treatments measure effectiveness by the number of 
individuals treated and reported programme coverage; (ii) treatments have a proven association in 
improving the health of infected individuals and prevention of chronic disease sequelae in the treated, 
and also in the untreated, population. The cost per person has been reported in three ways: 
 
1) Financial cost per person treated, which includes all programme financial expenditure but 
excludes the cost of the purchased drugs. This is the equivalent to the delivery cost per person 
treated, regardless of how many rounds are required, during an MDA campaign.  
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2) The economic cost per person treated, which is the full economic cost per person but excludes 
the cost of purchased and donated drugs. This includes all of the financial costs and the value of 
all contributions from the Government of Uganda. 
3) The full economic cost per person treated, which is all financial and economic costs including 
the value of purchased and donated drugs 
 
The reasons for not presenting the financial cost per person including the cost of only purchased drugs 
(PZQ and ALB) was twofold; (i) some districts required purchased drugs and others did not, thus little 
would be gained at looking at these data, instead the full economic costs including the values of 
purchased and donated drugs was used; and (ii) a recent announcement by Merck Serono to increase 
their annual donation of 25 million tablets of PZQ to 250 million [214], will mean many large scale IPCT 
programmes for NTD control will have all drugs donated.  
 
Due to the importance of the US$0.50 threshold in international NTD treatment advocacy and 
fundraising, which is that all seven PCT NTDs can be treated for US$0.50 or less as highlighted in the 
Introduction of this chapter, it was decided to incorporate this threshold in the cost analysis that is 
presented herein.  
 
Statistical Analysis 
The relationship between the annual cost per person treated and the percentage of overall costs due to 
different cost drivers, inputs, total number of people treated3, programme coverage4, the number of 
IPCT delivery rounds (one, two or three) per MDA and other independent demographic and geographic 
variables was assessed using a non-parametric Spearman’s rank correlation. Cost data are typically 
positively skewed and thus parametric methods which rely on normal distributions are likely to be 
inadequate for analysis of such data [216,217]. Non-parametric methods based on ranks are used to 
analyse a numerical outcome variable without assuming that it has a particular parametric distribution. 
                                                          
3 Total number of people treated was taken as the maximum number of individuals treated for at least one NTD in 
each district. In each district the diseases most widely distributed and treated were the soil-transmitted helminths, 
lymphatic filariasis or trachoma. 
4 Programme coverage was taken as the average reported coverage across the different PCT drug packages in a 
district. For each PCT drug package the reported programme coverage was calculated as the total number of 
individuals targeted who were reported to have received at the PCT drug package in a district/the eligible 
population targeted for that PCT drug package in a district. In each district the drug most widely distributed and 
with the largest eligible population was either ALB or ZIT [215] 
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They are particularly useful in small, non-normally distributed data sets when we do not wish to 
transform the variable because transforming the variable would make interpretation of the results 
harder, as is commonly the case with cost data [218], [219,220]. Due to the nature of the data and the 
need to measure the strength of association between two variables, non-parametric Spearman’s rank 
correlation was used to test the correlations as it has been in similar costing studies [150,221,222].  
 
To test the null hypothesis that there was no difference between pairwise comparisons of the means of 
cost per person per number of delivery rounds (one delivery to two deliveries; two deliveries to three 
deliveries; one delivery to three deliveries) in an MDA, non-parametric bootstrap methods were used. 
Bootstrapping provides a way of deriving confidence intervals for the difference in arithmetic mean 
costs without making parametric assumptions about the cost distribution. A non-parametric method 
such as the Wilcoxon rank sum was not used as it compares medians instead of means which are 
problematic for the interpretation of cost data by economists due to the potential skewed nature of the 
data [223]. The analysis undertaken follows the methodology reviewed in Briggs and Gray [223] and 
Barber and Thompson [220]. First a simple t-test of untransformed costs was performed (mid-point 
analysis) and due to the small size of the sample and presence of skewedness, as tested by Shapiro-Wilk 
tests [216,217], non-parametric bootstraps were undertaken with 2000 bootstrap samples and included 
the calculation of Bias-corrected and accelerated (BCa) confidence intervals. The two different 
approaches used (midpoint analysis and non-parametric bootstrap) allowed the calculation of different 
values for the confidence intervals, leading to a better interpretation of mean cost per person treated 
across the number of delivery rounds per MDA. 
 
To determine whether or not the null hypothesis is rejected, a critical significance level equal to 0.05 
was set. All statistical analyses were carried out using STATA 11.2 (StatCorp LP, TX, USA). 
 
Sensitivity Analysis 
Sensitivity analysis allows for uncertainty within an economic evaluation. It shows how responsive the 
result is to changes in key economic parameters but also gives an indication of the robustness of the 
estimate to changes in variables that are uncertain, prone to change over time or susceptible to change 
in different settings. Sensitivity analysis was performed on the inputs which consumed the highest 
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proportions over a range of values, which were based on existing literature and intuition, and are listed 
below. The base case values are presented with the results. 
 
1. discount rate, which was a base case of 3% was reduced to 1% and increased to 10%,  
2. the prices of the drugs were reduced by 10% and 20% to reflect the use of cheaper drugs in the 
future, and the price of the purchased drugs was reduced to 0% in light of the future donations 
from the manufacturer.  
3. drug wastage was increased to 10% as used by Goldman et al. [208] and also to 5% as the 
midpoint between 1%, the base case, and 10%.  
4. the percentage of ‘volunteer’ time of the CDD was decreased to 1%, to one working week (2.8%) 
and increased to 50%.  
5. the monetary valuation of CDD time was valued as the lowest earner on the Government of 
Uganda salary scale and as GNI per capita, which is the gross national income for Uganda, 
converted to U.S. dollars using the World Bank Atlas method/ midyear population. The GNI per 
capita values for mid-2008 =US$420, mid-2009 = US$470, mid-2010 = US$500. In addition, 
different rates of financial compensation (in USh) were also included in the model to test at 
what point the increase would lead to the financial cost per person treated to go beyond the 
US$0.50 threshold.   
6. the proportion of teacher time was decreased to 1% and increased to 10%  
7. per diems received by the CDDs during training were increased from 10% to 400%. The reason 
such a significant increase in per diem was used in the sensitivity analysis was, to test at what 
point the increase would lead to the financial cost per person treated going beyond the US$0.50 
threshold.   
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Results 
Final analysis was carried out in eleven districts in Y2 (2007/8), twelve districts in Y3 (2008/9) and seven 
districts in Y4 (2009/10). From the original 13 selected districts, Buliisa district was dropped because 
changes in staff at the district level meant there was, at times, no DVCO or focal NTD person and thus 
the financial records related to the programme were poor and hard to follow-up on. In Y2 the first round 
of integrated treatment in Kitgum district was postponed until Y3, leaving 11 districts participating in 
that year. In Year 4 the funds became available to continue data collection in 6 districts, as well as, to 
continue data collection in Kitgum district. 
 
Time spent on the NTDCP 
During the study period 596 interviews and questionnaires were completed from school teachers and 
CDDs up to central MoH programme managers. At the central level 23 interviews were held, followed by 
59 at the district level, 86 at HC and with supervisors and finally 428 with CDDs and school teachers who 
distributed drugs (Table 3.2). 
 
The average percentage, and range, of time spent on integrated NTDCP cost centres (equivalent to 
programme activities) annually by each level of staff is shown in Table 3.2. The NTDCP staff spent 100% 
of their time on the programme as that was the sole purpose of their employment by RTI International. 
Whereas, the MoH Programme Managers, of the NTD programmes and other MoH staff at the central 
level annually spent an average of 33.4% and 18.1% of their time on the integrated NTDCP, respectively. 
For the NTDCP the MoH Programme Managers spent, on average, the majority of their time on 
advocacy (25.8%), mapping and assessment (30.0%), and planning and budgeting (32.9%). A similar 
allocation of time was spent on each of the cost centres by the other MoH staff at the central level, 
except for planning and budgeting which was only, on average, 9.2% of the time spent on the NTDCP. 
As the level of staff went from district to community the total amount of time spent annually on the 
programme reduced which mirrors the amount of responsibility and accountability required at each 
level. The amount of time spent on each of the programme cost centres at the district and below varied 
between the different levels of staff, however, delivery and distribution of treatment was approximately 
a 20% of time spent on the NTDCP by all except for teachers who only apportioned 12.0% of their time 
to this cost centre. 
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Annual costs of Inputs for the NTDCP 
Input Annual cost (US$)** 
Capital 
Buildings (room/building) 297 – 3,159 
Project vehicles 39,441 - 43,744 
Furniture 948 - 5,058 
Assorted office hardware 6,232 – 11,197  
Salaries  
MoH Programme Manager 533 – 2,917 
MoH Central level staff 471 – 1,361 
NTD Country Programme Manager 28,276 – 32,693 
NTD Staff 3,925 – 22,520 
NTD staff benefits 14,254 - 16,481 
District officers 254 88 – 1,453 
Supervisor 26 - 722 
Teacher 70 - 82 
CDD 23 - 112 
Transport 
Vehicle hire 33,576 - 43,201 
Vehicle maintenance 16,793 - 21,607 
Fuel 50,369 – 64,808 
Supplies 
Field and laboratory consumables  10,272 - 23,960 
Office running Stationery 24,515 – 35,289 
Drug/equipment clearance charges 82,568 - 128,843 
IEC materials, media & training materials 81,341 – 188,988 
Per diems/allowances† 
MoH Central level staff   14.23 - 56.90 
NTD Country Programme staff 23.71 - 45.05 
District officer 14.23 - 28.45 
Supervisor 2.85 - 16.60 
Teacher  2.85 - 3.79 
CDD  0.95 - 1.90 
Overheads 
Operations & maintenance 14,315 – 30,537 
Vehicle - fuel, maintenance & hire (administrative) 75,724 - 89,625 
Communications (phone and internet) 16,036 - 20,235 
Table 3.3: Annual range of costs of Inputs for the NTDCP 2006* - 2010 
*no MDA in year 1 (2006/7) so costs were allocated across the subsequent three years proportionally to the 
number of people treated  
**US$ in 2010 prices 
† per diem/allowances given as per day unit rates (annual costs not broken down by staff level) 
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The annual costs, both financial and economic, for each of the NTDCP inputs are identified in Table 3.3. 
These annual costs were determined from financial expenditure records. The annual costs of the staff 
and volunteers were calculated from the data on time spent on the NTDCP, retrieved through the 
interviews and worklogs held with the staff and volunteers (Table 3.2), and information provided during 
these interviews as to what level each staff member was on the Ugandan public service pay scales for 
2010/11. 
 
Nevertheless, not all individuals from the district level and below that had participated in the NTDCP 
were interviewed, thus the time spent on a cost centre for each interviewed individual was averaged 
across their level (district, supervisor, teacher, CDD) and multiplied by the average annual salary spent 
on the NTDCP to determine the value of staff time for the whole district. Table 3.4 illustrates how this 
was done in Kamuli district for Y2 of the NTDCP.  
 
Annual District Level Costs 
Central level financial and economic costs were calculated for all Inputs and Cost Centres for each 
programme year (data not shown) and were then divided over all of the implementing districts for that 
year. For each study district the district level financial and economic costs were calculated to include 
both the allocated central levels costs and the resources used at the district level for each Input and Cost 
Centre as is illustrated for Kamuli district Y2 in Appendix III, page 3.  
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Total Numbers Treated for any NTD 
The total numbers of people treated for any NTD and programme coverage in a district and for each 
year are shown in Table 3.5. This table also shows the PCT package of drugs in each year and the 
corresponding number of delivery rounds implemented by the drug distributors to distribute the 
packages. The total number of people treated for any NTD in the study districts was 1,845,109 in Y2 of 
the programme, 2,924,823 in Y3, 1,801,290 in Y4 out of 8,767,739, 14,136,742 and 13,885,916 total 
individuals treated in the respective years nationally for any NTD.  
 
Programme coverage reached as high as 95% (Busia in Y2 and Pallisa in Y3) and as low as 41% (Mayuge 
Y3 and Yumbe Y4). Within each district, in each year, the programme coverage often varied quite 
considerably, for example in Yumbe Y4 only 19% PZQ coverage was achieved and 33% coverage for ALB 
alone whereas, coverage was 72% for IVM+ALB for the treatment of lymphatic filariasis. The distribution 
of IVM+ALB most commonly had the highest programme coverage of the targeted eligible population, 
and ZIT for the treatment of trachoma most frequently had low reported coverage. 
 
Busia (PZQ+ALB) and Katakwi (IVM+ALB) only had one delivery round per year. Dokolo (IVM+ALB and 
then PZQ) and Kibaale (IVM and then PZQ+ALB) each had two delivery rounds per year and Kitgum 
(IVM+ALB, then PZQ and then ALB) had three each year. The remaining seven districts increased the 
number of rounds each year due to the addition of disease(s), previously unmapped and untreated in 
the district, being added to the district treatment package.  
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Total costs of IPCT delivery for NTDs 
IPCT for the NTDs over four years to eligible populations through an integrated strategy, excluding the 
cost of purchased drugs, from Y2-Y4 were US$358,571, US$289,275 and US$175,778 (Table 3.6), 
showing a reduction in costs over time despite an increase in number of treatments. Including the cost 
of purchased drugs the annual financial costs were US$427,827, US$456,698 and US$217,706 
respectively (Table 3.7), although there is a trend in reduction of financial costs over all time, there is an 
increase in costs for Y3 from Y2 which corresponds with an increase and then decrease in the numbers 
of people treated both in the study districts and nationally. The economic costs, excluding purchased 
and donated drugs were US$1,205,624, US$2,245,825 and US$649,208 for programme years 2 to 4 
(Table 3.6) and for the same years the full economic costs including the value of all drugs, were 
US$21,910,834, US$34,249,726 and US$24,048,962 (Table 3.7). In both sets of economic cost 
calculations, Y3 had the highest costs in the study districts.  
 
Total Costs of IPCT delivery for NTDs by Cost Centre 
The total financial and economic costs of delivering IPCT for the seven NTDs, and broken down by cost 
centre but, excluding the cost of drugs, are shown in Table 3.6. Purchased and donated drug values were 
excluded from this table to allow the cost profiles to be comparable across the cost centres, when drugs 
are included the cost profiles are skewed with >90% of the economic costs being apportioned to drugs. 
In the first programme year to distribute drugs (Y2) the main financial cost drivers were health 
education and mobilisation to communities and schools (21%), cascaded training of central health teams 
down to CDDs and teachers (21%), followed by the delivery and distribution of treatment (19%) and 
administration (16%). For the subsequent two programme years (Y3 and Y4) the four same cost centres 
remained the main financial cost drivers, with delivery and distribution being the highest with a quarter 
of all costs (24% and 25%). Across the programme years delivery and distribution of treatment was also 
the key economic cost driver with a third of all costs in each year (31%, 38%, 33%), followed by health 
education and mobilisation (23%, 22%, 23%). For Y2 and Y4 the other important economic cost drivers 
were training (13%, 10%) and registration (10%, 10%), whereas, for Y3 the key activities were, 
registration (11%) and monitoring and evaluation (10%). All other financial and economic cost drivers 
(advocacy, data management and reporting and planning and budgeting) fell below 10% each year,
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except for mapping and assessment which accounted for 11% of financial costs in Y3. The financial and 
economic costs for advocacy fell from 4% in Y2 to 1% of programme costs in Y4. Below 1% of the 
financial costs were spent on data management and reporting in Y3 as there were no district workshops 
held where district health teams report their achievements and challenges in NTD control to their peers 
at a regional or national level. However, 5% of full economic costs were allocated to this same cost 
centre, data management and reporting, which were due to the opportunity costs of the district and 
community personnel participating in drug coverage report compilation and writing. 
 
Figure 3.2 (a) clearly shows that the key financial cost drivers, when broken down across the districts, 
remain administration, delivery and distribution, health education and mobilisation and training. 
Whereas, delivery and distribution, health education and mobilisation, registration and training were 
the main economic cost drivers (Figure 3.2 (b)).  
 
Total Costs of IPCT delivery for NTDs by Programme Input 
Total financial and economic costs for integrated NTD control in Uganda were also analysed by input 
costs across the programme years (Table 3.7) and across districts (Figures 3.3 (a) and (b)). The largest 
financial inputs across all years (Y2-4) were per diems (35%, 23%, 32%), purchased drugs (16%, 37%, 
19%), supplies (24%, 18%, 19%) and transport (13%, 11%, 15%). Capital costs were 1% for Y2 and Y3 but 
doubled in Y4 in part due to the purchase of motorbikes for ten of the programme districts. Overheads 
incurred for the NTDCP ranged between 6% (Y2) and 8% (Y4). Due to the high value of donated drugs for 
treatment (approximately US$4.55 per dose for onchocerciasis; US$4.60/dose for lymphatic filariasis; 
US$29.58/dose for trachoma) and also due to the quantities required of the purchased drugs, PZQ and 
ALB and their clearance and handling charges (US$0.24 per dose for schistosomiasis and US$0.02 per 
dose for the STH), the largest economic cost inputs were for drugs (94%, 93%, 97%) across the 
programme years. When the costs allocated to drugs were removed from the cost profile it is easier to 
see the proportion of the other inputs. Volunteer time of the CDDs accounted for over a third (37%, 
41%) of economic input costs in Y2 and Y4 respectively and over a half (58%) in Y3. The opportunity 
costs of the time spent by the other key distributors, the teachers, and supervisors and district 
personnel were captured under salaries which were the second largest economic cost input after 
volunteer time (32%, 26% and 29%).  
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Figure 3.3 (a) shows the average proportion, over all programme years of financial costs, with purchased 
drugs and without, broken down by district. Without drugs there is very little variation between districts 
and the proportions reflect those seen in Table 3.7. Nevertheless, when the financial cost of purchased 
drugs PZQ and ALB are included there is a clear pattern which shows that in the districts where PZQ has 
been given for two years or more (Busia, Dokolo, Kibaale, Kitgum, Mayuge, Yumbe) there is marked 
increase in the proportion of financial costs towards the drugs (range 23% - 49%). Where only one year 
has included the cost of PZQ, the proportion of financial input costs reduces to 8% (Kamuli, Pallisa). In 
the remaining districts where only ALB has been purchased (Katakwi, Kotido, Kyenjojo, Namutumba) the 
proportion of financial input costs is ≤7%. The average proportion of full economic costs by input for 
each district including drugs and also no drugs is illustrated in Figure 3.3(b). Where purchased and 
donated drugs are not incorporated into the cost profiles for nine of the twelve districts, salaries and 
volunteer time are the largest proportions of economic input costs, as in Table 3.7. However, in 
Namutumba, Kyenjojo and Kotido there is variation with salaries being the largest proportion of 
economic input costs and with supplies, per diems and volunteer time having similar proportions (10%, 
14%, 14% in Namutumba; 10%, 11%, 10% in Kyenjojo; 12%, 18%, 18% in Kotido). When the value of 
donated and purchased drugs is included, all ten districts with donated drugs IVM, ALB and/or ZIT have 
three-quarters and above (range 73% - 98%) of their economic costs apportioned to this input. It is only 
in Mayuge district, which has no donated drugs in Y2, and Busia which has no donated drugs in any year, 
where the proportion of economic input costs for drugs (67% and 14% respectively) is less marked. 
which has no donated drugs in any year, where the proportion of economic input costs for drugs (67% 
and 14% respectively) is less marked. 
 
Unit costs of IPCT delivery for NTDs 
 Cost per Person Treated 
The financial cost per person (Table 3.8), excluding purchased drugs, was US$0.28, US$0.12 and US$0.11 
for each of the programme Y2 to Y4. The economic cost per person treated, excluding purchased and 
donated drugs, was US$0.81, US$0.76 and US$0.38 and including the drugs was US$10.73, US$11.03 
and US$14.43 for each programme year. These annual costs show substantial variation and, where 
drugs are not included, a decrease over time. The district financial costs per person treated also showed 
considerable variation from Y2 US$0.09 to US$0.70, to Y3 and Y4, US$0.06 to US$0.18 and US$0.06 to 
US$0.17, with the latter two years being more similar in their range of costs; as did the economic costs 
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per person treated US$0.33 to US$1.91 (Y2), US$0.32 to US$2.58 (Y3) and US$0.22 to US$0.44 (Y4). The 
most marked variation between districts and years was for the full economic costs per person treated 
which ranged from US$0.58 to US$30.23; US$0.83 to US$28.71 and; US$3.63 to US$30.97 for each of 
the consecutive programme years.  
 
The financial cost per person per year and by district remained below the US$0.50 threshold (Figure 
3.4a) except for in Kyenjojo district in Y2. The financial cost per person plus the cost of purchased drugs 
(data not shown) only rose above the US$0.50 threshold for Kyenjojo as before and in Mayuge district in 
Y2 with a cost per person treated of US$0.69. The range of financial cost, including purchased drugs, per 
person for each year was US$0.19 – US$0.69 (Y2); US$0.08 – US$0.30 (Y3) and; US$0.07 – US$0.15 (Y4). 
When including the value of labour and annuitized capital costs the economic cost per person is above 
the US$0.50 threshold by district and by year except for Pallisa districts which remains below US$0.34 
per person treated (Figure 3.4b). When the value of purchased and donated drugs is included the full 
economic costs in all districts and for each year are above the US$0.50 threshold per person treated 
(Figure 3.4c), as would be expected.   
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Figure 3.4: Financial (a), Economic (b) and Full economic (c) cost per person treated (2010 US$ prices) in Uganda 
under the integrated NTDCP by district and by year (2006* – 10) 
*no MDA in year 1 (2006/7) so costs were allocated across the subsequent three years proportionally to the 
number of people treated 
 
 
Cost per Person Correlations with Treatment Numbers, Cost Centre and Input Costs 
The financial cost per person treated is highly sensitive to the total number of persons treated. 
Increasing the number of individuals treated can significantly decrease the financial cost per person 
treated (Figure 3.5a, Spearman’s rho: -0.99, p<0.001 (Y2); Spearman’s rho: -0.82, p<0.001 (Y3); 
Spearman’s rho: -0.93, p=0.003 (Y4)), suggestive of economies of scale. Similar economies of scale were 
not observed in the economic and full economic cost, per person treated (Figure 3.5b and c). 
 
In order to investigate possible causes of observed variation in costs, the relationship between cost per 
person treated and the percentage of overall costs due to different cost centres and inputs was 
investigated. Financial cost per person treated was significantly positively associated with the costs due 
to the activities of advocacy, data management and reporting, mapping and assessment, planning and 
budgeting, administration, monitoring and evaluation in Y2 (each value was, Spearman’s rho: 0.82, 
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Fig. 3.4(c) Full economic (including drugs) cost per person (US$) treated by year 
and district
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p=0.002) and data management and reporting again in Y4 (Spearman’s rho: 0.76, p=0.04) and was 
negatively associated with training in Y2 (Spearman’s rho: -0.68, p=0.02). There were no significant 
associations between cost centres and cost per person treated in Y3. The majority of financial input 
costs in this category were per diem (allowances) rates paid to district officials and central NTD Control 
Program salaries which were both, in Y2, significantly correlated with cost per person treated 
(Spearman’s rho: 0.74, p=0.009 and Spearman’s rho: 0.82, p=0.002) as are capital costs and overheads 
(Spearman’s rho: 0.82, p=0.002) and supplies (Spearman’s rho: 0.61, p=0.04). There were no significant 
correlations between input costs and financial cost per person treated in Y3 and Y4. These results are 
indicative of higher ‘start up costs’ in the first year or two of a control intervention. 
 
The economic cost per person treated, not including drugs, had significant correlations in programme Y3 
with the following cost centres being negatively associated with the cost per person treated, mapping 
and assessment (Spearman’s rho: -0.72, p=0.008), administration (Spearman’s rho: -0.72, p=0.008) and 
advocacy (Spearman’s rho: -0.71, p=0.01). Meaning that as there was an increase in the cost of these 
activities there was a decrease in the economic cost per person. The majority of input costs in the 
aforementioned cost centres do not include volunteer time or other imputed values of labour, and the 
inputs that were significantly associated with the cost per person treated were capital costs (Spearman’s 
rho: -0.70, p=0.01), overheads (Spearman’s rho: -0.72, p=0.008), per diems (Spearman’s rho: -0.73, 
p=0.01), supplies (Spearman’s rho: -0.73, p=0.007) and transport (Spearman’s rho: -0.80, p=0.001).  
 
Delivery and distribution of drugs was positively correlated (Spearman’s rho: 0.59, p=0.04) with, and 
training negatively correlated (Spearman’s rho: -0.57, p=0.05) with, full economic cost per person 
treated in Y3; and data management and reporting and training (both Spearman’s rho: -0.86, p=0.01) in 
Y4. There was a significant negative relationship between full economic cost per person treated and 
each input cost in each programme year with the exception of volunteer time in Y3 (Spearman’s rho: -
0.22, p=0.48) and Y4 (Spearman’s rho: -0.54, p=0.21) and salaries (Spearman’s rho: -0.68, p=0.09) in Y4. 
Drugs were positively associated with full economic cost per person treated which was strongly 
significant in Y2 (Spearman’s rho: 0.85, p=0.001) and Y3 (Spearman’s rho: 0.71, p=0.001). 
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Figure 3.5: (a) – (c) Relationship between the number of individuals treated and the Financial (a), Economic (b) and 
Full Economic (c) cost per person treated in the 12 districts  by NTDCP year.  
Numbered labels illustrate the number of deliveries borne by the CDD for each district in each year. 
 
 
 
Correlations with Coverage and Delivery 
The relationship between the cost per person in each year and the programme coverage was also 
explored. Figure 3.6 (a), (b) and (c) illustrate that there may be a relationship between a lower cost per 
person treated with a higher programme coverage but none of these associations were significant. 
When looking at the number of IPCT drug deliveries that a CDD or teacher has to carry out per MDA 
campaign, Figure 3.7a shows that with increasing number of deliveries the financial cost per person 
treated is less. To determine if the differences seen in Figure 3.7 were statistically significant bootstrap 
sampling was used to test the hypothesis that the mean difference between delivery round pairs was 
zero (Table 3.9).  There was a significant difference in the financial cost per person treated between one 
delivery round and three delivery rounds carried out by the distributors per MDA campaign (US$0.17; 
95% CI 0.05, 0.34; p=0.02). The differences between median economic cost per person per number of 
delivery rounds were non-significant (one delivery to two deliveries p=0.321; two deliveries to three 
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deliveries p=0.50; one delivery to three deliveries p=0.78) (Fig. 3.7b). However, with full economic cost 
per person treated there were significant differences between delivering one and two rounds of 
treatment (US$-7.96; 95% CI -15.07, -1.17; p=0.04) and one and three rounds of treatment (US$-14.90; 
95% CI -21.26, -7.85; p<0.001) in an MDA campaign that shows with increasing the number of deliveries 
the cost per person treated also increases (Fig 3.7(c)). 
 
Differences in demographic and geographic factors, including distance of each district from Kampala 
(financial, Spearman’s rho: 0.01, p=0.97; economic, Spearman’s rho: -0.38, p=0.23; full economic, 
Spearman’s rho: -0.12, p=0.72), population size (financial, Spearman’s rho: -0.48, p=0.12; economic, 
Spearman’s rho: -0.35, p=0.27; full economic, Spearman’s rho: -0.31, p=0.32) and population density of 
the district (financial, Spearman’s rho: -0.31, p=0.33; economic, Spearman’s rho: -0.35, p=0.27; full 
economic, Spearman’s rho: -0.07, p=0.83) which were tested by Spearman’s rank correlation, were not 
significantly associated with costs per person treated.  
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Figure 3.6: Financial (a), economic (b) and full economic (c) cost per person by programme coverage and by 
programme year 
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Fig. 3.6.(b) Economic cost (excluding drugs) per person (US$) 
by programme coverage and year
2007/8 (rho -0.17, p=0.61)
2008/9 (rho -0.52, p=0.09)
2009/10 (rho -0.29, p=0.54)
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
0% 20% 40% 60% 80% 100%
Fu
ll 
ec
on
om
ic
 c
os
t p
er
so
n 
tr
ea
te
d 
(U
S$
)
Programme coverage (%)
Fig 3.6(c) Full economic cost (including drugs) per person (US$) 
by programme coverage and year
2007/8 (rho -0.38, p=0.25)
2008/9 (rho -0.53, p=0.08)
2009/10 (rho -0.11, p=0.82)
  Page | 109  
 
 
 
 
Figure 3.7: (a) to (c) Cost per person by number of IPCT delivery rounds per MDA and by programme year 
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Mean cost (US$) 
Mean  
difference  
95% CI   
    Lower limit Upper limit p-value 
Financial cost per person           
1 & 2 deliveries midpoint 1 delivery = 0.28 0.109 -0.040 0.258 0.141 
bootstrapa 0.109 -0.043 0.261 0.160 
bootstrapb -0.028 0.276 
bootstrapc -0.020 0.285 
2 & 3 deliveries midpoint 2 deliveries = 0.17 0.059 -0.005 0.123 0.069 
bootstrapa 0.059 -0.001 0.119 0.054 
bootstrapb 0.002 0.124 
bootstrapc 0.004 0.126 
1 & 3 deliveries midpoint 3 deliveries = 0.11 0.168 0.034 0.302 0.017 
bootstrapa 0.168 0.023 0.314 0.024 
bootstrapb 0.045 0.330 
bootstrapc 0.049 0.340 
Economic cost per person           
1 & 2 deliveries midpoint 1 delivery = 0.80 0.221 -0.190 0.631 0.272 
bootstrapa 0.221 -0.216 0.657 0.321 
bootstrapb -0.158 0.709 
bootstrapc -0.150 0.737 
2 & 3 deliveries midpoint 2 deliveries = 0.58 -0.143 -0.586 0.300 0.509 
bootstrapa -0.143 -0.556 0.270 0.498 
bootstrapb -0.602 0.194 
bootstrapc -0.639 0.188 
1 & 3 deliveries midpoint 3 deliveries = 0.72 0.078 -0.548 0.704 0.796 
bootstrapa 0.078 -0.478 0.634 0.784 
bootstrapb -0.485 0.615 
bootstrapc -0.486 0.612 
Full economic cost per person           
1 & 2 deliveries midpoint 1 delivery = 3.65 -7.096 -15.829 1.638 0.105 
bootstrapa -7.096 -13.845 -0.347 0.039 
bootstrapb -14.476 -0.790 
bootstrapc -15.066 -1.173 
2 & 3 deliveries midpoint 2 deliveries = 10.74 -7.802 -17.921 2.317 0.123 
bootstrapa -7.802 -16.990 1.386 0.096 
bootstrapb -16.994 1.721 
bootstrapc -16.374 2.179 
1 & 3 deliveries midpoint 3 deliveries = 18.54 -14.898 -23.507 -6.288 0.002 
bootstrapa -14.898 -21.575 -8.220 <0.001 
bootstrapb -21.363 -7.948 
  bootstrapc     -21.255 -7.852   
Table 3.9: Delivery mean cost per person (financial, economic, full economic) with midpoint and bootstrap (2000 
bootstrap samples) analyses on difference in mean costs between delivery pairs. 
a normally distributed (Shapiro-Wilk test: p-value >0.001); b not normally distributed (Shapiro-Wilk test: p-value 
<0.001); c bias-corrected accelerated confidence interval 
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Sensitivity Analysis 
Sensitivity analysis was performed to assess how much variation in the values of the inputs that 
consumed the highest proportion of resources, drugs, per diems and volunteer time, would affect 
overall results (Table 3.10). Varying the discount rate from 1% to 10% had very little effect on the cost 
per person treated. Decreasing the value of drugs by 10% reduces the full economic cost per person by 
approximately US$1 per person and when reduced to 20% the reduction in full economic cost is US$2 or 
more per person. Nevertheless, by reducing the value of purchased drugs to 0% there is little change in 
the full economic cost per person treated. By increasing the wastage of drugs from 1% to 5% and then 
10%, due to loss, theft or damage, per person cost also increases. When the percentage of volunteer 
time spent by CDDs was varied across a range of proportions the cost per person changes 
simultaneously, when increased by 10% the economic cost is still very reasonable at US$1.16, US$1.00 
and US$0.55 per person treated (Y2-Y4). By changing the value of the volunteer time from the local cost 
of manual labour to GNI per capita and the lowest salary on the Ugandan national salary scale, has little 
impact on the cost per person treated. Increasing the financial compensation for each CDD per MDA 
campaign to 300% and 1500% also has very little effect on the cost per person treated, the financial cost 
per person treated remained far below the US$0.50 threshold. Indeed to reach this US$0.50 threshold in 
each programme year the CDDs would have to be awarded or the equivalent funds allocated to their 
capacity building, 70,000USh in Y2, 160,000USh in Y3 and 240,000USh in Y4, per MDA campaign as 
compared to the 4,000USh per campaign they were receiving. In addition to the inputs varied shown in 
Table 2.10, teachers time was decreased to 1% and increased to 10% with the result that the economic 
cost per person did not fall below US$0.30 at the lower end and did not increase above US$1.00 at the 
higher end. There was minimal change in the full economic cost per person when teacher time was 
varied. Per diems were also increased in the model from 10% to 400% and remained below US$0.50 per 
person for financial costs and below US$0.90 economic cost per person, once again the change to the 
full economic cost per person each year was minimal.  
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Discussion 
This study provides evidence that an integrated strategy for the control of NTDs in Uganda using 
IPCT is a low cost health intervention to both donors and the Government of Uganda. Over all 
programme years the average financial cost per person treated was US$0.17, the average economic 
cost (no drugs) was US$0.65 per person and when including the value of all drugs, the average full 
economic cost per person (purchased and donated drugs) was US$12.06. These costs are 
comparable to the other studies looking at the cost of integrated strategies. Evans et al. [209] 
demonstrate in Nigeria that by TDA of IVM, ALB and PZQ a cost per treatment of US$0.05 (excluding 
drugs and all overheads) and per child treated of US$0.22 (including the price of PZQ but excluding 
overheads) were achieved. The first of these costs was calculated as the total cost/the number of 
treatments of IVM+ALB plus the treatments of PZQ; the second was the total cost/(the number of 
treatments given to children) x 2. The latter was calculated in this manner to give a comparison 
against the previous year’s SA distribution of the three drugs and showed a saving between the 
years. Determining cost savings by integration in Uganda is covered in chapter 3. In Niger, results 
from an unpublished study report US$0.09 financial cost per treatment (excluding drugs) (US$0.18 
for a district with two drug deliveries) and US$0.19 economic cost per treatment (US$0.38 for a 
district with two drug deliveries) (SCI, unpublished data). In Haiti [208] the financial cost per person 
of treating lymphatic filariasis and the STH was reported as US$0.42 (excluding donated ALB but 
including purchased DEC) and the economic cost per person was US$0.64. What these finding 
demonstrate is that, despite variations in cost per person treated due to differences in costs 
included and excluded, integrated treatment interventions using mass PCT for the NTDs are within a 
similar range. It is only when the value of all the donated drugs is included, as observed in Uganda, 
that the cost per person is substantially higher and in comparison could be deemed unaffordable 
especially if drug donations were stopped. However, as discussed in Chapter 1, the commitment to 
current drug donations has recently been re-stated by the pharmaceutical companies who have 
been donating for many years and has also been increased by others during the London Declaration 
for NTDs [22]. 
 
Estimates of financial cost per person treated were sensitive to the number or people treated 
through the programme. The average financial cost per person treated ranged from US$0.70 at an 
output of 42,113 individuals treated to US$0.07 at an output of 573,573 individuals treated. There 
are several reasons that could explain the economies of scale seen. First, a number of the cost 
categories, such as capital costs, overheads and government salaries, are fixed and therefore 
increasing the output reduces the average fixed cost per child treated. Second, as programmes 
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expand there is increased knowledge on how to repeat the same processes more efficiently [224]. 
Economies of scale were also observed in the aforementioned studies in Niger, Nigeria and Haiti and 
have been reported for other large-scale health interventions [225]. This study did not show 
economies of scale for economic cost per person treated when drugs were excluded. Further 
analysis, not shown, shows that economies of scale were observed in Y2 but not in Y3 and Y4 for 
economic cost per person, this could be explained by the increased unpaid labour time required to 
carry out the scale up of treatment within a district from one delivery per treatment campaign to 
two or three deliveries of treatment to the same targeted populations in subsequent years. Indeed 
when the cost of purchased and donated drugs is included in the analysis (see Figure 3.5c) there are 
diseconomies of scale observed and the cost per person increases as the number of people treated 
increases. All districts which were >US$20.00 full economic cost per person treated carried out 
trachoma control as part of their NTD package, therefore the value of donated ZIT is largely 
responsible for driving the high full economic cost per person. Brooker et al. [150] suggested that 
following further scale up of the schistosomiasis and STH control programme into more remote 
areas of Uganda, diseconomies of scale may be encountered. However, despite the increase to 
harder to reach areas of the integrated NTD programme, this study showed that district population 
density and distance from Kampala were not significantly associated with cost per person treated.  
 
There was clear intra-country variation in cost per person treated within and across each year. 
Pallisa consistently had the lowest financial and economic costs per person treated which could be 
attributed to better decision making at the district which led to a more efficient combination of 
inputs to achieve higher treatment coverage. Kyenjojo district in Y2 and Mayuge district in Y2 and Y3 
had the highest financial and economic costs per person treated but in subsequent years had costs 
more comparable across the districts which can be explained by them treating nearly 3.5 times and, 
3.5 times and 6.5 times, respectively, more people for the same amount of financial funds disbursed 
to them than in Y2. This resulted in decreases in the cost per person treated. The difference in 
underlying epidemiology of NTDs and thus number of treatment delivery rounds required per MDA 
campaign, as a consequence of treatment package, is another factor for variations in district cost per 
person. For example, in Mayuge district the economic costs of increasing from one delivery in Y2 to 
three in Y3 could be seen by substantial increases in salaries and volunteer time in the cost centre 
delivery and distribution. In economic terms, variations in costs may reflect underlying differences in 
the production and cost frontiers and in the technical efficiency in delivering the intervention [226].  
In addition to the high number of participants included in this study, a strength of this study in 
comparison to similar studies is the length of time for which districts were followed and costs 
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collected. From inception over the subsequent four programme years (three treatment rounds) the 
effects of scaling up on costs and financial and economic cost per person (excluding drugs) were 
seen to have an overall reduction in the cost per person treated. The general trend for the districts 
was to have decreasing financial expenditures over time but with increasing economic costs. The 
reduction in financial costs is in part due to the increase in knowledge and efficiency previously 
mentioned but also due to higher programme ‘start up’ costs in the first few years [145,224,226]. 
The change in financial costs over time is also influenced by how much the central programme 
receives from the donor and how much it can afford to disburse to the districts. USAID, the overall 
financial support for the Ugandan NTDCP, secures its funds on an annual basis which are at the 
mercy of political and policy changes. When ministries of health are expected to (rapidly) expand to 
new districts and, in turn, districts increase their targeted population, they do not always receive the 
reciprocal funding required. Instead the districts receive what can be afforded to be allocated from 
the central level. When the districts do not receive all the funds required for the scale-up of 
treatments this drives down the cost per person treated, as more people are treated with the 
equivalent, or a slight increase in, money from the previous year. This restricted funding also means 
that often there is slack human resource time i.e. the same number of health workers conduct the 
treatment despite there being fewer resources; and it can affect the programme coverage in a 
district by reducing the number of targeted persons that can be afforded to be reached.  
 
The increase of fulll economic costs over the four programme years is due, again, to the increase in 
numbers of deliveries of treatment required in a district; following the mapping of previously 
unknown prevalence of infection and thus inclusion into the district package of diseases to be 
targeted. By increasing the disease portfolio, CDDs, teachers and supervisors have to spend more of 
their unpaid time of delivery and distribution of the drugs. District staff also incur extra hours spent 
on the programme which may not be remunerated. The amount of time spent on the programme 
can be amplified further when there are logistical issues with the drug supply. Due to the rapid 
expansion of the NTDCP there was a substantial increase in demand for drugs required to treat 
infected populations [14] and consequently drug orders went to the donors and manufactures in an 
uncoordinated fashion. The resultant undersupply and late arrival of drugs in Uganda, especially in 
Y3 (2008/9) of the programme, had far-reaching effects including on time spent on programme 
activities from central level downwards and on overall programme costs. The increase in the full 
economic costs and cost per individual treated over time were influenced by these factors in 
addition to the costs of the purchased and donated drugs. A further knock-on effect of increased 
responsibilities and time which is not recompensed, financially or in-kind, and late and insufficient 
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supply of drugs is that targeted and sustained geographical and programme coverage are not 
achieved. The results show that programme coverage in the districts ranged between 41% and 95% 
and in a district could range between 41% and 90% over three years, demonstrating clear 
inconsistencies.  
 
The average costs reported here can be in line with those projected for the cost of integrated control 
of NTDs in sub-Saharan Africa by Brady et al. [166], Fenwick et al. [207] and the US$0.50 and 
GBP£0.50 campaigns (www.End7.org, www.50pence.org). Nonetheless, it must be emphasised that 
the Ugandan NTDCP used a platform of existing mature and large-scale, SA control programmes for 
NTDs in the country, thus the same costs may not been seen in a country where treatment for NTDs 
has not been previously implemented and/or a country emerging from a post-conflict background 
[227]. In these situations it is likely that cost per person treated will exceed US$0.50 per person 
treated. In addition a cost of US$0.50  per person for treatment of a package of NTDs assumes a 
constant rate of returns which is highly unlikely for an integrated NTD strategy and has not been 
seen in the NTDCP where there has been variation over time or in other published literature 
[228,229]. 
 
Limitations 
There are some caveats to this study: The first is that in some districts the personnel work logs to be 
filled on prospective basis by the DVCOs were often completed retrospectively on collection. 
However, in such circumstances an additional interview was held with the DVCOs to ensure that 
each programme activity was fully described to the interviewer and included any paid or unpaid time 
spent on the programme. Thus, it is assumed that recall bias was minimised and the data used in the 
analysis will be reasonably accurate. Secondly, despite dropping Buliisa district from the analysis due 
to insufficient data, it is still felt that the districts selected were representative of the Ugandan 
NTDCP. Nevertheless, due to the intra-country variation reported, caution should be given to 
extrapolating data across settings without understanding the nature of observed variations. Failure 
to do so will ultimately hinder the efficient allocation of health care resources. However, the 
consistency of programme costs in the findings and with other programmes suggests that it may be 
possible to adjust for such variations when projecting costs. Finally, for the optimal allocation of 
scarce resources policy makers must know not only that a programme is affordable but that it is 
having an impact on health. This chapter does not cover the effect of the Ugandan NTDCP, however, 
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that is the focus on Chapter 4 which will determine the increased savings of IPCT in relation to 
previous SA programmes and cost per morbidity and DALYs averted.  
 
 
Conclusion 
The current analysis is the first to document the cost of an integrated NTDCP using all four PCT drugs 
and seven PCT diseases. I have clearly shown that in financial and economic terms the IPCT strategy 
for control is a low cost option, especially when compared to other interventions such as an 
outpatient visit to a health centre in Uganda which was valued at US$0.95 (2008 prices) 
(http://www.who.int/choice/country/country_specific/en/), US$2.20 for insecticide treated bed-
nets and US$4.03 per child treated with intermittent preventive treatment for malaria (2009 prices) 
[225]. I have reported on the existence of economies and diseconomies of scale and the intra-
country variation in financial and economic costs and cost per person treated and present an 
exploration of the causes of observed variation. Finally I have presented and discussed the effects of 
scaling up a programme on the programme costs and cost per person, including the potential pitfalls 
and consequences in rapid scale-up. Although a programme may be deemed affordable, and cost as 
little as, or less than, US$0.50 per person treated annually it must also be achieving its ultimate 
purpose, in the case of the NTDs to treat above 75% of all eligible populations to control, and even 
higher coverage, to eliminate disease. This study highlights that when the number of treatment 
deliveries carried out during and MDA campaign is increased, the economic costs are greater and 
ultimate treatment coverage is not attained. This is suggestive of diseconomies of scope, whereby 
adding more treatments to the community distribution system results in less efficient treatment 
[224]. These important issues must be addressed by NTD control programmes and the NTD 
community whilst moving forwards. 
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Chapter 4. Cost-Effectiveness of integrated PCT 
for NTD control in Uganda: more health for less 
money? 
 
 
Abstract  
Background: IPCT for the control of NTDs currently involves the mass distribution of up to three safe 
and effective drugs to target populations, without the requirement of individual infection status 
prior to diagnosis. Whilst the cost-effectiveness of these new IPCT programmes over that of their SA 
predecessors is both plausible and predicted, direct empirical evaluation has rarely been performed. 
Methodology: Detailed financial and economic cost data were available from three SA control 
programmes in Uganda – those for combined schistosomiasis and the STH; onchocerciasis; and 
lymphatic filariasis - that had been operating for at least three years prior to 2007 and the inception 
of the integrated NTDCP. Four years of NTDCP cost data (2007-2011) were then used to measure the 
cost-effectiveness of the IPCT strategy for NTD control in Uganda in terms of cost-savings and 
efficiencies of moving from three programmes to one and combined with health impact data to 
estimate DALYs averted. 
Results: Each SA programme cost less per person treated than the NTDCP, however, when the unit 
costs per person for the SA programmes were combined cost savings were observed. Data were 
analysed per number of delivery rounds borne by the drug distributors over one MDA campaign and 
cost savings of 72% and 54% were realised over three and two delivery rounds for the NTDCP when 
compared to combinations of the SA programmes. Cost savings were not detected for the NTDCP 
when only one delivery round was required in an MDA campaign. With the inclusion of volunteer 
time for all programmes cost savings were also achieved by the NTDCP. Overall, 43.5 million 
treatments were received by individuals at an estimated economic cost of US$16.5 per case averted 
and US$10.2 per DALY averted. 
Conclusions: Results show IPCT to be highly cost-effective in NTD control in Uganda. Cost savings 
were achieved over simultaneous implementation of two or more SA programmes. The integrated 
approach also results in a substantial reduction in DALYs over a two year period and thus will have 
greater impact with full therapeutic and geographical coverage over a longer time-frame. If goals of 
elimination are to be reached, for the majority of these NTDs, in Uganda then it must be taken into 
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consideration that cost per DALY averted will become more expensive as costs increase and 
programme health impact will be less due to decreased numbers of infection and morbidity in the 
population. 
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Introduction 
IPCT for the control of NTDs involves the mass distribution of up to three safe and effective drugs to 
target populations, without the requirement of individual infection status prior to diagnosis.  Since 
these, largely donated, drugs are effective against seven of the major NTDs, substantial health gains 
as well as administrative efficiencies are expected to be achieved through coordinating efforts of 
control and/or elimination. One study predictively estimated that, if previously SA NTD programmes 
were combined and using a platform of lymphatic filariasis control, the drugs could be delivered and 
individuals treated at cost savings of 26 to 47 percent in contrast to if all the programmes treating 
each disease separately [166].  
Despite the seven diseases manifesting differently, it is frequently the same populations that are 
affected and are hindered in their physical and economic development as a consequence. Each of 
the NTDs involve chronic morbidities that lead to impairment of childhood development and 
reduced productivity caused by reduced physical and/or cognitive function and, ultimately, to a 
decreased capacity for wage-earning [72,98,128,129,230]. The burden of these NTDs, prior to 
integrated NTD control, was estimated at 57 million DALYs lost annually, including 534,000 deaths 
per year worldwide [7]. Furthermore, as discussed in Chapter 1, such figures are likely to represent 
substantial underestimates of the actual burden due to the, at times, very low disability weights 
assigned to the NTDs which do not account for the full impact of the disease sequelae [123,125]. 
This debate over the value of DALYs lost is of paramount importance from an economic perspective 
as it will lead to a miscalculation of the ICER of any economic evaluation. To be precise, if the DALYs 
lost due to an NTD are undervalued, the benefits in the form of DALYs averted from an effective 
intervention will be underestimated, thus increasing the ICER  because the costs (the numerator) 
would be divided by a smaller benefit (the denominator) [168].  
Whilst the cost-effectiveness of these new IPCT programmes over that of their SA predecessors is 
both plausible and predicted, direct empirical evaluation has rarely been performed. To date, to the 
author’s knowledge, there appears to be a single study published in Nigeria which looks at the cost-
savings achieved when treatment with IVM and ALB is combined with PZQ for the treatment of 
onchocerciasis, lymphatic filariasis, STH and schistosomiasis [209]. Yet, at a time when many national 
control programmes move to, or begin, integrated control of NTDs using PCT, and as international 
funding for this strategy increases, it is imperative that empirical evidence is available. Such 
empirical evidence will evaluate definitively, and thereby determine, if cost savings exist and 
effectiveness is being achieved to validate turning this practice into policy.  This may be particularly 
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pertinent at the current time when further global policies are developing with a change from 
morbidity control to that of potential elimination of certain NTDs [231]. 
Using the Ugandan NTDCP as a model here, the current study aimed to ascertain the cost-
effectiveness of IPCT in comparison to SA programmes for NTDs. Similar to many other developing 
countries, Uganda is affected by a high burden of the PCT NTDs: trachoma [232], STH [185], 
schistosomiasis [233] lymphatic filariasis [199] and onchocerciasis [234] which are described more 
fully in Chapter 1 and summarised below in Table 4.1. Uganda provided useful insight into the 
potential for an integrated strategy to control the NTDs because it was one of the few African 
countries that had undertaken nationwide assessments for several NTDs and had already piloted 
integrated control of several of its SA control programmes [235]. It had also implemented a broader 
integrated health package of maternal and child health interventions including deworming through 
the ‘Child Days Plus’ as described in Chapter 1. Consequently, in 2006 it was selected to be one of 
RTI International’s ‘fast-track’ countries, which would receive funding from USAID, for an integrated 
NTD Control Program to treat the seven endemic PCT diseases 
http://www.rti.org/page.cfm?objectid=4A9941F1-DA0C-4CDB-A96038D35D176033 . Uganda has a 
population of approximately 33.4 million with an estimated 33.2 million at-risk of two or more of the 
NTDs (unpublished data, Uganda MoH Master Plan for the Control of NTDs 2011-15).  Nine of the 
112 districts are endemic for all seven of the NTDs, however 38 of the districts have at least six 
endemic NTDs, thus highlighting that distributions are overlapping and within a district it is often the 
same populations that are afflicted with these diseases (unpublished data, Uganda MoH Master Plan 
for the Control of NTDs 2011-15, [236]).  
This study is the first of its kind to establish the benefits of IPCT for NTDs in terms of not only costs 
saved but also health effects gained. The specific aim of this study was to determine the cost-
effectiveness on the Ugandan NTDCP with detailed cost-analysis on: 1) the key cost drivers in 
determining cost savings between SA and IPCT; 2) the difference in cost per person treated between 
SA and IPCT; 3) calculations of DALYs averted; and 4) determining the ICER between SA and IPCT in 
terms of cost per DALY averted. DALYS averted were chosen as an outcome measure as treatment of 
each disease has different health outcomes and to enable comparison with other health 
interventions. The data generated by the study will help to inform policy makers in African 
governments and elsewhere on the ‘better buy’ aspect of an integrated control strategy for NTDs. 
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Disease Distribution Burden1 Refs 
Onchocerciasis 
(Onchocerca volvulus) 
The western border districts and 
selected foci around Mount Elgon in 
the east.  
 
In total 37 districts are endemic 
Nodule prevalence of >10% 
and <100%.  
 
 
4,290,500 at-risk[237] 
[80] 
[186] 
Schistosomiasis 
(Schistosoma mansoni and 
S. haematobium) 
Concentrated near the shores of lakes 
Victoria and Albert and in the Albert 
Nile basin. 
 
In total 63 districts are endemic 
Prevalence ranging from 60 
to 100% in high-risk areas. 
 
 
5,180,900 at-risk 
[182] 
Hookworm 
 
 
Ascaris lumbricoides and 
Trichuris trichiura  
Hookworm infection is spread 
homogenously throughout the 
country.  
A. lumbricoides and T. trichiura are 
more concentreated in the south-west 
of the country 
 
In total all 112 districts are endemic 
for the STH 
Prevalence of >50% 
 
 
Average prevalence of 
<10%, but >50% in the 
southwest of the country 
 
33,187,100 at-risk 
[185,1
86] 
 
 
 
 
Lymphatic filariasis 
(Wuchereria bancrofti) 
Infection concentrated in the districts 
in the east and north-east, north of 
Lake Kyoga, and in the Albert Nile 
basin.  
 
In total 56 districts are endemic 
Prevalence of CFA in 
schoolchildren 0.4-30.7%;  
 
 
14,493,100 at-risk 
[87,19
9] 
Trachoma 
(Chlamydia trachomatis) 
In the Busoga region in eastern Uganda 
and in the north and the Karamoja 
region in the north-east.  
 
 
In total 35 districts are endemic 
700,000 children <10 years 
have active infection, 
35,000 with TT, 12,000 are 
blind from trachoma  
 
10,806,200 at-risk 
[238] 
Table 4.1: Summary of the distribution and burden of the PCT NTDs in Uganda 
1The burden is estimated from studies carried out pre-treatment under SA and integrated NTD programmes 
 
 
 
 
Material and Methods 
Control Interventions 
MoH SA programmes were in operation in Uganda prior to the inception of the NTDCP. The NTDCP 
brought the coordination of these programmes together under one umbrella whilst receiving 
funding from, largely, one donor [203]. The history and management of each SA programme and the 
NTDCP are detailed in Chapter 1. What follows are a summary of the intervention activities for each 
SA programme in the year(s) in which the costing studies, which are subsequently described, were 
carried out.  
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National Onchocerciasis Control Programme 
In 2003, the NOCP carried out treatment in 21 onchocerciasis endemic districts with a total 
1,766,317 individuals treated out of a targeted population of 2,022,446 estimated to be at-risk of 
infection at that time (87.3% therapeutic coverage). The NOCP was financially supported through 
APOC and assisted further, technically and financially, through Sightsavers and The Carter Center 
[194]. The NOCP at VCD was responsible for the application of IVM donations from Merck & Co. Inc 
through the Mectizan Donation Program. The NOCP then supported the District Health Team who in 
turn assisted the communities by 1) collecting IVM from the national store and delivering it to 
designated points within the district where the community collected from; 2) conducting health 
education; 3) training and supervision of the CDDs; and 4) providing financial support, where 
necessary. CDTI was then employed to treat eligible members of communities at a time and venue, 
including whether distributed from door to door or at a focal point, by community selected CDDs.   
 
National Bilharzia and Intestinal Worm Control Programme 
The BWCP treated 432,746 (78.6%), 1,230,000 (88.0%) and 2,988,454 (87.0%) school-children and 
adults in the years 2003 to 2005 respectively, with programme coverage in parenthesis. Mass 
treatment with PZQ and ALB was distributed in 18 districts in 2003 and 2004 and 23 in 2005. The 
programme, financially and technically supported through SCI, was based at the VCD with district 
activities managed and supervised by the District Health Team specifically by the DVCO. Training was 
cascaded down to sub-district level supervisors at the HC (levels II and III), school teachers and CDDs 
and each was responsible for community mobilisation and registration, health education, drug 
distribution in SAC and high-risk communities and reporting [239]. MDA in schools and communities 
was carried out in April each year alongside the Child Days Plus campaigns which are described in 
Chapter 1.  
 
Programme for the Elimination of Lymphatic Filariasis 
PELF in Uganda was technically and financially supported by the WHO and the GAELF. The five 
districts in 2004 treated 1,326,728 individuals, followed by ten districts and 3,196,204 treated in 
2005. Mass treatment with IVM and ALB was carried out in schools by teachers and in communities 
by CDDs who chose to either distribute the medicines door to door or from a central location within 
the community. The decision of how to treat was generally decided by the District Health Team who 
managed and supervised the programme ensuring that all programme activities, such as training, 
social mobilisation, registration and treatment were carried through and that treatment reports 
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were complied. Due to logistical and financial challenges treatment was carried out in different 
months in each treatment year.  
 
National Trachoma Task Force 
As highlighted in Chapter 1 there was no large-scale distribution of treatment for trachoma through 
the MoH or NGDO’s prior to 2007 and the NTDCP. Thus there was no SA programme for trachoma 
control and all trachoma treatment began under IPCT. 
 
Study Sites 
The districts included in each of the SA programme costing studies varied, some of which 
overlapped, and are listed below. Nevertheless, five of them were the same as those selected to cost 
the NTDCP which is covered in Chapter 3.  
 
National Onchocerciasis Control Programme 
Four districts in the west of Uganda, Hoima, Kasese, Kisoro and Masindi, were selected on the basis 
that they were mature projects that is, that they were in their 5th year or more of APOC support 
[144]. The purpose of the study was to determine the economic sustainability of the CDTI strategy 
and these selected districts represented a range of sizes defined as number of treatments in a cost 
year, as well as other factors. The study district population treated was attributable to 13% of the 
total population treated in all programme districts for that year.  
 
National Bilharzia and Intestinal Worm Control Programme 
Six districts, Busia, Mayuge, Hoima, Masindi, Moyo and Nebbi, of the 23 implementing control at 
that time were included in the costing study [150]. The districts were chosen to reflect differences in 
disease transmission and in socio-economic and health service infrastructure, because the study 
aims were to identify cost-effectiveness as cost per anaemia averted in addition to cost per person 
treated. The study district population treated over all years was attributable to 30% of the total 
population treated in all programme districts over all years.  
 
Programme for the Elimination of Lymphatic Filariasis 
The two districts of Katakwi and Lira were chosen so that three years of programme costs could be 
analysed. However, the central and district financial records for 2002, the first year of 
implementation, were poor and were not included in the final analysis. The aim of the study was to 
collect data on PELF to determine cost per person treated, for comparison to the BWCP and with a 
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view to comparisons with integrated NTD programme costs. The study district population treated 
over both years was attributable to 34% of the total population treated in all programme districts 
over both years.  
 
Measuring Costs 
Financial and economic cost data were collected prospectively and retrospectively in Uganda for the 
first four years of the integrated NTDCP. The methods on how these NTDCP data were collected are 
fully described in Chapter 3. Costs for the SA control programmes were collected using marginally 
different methods for which full details can be found in Brooker et al. 2008 [150] (Appendix IV for 
which I am a co-author) for the costing of the schistosomiasis and STH control in Uganda between 
2003 and 2005 and in McFarland et al. 2005 [144] for the costing methods used in evaluating CDTI 
strategy for onchocerciasis control in Uganda in 2005. I collected the PELF programme cost data in 
2008 using the same methods described in Brooker et al. [150] (Appendix IV ). The methods used for 
costing the SA programmes are described below and specific differences between the costing 
methods are highlighted.  
(1) Perspective and time horizon 
The costing study took the perspective of collecting all in-country costs borne by the major in-
country partners for each SA programme for example, the government, the NGDOs, the GAELF and 
the community. Household costs of accessing treatment were deemed to be negligible, as children 
were treated in their own schools and adults were either treated at home or in a central locality 
within the community. Only the costs on all the resources consumed to manage and deliver the 
treatment programme with the appropriate chemotherapy were included and not the cost of any 
‘add-ons’ such as Vitamin A distribution or clinic based treatment. The costs of any epidemiological 
or sociological studies were not included in the costing. Neither were the costs for morbidity 
management and hydrocele surgery for lymphatic filariasis included. The project cost years 
overlapped and were calendar year 2003 (NOCP), 2003 to 2005 (BWCP) and 2004 to 2005 (PELF).  
(2) Cost Disaggregation 
Each of the costing studies clearly identified how costs had been similarly allocated to different 
inputs or programme activities and thus it was a relatively straightforward process to re-allocate 
costs under each programme into the same defined disaggregated categories. The programme 
inputs were defined as transportation, consumables, salaries, per diems, overheads, volunteer time 
and capital costs; and the programmatic activities were grouped as administration costs, community 
sensitisation and health education, training, registration, drug delivery and distribution and 
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reporting. Unlike the original costing of the NOCP this study has not presented the disaggregation of 
the contributions made by the Government of Uganda and all implementing partners, however the 
contribution of the MoH is clear in the results. The NOCP costing did this to determine the 
sustainability of the programme, yet with move to elimination for many of these diseases; there is 
less expectation that governments will ever fully become responsible for the running of NTD 
programmes. Nonetheless, the desire is still for governments to see these programmes as affordable 
with high impact and continue to politically and financially support them during control and 
elimination strategies through staff, buildings and other resources.  
(3) Collection of central, district and community costs 
In each programme the resources used which were directly attributable to the programme activities, 
such as per diems, fuel, supplies, capital inputs and those resources not directly attributable to the 
programme but incurred because the programme exists, for example, rent, electricity and other 
overheads and the opportunity cost of MoH building and office space, were included. All the 
programmes collected financial (expenditure) and economic cost data by reviewing accountancy 
records and programme documentation in addition to interviewing key personnel. The amount of 
time spent on specific programmatic activities by different personnel and what inputs were required 
to achieve these activities were defined through these sources.  
(4) Valuation of resource use  
Economic costs were the opportunity costs of using MoH staff, school teachers and CDDs as well as 
annuitized capital costs of buildings and other capital inputs. The opportunity costs of the staff were 
calculated from salary costs, based on Ugandan civil service scales for the appropriate years of the 
studies. In the NOCP study, the CDD volunteer time was valued as the average per capita GNI in 
2003. However, to ensure comparability with the BWCP, PELF and NTDCP programmes the volunteer 
time was re-estimated using the equivalent to the Uganda casual labour wage [211]. Capital costs 
were annuitized over the useful life of each item using a discount rate of 3%, following standard 
practice [212]. Such annuitization enables an equivalent annual cost to be estimated and reflects the 
value–in-use of capital items, rather than reflecting when the item was purchased. The NOCP costing 
study used an average useful life of 5 years for all capital items and for buildings rental price was 
used. For all the other costing studies, SA and integrated, the assumed useful life of buildings was 30 
years, vehicles 7.5 years, motorcycles 4 years and computers 3 years in line with standard economic 
evaluation guidelines [211]. That the valuation methods differ matters less than the fact their 
economic cost was estimated and included. All costs were paid in Ugandan Shillings (USh) and were 
converted in each of the separate studies to US dollars using: the exchange rate that existed at the 
 Page | 127  
 
time and then inflated to 2004 prices (NOCP); average yearly exchange rates for 2003, 2004, 2005 
and then inflated over time using the GDP implicit price deflator and expressed in 2000 prices (PELF 
and BWCP); and for the integrated NTDCP the average annual exchange rates for the programme 
years 2006/7, 2007/8, 2008/9 and 2009/10 were also adjusted for inflation over time using the GDP 
implicit price deflator and were expressed in 2010 prices (IMF, 2008 
http://www.imf.org/external/pubs/ft/weo/2008/01/weodata/index.aspx). For the purposes of this 
study, the prices for the NOCP, PELF and BWCP were then inflated to US$ 2010 prices for 
comparison in the analysis to the NTDCP.  
 
(5) Shared costs 
For each programme it was not feasible, due to the number of districts and individuals involved, to 
collect cost data at all levels and therefore costs at the central level were apportioned equally to 
each district in that particular programme. At the district and sub-district level any costs that were 
collected on a sample of units, for example health-worker supervisors or CDDs, were pooled and 
then an average cost per unit was calculated. To give an estimation of the costs at the district level, 
the cost per units would be multiplied by the total number of units known (health-worker 
supervisors, CDDs, or other resources), from records, to be used at that level.  
 
(6) Assumptions 
Table 4.2 shows how all the data sets are comparable in key types of cost data collected. As the 
study on the NOCP did not collect data on the cost of the IVM used in the programme, the drug 
related cost data were excluded from the cost-effectiveness study reported here. The cost study on 
the PELF did not collect data on the time spent by the drug distributors, therefore, the opportunity 
cost of two days by the teachers and three days by the CDDs were retrospectively added to each of 
the districts for the MDA period. These days are known, from experience, to be the minimum 
number of days that a teacher and CDD could perform a mass treatment campaign for their schools 
and communities respectively. The number of days, however, could be an underestimation and thus, 
to ensure comparability, the data have also been analysed excluding all volunteer costs. Lastly, the 
PELF was implemented solely through the MoH and no extra salaried staff were employed. This was 
not the case for the NOCP, the BWCP and the integrated NTDCP which all had salaried staff, 
additional to the MoH staff, working on the programmes. Therefore all the costs of salaried staff 
other than those of the MoH, which are paid for by the Government of Uganda, were removed from 
the costings of the NOCP, the BWCP and integrated NTDCP.  
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Type of cost data  NOCP BWCP PELF NTDCP 
supra-national no no no no 
drugs no yes yes yes 
volunteer time yes yes no (estimated) yes 
non-MoH salaries yes (removed) yes (removed) no yes (removed) 
financial expenditure† yes yes yes yes 
economic†† yes yes yes yes 
Table 4.2: Types of cost data collected by each SA programme and the NTDCP 
† financial expenditure as opposed to budgetary data 
†† in addition to financial expenditure the full economic cost of items were valued 
 
Estimating Impact of integrated PCT on Infection Prevalence 
A health impact study to determine reductions in the prevalence, intensity of infection and specific 
disease morbidity markers in the target populations, due to IPCT distributed through the NTDCP, 
was conducted concurrently to the costing study of the programme.  
(1) Study Design 
Parasitological and morbidity data were collected in 18 schools and in 16 communities across six 
districts in Uganda following stratified random sampling according to NTD endemicity and 
overlapping distributions. The selected districts were Nebbi, Yumbe, Busia, Mayuge, Kitgum and Lira-
Amolotar districts; the latter district had been split into two administrative districts, but for the 
purpose of the study was treated as one district. Details on these districts and inhabitants are 
provided in Chapter 1. An observational study design was chosen rather than an randomised trial, 
for the following reasons: (i) it would be unethical to have a ‘control’ where populations would not 
receive IPCT which is known to treat infection and, (ii) the ability to control when the intervention, 
IPCT, was delivered was under the control of the MoH and RTI and not the primary investigator.  
Due to the different epidemiology of each disease, different, albeit overlapping, age groups needed 
to be monitored to assess the impact of the intervention. These were: 
 longitudinal cohorts in school children, aged 6 to 11 years old (schistosomiasis, STH and 
trachoma) 
 cross-sectional survey of 6 and 11 year olds (onchocerciasis) 
 cross-sectional surveys of adults, aged 15 years old and above (schistosomiasis, STH, 
onchocerciasis and trachoma) 
 cross-sectional surveys of whole communities above 1 year old (lymphatic filariasis) 
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Longitudinal cohorts allowed the same school-children to be followed up at each data collection 
time point. Baseline was in NTDCP Y2 (2007/8), first follow-up in Y3 (2008/9) and second follow-up in 
Y4 (2009/10). Due to the invasive nature of some of the diagnostic tools used and the previously 
experienced poor adult cohort follow-up rates, it was decided that longitudinal cohorts in adults 
would not be appropriate. Therefore, cross-sectional surveys were carried out in adults to assess 
schistosomiasis, STHs, onchocerciasis and trachoma infection. The only ethical and logistically 
feasible method of obtaining estimates of parasite intensity in lymphatic filariasis is by conducting 
night bleeds on patients (to assess microfilaraemia). As a result of this sampling being carried out at 
a different time of day, separate cross-sectional surveys in lymphatic filariasis endemic communities 
were carried out at baseline (Y2) and Y4. 
 
(2) Sample Size 
Sample sizes were calculated using an expected reduction of 50% in mean intensity of S. mansoni 
infection (by means of faecal egg counts) following IPCT to achieve 80% statistical power and a 
significance level of 5%, as projected by the computer model EpiSchisto. The value of 50% was 
chosen as a conservative estimate of the expected reduction over a three-year period (2007 – 2009). 
Drop- out rates as estimated from past SCI data in Uganda were also allowed for in the calculations 
of the sample sizes over the course of the monitoring period. The full sample size calculations as 
derived by the then SCI Biostatistician, Artemis Koukounari, as well as Professor JP Webster and 
Professor CA Donnelly are described in Appendices V and VI. Where there was no pre-existing data 
for each NTD, WHO recommendations for sample sizes were used [240,241]. Calculated sample sizes 
were (also see Table 4.3): 
 In longitudinal cohort sentinel sites in school-children where S. mansoni and STH, or S. mansoni, 
STH and trachoma, or each of these infections was endemic separately, a minimum of 240 
children per school ages 6 to 11 years, and 3 schools per survey district were sampled annually.  
In each school the 6 year olds and 11 year olds would also be sampled, if not part of the cohort, 
for cross-sectional analysis. The purpose of this was, in the 6 year olds to measure transmission 
of infection. For each of the age-groups 60 children would be sampled. 
In areas where onchocerciasis was endemic additional cross-sectional surveys were collected 
from 6 and 11 year olds in each school at baseline (Y2) and Y4. 100 children were sampled, 50 
children in each of the two age groups. 
 In all study districts 2 cross-sectional survey sentinel sites with 180 adults, 15 years and above, 
were surveyed at baseline (Y2) and Y4. These sites were to measure schistosomiasis, STH, 
trachoma and onchocerciasis infection markers where appropriate.  
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 In each survey district where there was lymphatic filariasis only, or overlap of lymphatic 
filariasis with any of the aforementioned NTDs, there was 1 cross-sectional survey sentinel site 
with a minimum of 500 individuals carried out at baseline and Year 3. This site was used for 
measuring lymphatic filariasis clinical and infectious status in children >1 year of age, as well as 
pregnant women, should be included in the surveys. 
In these lymphatic filariasis survey districts, one additional spot-check survey sentinel site was 
carried out with a minimum of 500 individuals at Year 3 in line with WHO recommendations 
[240]. 
 
Sentinel Sites 
Age 
(cohort in bold) Size 
Year Two 
(baseline) Year Three Year Four 
School Cohort 
 
3 schools per district 
60 children per age-group 
 
Yr2  6  7  8  9  10  11 
 
Yr3  6  7  8  9  10  11 
 
Yr4  6  7  8  9  10  11 
 
240 
 
300 
 
360 
 
 
Yes 
 
 
Yes Yes 
School  
Cross-sectional 
(skin snips only) 
In each school cohort where 
onchocerciasis is endemic 
 
6 year olds 
 
11 year olds 
 
60 
 
60 
Yes  Yes 
Cross-sectional 
(Schistosomiasis/STH/ 
Onchocerciasis/Trachoma) 
2 x sentinel sites per district 
>15 yrs 180 Yes  Yes 
Cross-sectional  
(Lymphatic filariasis) 
1 x sentinel sites 
1 x spot check sites per district 
>1 yr ≥ 500 
Yes 
(no spot 
check) 
 Yes  
Table 4.3: Sentinel site data collection by year of study 
 
(3) Methods and Materials 
Following local authority, school and parental approval, name registers of the cohort children in 
each age-group were recorded along with their unique code identifier. Before each follow-up the 
schools were visited by a pre-survey team to sensitize the children to ensure that as many children 
as possible in the cohorts were at school the day of survey. All the individuals enrolled in the cohorts 
and cross-sectional surveys were examined by trained MoH staff. Ethical clearance was obtained 
from the Ugandan National Council of Science and Technology and Imperial College London. 
The parasitological, clinical and haematological diagnostic methods that were performed for each of 
the NTDs, and the full sample size for each are detailed in (Table 4.4).  
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Infection Diagnostic method and clinical examination Sample size 
Onchocerciasis 
(O .volvulus) 
Microfilaridermia (microfilariae (mf) per skin snip). Two 
skin snips from the iliac crests taken from each individual 
using a 2mm Holth corneoscleral punch and incubated for 
24 hours in isotonic saline in microtitration plates. O. 
volvulus mf are then counted under a low power 
microscope (x40). 
Onchocercal dermatological examination following 
standardised grading system [78]. 
600 children  
720 adults 
Schistosomiasis 
(S. mansoni)  
and the STH 
 
Kato-Katz thick smear of stool and microscopy to measure 
eggs per gram of faeces from two samples per two days. 
All slides read within one hour of preparation to ensure 
presence of hookworm eggs could be read. 
Associated liver and spleen pathology using ultrasound 
examination following standardised protocols developed 
by WHO [45] and hepatosplenomegaly palpation by 
nurses. 
4320 children 
2160 adults 
Lymphatic Filariasis  
(W. bancrofti) 
Night-blood films (thick), made from 100 μl of fingerprick 
blood using a capillary tube, to measure microfilaraemia 
prevalence and intensity. 
Lymphoedema and hydrocoele palpation for the six 
chronic manifestations of lymphatic filariasis and 
examination for signs of acute episodes of ADL (recurrent 
attacks of fever associated with inflammations of the 
lymph nodes and/or lymph vessels) [242] 
2000 individuals 
Trachoma 
(C. trachomatis) 
Ophthalmological examination following  
simplified WHO grading system [104] 
3600 children 
1800 adults 
Anaemia Hb concentration (Hb)<110 g/L measured by 
haemaglobinometer 
4320 children 
2160 adults 
2000 individuals 
Nutritional markers Weight  using weight-scale; Height using stadiometer; Mid-
upper arm circumference using measuring tape; Skinfold 
thickness (biceps, triceps, subscapular, suprailiac) using 
callipers. Three measurements of each were recorded. 
4320 children 
 
Table 4.4: Infection and morbidity markers measured and sample size at NTDCP baseline (Y2) and annually 
until NTDCP Y4. Sample size in children represents those sampled as part of the longitudinal cohort and adults 
as part of the cross-sectional sampling.  
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Estimating Effectiveness in DALYs 
In addition to cost savings between SA programmes IPCT (detailed under Cost-Effectiveness Analysis, 
p134), programme effectiveness of the NTDCP was also measured in terms of infection and DALYs 
averted for each of the NTDs. The number of infection cases averted was calculated by multiplying 
the absolute difference in prevalence of infection between baseline (Y2) and second follow-up (Y4) 
by the total number of individuals treated over a two-year period. DALY’s averted were calculated 
using the GBD calculation [127,243] as laid out by Fox-Rushby and Hanson [244]. Years-of-life-lost 
(YLL) were not included in the analysis because the NTDs in this study rarely cause fatalities; it is 
their chronic consequences which are far more important in terms of disease and economic burden. 
Accordingly, the DALY calculation for nonlethal conditions was based on years-lost-to-disability (YLD) 
and using disability weights reflective of the impact due to ill health from each particular disease 
during the period it afflicts the individual were used. This calculation [244] in full is, with parameters, 
given in Table 4.5. 
 
 
 
 
Model Parameters 
The DALY model parameters were chosen after careful consideration of those used in the GBD 
studies [243] and the available literature supporting and criticising the GBD studies in relation to 
DALY calculations for the PCT NTDs [124,133,134,142,244-246]. The parameters chosen and the 
appropriate references are described in Table 4.5 and any assumptions in choice of parameters 
detailed below. 
 
Age of onset of disability: Age of onset of disability was taken to be the median age of onset of 
infection for each disease. The rationalisation for this is that these PCT diseases are chronic 
infections with long term sequelae which are a result of repeated infection and re-infection. Thus, if 
untreated, these infections cause developing disability from the initial infection, first through subtle 
morbidity and later through chronic morbidity symptoms and at times mortality [27,123,135,247-
251]. 
 
Duration of disability: When calculating the YLDs for the follow-up data (Y4), in addition to the 
reduction in prevalence of infection and morbidity over time, two years were removed from the 
durations of each infection i.e. two healthy years of life gained, to reflect the impact of treatment. 
This assumption is justified because treatment for the NTDs will only temporarily reduce those at-
YLDs[r,K,β] = D{KCera/(r + β)2{e-(r+β)(L+a)[-(r+β) (L+a) – 1] 
-e-(r+β)a [-(r+ β)a – 1]] + (1-K)/r (1– e-rL)} 
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risk of infection (represented by a change in prevalence) and arrest the progression of morbidity, if 
treatment is not repeated then rapid re-infection will occur [111,252,253].  
 
Incidence of infection: Prevalence of infection was used in these models instead of incidence which is 
the standard measure used in YLD calculations (incidence*disability weight*duration). Prevalence 
was used to represent the disease burden in one particular year. To compensate for the point 
prevalence measurement, future discounting (r) was removed from the models as it would be 
inappropriate to discount for future losses. Although not as common as the use of incidence in DALY 
calculations, prevalence has been used previously [124,254], including in the GBD 2010 study [255], 
and is an acceptable alternative as this model is not tied to mortality [256].  
Prevalence of infection: For onchocerciasis, skin snips were initially taken to measure prevalence of 
mf, however because the procedure to take the skin snips causes minor pain, the number of 
individuals willing to be sampled dropped substantially from baseline to follow-up. The sample sizes 
became too small to robustly measure the change in prevalence of mf and were not included in the 
analysis. Prevalence of nodules is not a good measure of infection after several rounds of CDTI and 
thus prevalence of itching and dermatological skin conditions were used instead throughout the 
analysis [73]. Prevalence of itching and dermatological skin conditions are more indicative of 
disability from an individual’s perspective as onset of skin disease is at a similar time to first infection 
[73]. 
 
Estimating DALYs in the presence of co-infections 
The standard DALY metric assumes a single-disease hypothesis and thus fails to consider the fact 
that multiple diseases may exist in a patient [257]. In sub-Saharan Africa, however, polyparasitism 
and co-infection of parasitic and bacterial and viral diseases are common [258-261]. Uganda is no 
exception and co-infections with different species of helminth infections, with and without malaria 
have been well reported [262-264]. In the absence of disability weights for co-infection in DALY 
calculations, in this study it was decided to use a composite measure of DALYs averted by each of 
the NTD infections to show the effectiveness of the IPCT strategy in Uganda. Using a composite 
measure is used in studies [7,265] nevertheless, a composite estimate of DALYs averted from the 
IPCT could be either an underestimation or an overestimation of what is actually being achieved.  
 
Underestimation: Evidence exists that two, or more, different parasites in a co-infected individual 
can have a synergistic effect which leads to worse health [139,140,266-268]. Where this effect 
occurs the DALYs lost may be higher than the sum of DALYs from each individual infection. Thus the 
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DALYs averted through IPCT would be an underestimation when a composite measure is used. 
 
Overestimation: In contrast to an underestimation of the DALYs lost due to co-infection, there is also 
the possibility that a composite measure may overestimate the DALYs lost and thus averted through 
IPCT in this study. The overestimation might occur because one infection has an antagonistic effect 
on another infection [140,269-271], and thus the morbidity in the co-infected individual is less than 
that suffered where there are no interactions between the co-infections. If the morbidity 
experienced is less in an individual then the DALYs lost will also be less and the effect of IPCT would 
result in less DALYs averted.  
 
In their 2011 study, Haagsma et al. [272] compare the three comorbidity adjustment approaches 
that exist for burden of disease studies: 
(i) The maximum limit approach. This approach counts the disease with the highest overall 
disability weight. The approach assumes that a comorbid disease does not affect the disability of 
an individual with a primary disease, unless the comorbid disease exceeds the disability of the 
former. 
(ii) The additive approach. This approach assumes that the additional effect, or more precisely, 
the utility loss, of comorbid disease simply adds to the effect (utility loss) of the primary disease 
observed in singly infected individuals. The disability weights of the comorbid diseases are added 
up. 
(iii) The multiplicative approach. This method assumes that a comorbid disease increases the 
utility loss of a patient, though it is less than the sum of the utility loss of both diseases 
independently. 
The authors conclude that the additive and multiplicative models tested in the study showed the 
strongest associations between predicted and observed disability weights. The composite measure 
in this study is in line with the additive approach. Justification for using this approach is due to the 
unclear relationship between the potential co-infections in the Uganda study population. Estimates 
of the number of individuals with co-infections have not been done. The best way to solve this 
problem would be obtain separate disability weights for co-infections that would entail conducting 
an elicitation workshop where relevant individuals were asked to value living one year in a co-
infected state, for each possible combination of co-infections, on the scale of 0, which represents 
perfect health, to 1 which represents death. This solution is, however, beyond the scope of this 
study. More feasible solutions for the future are addressed in the Discussion section of this chapter.  
 Pa
ge
 | 
13
5 
 
 Pa
ra
m
et
er
 
Va
lu
e 
Pa
ra
m
et
er
 so
ur
ce
 a
nd
 n
ot
es
 
K,
 a
ge
 w
ei
gh
tin
g 
m
od
ul
at
io
n 
fa
ct
or
 
1 
a b
as
e 
ca
se
 re
co
m
m
en
de
d 
an
d 
us
ed
 b
y 
M
ur
ra
y 
an
d 
Lo
pe
z [
12
7]
 a
nd
 F
ox
-R
us
hb
y 
&
 H
an
so
n 
[2
44
] 
C,
 c
on
st
an
t 
0.
16
58
 
a 
r, 
di
sc
ou
nt
 ra
te
 
0.
03
 
a  
a,
 a
ge
 o
f o
ns
et
 o
f d
isa
bi
lit
y 
5 
ye
ar
s o
f a
ge
 
2 
yr
s 
2 
yr
s 
4 
yr
s 
4 
yr
s 
on
ch
oc
er
ci
as
is[
73
,2
73
]  
sc
hi
st
os
om
ia
sis
, c
on
se
rv
at
iv
e 
es
tim
at
e 
of
 o
ns
et
 o
f i
nf
ec
tio
n 
[2
74
,2
75
] 
ho
ok
w
or
m
[6
6,
14
0]
 
ly
m
ph
at
ic
 fi
la
ria
sis
 [8
7]
 
tr
ac
ho
m
a,
 m
ed
ia
n 
ag
e 
in
 p
ea
k 
pr
ev
al
en
ce
 o
f a
ct
iv
e 
in
fe
ct
io
n 
in
 c
hi
ld
re
n[
10
5,
10
7]
  
β,
 p
ar
am
et
er
 fr
om
 th
e 
ag
e 
w
ei
gh
tin
g 
fu
nc
tio
n 
0.
04
 
a  
L,
 d
ur
at
io
n 
of
 d
isa
bi
lit
y b
 
 
47
 
50
 
50
 
48
, 1
6,
 3
2 
48
, 1
7,
 7
 
on
ch
oc
er
ci
as
is 
[7
3,
27
3,
27
6]
 
sc
hi
st
os
om
ia
sis
 [1
23
,1
24
] 
ho
ok
w
or
m
 [6
6,
14
0,
25
1,
27
7]
 
ly
m
ph
at
ic
 fi
la
ria
sis
: s
ub
cl
in
ic
al
 d
ise
as
e,
 h
yd
ro
ce
le
 a
nd
 ly
m
ph
oe
de
m
a 
[8
7,
14
2]
 
tr
ac
ho
m
a:
 n
or
m
al
 v
isi
on
, l
ow
 v
isi
on
, b
lin
dn
es
s [
25
0,
27
8,
27
9]
 
D,
 d
isa
bi
lit
y 
w
ei
gh
t 
0.
06
8 
0.
05
 
0.
03
0 
0.
06
8,
 0
.0
73
 
0.
06
8,
 0
.2
45
, 0
.5
81
 
on
ch
oc
er
ci
as
is 
[6
9,
24
3,
24
6]
 
sc
hi
st
os
om
ia
sis
 [1
23
,1
24
,1
33
,1
34
,2
43
] 
ho
ok
w
or
m
[2
43
,2
45
] 
ly
m
ph
at
ic
 fi
la
ria
sis
: s
ub
cl
in
ic
al
 d
ise
as
e,
 h
yd
ro
ce
le
 a
nd
 ly
m
ph
oe
de
m
a 
[2
43
,2
46
] 
tr
ac
ho
m
a:
 n
or
m
al
 v
isi
on
, l
ow
 v
isi
on
, b
lin
dn
es
s [
24
3,
25
0,
27
8,
27
9]
 
e,
 N
ap
ie
r's
 m
at
he
m
at
ic
al
 c
on
st
an
t 
2.
72
 
a  
Ta
bl
e 
4.
5:
 P
ar
am
et
er
s u
se
d 
in
 D
AL
Y 
es
tim
at
es
 a
nd
 th
e 
so
ur
ce
 o
f p
ar
am
et
er
s 
a b
as
e 
ca
se
 re
co
m
m
en
de
d 
an
d 
us
ed
 b
y 
M
ur
ra
y 
an
d 
Lo
pe
z 
[1
27
] a
nd
 F
ox
-R
us
hb
y 
&
 H
an
so
n 
[2
44
] 
b 
W
he
re
 a
pp
lic
ab
le
 fo
r e
st
im
at
in
g 
du
ra
tio
n 
th
e 
av
er
ag
e 
lif
e-
ex
pe
ct
an
cy
 in
 U
ga
nd
a 
= 
52
.3
4 
ye
ar
s[
17
4]
 
 Page | 136  
 
Cost-Effectiveness Analysis 
Cost Savings  
Cost savings were measured by changes in the average unit economic cost per person treated 
between the SA programmes and the NTDCP. Changes between SA programmes and the NTDCP 
were measured at the national level rather than at a sub-national level. For each programme the 
national level unit economic cost per person treated was calculated as the annual programme costs 
divided by the annual number of treatments for each control programme. Costs were disaggregated 
by input and activity as listed previously. The SA control programmes, NOCP, BWCP and PELF were 
all run concurrently in Uganda, prior to integration, and were held as separate events at different 
points of the same year. In areas with overlapping disease distributions, the community members 
might receive treatment from all of the three programmes or, any two of the programmes or, just 
one of the programmes. Thus, incremental cost savings were calculated by the difference between 
the unit costs of the NTDCP and the sum of the unit costs of the SA programmes 
(NOCP+BWCP+PELF). Nevertheless, not all districts required the delivery of all three SA programmes 
due to underlying disease endemicity. Accordingly, the mean of the unit costs to deliver two SA 
programmes (NOCP+BWCP, NOCP+PELF, BWCP+PELF) and one SA (NOCP, BWCP and PELF) 
programme were compared to the equivalent mean cost of three, two and one delivery rounds per 
MDA in a district for the NTDCP (all in 2010 US$ prices).  
 
Cost per case and DALY averted 
Cost-effectiveness in this study was also defined as cost per infection case averted for each of the 
diseases and cost per DALY averted. These were both calculated by dividing the total costs - the 
number of individuals treated multiplied by the economic cost per person - by either the number of 
cases or DALYs averted for each infection.  
 
Incremental Cost-Effectiveness Ratio 
ICER is the measures used to report the cost-effectiveness of different interventions in cost-
effectiveness analysis (CEA) and cost-utility analysis. The ICER is calculated by: 
total cost of new intervention – total cost of old intervention    (CostsB – CostsA) 
outcome of new intervention – outcome of old intervention    (EffectB – EffectA) 
As some of the districts in Uganda had not received any mass treatment for NTDs prior to the 
integrated programme the counter factual could be defined as ‘do nothing’ i.e. no treatment. A 
comparison with the combined SA programmes is also important to determine whether an 
integrated strategy is more cost-effective. Effectiveness data for measuring programme impact for 
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the SA programmes were not available to use in this study. For that reason, it was assumed that the 
SA programmes, if they had continued independently, would achieve the same outcomes and health 
impact as those observed under the NTDCP. Excluding the effects of treating trachoma as it had not 
been mass treated prior to the integrated NTDCP. Hence the outcomes of treating 100,000 
individuals, as determined in the effectiveness analysis, and the costs of treating 100,000 individuals, 
as determined in the cost savings analyses were calculated, for the SA programmes and the NTDCP 
by the following calculations, when 
(i) SA = onchocerciasis + schistosomiasis + hookworm + lymphatic filariasis, and 
(ii) NTDCP = onchocerciasis + schistosomiasis + hookworm + lymphatic filariasis + trachoma 
 
(a) Proportion of total number of treatments to give cases averted by treatment for (i) and (ii) in 
a population of 100,000 
(b) Proportion of total number of treatments to give DALYs averted by treatment for (i) and (ii) 
in a population of 100,000 
(c) The total cost per (i) and (ii) was cost/person treated (US$) for (i) and (ii) multiplied by 
100,000  
(d) The cost per case averted (US$) was (c)/(a) for (i) and (ii) 
(e) The cost per DALYs averted (US$) was (c)/(b) for (i) and (ii) 
(f) The incremental cost (US$) was (c) (ii) minus (c) (i) 
(g) The incremental DALYs averted was (b) (ii) minus (b) (i) 
(h) Incremental cost per DALY averted (ICER US$) was (e)/(f) to give the difference the 
difference in treating 100,000 individuals under each strategy. 
 
Statistical Methods 
Economic data 
For reasons covered in Chapter 3, a non-parametric statistical test, the Wilcoxon rank sum, was 
chosen to test the null hypothesis that there were no differences between the means of the units 
costs per person treated across the control programmes.  
Impact of IPCT data  
A longitudinal observational analysis was performed in order to provide an overview of the effects of 
the mass treatment programme. SAS vs. 9.13 (SAS Institute, Cary, NC) software was used for data 
management and the production of descriptive statistics. MLwiN (Version 2.23; Centre for Multilevel 
Modelling, University of Bristol) was used to generate multilevel regression models to determine the 
impact of mass treatment on prevalence of S. mansoni, hookworm, onchocercal dermatitis and 
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active trachoma infection while accounting for variation between sentinel schools, individuals and 
time points. All models controlled for age and gender. As the prevalence of lymphatic filariasis was 
very low in the communities sampled the Wilson Score Interval was used to determine the 95% 
confidence intervals. The Wilson Score Interval was used to express the uncertainty associated with 
the small sample size as the statistical formula performs better with small sample sizes and a 
proportion which is close to zero or one to provide a more accurate interval [280]. A multilevel level 
random-effects model was run to determine the impact of mass treatment on prevalence of W. 
bancrofti mf, however this model did not control for age or sex due to missing information.  
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Results 
Cost savings of the integrated PCT 
The total economic costs for the districts included in the integrated NTDCP and each SA programme 
by input are shown in Table 4.6. Volunteer time is the largest input across all programmes with 
salaries and per diems also universally high proportions of input costs. Although volunteer time was 
the greatest input for all, the unit cost was lower in each of the SA programmes, which was 
significant for the BWCP (p<0.001) and PELF (p<0.05), than in the NTDCP (US$0.44). The PELF 
programme had the lowest overall unit input costs of all the programmes, and total cost per person 
treated (US$0.10) the latter value is a reflection of the lower total costs for the study districts and 
higher numbers treated in comparison to the other programmes. The total cost per person treated 
for both BWCP (US$0.20) and PELF (US$0.10) were lower than the NTD control programme 
(US$0.60), yet, the cost per person treated for the NOCP (US$0.65) was the highest. These results 
were highly significant for PELF (US$0.10, p<0.001) and BWCP (US$0.20, p<0.001). Figure 4.1 
represents the breakdown of the cost per person treated by each SA programme, the NTDCP and 
also the combined unit costs of all of the SA programmes, by programmatic activities. Drug 
distribution and delivery were the largest portion of unit cost for each programme with (range, 
US$0.02 to US$0.31) and without (range, US$0.01 to US$0.16) volunteer time included in the 
analysis.  
 
The SA control programmes were implemented separately in the same years and often in the same 
communities and the costs in Tables 4.7 show the total unit costs, and by input, when the cost of 
delivering these independent SA programmes is summed together either as three concurrent 
programmes, or as a combination of two programmes, or just one programme. These combinations 
of SA programmes were compared to the costs of the integrated NTDCP and the different number of 
delivery rounds that were carried out under it. All input costs under three delivery rounds and two 
delivery rounds show cost savings from the integrated NTDCP to the SA programmes with the 
exception of opportunity cost of volunteer time. The value of the volunteer time was 34% and 24% 
greater for NTDCP than for the combined SA programmes for three deliveries and two deliveries, 
respectively. When the opportunity costs for volunteer time are excluded from the analysis 
incremental costs savings are made for three delivery rounds and two delivery rounds of treatment, 
but not for a single delivery round. The unit cost of delivering one round of treatment in an NTDCP 
MDA campaign is more expensive than the mean cost of delivering one round of treatment by a SA 
control programme and this holds even when the value of volunteer time is removed, as the inputs 
consumables and salaries have higher unit costs for the NTDCP.  
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Figure 4.1: Programme activity unit cost and total unit cost per person treated (in US$2010 prices), including 
and excluding volunteer time, for each SA control programme, combined unit costs of SA programmes and the 
unit costs for the NTDCP. 
The colours of the bars show orange for where the costs of volunteer time were included and blue for when 
they are not. Although not represented in the key, the degree of shading and order of activities is the same for 
‘without volunteer time’ as those shown in the key for ‘with volunteer time’. 
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Figure 4.2: a and b. Illustrate the relationship between the number of persons treated for each district in each 
control programme and the unit cost per person treated (in US$2010 prices) with the opportunity cost of 
volunteer drug distributor time included (a) and excluded (b). Both figures show that across the programmes 
there are economies of scale. 
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Figures 4.2 (a) and (b) illustrate the relationship between the number of person treated for each 
control programme districts in each year, and the unit cost per person treated (US$ 2010 prices) 
with the opportunity cost of volunteer drug distributor time being included (a) and excluded (b). 
Both figures show that across the programmes there are economies of scale showing that as the 
scale of the operation changes (numbers treated) there is a change in the level and cost of output 
(unit cost decreases). In Figure 4.2 (a) we can see that the number of deliveries carried out by the 
volunteer drug distributors can have an additional effect on the cost per person treated by 
increasing the unit cost. This has been explained in a previous chapter but, in summary, is a result of 
the volunteers having to spend more time in collecting drugs from the health units and in delivering 
drugs to the SAC and communities.  
 
Effectiveness  
Among the individuals monitored for health outcomes, the percentage of those presenting with 
onchocercal skin disease was 14.1% at baseline (Y2) and 9.4% at second follow-up (Y4). 
Schistosomiasis fell from 30.6% at baseline to 16.3% at follow-up and 17.3% to 14.9% for hookworm 
prevalence of infection. Prevalence of trachoma active infection (TI/TF) decreased to 4.0% from 6.5% 
and 2.4% to 1.2% for infection with lymphatic filariasis between Y2 and Y4 of the NTDCP, following 
two rounds of treatment. These changes in prevalence of infection are translated to a reduction in 
proportion of NTD cases and DALYS averted which are reported in Table 4.8. Overall, 41,503,106 
million individuals were treated at an estimated economic cost of US$16.5 per case and US$10.2 per 
DALY averted (in US$ 2010 prices).  
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Incremental Cost-Effectiveness  
The NTDCP costs US$35,000 less per 100,000 individuals treated than the combined SA programmes 
which is equivalent to a saving of 37% (Table 4.9). An incremental effect of 576 DALYs averted is also 
achieved through the integrated strategy; this is a 11% increase in effect. The cost-effectiveness analysis 
also showed an ICER of US$60.75 per DALY averted between the NTDCP and the SA programmes 
combined. 
 control programme 
 SA combined  
(NOCP+BWCP+PELF)a 
 
NTDCP 
number treated 100,000  100,000 
cases averted 3,556   3,637  
DALYs averted 5,314   5,890 
cost/person treated (US$) 0.95b   0.60c  
total cost (US$) 95,000   60,000  
cost per case averted (US$) 26.72   16.50 
cost per DALY averted (US$) 17.88  10.19 
incremental cost (US$)   -35,000 
incremental DALYs averted   576  
incremental cost per DALY averted (ICER US$)   -60.75 
Table 4.9: The incremental cost-effective ratio for, the costs and effects of IPCT as compared to, the combined 
costs and effects of running concurrent SA programmes for the NTDs, in Uganda (in US$2010 prices).  
a Due to unavailability of data the effects of the three SA programmes were calculated based on the NTDCP 
effectiveness data, assuming that if the same therapeutic coverage was achieved the same health impact would be 
achieved. 
b value given as ‘Total cost per person treated for NOCP+BWCP+PELF’ in Table 3.7. 
c value given as ‘Total cost per person treated for the NTDCP’ in Table 3.6. 
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Discussion 
This study comparing the integrated strategy of NTD control in Uganda to the previous SA control 
programmes for onchocerciasis, schistosomiasis and STH and lymphatic filariasis, found that through the 
coordinated efforts and shared resources of integrating, cost savings were achieved. These savings, 
however, were not realised with regards to the volunteer time contributed by the unpaid drug 
distributors which has been explored in more detail in chapters 3 and 5. The NTDCP resulted in a 
significant number of DALYs averted in the populations where treatment was targeted and the cost-
effectiveness offered strong support for replacing the SA programmes with an integrated strategy on 
economic grounds. Indeed, both strategies would be deemed to be highly cost-effective by WHO [281] 
as they are well below GDP per capita for Uganda ($470.2 in US$ 2010 GDP per capita price) (IMF, 2008 
http://www.imf.org/external/pubs/ft/weo/2008/01/weodata/index.aspx). These findings could be used 
as evidence for other African governments to secure additional support internally from the policy 
makers and purse holders and moreover, from the international donor forum.  
 
That this integrated delivery strategy is affordable has been demonstrated in Chapter 3 and this further 
study supports the recommendation in published literature that cost savings, over SA programmes, are 
achieved [10,159,207]. Each of the SA programmes in Uganda was rolled out from the VCD at the MoH 
and thus there was already a degree of sharing costs between the programmes, such as vehicles 
borrowed or staff shared. Programmes where this is not the case may see larger cost savings. Only one 
other study investigating the cost-savings of an integrated strategy has been published to date [209]. 
This study, carried out in north-central Nigeria, showed that the strategy when three of the drugs were 
administered to the beneficiary simultaneously in 2009 was more cost effective in terms of 41% reduced 
costs, compared to the MDA campaign in 2008 when there was staggered administration of the 
medicines. This TDA of IVM, ALB and PZQ is suggested where there have been several years of previous 
separate rounds of treatment with IVM and ALB and another with PZQ [53]. These initial separate 
treatment rounds are required to ‘knock down’ an individual’s worm load for the parasitic diseases and 
thus decrease the possibility of adverse reactions. As Uganda has implemented at least three years of 
treatment for these parasitic infections and efficacy of TDA in the country has been tested [282], further 
cost savings could be achieved and importantly with regards to reduced volunteer efforts as the amount 
of time the volunteers would spend distributing the drugs would be reduced, if TDA were to be 
employed. 
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The cost-effectiveness of the NTDCP was determined using two measures, the cost savings achieved and 
the DALYs averted. This was to demonstrate that if the same number of individuals are being treated for 
a range of diseases, it will cost less to treat them through an integrated approach and that, even if the 
same health impact is being achieved by both SA and integrated strategies, the latter is a more cost-
effective option. There are two caveats to these findings; the first is that in Uganda where there have 
been several years and even decades of successful treatment for most of the PCT NTDs the change in 
prevalence and intensity of infection over time is likely to get smaller. Thus a reduced number of DALYs 
averted will have been achieved than what would be seen in an integrated NTDCP in an untreated or 
less treated country. Secondly, in saying that both approaches have the same health impact the 
assumption is that the same therapeutic coverage was achieved under the NTDCP for the treatment of 
onchocerciasis, schistosomiasis, lymphatic filariasis and the soil transmitted helminths, as was achieved 
through the SA programmes. Yet in reality, geographical coverage, but not therapeutic coverage, 
increased for the helminth infections through the NTDCP and there was the addition of trachoma mass 
treatment being rolled out for the first time. The targets of the Ugandan NTDCP are elimination of 
disease or disease-related morbidity (unpublished data, Uganda MoH Master Plan for the Control of 
NTDs 2011-15).  Such ambitious and differing aims can create a level of complexity, and even hierarchy, 
in integrating programmes with regards to achieving geographical and therapeutic coverage. It is 
recommended that future analysis should take into account the levels of therapeutic coverage achieved 
through both strategies.   
As previously mentioned these cost per DALY averted estimates show the integrated programme to be a 
highly cost-effective option for the control of the NTDs. The findings are largely in agreement with those 
from previous results for SA programmes for the same NTDs, if differences in parameters are taken into 
account. The most comprehensive source of per DALY averted estimates is in the Disease Control 
Priorities in Developing Countries [283]. In this, Hotez et al. calculate the cost per DALY averted for STH 
infections to be US$3.41 when SAC are treated and then re-infected with a range of US$3.36 to US$6.92 
and when combined with PZQ for treatment of schistosomiasis US$8 to US$19 per DALY averted This 
differs from the calculation of US$17.32 for several reasons; 1)  DALYs averted calculated for hookworm 
only and not all of the STH combined due to the negligible prevalence at baseline of A. lumbricoides and 
T. trichuria  (1.5%, 1.4% in school-children) in the study population, and low prevalence reported in 
general [185], 2) lower disability weights and exclusion of the anaemia weight to balance the 
predominantly low intensity of infection found in the study participants [284], 3) although the low costs 
of drugs are not included in this analysis, as they are in Hotez et al. [7], the economic costs and 
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opportunity costs of volunteer time are, and lastly, 4) the change in prevalence over time is small in this 
study resulting in fewer DALYs averted. In contrast the cost per DALY averted for schistosomiasis 
infection (US$ 3.1) is considerably lower than that mentioned above [7] and in a review paper by Conteh 
et al. [168]. The reasons are that the previous estimations quoted have used the lower disability weight 
of the GBD study [243] of half a percent (0.005) whereas in this study the weight of 0.05 was used which 
is a conservative increase based on re-evaluation efforts to include more subtle morbidity caused by 
schistosomiasis [123,124,133,134].  
Lymphatic filariasis cost per DALY averted has previously been calculated as US$5.90 [142] and between 
US$4 to US$8 [246], while this study estimated a cost of US$27.7 per DALY averted. In the study a 
disability weight for sub-clinical disease was included, however, prevalence in the communities sampled 
was extremely low (2.4% prevalence at baseline and 1.2% at second follow-up). DALY calculations for 
onchocerciasis indicate that the cost per DALY averted when measuring the impact of treatment on 
troublesome itching caused by onchocercal infections and not including blindness, as the latter is not a 
manifestation seen in Uganda, is US$7.2 which is the same estimated by Remme et al. in the DCP2 
report [246] for CDTI for onchocerciasis control. Finally, trachoma control requires a multi-faceted 
approach known as SAFE. This analysis only measured the impact of treatment and not the other 
interventions. To account for disease with normal vision this study used a disability weight of 0.068 
which was used by [250] when estimating the burden of trachoma in Southern Sudan. Similar disability 
weights for low vision and blindness for durations in infected populations from Tanzania and The 
Gambia [278,279] were used. Results for trachoma for the Uganda NTDCP were US$3.4 per DALY 
averted which is significantly lower than previous estimates of I$13 to I$78 per DALY [285]. The latter 
figure includes the market value of ZIT, which as discussed in a previous chapter, is highly expensive per 
treatment. Lower costs per DALY averted reported in this study likely occurred because of differences in 
disability weights used in calculating the burden for each NTD and due to the incorporation of  the 
‘unseen’ morbidity, which begins with first infection and increases with the length of infection and 
repeated re-infections in the calculations.  
Cost per DALY averted for an integrated NTD programme is comparable to other public health 
interventions in sub-Saharan Africa such as distribution of insecticide treated bednets for malaria (US$5 
to US$31 per DALY averted), and immunization of children (US$7 cost per DALY averted). IPCT for  NTDs 
are more cost-effective than condom promotion and distribution (US$52 – US$ 112 per DALY averted), 
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and treatment for malaria with artemisin-based combination therapy (US$150 per DALY averted)but 
more expensive than hygiene promotion for diarrhoeal disease (US$6 per DALY averted) [283].  
Limitations 
There are several limitations to this study. The first is the DALY calculation includes estimation of YLD 
only and omits the years of life lost (YLL) which is the measure of death in the standard DALY formula 
[243,244]. NTDs are estimated to cause 534,000 deaths per year worldwide [7] which is significantly 
lower than for other infectious diseases which in sub-Saharan Africa alone result in 1,133,000 [286] 
malaria related deaths and 527,000 deaths due to TB [287]. The effects of infection and chronic 
manifestations are most important in NTDs and it was beyond the scope of this study to include 
measurements of mortality. A second shortcoming of this study was the decision not to include the 
indirect benefits of treating the diseases.  Indirect benefits include reducing the force of infection and 
the ancillary impact of reducing community transmission which could provide health benefits to those 
who do not receive treatment [253]; the benefits of using broad-spectrum anthelminthics and 
antibiotics and their treatment of additional infections [142,209,288]; reducing the synergistic effects 
between in vivo polyparasitism between helminths, with malaria and even with HIV/AIDS that lead to 
worse health in an individual [139,140,289,290]; and reducing the  impact on education and worker 
productivity [59,248,291,292]. Not including these unmeasured benefits in the analysis will seriously 
underestimate the value of the DALYs averted through the NTDCP, and to date no studies have 
projected the gains from treating each of the diseases and all of the indirect benefits.  
With regards to the potential synergistic effects of co-infections as mentioned above, and in the 
Methods section of this study (p. 131), it would be feasible to attempt a sensitivity analysis to determine 
if the cost per DALY averted in this study is sensitive to this co-infection conundrum. The author intends 
to conduct this further sensitivity analysis when additional data becomes available, from the Uganda 
dataset and from the growing body of literature on the relationships between co-infections of NTDs. The 
sensitivity analysis would assume different disability weights for co-infected individuals, for instance: 
 
Lowest: The disability weight for a co-infection will be equal to the highest disability weight of the 
individual infections. This is equal to saying that having two infections is not worse than just having one 
infection. This can be interpreted as a lower limit. 
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Baseline: The disability weight for a co-infection will be equal to the sum of disability weights of the 
individual infections i.e. what has been used in the current analyses 
 
Highest: The disability weight for a co-infection will be higher than the sum of disability weights of the 
individual infections to incorporate synergistic effects. This higher value will be arbitrary but estimated 
from existing literature. 
 
Thirdly, there may be issues in assuming that the unit costs from different districts in Uganda, for each 
of the SA programmes, could be comparable to those of the NTDCP. As we saw in Chapter 3 there is 
considerable intra-country variation in the cost per person treated in Uganda under the NTDCP. 
Variability between districts was also seen by Brooker et al. [150]. Nonetheless, as the proportion of the 
study populations were 13%, 30% and 34% for NOCP, BWCP and PELF respectively, of the total 
population treated during the costing studies, and because the studies were carried out for two or more 
years, the heterogeneity of the cost per person treated was potentially captured and accounted for in 
the average unit costs of the programmes. The exception were the costs for the NOCP which only 
included one year, however the programmes were ‘mature’ and had been running for over five years 
and were consequently less likely to suffer variability in costs over time. Fourthly, as previously 
discussed, the same effects, due to the assumption of equivalent coverage, were applied to the 
combined SA programmes as those observed for the NTDCP, with the exception of treatment effect on 
trachoma. It is probable, however, that the effects applied to the combined SA programmes were an 
overestimation because the NTDCP has resulted in considerable geographical scale-up for many of the 
NTDs in Uganda [14]. A further investigation on the differences in therapeutic coverage, nevertheless, 
may be required as evidence in Chapter 3 highlights that the NTDCP is achieving only moderate 
programme coverage as opposed to the high reported coverage for onchocerciasis [293] and 
schistosomiasis and STH control [239] prior to the NTDCP in Uganda. 
Finally, although not the rule in CEA, the uncertainty surrounding the results of the ICER could be further 
explored by using sensitivity analysis [294]. The robustness of results from this model could be assessed 
by one-way sensitivity analysis (Chapter 3), probabilistic sensitivity analysis (PSA), or both [211,212]. It is 
highly likely that several parameters which contribute to the ICER will have interacted with one another 
thus multivariate sensitivity analysis could be used to vary two or more outputs at once and study the 
effects on the outcome (ICER). PSA could be undertaken to reflect the robustness of the ICER to the 
influence of uncertainty associated with the health outcome and the unit cost (cost per person treated) 
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parameters simultaneously. This could be done by assigning distributions to each of the chosen 
parameters and then running a Monte Carlo simulation through the model. The model would then be 
run 10,000 times using randomly selected values from the distributions in order to derive a mean ICER 
[294]. The results of the PSA could then be summarised by a scatter plot of the cost-effective plane and 
cost-effectiveness acceptability curve. This is an area of further work which the author will carry out to 
test the robustness of the ICER formulated in this study.   
 
 
Conclusion 
To conclude, the results of this study, taken from a large scale integrated programme to control NTDs, 
are the first of their kind to demonstrate the cost-effectiveness of the strategy.  Cost savings were 
achieved over the simultaneous implementation of two or more SA programmes. Nevertheless, savings 
were not seen in the volunteer time contributed to the NTDCP which is addressed in Chapter 5. This 
integrated approach also results in a substantial reduction in DALYs over a two year period and thus will 
have a greater impact with full therapeutic and geographical coverage over a longer time-frame. If goals 
of elimination are to be reached in Uganda then it is likely that the cost per DALY averted will become 
more expensive as the numerator (cost) increases and the denominator (DALYs averted) will decrease 
due to less morbidity in the population.  
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Chapter 5. The role of the Community Drug 
Distributor in an integrated PCT: are large-scale 
community-based and volunteer-dependent 
interventions sustainable? 
 
 
Abstract  
Background Trusted literate, or semi-literate, CDDs are the primary implementers in IPCT programmes 
for NTD control. The CDDs are responsible for safely distributing drugs, but also for galvanising 
communities to repeatedly, often over many years, receive annual treatment, create and update 
treatment registers, monitor for side-effects and compile treatment coverage reports. These individuals 
are ‘volunteers’ for the programmes and do not receive remuneration for their annual work 
commitment.  
Methods and Principal Findings: Using a mixed methods approach, which included pictorial diaries to 
prospectively record CDD use of time, it was determined how CDDs allocated their time towards 
Ugandan NTDCP and routine activities. The opportunity costs of CDD time were valued; performance 
was assessed by determining the relationship between time and programme coverage, and CDD 
motivation for participating in the programme was explored. Key findings showed approximately 2.5 
working weeks (range, 0.6 to 11.4 working weeks) were spent on NTDCP activities per year.. The amount 
of time on NTDCP activities significantly increased with each additional drug delivery that was required 
within an MDA period, with the size of population served by the CDD, and as a result of poorly planned 
drug logistics. CDD time spent on NTDCP activities had an impact of time available for subsistence and 
income generating engagements As CDDs took more time to complete NTDCP activities their treatment 
performance decreased. Motivation for the programme was low and CDDs felt undervalued. 
Conclusions: CDDs contribute a considerable amount of opportunity cost to the overall economic cost of 
the NTDCP in Uganda due to the commitment of their time. Nevertheless, programme coverage of at 
least 75%, as required by WHO, is not being achieved and vulnerable individuals may not have access to 
treatment. This chapter makes recommendations for improvements in drug logistics and alternative 
support systems for the CDDs in order to utilise resources effectively and efficiently.  
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Introduction  
To roll out large scale IPCT interventions requires input across different levels of any health system. 
There are challenges at each level within the sub-Saharan African context of relatively weak and frail 
health systems. Several such challenges are an inefficient mix of inputs and health interventions that 
operate at an inappropriate scale. For instance the failure to sufficiently pay staff to encourage good 
performance, and an inadequate health workforce supply, both have a significant contribution to a 
weakened health system [295-297]. The global health worker shortage crisis where 2.3 nurses, doctors 
and midwives for every 1,000 people are required to deliver the basic level of care needed, is worst in 
sub-Saharan Africa. [298-300]. Without this human resource the delivery of healthcare to meet the 
MDGs by 2015 is at serious risk.  
Analyses of cost-effectiveness data can be used to identify combinations of inputs that will improve the 
efficiency of resources used within the health system or for a particular intervention. This is  achieved by 
finding a mix of inputs, for example salaries and drugs, resulting in the same level of output, such as 
numbers treated, at a lower total cost, or a mix of inputs with the same level of total cost, but with a 
higher output. In addition, cost-effectiveness analyses can be used, as they were in chapter 4, to choose 
between competing health interventions. However, such analyses alone are insufficient unless 
complemented by indicators on health system failures and how these can be alleviated and, 
consequently, health systems strengthened to deliver interventions effectively, efficiently and equitably 
[295,296].  
In Uganda, where there is an overall health worker deficit of approximately 80% [301]. ‘Task shifting’, 
the process whereby, when appropriate, tasks are delegated to less specialised health workers including 
community health workers and volunteers has been introduced for HIV/AIDS services [302-304].  
Uganda’s health system also incorporates the utilisation of Village Health Teams (VHT) as level one of a 
five-tiered system which culminates at central hospitals (level V) in each district. The VHT was 
introduced through the Health Sector Strategic Plan I (unpublished data MOH HSSP I) on the basis that 
only approximately 49% of the population lived within five kilometres from a health facility [305] and 
due to an acute shortage of health workers in rural areas [306]. The VHT is intended to harmonise and 
consolidate MoH and partner programmes at the village level which focus on preventive and behaviour 
changing practices and the distribution of health commodities whilst engaging community participation 
and ownership [305] (unpublished data MOH HSSP III). 
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Village-elected CDDs and school teachers are the primary implementers of PCT for NTDs in sub-Saharan 
Africa [188,195,307]. In Uganda the CDDs which, in theory, are now part of the VHT level I health 
system, play a pivotal role in the NTDCP’s implementation and success. The SA control programmes for 
the NTDs that existed prior to integration also used community volunteers for drug distribution and in 
many cases the same individuals participate under the current NTDCP. As part of the VHT these same 
individuals are often involved in other health-related activities and programmes. The NTDCP trains, on 
average, two CDDs per village to carry out programme activities (A. Onapa, RTI International pers 
comm.). There are several conflicting views in the literature as to how integration of several control 
interventions affects health workers such as CDDs. One view is that co-implementation of interventions 
can effectively make it easier for health workers, because they only have one multi-layered intervention 
to be responsible for which results in increased health worker efficiency, reduced reporting 
requirements, increased intervention utilisation as well as reduce time and transportation costs [308-
310]. For example, CDDs implementing an integrated NTD programme in place of several SA 
programmes, would spend less time ‘volunteering’ throughout the year on multiple programme 
activities [165]. In contrast, is the view that by requesting  health workers to be responsible for an 
intervention with multiple and additional services they will become overburdened, resulting in increased 
time and a subsequent effect on their performance in that intervention [164,236,310]. 
Sustainability in global public health is a multi-faceted concept which is not always clearly defined or 
applied consistently [311]. Shediac-Rizkallah and Bone [312] give six definitions which are used 
interchangeably but are not synonymous, for example:  ‘Sustainability is the capacity to maintain service 
coverage at a level that will provide continuing control of a health problem’ [313] and ‘Project 
sustainability is defined by many economists and international development agencies as the capacity of 
a project to continue to deliver its intended benefits over a long period of time.’ [314]. More recently 
Shigayeva and Coker [315] organise the concept of sustainability in health systems into three 
components: Health Intervention (an intervention, innovation, project or programme), Health 
Organisation (A health service organization, community-based organization, institution, partnership or 
coalition) and Health System. Sustainability of the NTDCP in Uganda falls best under the first component 
and can be described as ‘Sustainability is the ability of a health project or programme to deliver health 
services or sustain benefits after major technical, managerial and financial support has ceased.’ (USAID, 
cited [316]) with the benefits being defined as improvements in health or the continuous control of a 
health problem through maintaining sufficient levels of effectiveness, accessibility, acceptability or 
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coverage of interventions [317,318]. Similarly APOC measures sustainability of onchocerciasis control 
programmes by identifying to what extent the following criteria are present [319]: 
Integration: Projects which have become integrated into the routine running of the health care services 
are more likely to be sustainable. 
Resources: Projects are more likely to be sustainable if they have enough resources (human, material, 
financial) to support what they are trying to do. 
Efficiency: Projects that are run cost-effectively are more likely to be sustainable. 
Simplicity: Projects that use simple, uncomplicated routines and procedures are more likely to be 
sustainable. 
Health staff acceptance (Attitude of the health staff): Projects are more likely to be sustainable if 
health staff have accepted CDTI as a routine activity, which they will continue to do even in the absence 
of additional material reward. 
Community ownership: Projects are more likely to be sustained if the communities where CDTI takes 
place support it wholeheartedly, and are willing to take responsibility for it. 
Effectiveness: Projects that are functioning effectively are more likely to be sustainable. 
We have to scrutinise projects in such a way that we see whether these aspects are developing as they 
should, to bring about sustainability. 
 
These criteria can be equally applied to the NTDCP and within this chapter sustainability is explored for 
the criteria of ‘human resources’, ‘health staff acceptance’, ‘community ownership’ and ‘effectiveness’, 
as measured by programme coverage, from the perspective of the CDD. The time, which is volunteered 
and thus obviates other remunerative activities, and efforts of the CDD are only one facet of 
sustainability of an NTDCP. Nevertheless as we have seen from Chapters 3 and 4, and findings from 
other published studies, is that the contribution of the CDDs towards NTD programmes whether 
integrated or SA is substantial and crucial for success and sustainability [293,310,320-324]. 
Diaries have been used in many contexts as a research tool to monitor daily experiences and behaviours 
which are expected to change over time  The events that are recorded can be as wide-ranging as the 
’high-risk’ behaviours of commercial sex workers to incidence of colds or household consumption and 
expenditure [325-329]. The benefit of using diaries for data collection is that the information is being 
recorded at the time of the event and so is ‘prospective’ data which greatly minimises recall bias. In low-
income countries where the majority of the population is illiterate, keeping diaries with written 
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information can be a challenge and hence an inappropriate method of data collection [330]. The use of 
pictorial diaries, however, overcomes many of such challenges and have been shown to be effective 
tools for measuring a range of activities from, for example, expenditure activities to daily frequency and 
consistency of stools [325,331,332]. 
Although there is substantial literature about the CDDs roles in CDTI for onchocerciasis control and in 
trachoma and schistosomiasis control [188,195,307], there is currently no evidence of the CDDs role in 
IPCT. Furthermore, although diaries and work logs are used extensively in research, there are no (to the 
author’s knowledge) published data which refers to pictorial diaries recording information on daily 
activities of community volunteers in mass treatment programmes.  
 
The aim of the current study was therefore, to use a mixed methods approach [333], to determine the 
role and the work burden of the CDD in the Ugandan NTDCP. A novel Pictorial Diary (PD) was designed 
to collect daily prospective data on the time spent by CDDs on both their routine activities and NTD 
activities. By recording time spent on NTD activities and assigning a monetary value the opportunity 
costs of CDD time were determined. CDD performance was estimated from a validation IPCT coverage 
survey. Additionally semi-structured interviews, questionnaires and FGDs captured qualitative and 
socio-demographic data and the CDDs perceptions of their role in the NTDCP. The results of this study 
will help to inform those managing the programme, as well as the CDDs, on the optimum ways to 
achieve and sustain high coverage of IPCT, motivate CDDs and strengthen programme sustainability in 
Uganda.    
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Materials and Methods 
Study Design 
A prospective longitudinal survey was designed which used a mixed methods approach [333,334] to 
collect both quantitative and qualitative data on the CDD contribution to the Ugandan NTDCP.  
The CDDs were selected across four of the original 13 cost study districts (Table 3.1 and Figure 3.1). The 
districts were listed and stratified according to the number of drug delivery rounds a CCD would have to 
carry out in their community over a mass treatment campaign. These were either three, two or one 
delivery rounds depending on the drug package for NTDs in that district. From each strata, one district 
was randomly selected to take part in the study. Random selection of a further district for the two 
delivery round stratum was chosen as this represented the largest number of districts. Kamuli district 
represented three delivery rounds (IVM+ALB, PZQ, ZIT), Mayuge district (PZQ+ALB, ZIT) and Yumbe 
(IVM+ALB, PZQ) were representative of two rounds and Pallisa (IVM+ALB) was selected from the 
stratum with one delivery round.  
In addition to being representative of the whole CDD population, the sample size needed to take into 
consideration the costs of logistics and the length of the PD study. It was thus determined that 
approximately 32 villages, or communities, was a feasible sample size and was in-line with other similar 
studies [196,335,336]. Each village has two CDDs which it elects to take part in the NTDCP, and thus with 
64 CDDs it was agreed that both the depth of information from repeat engagement with the 
participants, as well as breath of information across variables such as number of number of deliveries, 
distribution method and number of households served to allow for generalizability of the findings 
[337,338].  
The villages were randomly selected from parishes rather than the whole district for logistical reasons 
and the time and costs of data collection. Decisions on method of how treatments will be delivered i.e. 
from a central point and/or door to door, tend to be made at the sub-county level, thus the parishes 
were selected from sub-counties. The sampling was therefore that in each selected district (4 districts), 
two sub-counties were randomly selected (8 sub-counties) from a full list of all sub-counties and from 
these, two parishes (16 parishes) were again randomly selected from a full list of parishes. Finally, from 
each parish, from a full list of villages two were selected (32 villages).  
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The total population of the study areas was an estimated 34,615 and approximately 5724 households 
would be served by the CDDs. The CDDs were enrolled into the study at least two weeks prior to the 
beginning of NTDCP activities for programme year 2008/9 (Y3) and until after all programme activities 
for which they were involved, as described below, had been completed.   
 
CDD role in the NTDCP 
Distribution mechanisms for IPCT through the Ugandan NTDCP are community-based and school-based. 
CDDs are elected by their communities or requested by their local councillors to participate in the 
programme and teachers are selected by their head-teachers. After receiving training from sub-district 
health personnel, the CDDs and teachers ‘volunteer’ their time to sensitise and mobilise communities, 
parents and students about treatment for the NTDs and subsequent health benefits. Following this they 
distribute drugs to the target population; for CDDs these are the eligible individuals in their village and 
distribution is done either from a focal point such as a church, health clinic, trading centre or distribution 
is carried out by the CDD moving from door to door. For teachers, the target populations are enrolled 
and non-enrolled SAC and treatment takes place at school and during school hours. Following 
distribution CDDs and teachers are expected to write coverage reports based on their treatment 
registers and submit the results and any remaining drugs to the nearest health unit (level II or III).  
 
Data Collection 
Collection of both quantitative and qualitative data was carried out in the four districts using a mixed 
methods approach. Its central premise is that the use of quantitative and qualitative approaches in 
combination provides a better understanding of research problems than either approach alone [333]. In 
the four Ugandan districts data collection was led by the investigator in collaboration with Dr Matovu, 
MUK and a select group of four Bachelor of Arts graduate research assistants also from MUK. The 
students were chosen on their fluency in the local languages of the selected districts. All were 
subsequently trained in qualitative data collection techniques such as key informant interviews and 
FGDs by an experienced social scientist, Mr Dauda Waiswa from MUK. The training aimed to reduce the 
risk of interviewer bias in the study by each research assistant having the same set of taught skills.  
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Development and implementation of the Pictorial Diaries 
The following summaries describe the methodological stages used in developing the CDD pictorial 
diaries (PDs). The PD development was carried out before the stratified sampling had taken place and 
thus all districts are not the same as those in the final study. All interviews and FGD were held in the 
relevant local languages Lusoga for Kamuli and Mayuge districts, Lugwere in Pallisa district, Luo in 
Dokolo district, Luganda in Mukono district and Aringa Lugbara in Yumbe district. 
Daily routine and NTD programme activities: Two FGD were held in Kamuli district to identify the CDDs 
main routine and NTDCP activities. In Group 1 there were 10 CDDs, five of which were asked to recount 
their daily activities from when they awoke to when they went to bed. We then asked the remaining five 
if there were other routine activities that had not been previously mentioned by the first five CDDs.  
Then the CDDs were requested to describe the NTD activities they had been involved in the previous 
year. We finished the discussions by asking the CDDs to identify what symbols or pictures they thought 
might best represent the daily and routine activities they had discussed. Meanwhile two Ugandan artists 
were sketching these symbols and pictures. Group 2 also had 10 CDDs and they too were asked about 
the daily routine and NTD activities that they carried out. Following this the CDDs were asked to look at 
the symbols and pictures developed by the artists, in the interim, and asked to identify which activities 
they represented. Where the pictures were identified incorrectly or were not clear the CDDs in Group 2 
were asked to describe how they could be improved to be easily recognizable.  
After further development of the pictures, two more sub-counties in Kamuli and three sub-counties in 
each of Pallisa and Dokolo districts were visited. In each sub-county FGDs were held with between seven 
to 12 CDDs participating in each. Following an explanation of the purpose of the visit, several CDDs 
would be asked, as before, about their daily routine and NTD activities and about any seasonal 
variations in routines. They were then requested to look at a set of illustrations representing different 
activities or groups of activities and asked to identify the activities and suggest any improvements. All 
comments were noted by the artist. Finally, further discussions were held with the CDDs about the 
development of pictorial diaries and how they would feel if they were selected to be responsible for 
filling a diary on a daily basis. 
Time: In each of the FGDs, the CDDs were asked to describe how they measured their time, for example, 
what tools or features they might use to identify the time of day and how they split the day. The most 
common methods of telling the time used by the CDDs were radio programmes, especially the news; 
mobile phones; clocks in their houses; Muslim call to prayers; and for those who lived near schools, the 
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school bell (the banging of a wheel) at different times during the day. In each district the CDDs split the 
day into morning, afternoon, evening and night with only minor differences at what time they began 
and ended. All CDDs reported that they use ‘Swahili’ time throughout the day, this means that 7 a.m. is 
1 o’clock, 8 a.m. is 2 o’clock and so on. 
 
Pictorial diary development: The next step was to use the finalised pictures and the information 
collected about time to develop a diary format. Discussion on time had revealed that despite not 
everyone having clocks or watches, the CDDs felt confident they knew the time of day from hour to hour 
and thus two formats of the dairy were developed. The first (see Appendix VII p2) broke each day into 
hours e.g. 7, 8, 9 and would require the CDD to identify what activities they were involved in hour by 
hour and tick in the relevant boxes. This was called the ‘hour’ PD. The other format known as the ‘time’ 
diary (see Appendix VII p3), had only one column for each day, as opposed to for every hour in the 
‘hour’ diary’, and would require them to mark down the number of minutes spent doing an activity each 
time they carried it out in that day.  
 
Pre-test of Pictorial Diary: After sample PDs were printed for each format, they were pre-tested in Katosi 
sub-county, Mukono district. Mukono district was chosen due to its proximity to Kampala for logistical 
reasons, but that it was still a rural environment with CDDs involved in the NTDCP. Within the sub-
county four villages were chosen and we found seven out of a potential eight CDDs at their homes. The 
CDDs were then randomly given the hour-based or the time-period based PD and talked through each of 
the pictures and asked to interpret what routine or NTD activity they saw. An explanation of how the PD 
works and the purpose of it were given and the CDD asked if they consented to record their time in the 
diary for one week. Each interview took between 30 to 40 minutes to complete.  
 
One week later the CDDs were revisited and after the CDDs had gone through their PD entries day by 
day, a short questionnaire of 10 questions which focused on how user-friendly the PD was and what 
improvements they would make was completed. The feedback from the pre-test revealed that those 
who had filled the hour PD had found it easier to use than those who had been filling in the time PD. 
There were also more inconsistencies in the time PD, for example, in two of the time diaries the amount 
of time marked down for some of the days was over 24 hours. There were only minor improvements to 
the pictures that were mentioned. How long the CDDs would be happy to fill the PD ranged from two 
months to one year, and all felt that it was no extra burden as it took between 30 to 60 seconds to fill 
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when marking after every activity or up to 35 minutes if filled at the end of the day. Some volunteers 
also reported that it was helpful to see how they spent their day and which activities they were 
spending too little or too much time on. Each follow-up interview with the CDDs took between 30 to 60 
minutes to complete. 
Implementation: Final adaptations were made to the pictures and the development of an aide mémoire 
(see Appendix VII p4-6) which had each of the activity illustrations at an increased size than in the actual 
diary page. These were then incorporated into a spiral bound booklet which had sufficient space for 
three weeks of diary entries. These pictorial diaries were then set up with the 64 CDDs at their homes in 
the four selected districts by the four trained and experienced research assistants. During the initial visit 
the CDDs were given an explanation to the purpose of the diary, how to complete it including a practice 
for the previous day’s activities. CDDs were also asked if they would be willing to take part in interviews 
and FGDs. It was explained that all information collected would remain confidential. Informed written 
consent was given by each CDD to take part in the study until the NTDCP activities were completed, 
approximately three months or less. It was explained to the CDDs that they could drop out of the study 
at any point they chose and that this would not affect their involvement in the overall programme.   
 
The CDDs were followed-up one week later to check on the progress on their PD entries by reviewing 
the activities recorded hour by hour for each day. Any difficulties or confusions encountered, for 
example not remembering exactly where a certain activity be marked, were discussed in detail and 
often all the pictures were reviewed to ensure the CDD fully understood each one. The CDDs were 
visited at their homes for a third time two weeks after their previous visit and again the progress of the 
diaries was reviewed. This time a pre-defined random selection of six days were reviewed. If all six days 
had been filled inaccurately myself and the research assistant would go through all remaining days over 
the previous two weeks and the explanation of the pictures and the diary was repeated. If less than the 
six days were filled inaccurately then no more days were reviewed.  CDDs were subsequently visited 
every two weeks, during which their diary records were reviewed and semi-structured interviews were 
held after each NTD activity has been completed which are described below. No compensation was 
mentioned by the study team to the CDDs at the beginning, or during the duration of the study. Each 
CDD who participated until the end of the study data collection was given two kilograms of sugar, a large 
bar of soap and a ‘Permanet’ insecticide treated mosquito net.  
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CDD Interviews and Focus Group Discussions 
Semi-structured interviews: During the first visit each CDD was asked a series of background questions 
pertaining to socio-demographic characteristics, their past and present involvement in CDD activities for 
NTD and involvement in other health-related programmes (see Appendix VIII Instrument 2). Once a 
specific NTDCP activity, for example, training, registration or MDA, had been completed an interview 
with a pre-defined set of closed and open-ended questions was held at the next visit (see Appendix VIII 
Instrument 4 a to f). The semi-structured interviews focused on the CDDs role in and experience of the 
NTDCP activity. Finally, post-MDA, once all the NTDCP activities had been completed, a performance 
questionnaire was carried out to assess the self-reported performance of the CDDs during the mass 
treatment period. The questionnaire also asked whether the CDD would remain in their post, reasons 
for their choice and an attitude scale was completed by each CDD (see Appendix VIII Instrument 5). 
Focus Group Discussions: FGDs were held in each sub-county with between six and eight participants. 
The purpose of the FGDs was to identify what the participants thought about the main public health 
problems in their communities, what their responsibilities had been under the NTDCP and how adept 
they felt at carrying out the NTDCP activities with the resources with which they had (or had not) been 
provided. Finally the motivation of the CDDs to participate in the NTDCP was explored. The FGD guide 
and open-ended questions were first translated and back-translated before the group discussions began 
to ensure their intention was still clear following the translation process (Appendix IX). The FGDs were 
conducted in convenient public places identified by the CDDs. The discussions were guided by pre-set 
open ended questions which were followed by probes to enable discussions within the group and to not 
create a group interview. Consensus amongst the group members was not sought; instead all unique 
ideas expressed by the individual participants were captured. Each FGD was managed by two research 
team members one of whom was the moderator while the second one was the note-taker. The 
moderator stimulated the participants to actively discuss the topics provided and not to just provide 
answers and controlled the group to proceed in the direction that the focus group took. The note-taker 
recorded the key issues emerging and other factors such as non-verbal responses e.g. head nodding in 
agreement or laughing. A tape-recorder was used to record the discussions which were conducted in the 
local language. The note-taker and moderator transcribed the FGDs in the local language before 
translating to English at the end of each day for use in the analysis. All the researchers were trained in 
the use of the FGD guide and best practices for FGDs and the number of those acting as moderators was 
restricted to reduce interviewer bias, which is where each interviewer may ask the same question to the 
same participants in a different way and thus elicit inconsistent responses [338,339].  
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No compensation was mentioned by the study team to the CDDs at the beginning, or during the FGDs, 
however, each CDD who had participated until the end was given a soda, a packet of biscuits and a 
travel allowance. 
 
Measurement of CDD time  
In the PDs time was measured by the CDD marking each activity s/he carried out within a particular 
hour. An hour was split by the number of activities within it to give the number of minutes spent on 
each of these pre-defined activities. For analyses these data were entered into a specially designed 
Microsoft Excel database (Microsoft Corp. Seattle, WA, USA) that was the result of a consultation 
between the investigator, Dr Matovu and an IT technician Mr Godfrey Mayende from MUK. The total 
number of minutes spent on each activity was then totalled and a mean calculated for all routine daily 
activities and for each NTDCP activity. Minutes were then converted into hours. Working days were 
based on an eight-hour day and working weeks were based on five working days, therefore 40 hours 
were in a working week. To calculate the annual proportion of time spent on NTDCP activities 246 
working days was used.  
 
Measurement of CDD performance 
NTDCP effectiveness is measured by performance indicators, the main being therapeutic and 
programme coverage of at-risk and eligible populations, respectively [13,53,203]. Reported treatment 
coverage for a programme is compiled from a district report which in turn originates from each CDDs 
treatment report based on the individual treatment register. In this study the CDDs treatment registers 
were reviewed to assess the accuracy of the total treated for each drug in the register. The accuracy of 
the numbers entered into the registers would have required direct observation of the CDDs during their 
treatment periods and was beyond the scope of this particular study. The total numbers recorded by the 
CDDs were validated against two recounts using a calculator by the investigator or Dr Matovu and one 
of the four research assistants previously mentioned (Page 160). In all cases the total numbers recorded 
by the CDDs were inaccurate by more than 12% with the majority being overestimations. Since the 
NTDCP was to carry out a post-MDA coverage survey to validate reported programme coverage, it was 
decided to include the PD study sub-counties and villages in the post-MDA survey and use this data to 
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report on coverage.  Full details of the post-MDA coverage survey protocol can be found in the Appendix 
X, however, a summary description will now be given.  
Post-MDA Drug Coverage Survey: Drug coverage in the survey was defined as the proportion of eligible 
individuals who actually ingested the drugs. It is calculated as [53]:  
 
 
 
The post-MDA drug coverage survey was conducted on sample of the population that received 
treatment during the last MDA round, based on a cluster sample methodology. Clusters were chosen 
separately for each drug package (stratum) and chosen in proportion to their population or “population-
proportion sampling”. Ultimately the primary sampling unit or clusters were parishes with 20 being 
randomly selected for each drug package delivered. Villages were the second stage sampling unit with 
five villages randomly selected per parish. Household were the third and final sampling unit with 10 
households randomly sampled per village. In each of the PD study districts two of the villages per study 
parish were purposively sampled and the remaining were randomly selected using a random number 
generator. The households were randomly sampled from a list of all households in the village, provided 
by the local councillor, using a random numbers table. 
The survey was carried out within three months of treatment to minimize recall bias in Kamuli, Mayuge 
and Yumbe. For Pallisa district treatment had been completed for longer than four months, however, a 
recent study suggests that recall bias may not actually be an issue in such a circumstance [340]. The 
supervisors who oversaw the survey were pre-trained in the methods during a one day training 
workshop in Kampala at the VCD, MoH. The supervisors then moved to the selected districts and held 
one day training for three interviewers to conduct the survey. The interviewers were not to have been 
involved in the implementation of the MDA as this could potentially influence the response of the 
household members. The training covered the use of the household questionnaire and how to random 
sample households. Subsequently the team moved to each parish and each village and identify the local 
leader to assist them with the list of households and household heads in the village. This list was used to 
randomly sample the ten households for the study. Following this a village guide was selected to assist 
the interviewers in finding each household for interview. Finally in each household all members living in 
total number of individuals identified by household surveys as having ingested the drugs 
 
total number of individuals residing in all the surveyed households on whom information 
on drug ingestion could be assessed 
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the household at the time of MDA were interviewed and asked if they had ingested a particular 
medicine and were shown the corresponding tablet in addition to other information. For children below 
10 years of age the primary caretakers responded to the questions.  
Motivation 
The CDDs motivation towards the NTDCP was measured during the semi-structured interviews and 
FGDs. CDDs were asked why they were motivated to take part in the NTDCP and how the perceived their 
motivation for that programme in comparison to their other health-related duties. In addition, CDDs 
were asked to complete an Attitude Scale which asked a series of questions about their NTDCP 
involvement and whether they strongly agreed, agreed, were indifferent, disagreed or strongly 
disagreed.  
 
Valuation of CDD involvement in NTDCP  
The CDDs volunteer their time to take part in the NTDCP and are only given a financial stipend of 2,000 
to 4,000 Ugandan shillings (USh) when they attend training. Nevertheless, from the societal perspective 
time spent on NTDCP activities by the CDDs incurs an opportunity cost to society as they are unable to 
perform their normal activities. Opportunity costs include the value forgone by the CDDs time not 
working in their shamba (gardens), doing casual labour or carrying out their retail business. There were 
several ways in which the CDDs volunteer time was valued. The base case was the method used in 
Chapter 2 of 6,000 USh per day (US$2.70, 2008 prices inflated to 2010 prices), the value of local casual 
labour wages [211]. This was equivalent to an hourly rate of 0.75 USh (US$ 0.34) based on an eight hour 
working day. The sensitivity analysis in the same chapter used values for the minimum wage on the 
Government of Uganda salary scale (4,193 USh or US$1.95 per day) and GNI per capita (7,931 USh or 
US$3.70 per day). These data were then presented for each method of valuing CDD opportunity costs by 
the number of deliveries carried out by a CDD in a MDA campaign.  
Data Analysis 
All statistical analyses were carried out using STATA 11.2 (StatCorp LP, TX, USA). PD time data were 
analysed using a paired t-test to compare means between before/after and during NTD activities in daily 
routine activities. One-way analysis of variance (ANOVA) and simple linear regression were used to test 
for differences in the mean times between different levels of the independent variables, such as, 
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administration level, distribution method (door to door and focal point), population and number of 
households served, length of tenure as a CDD, the number of deliveries (one delivery against two 
deliveries, one delivery against three deliveries, two deliveries against three deliveries and overall), and 
socio-demographic variables such as age, gender, marital status, education level, and occupation. All 
time variables which were not non-normally distributed were transformed to the logarithmic scale. 
Mixed model linear regression was then performed to determine if the total hours spent by the CDDs on 
the NTDCP, whilst controlling for confounding and clustering at the parish level, were still significantly 
associated with those independent variables which had been identified during simple linear regression.  
Coverage data were entered into (EPI) INFO (Version 6.04, USA CDC, Atlanta, GA). Mean coverage were 
calculated using the survey function in STATA which takes into account the clustered sampling design. 
Simple linear regression was also used to look at which variables were associated with treatment 
coverage. For both time and coverage, multiple linear regression included all variables that were found 
to be statistically associated with the outcome variable to adjust for the effects observed by these 
variables.  
For the semi-structured and FGD quantitative and qualitative data, a coded scheme was developed by 
pre-defined topics together with themes emerging from the data using the qualitative data analyses 
software NVIVO (Version 9. QSR International, Doncaster, Australia). 
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Results 
Participant Characteristics 
Data collection of the PDs was from October 2008 to June 2009. A total of 58 CDDs out of 64 
participated in the study. Reasons for the six non-participators were, in two villages only one CDD was 
trained to carry out all NTDCP activities and four CDDs dropped out after training but before MDA. The 
reasons given for drop out were no time to carry-out NTDCP and run local drug shop, migration for 
fishing purposes and two CDDs provided no reasons. All four did not participate any further in the 
NTDCP either. Socio-demographic and study characteristics are summarised in Table 5.1 by district and 
in Table 5.2. A third of participants were female (18) and the average age of all participants was 36 years 
(21 – 64 range). Of the CDDs, 98% were married and 27% (16) had completed primary education; 71% 
(41) had completed three years of secondary school education and 2% (1) had achieved a tertiary level 
education. In addition, 40 CDDs reported their main occupation was subsistence farming, five were in 
retail and six CDDs were market traders. Other occupations included housewife (three), religious leader 
(two), fisherman (one) and secondary school teacher (one). CDDs distributed the drugs either door to 
door, i.e. visiting each village house and treating all members present (47%), or from a focal point such 
as a health centre, market place, school (53%). The average population size served by a CDD was 497 
(161 – 1437 range) and approximately 90 households (31 – 313 range). The length of tenure for the 
CDDs in the NTDCP and, if applicable prior SA programmes, was one to five years which included the 
year of study.  
 
CDD Time 
Mean number of hours on routine and NTDCP activities 
Mean hours spent on routine activities not during the NTDCP activities, or non-NTDCP time, for all of the 
58 participants was 16.87hrs (95% CI: 16.67 to 17.06) and Table 5.2 shows the variance observed around 
this mean across the participants characteristic variables. The variance for the mean hours spent on 
routine activities during the NTDCP implementation period (12.50hrs 95% CI: 11.97 to 13.04), and for 
the mean hours spent by the CDDs on partaking in the NTDCP activities (105.99hrs 95% CI: 83.80 to 
128.19) are also shown. No differences between the overall mean hours and the mean hours across the 
participant characteristic variables were seen for either routine activities grouping. However significant 
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differences between the overall mean were seen in the mean hours spent across the categories of 
households served (F (2, 55)=8.4 p<0.001) and population served (F (2, 55)=12.8 p<0.001) under NTDCP 
activities.  
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Variable 
Number 
(%) 
Routine activities  
NTDCP activities 
mean hours (95% CI)  
non-NTDCP 
mean hours  (95% CI) 
during-NTDCP 
mean hours (95% CI) 
Overall  58 (100%) 16.87 (16.67 to 17.06) 12.50 (11.97 to 13.04) 105.99 (83.80 to 128.19) 
Gender 
women  18 (31.03%) 16.89 (16.47 to 17.30) 12.43 (11.13 to 13.72) 88.01 (59.30 to 116.73) 
men 40 (68.97%) 16.86 (16.65 to 17.08) 12.54 (12.01 to 13.07) 114.08 (84.75 to  143.42) 
Age groups  
<30 11 (18.97%) 16.63 (16.28 to 16.98) 12.61 (11.56 to 13.67) 119.56 (64.91 - 174.22) 
30 - 34 15 (25.86%) 17.06 (16.71 to 17.41) 12.84 (11.93 to 13.74) 83.37 (68.07 - 98.67) 
35 - 49 22 (37.93%) 16.84 (16.48 to 17.21) 12.25 ( 11.14 to 13.36) 94.77 (65.70 - 123.84) 
50≤ 10 (17.24%) 16.92 (16.48 to 17.36) 12.44 (11.53 to 13.35) 149.69 (59.39 - 239.98) 
Marital status   
Married 57 (98.28%) 16.87 (16.67 to 17.06) 12.52 (11.98 -13.07)  105.97 (83.39 to 128.56) 
Single 1 (1.72%) 16.91 (NA) 11.22 (NA) 107 (NA) 
Education level   
Primary 16 (27.59%) 16.66 (16.25 to 17.07) 12.24 (10.79 to  13.69) 87.19 (47.18 to 127.19) 
Secondary & above 42 (72.41%) 16.95 (16.74 to 17.17) 12.60 (12.09 to 13.11) 113.16 (86.61 to 139.70) 
Occupation   
Subsistence farming 40 (68.97%) 16.82 (16.56 to 17.08) 12.47 (11.78 to 13.16) 106.2 (79.07 to  133.31) 
Retail 5 (8.62%) 16.85 (16.51 to  17.19) 13.07  (11.83 to 14.32) 69.26 (38.13 to 100.40) 
Market trader 6 (10.34%) 17.26 (16.88 to 17.65) 11.94 (10.75 to 13.13) 130.84 (69.64 to 192.04) 
Fisherman 1 (1.72%) 17.09 (NA) 9.56 (NA) 94.17 (NA) 
Housewife 3 (5.17%) 16.82 (15.96 to  17.68) 13.29 (10.31 to 16.28)  55.31  8.35 to 102.26) 
Religious leader 2 (3.45%) 16.66 (16.29 to 17.03) 12.34 (11.88 to 12.80) 202.91 (102.99 to 508.80) 
Teacher 1 (1.72%) 16.85 (NA 15.09 (NA 102.57 (NA) 
Distribution method  
Door to door 27 (46.55%) 16.95 (16.70 to 17.20) 12.61 (11.89 to 13.33) 103.67 (78.63 to 128.72) 
Focal point 31 (53.45%)  16.80 (16.51 to 17.09)  12.41 ( 11.61 to 13.20) 108 (72.28 to 143.74) 
Number of households served  
0 - 69 24 (41.38%) 16.93 (16.56 to 17.29) 11.72 (10.69 to 12.74) 79.58 (65.04 to 94.12) 
70 - 99 16 (27.59%) 16.92 (16.63 to 17.20) 13.13 (12.44 to 13.81) 72.09 (51.14 to 93.05) 
100≤ 18 (31.03%) 16.76 (16.45 to 17.07) 12.99 (12.28 to 13.71) 171.33 (115.41 to 227.27) 
Population size served  
0 - 399 26 (44.83%) 16.97 (16.67 to 17.26) 11.93 (10.95 to 12.91) 75.43 (63.80 to 87.05) 
400 - 599 16 (27.59%) 16.60 (16.23 to 16.97) 12.86 (12.18 to 13.53) 71.66 (51.77 to 91.55) 
600≤ 16 (27.59%) 16.98 (16.64 to 17.32) 13.07 (12.27 to 13.88) 189.99 (131.54 to 248.45) 
Length of tenure as a CDD  
NTDCP only - 1 year 9 (15.51%) 17.05 (16.50 to 17.60) 13.06 (11.89 to 14.23) 105.28 (64.81 to 145.75) 
NTDCP only - 2 years 33 (56.90%) 16.77 (16.49 to 17.04) 12.04 (11.31 to 12.76) 88.71 (67.05 to 110.37) 
NTDCP+SA 3 - 6 years 16 (27.59%) 16.98 (16.72 to 17.25) 13.14 (12.16 to 14.12) 142.03 (81.05 to 203.02) 
Table 5.2: Mean time (hours) per day spent on routine activities carried out not during the NTDCP and during the 
NTDCP, and on NTDCP activities according to descriptive characteristics for the 58 CDDs.      NA = Not available 
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Routine activities during and not during NTDCP activities 
Time spent on routine activities by the CDDs before and after NTDCP activities, or non-NTDCP time, did 
not differ between districts (F (3, 54)=2.38, p=0.08), sub-counties (F (7, 50)=2.17, p=0.05) or at parish 
level (F (15, 42)=1.6 p=0.12). However, there were significant differences seen at each administrative 
level for the same routine activities carried out during the NTDCP period of implementation, district (F 
(3, 54)=5.41, p=0.002), sub-counties (F (7, 50)=3.10, p=0.008) or at parish level (F (15, 42)=2.44 p=0.01). 
The activities which were identified by the CDDs during PD development, and which were subsequently 
included in the PDs, are listed in Table 5.3. The total time spent on daily routine activities was 
significantly lower during-NTDCP than when programme activities were not being carried out (12.50hrs, 
16.87hrs, t(57)=17.79 p<0.001). A significant reduction in time spent on daily activities which consumed 
a larger portion of working time, was observed between non-NTDCP to during-NTDCP, these were, in 
the shamba (2.78hrs, 1.87hrs, t(57)=6.37 p<0.001), preparing and eating meals (2.14, 1.81, t(57)=5.41 
p<0.001), relaxing and socialising (3.33hrs, 1.85 hrs, t(57)=11.96 p<0.001) and family-time (2.03 hrs, 1.78 
hrs, t(57)=3.66  p<0.001). 
Activity† 
non-NTDCP 
mean hours (SD)  
during-NTDCP 
mean hours (SD) Difference p value 
Bathing 1.30 (0.37) 1.23 (0.37) -0.07 0.003 
Praying 1.58 (0.86) 1.46 (0.72) -0.12 0.035 
Preparing children for school 0.13 (0.15) 0.11 (0.14) -0.02 0.150 
Work in the shamba 2.78 (1.09) 1.87 (1.17) -0.91 <0.001 
Preparing and eating meals 2.14 (1.48) 1.81 (1.89) -0.33 <0.001 
Tending to animals 0.89 (0.82) 0.62 (0.63) -0.27 <0.001 
Relaxing and socialising 3.33 (1.46) 1.85 (1.19) -1.48 <0.001 
Household chores 0.69 (0.65) 0.48 (0.47) -0.21 <0.001 
Family time 2.03 (1.21) 1.78 (1.16) -0.25 <0.001 
Business 1.50 (1.79) 0.95 (1.50) -0.55 <0.001 
Non-NTD  health activities†† 0.49 (0.62) 0.34 (0.61) -0.16 0.043 
Total time 16.87 (0.73) 12.50 (2.04) -4.37 <0.001 
Table 5.3: Difference in the mean time (hours) per day, between daily routine activities not during and during the 
NTDCP  
† sample size was 58 CDDs for each activity 
†† Non-NTD health related activities included CDD involvement in home-based management of fever for malaria, 
community mobilisation for immunisation campaigns and health educator of HIV/AIDS or good hygiene practices  
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NTD Control Programme Activities  
The 58 CDDs in the four study districts spent an average of 106 hours or 13.31 work-days (range 2.65, 
56.93 days) on NTDCP activities over one year. In the study design, districts were selected to represent 
the different number of deliveries that would take place over one MDA campaign. However, in Mayuge 
district an insufficient supply of ZIT, PZQ and ALB was delivered and thus not all target areas received 
the necessary PCT. Subsequently Kityerera subcounty had only one delivery round for azithromycin and 
not a second for PZQ and ALB as planned. The following analyses were therefore broken down by 
number of delivery rounds and not district. One delivery of PCT drugs was borne by 23 CDDs, two 
deliveries by 22 CDDs and three deliveries by 13 CDDs (Table 5.4). When split by delivery, the mean time 
spent on the NTDCP activities by the CDDs increased from 83.30 hours (one delivery), to 112.09 hours 
(two deliveries) and to 135.81 hours (three deliveries), with a significant difference between one and 
three deliveries (t(35)=2.69 p=0.01). Table 5.4 shows the mean time on each NTDCP activity per delivery 
and Figures 5.1a to c show the proportion of overall time spent on routine non-NTDCP activities and the 
proportion of time spent on each NTDCP activity by number of deliveries during the implementation 
period of the NTDCP. There were no statistically significant differences in hours between a CDD 
conducting either one or two deliveries for each of the NTDCP activities. The hours spent collecting 
drugs from the health units was significantly higher between two and three (t(34)=2.54 p=0.02), and one 
and three deliveries (t(35)=3.50 p=0.001), whereas with distributing the drugs during the MDA campaign 
there was a statistically higher number of hours spent between one and three deliveries only (t(35)=2.66 
p=0.01). Both the conducting of health education and mobilisation (t(34)=-2.32 p=0.03), and registration 
(t(34)=2.39 p=0.02) required a statistically different number of hours between those CDDs which had to 
deliver two rounds of PCT as compared to those who had to deliver three rounds of PCT, with the 
former activity actually requiring less hours spent on it with increasing number of deliveries 
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Number of deliveries 
 
Activity one [hrs] (SD)†  two [hrs] (SD) three [hrs] (SD) p value‡ 
Collecting Drugs 6.42 (16.99) 6.74 (8.06) 16.87 (17.10) 
<0.001 
1d – 2d, 0.21 
2d – 3d, 0.02 
1d – 3d, 0.001 
MDA 37.94 (37.03) 57.10 (51.87) 77.10 (73.04) 
0.02 
1d – 2d, 0.19 
2d – 3d, 0.26 
1d – 3d, 0.01 
Health Education 
& Mobilisation 16.03 (19.51) 21.09 (34.50) 9.05 (8.63) 
0.09 
1d – 2d, 0.73 
2d – 3d, 0.03 
1d – 3d, 0.08 
Registration 13.18 (17.57) 13.04 (24.87) 24.04 (20.81) 
0.35 
1d – 2d, 0.23 
2d – 3d, 0.02 
1d – 3d, 0.19 
Reporting 4.28 (5.07) 6.01 (4.17) 2.12 (2.68) 
0.93 
1d – 2d, 0.26 
2d – 3d, 0.12 
1d – 3d, 0.61 
Training 5.45 (4.07) 8.13 (7.86) 6.63 (3.27) 
0.28 
1d – 2d, 0.06 
2d – 3d, 0.26 
1d – 3d, 0.35 
Total  
[range] †† 
83.30 (57.88) 
[25.67 – 243.50] 
112.09 (104.98) 
[21.17 – 455.45] 
135.80 (79.98) 
[50.15 – 310.50] 
0.02 
1d – 2d, 0.32 
2d – 3d, 0.16 
1d – 3d, 0.01 
Number of CDDs 23 22 13  
Table 5.4: Total mean time spent by CDDs on NTDCP activities by the number of delivery rounds borne by the 
volunteer, over the MDA campaign.  
† Standard deviations (SD) of the mean are given in the parenthesis.  
† † The range in total hours for each delivery is highlighted in the bottom row of the table 
‡ Overall p value between the number of deliveries and then between one delivery (1d) and two deliveries (2d), 
two deliveries (2d) and 3 deliveries (3d) and one delivery (1d) and 3 deliveries (3d) 
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In addition to number of deliveries, the number of households (t(57)=3.51, p=0.001) and village 
population size (t(57)=4.36, p<0.001) served by a CDD were also significantly associated with the overall 
time spent of NTDCP activities. Distribution methods of door to door or from a focal point used by the 
CDD were not significantly associated (t(57)=-0.27, p=0.79) with the amount of time CDDs spend on 
NTDCP activities. Neither were any socio-demographic variables such as gender (t(57)=-1.44, p=0.16), 
age (t(57)=0.44, p=0.66), marital status (t(57)=0.36, p=0.72), education level (t(57)=1.53, p=0.13), 
occupation (t(57)=0.19, p=0.85) and length of tenure as a CDD (t(57)=1.31, p=0.20). Mixed model linear 
regression (Table 5.5) indicated that both delivery and population were still significant when controlling 
for confounding and clustering seen at the parish level.  
dependent variable: total hours spent on NTDCP by the CDDs  
independent variable coefficient standard error z p value 
number of deliveries per CDD 0.228 0.112 2.03 0.042 
population served per CDD 0.002 0.001 2.68 0.007 
number of households per CDD -0.007 0.004 -1.58 0.114 
constant 3.474 0.259 13.41 <0.001 
Table 5.5: Mixed model linear regression to test associations between independent variables on total hours spent 
on the NTDCP by CDDs whilst controlling for confounding and clustering at parish level. 
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Figure 5.1: (a) to (c). These figures represent the proportion of time spent on NTDCP activities by CDDs during an 
average working year of 246 working days for each number of delivery rounds required during an MDA campaign. 
95.16%
4.58%51.3%
17.13%
13.22%
6.13%
7.64%4.84%
5.1 (a). Percentage of overall CDD work (hrs) in Y3 (2008/9)
for one delivery round during the MDA campaign 
Non-NTDCP activities
Collecting Drugs
MDA
Health Education & Mobilisation
Registration
Reporting
Training
93.49%
7.9%
51.6%
16.1% 7.9%
8.0%
8.4%6.51%
5.1 (b). Percentage of overall CDD work (hrs) in Y3 (2008/9)
for two delivery rounds during the MDA campaign 
Non-NTDCP activities
Collecting Drugs
MDA
Health Education & Mobilisation
Registration
Reporting
Training
92.11%
13.8%
48.4%
8.9%
18.7% 3.3%
6.9%7.89%
5.1 (c). Percentage of overall CDD work (hrs) in Y3 (2008/9)
for three delivery rounds during the MDA campaign 
Non-NTDCP activities
Collecting Drugs
MDA
Health Education & Mobilisation
Registration
Reporting
Training
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CDD Performance 
Reported programme coverage (from CDD treatment registers which feed into districts level reports) 
and survey coverage (from the post-MDA coverage survey) for specific drug combinations in the study 
districts are shown in Table 5.6. Median survey coverage and confidence intervals reported take into 
account the cluster design effect. The reported therapeutic or programme coverage lies within the 95% 
confidence interval for the validated survey coverage for only PZQ+ALB in Mayuge district (35% eligible 
vs 36% survey (32 – 30%, 95%CI)) and IVM+ALB in Yumbe district (74% at-risk vs 73% survey (70 – 76%, 
95%CI)).  
 
District 
Drug  
Packages 
Coverage 
Reported Survey 
Treated 
Therapeutic 
coverage % † 
Programme  
coverage (%)‡ Median  (N)  95% CI 
Kamuli ZIT 396,700  61% 63% 36.73%* [1078]  (33.85, 39.61) 
IVM+ALB 508,573  78% 97% 52.71%* [1089]  (49.73, 55.67) 
PZQ 29,470  75% 94% 57.39%* [1089]  (54.45, 60.33) 
Mayuge ZIT 182,763  44% 46% 13.07%* [1094]  (11.07, 15.07) 
PZQ+ALB 37,666  28% 35% 36.42% [1102]  (32.43, 40.42) 
Yumbe IVM+ALB 295,179  74% 93% 72.76% [984]  (69.97, 75.55) 
PZQ 278,670  70% 88% 77.16%* [972] (74.51, 79.80) 
Pallisa IVM+ALB 386,859  92% 96% 62.59%* [1096]  (59.72 - 65.46) 
Table 5.6: District reported coverage and validated survey coverage data from national post-MDA drug coverage 
survey 
† Therapeutic coverage is the (Number of individuals ingesting the PCT drugs for a specific disease in an endemic 
country/district etc /Total number of individuals in the country/district etc, all at risk of infection) x 100 [215] 
‡ Programme coverage is the (Number of individuals in the target population ingesting the PCT drugs in [x] endemic 
area / All the eligible individuals targeted for treatment in the [x] endemic area) x100 [215] 
*reported at-risk or eligible coverage lies out-with the validated survey coverage 95% confidence interval 
 
The performance of the CDD was measured by village level programme coverage i.e. the proportion of 
targeted eligible individuals treated. Estimates of programme coverage came from a coverage validation 
survey rather than reported coverage due to the inaccuracy of records submitted from the treatment 
registers and the differences seen following analyses. Programme coverage at the village level was taken 
to be the highest coverage that was achieved by any of the drug deliveries in each particular village. It 
was found that village-level programme coverage was significantly associated with number of deliveries 
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(t(31)=2.03, p=0.05), significantly associated with district (t(31)=2.49 p=0.02) and negatively associated 
with the number of hours spent on NTDCP activities (t(31)=-2.16 p=0.04). When controlled for 
confounding, only the latter variable continued to be significantly associated with programme coverage 
(t(31)=-2.54 p=0.02). Figure 5.2 also indicates that lower programme coverage is achieved at the parish 
level with increasing time spent on NTDCP activities.  
 
 
Figure 5.2: Mean number of 8 hour working days spent carrying out NTDCP activities by the CDDs at the parish 
level in year three of the programme (2008/9) plotted against the mean highest therapeutic validated programme 
coverage achieved by each CDD in the parish.  
The different colours represent how many deliveries were carried out in each parish by the CDDs.  
The upper and lower 95% confidence intervals are shown by the error bars around each plot.  
 
CDD Motivation and Attitude 
In semi-structured interviews, when asked about their motivation for taking part in the NTDCP as a 
volunteer, 82% of CDDs responded that they participated to reduce sickness in their community.  
Alternative leading reasons given were that of their recognition as a ‘Musawo’ or doctor (61%), to 
support government health programmes (57%), to reduce stigma for affected individuals (47%) and to 
increase knowledge on health issues (36%). The same reasons were given by the 83% of volunteers 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80
Th
er
ap
eu
tic
 co
ve
ra
ge
 (%
)
Number of 8-hour work days
CDD time on NTDCP and therapeutic coverage 
achieved by parish for Y3 (2008/9)
One delivery
Two deliveries
Three deliveries
 Page | 179  
 
when later asked, if, and why, they would commit again to being a volunteer for the NTDCP. During the 
FGDs such responses were elucidated by the CDDs  
“I was motivated by the trust that the people put in me.  They thought I would serve them truthfully, I 
had to accept to work for them, not to let them down.” Kagulu, Kamuli 
“What motivated me to do this job is the magnitude of disease that is in my community. I knew that if I 
did the work of distributing drugs well, then my people will become healthier.” Romogi, Yumbe 
In total 44 CDDs (76%) were involved in other health-related activities such as health mobiliser, 
sanitation and hygiene education, home-based delivery of malaria treatment, bed-net distribution, 
HIV/AIDS and TB awareness training, and polio and immunisation campaigns. Figure 5.3 illustrates that 
the CDDs responded that they were less motivated (63%) to carry out their NTDCP activities in 
comparison to their other health related activities with major reasons being, HIV/AIDs, malaria and TB 
were major public health concerns in the area and cause mortality, less is known in the community 
about NTDs, financial incentives were given for other health-related activities and NTDCP treatment 
required more travelling around the community and to collect drugs. Below are several quotes from the 
CDDs with regards to their motivation for the NTDCP.  
“If they would give us some money it would motivate us to work with more interest.  But we forego our 
own activities to work for free, while people are assuring us that we are being paid.” Petete, Pallisa 
 
“Since it’s voluntary, we put aside our personal duties and do NTD work which is free. When we reach 
home from sensitization they need money for food, school fees and sometimes wives think (NTD) its 
paying. So, trouble can come up in the family.” Kei, Yumbe 
 
An excerpt of the Attitude Scale asked at the final CDD semi-structured interview is shown in Table 5.7. 
This presents the CDD participants responses pertaining to health activities in the communities and 
motivation. In summary, the CDDs agreed that by being involved in concurrent health-related activities, 
communities were easier to mobilise for the NTDCP and that their, the CDDs, overall performance was 
better. Due to limited health facilities in the communities the CDDs regarded their work as enhancing 
and supporting health services. Nevertheless, the CDDs strongly agreed that they required monitoring 
and supervision by health staff. Finally the CDDs disagreed that the support given by the community was 
enough motivation and the majority agreed that further support was required from the MoH. 
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Figure 5.3: Motivation of the CDDS to carry out their NTDCP responsibilities in relation to the other health-related 
activities they are involved in such as home-based malaria treatment, HIV/AIDS awareness raising and EPI 
mobilisation.  
 
Statements 
Strongly 
Agree Agree Indifferent Disagree 
Strongly 
Disagree 
CDDs are capable of handling several 
health activities at the same time 7% (4) 79% (46) - 7% (4) 7% (4) 
When a CDD is involved in other health-
related activities, this helps in mobilizing 
the community for the NTD MDA 
50% (29) 50% (29) - - - 
The work of the CMD has improved since 
they got involved in additional health 
activities (non-NTD activities) 
- 100% (58) - - - 
To be effective, a CDD should not be 
involved in other health-related activities 
(non-NTD activities) 
- - - 100% (58) - 
Because there are few health 
services in the communities, CDDs have 
to carry out health activities (NTD and 
non-NTD) 
- 79% (46) - 7% (4) 14% (8) 
The involvement of CDDs in 
health activities enhances health services 
in this community 
7% (4) 93% (54) - - - 
The involvement of CDDs in NTD 
activities requires frequent monitoring 
and supervision by health staff 
57% (33) 36% (21) - 7% (4) - 
The type of support given by the 
community to CDDs is enough motivation - - - 71% (41) 29% (17) 
CDDs require more support from the 
MoH to motivate them 21% (12) 57% (33) - 14% (8) 7% (4) 
Table 5.7: Extract from the Attitude Scale in where CDDs provided a response to the statements asked in relation 
to their participation and motivation in the NTDCP.    
63%
25%
12%
CDD Motivation for NTDCP activities related to other 
health-related responsibilities
Less motivated Equally motivated More motivated
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Value of CDD Time 
The opportunity cost of the CDD time was estimated using the time spent on NTDCP activities combined 
with values for the local labour wage, the minimum wage on the national salary scale and GNI per 
capita. The results are presented in Table 5.8 and demonstrate the mean opportunity cost for being 
involved in the NTDCP for a CDD is US$35.71, US$25.77 and US$49.09 depending on which labour value 
is used. The number of hours increases with increasing number of deliveries and thus so does the 
opportunity costs of the CDD participating in the NTDCP. With proportion of annual income as a 
benchmark, it can be seen that the opportunity cost of CDD involvement in the NTDCP increases from 
4.23%, for one delivery, to 5.69% for two deliveries and to 6.91% for three deliveries.  
Number of delivery 
rounds 
Mean time on 
NTDCP(hrs) 
[days†] 
Labour wage 
(USD$††) 
Minimum 
national wage 
(USD$††) 
GNI per 
capita 
(USD$††) 
Proportion 
of annual 
income (%) 
one delivery 83.30 [10.4] 28.06 20.25 38.58 4.23% 
two deliveries 112.09 [14.0] 37.76 27.25 51.92 5.69% 
three deliveries 135.81 [17.0] 45.75 33.02 62.90 6.91% 
mean total 105.99 [13.3] 35.71 25.77 49.09 5.41% 
annual income‡  666.03 478.49 911.57 100.00% 
Table 5.8: Mean time (hours) and [days] spent by CDDs and estimated opportunity costs of CDD time spent on 
NTDCP activities using different salary values.  
†8 hour working day 
††In 2010 US$ prices 
‡estimated if 246 working days per year 
 
 
All 58 (100%) of the CDDs participating in the study responded that the monetary incentive they 
currently receive was not satisfactory. For all annual NTDCP activities CDDs only receive an allowance for 
lunch and transport during their training day which varies between district but which is on average 
US$1.80. This payment is regardless of the number of drug delivery rounds to be made. A NTDCP t-shirt 
(US$1.86) was received by 32% of the participants in the study. Calculation of out-of-pocket expenses 
incurred by the CDDs from the semi-structured interviews and questionnaires were approximately 
US$2.78 per person (range, US$1.32 – US$8.61). These expenses were predominantly for transportation 
to collect drugs from the health units and for drug distribution, as well as for lunch whilst CDDs carried 
out the NTDCP activities that required substantial travelling such as, registration and treatment and drug 
collection.  
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When asked what financial or non-financial reward would be compensation for NTDCP duties 67% of 
CDDs felt a bicycle would facilitate programme activities and 42% felt that a uniform was necessary 
which would help communities identify them clearly as NTDCP responsible persons. All felt that a 
financial reward should be received of approximately US$9 - US$18. The latter would compensate for 
out-of-pocket expenses and lost time on agricultural and business activities in their view.  
 
Discussion 
The use of PDs in this study was a unique approach to determine the amount of time that CDDs were 
allocating to their NTDCP responsibilities. The data have shown that during the period when NTDCP 
activities are being carried out, on average the equivalent of two and a half working weeks, the CDDs 
personal time and expenses, are affected. Consequently, less time is available for both work at home 
and in the shamba and for those who had another form of livelihood. The CDDs that only have one 
package of drugs to deliver over the MDA campaign spent substantially less time (two weeks) on the 
NTDCP than those who required three and a half weeks on average to deliver three rounds of 
treatment. Moreover, as CDDs took longer to deliver the treatment to targeted populations, their 
performance, in terms of programme coverage, decreased. Mixed methods provided evidence to 
evaluate the ability and motivation of the CDDs to successfully and sustainably deliver an integrated 
programme for NTDs. I found that, although the majority of CDDs would return to their role in the 
programme the following year, they were less motivated to participate in the NTDCP than in other 
health-related programmes. Lack of financial incentives was a major contributor to feeling less 
motivated and undervalued. The opportunity costs of the CDD time were determined and the value of 
their time will be discussed further. The evidence reported in this study is of significant importance to 
those managing the programme in Uganda and for the CDDs responsible for its implementation, but 
perhaps more so to those funding and donating drugs to large-scale NTD control programmes to 
observe how their inputs and those of the partner countries are being utilised for sustainable 
community-based programmes.  
There is a growing body of literature which highlights the importance of CDDs participation for the 
successful delivery and sustainability of PCT for the NTDs and other health-related programmes such as 
home-based management of fever and Integrated Community Case Management [321,341-344]. Few, 
however, look at the time spent by CDDs in distributing their health packages [322]. Moreover, the costs 
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of CDD involvement in programmes is rarely valued nor included in programme economic evaluations 
[209,227]. I found time allocated by the CDDs towards their NTDCP duties to be a significant factor 
affecting the performance of the CDDs for the NTDCP in Uganda. Unsurprisingly the number of 
households (on average 90 per CDD) and village population (on average 497 per CDD) were associated 
with the amount of time spent of NTDCP activities by the CDDs. Katabarwa et al. included the number of 
households served by a CDD in Uganda and Cameroon [322] and found that programme coverage 
tended to improve when distributors served fewer households (<20), worked within the kinship system 
and worked within a radius of 1km of their activities. This study aligns with those findings and it is 
intuitive that if there are more households in a population then it will take longer to sensitise and treat 
them all whether distribution is through door to door or from a central point within a community. 
Katarbarwa has extensively investigated the importance of the traditional kinship system in CDTI in 
Uganda [196,322,345]. The kinship system is the central social structure that defines human 
relationships and extended family social interactions which is in place in Uganda and extensively 
throughout sub-Saharan Africa. By only treating kin there are more CDDs in a community, consequently, 
CDDs have less people to treat, those whom they knew well, and distance to travel. Thus the CDDs have 
a reduced workload and tend to perform better.  
The number of drug delivery rounds over the 2008/9 MDA campaign was also influential in how much 
time the CDDs spent on the programme. With fewer deliveries required by the CDDs the time spent on 
NTDCP duties was significantly lower. The particular activities that were affected by the number of 
deliveries in the Ugandan NTDCP were registering the community, delivering health education messages 
and mobilising communities for treatment, collection of drugs from a local health unit and the 
distribution of the drugs to the community. Information elucidated from the CDDs during the semi-
structured interviews and FGDs revealed that the number of visits to the health unit to collect drugs was 
not just due to the number of drug delivery rounds expected of them but also due to availability. Poor 
drug forecasting by the NTDCP meant that, in many cases, there were insufficient quantities of drugs to 
reach target eligible population at the health units. This meant that CDDs would have to return 
frequently to the health units to see if more drugs had arrived from Kampala via the district 
headquarters. Consequently, CDDs delivered treatment to the communities over longer periods of time 
and this time was lengthened further still in areas with increasing number of drug delivery rounds. In 
some circumstances, for example Mayuge district, not all of the requisite drugs were delivered and 
whole sub-counties never received the treatment they had been expecting. Each of these factors, 
increased length of commitment required by the CDD, number of deliveries and the inadequate supply 
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of drugs, resulted in a poorer performance by the CDDs in programme coverage. This is in contrast to 
several studies where adding additional health interventions to the CDTI platform for improved 
programme coverage [235,310,346] but in agreement with the study in Cameroon and Uganda where 
the performance of the CDDs was compromised by added interventions [322].  
This study also estimated the opportunity costs of the CDDs involvement in the NTDCP in Uganda. A 
limited number of studies have reported the opportunity costs of the CDD in health interventions 
[151,310,336]. Depending on the method of valuation and the number of deliveries borne by the CDD, 
the opportunity costs for a CDDs participation in the programme ranged from US$20.25 to $62.90. To 
put this into context, the mean number of 13 days volunteered by a CDD for NTD activities is equivalent 
to a salary of $35.71, based on local casual labour wages. For the same number of days a teacher would 
earn $49.06, a Health Assistant at a health centre would earn $75.19 and a DVCO $121.11. When the 
average value of the CDDs opportunity cost is multiplied by the 61,000 CDDs that were trained under 
the NTDCP in that same year (unpublished data, RTI International semi-annual report 2008/9) this 
amounts to US$2,178,310 which is a substantial contribution by the CDDs to the overall economic 
programme costs. In reality the CDDs receive the equivalent of, on average, US$1.80 allowance for 
training and a t-shirt (US$1.86). If all were to receive a t-shirt, which was not the case in the study 
districts, the combined cost for allowance and t-shirts for the CDDs would be an estimated $223,260 for 
2008/9 which is 82% to 94% less than the value of the opportunity costs. This is not to say that the CDDs 
should be financially compensated for their time equivalent to the value of their time, this would go 
against the premise of community-directed and community-based interventions which are there to 
supplement existing health systems, and would render the programme unfeasible. Similar to other 
studies [310,335,347], CDDs in Uganda are fully aware that they were committing to unpaid work and 
testified that they assume the responsibilities of the NTDCP for intrinsic motivation such as health 
benefits to their community and to build capacity and knowledge in themselves. Nevertheless, this study 
highlights that with the significant amount of time forgone by the CDDs on their regular income or 
subsistence duties, their out-of-pocket expenses and that the CDDs themselves feel undervalued, a 
better incentive package would be justified and could improve motivation and ultimately performance 
of the CDDs. In a recent study Downs et al. describe a framework where the relationships between work 
complexity, demand for incentives and level of performance of CDDs are explored and suggest that the 
demand for incentives is influenced by changes in the complexity of the responsibilities expected of the 
CDDs [348]. If complexity is increased and so is the demand for incentives (monetary and non-
monetary), then efforts towards meeting these demands can lead to an increased perceived value of the 
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CDD position which can motivate CDDs to attaining a higher level of performance. Ultimately the 
consequence of low programme coverage is decreased access to these safe, effective and donated drugs 
for treating NTDs. Where there are barriers to access, studies have shown that it is frequently the 
poorest and those most afflicted by the NTDs that do not receive the necessary treatment or 
intervention [349,350]. 
Non-financial rewards suggested by the CDDs during the semi-structured interviews and the FGDs were 
t-shirts (by those who had not received), bags, hats, boots and waterproof coats with the programme 
logo and certificates. The use of pay for performance, alternatively known as results-based financing, is 
being increasingly tested and used in developing countries [351-353]. These systems involve rewarding 
individuals for reaching their targets, such as numbers treated or programme coverage attained with 
financial or materials to effect an improvement in performance. In the context of the NTDCP, however 
they might only be feasible for CDDs if there was a general health system shift to such a reward scheme. 
Additional areas of concern for such schemes are false reporting and the lowering and even removal of 
intrinsic motivation in participants [351]. In contrast to these reward schemes, and perhaps more 
realistic for the NTDCP, would be to employ alternative distribution mechanisms to what is currently in 
place. The traditional kinship system where each CDD treats below 20 households, which Katabarwa and 
colleagues have shown to be successful in terms of CDD performance, workload reduction and 
involvement in other health activities, in comparison to the standard CDTI system [196] offers one 
alternative distribution mechanism. In addition the demand for monetary incentives was reduced under 
the kinship system. Alternatively, the NTDCP could choose to support and strengthen the existing health 
system through the VHT [305]. In this system one VHT member should serve approximately 25 to 30 
households and in more sparsely populated areas, the fewer households per member [305]. To support 
the VHT the NTDCP would need to work closely with the MoH to establish what the needs of the VHTs 
were in the target districts, for example the provision or loan of bicycles and joint treatment registers. 
The NTDCP would also need to ensure that programme CDDs were indeed those voted by the 
community to be part of the VHT and that their reporting practices were standardised and in-line with 
those of the VHT [305]. Either of these distribution mechanisms would mean CDDs would be targeting 
less than a third of households than they are currently required to. Nonetheless, both of the suggested 
mechanisms would still cause an increased cost to the programme. In the case of the kinship system the 
numbers of CDDs requiring training would approximately double and the VHT system may also require 
more training and the periodic supply of support, however, the potential for increased continuity, 
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sustained performance and a decrease in the opportunity costs and out-of-pocket expenses incurred by 
the CDDs, would, could be argued to far outweigh the expense.  
Limitations 
There were several limitations to this study. The first is in regard to the teachers who carry out the drug 
distribution during school time under the NTDCP. The teachers receive a salary; yet still incur an 
opportunity cost for the time spent distributing the drugs and not teaching. PDs were not carried out 
with the teachers as they were with the CDDs due to the nature of their work and because they still 
receive their monthly salary whether they carry out the NTDCP activities or not. This is in contrast to the 
CDDs who are not paid a monthly salary and therefore work forgone due to participation in the 
programme is not reimbursed. The second limitation is that this study did not collect data on the 
number of drugs delivered to each district and the timeliness of their arrival. The arrival of drugs was 
unsystematic and untimely and the qualities were often insufficient which hampered the performance 
of the CDDs. As the programme was in its third year and was using previous SA programmes as a 
platform from which to base drug distribution mechanisms, poor drug logistics had not been perceived 
to be an issue at the time of study design. Finally, the study would be strengthened if it had been 
collected over a longer period of time and had measured attrition rates in the CDDs. Community-based 
interventions, as a consequence of ‘task-shifting’, are at-risk of high attrition rates in CDDs which, due to 
a lack of continuity, can undermine the effectiveness of programmes [354,355]. 
 
Conclusions 
The availability, capacity, acceptance, and indeed ownership of the programme by the CDDs may only be 
one facet of sustainability of an NTDCP, but it is critical for both effectiveness and longevity of the 
control and elimination efforts. The role of the CDD in the integrated NTDCP requires a substantial 
commitment of time to achieve treatment goals. Additional workload is created when national drug 
logistics and delivery are untimely and with increasing number of delivery rounds within an MDA 
campaign. CDDs, subsequently, fail to achieve their target treatment coverage and there is limited 
access to vulnerable individuals and families. For their performance, whether good or poor there is no 
feedback or consequence for the CDDs from the NTDCP.  Ultimately if programme coverage of 75% and 
over is not being achieved as a minimum then the NTDCP is not being effective and treatment will need 
to continue indefinitely where control of morbidly and elimination are the goals. In order to utilise 
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resources effectively and efficiently, I recommend that the Ugandan NTDCP introduces several 
improvements to the programme: (i) improved drug supplies and logistics to the districts and (ii) an 
alternative support system to the CDDs than that currently used where CDDs are responsible for smaller 
target areas. This would involve investment in financial and non-financial resources yet would pay 
dividends in programme performance and sustainability. Affordable programmes with high impact are 
extremely desirable in the African context and continued high coverage of treatment with community 
participation and ownership are essential elements in their success.  
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Chapter 6. General Discussion 
 
Introduction 
Since the first WHO report in 2010 that addressed the needs in the field of NTD control and elimination 
[11], there has been an unprecedented increase in commitment as witnessed in the ‘London Declaration 
on Neglected Tropical Diseases’ in [22]. This has occurred alongside a realisation that improvements in 
implementation strategies, protocols and technical tools are required to achieve the goals set out in the 
WHO’s 2012 Roadmap for NTDs [23]. In 2010, 711 million people globally received PCT for at least one 
of the NTDs [24]. The impact on the total burden of disease, however, goes beyond what is inferred by 
this statistic as several of the drugs are used to treat and protect against multiple diseases. In May 2013 
the World Health Assembly adopted a new resolution to accelerate these efforts which introduces new 
and ambitious control and elimination targets for the NTDs [24]. The Director General for the WHO, Dr 
Margaret Chan, highlighted that the resolution calls for better coordination of integrated drug delivery 
for NTDs and for integration of control activities into primary health-care systems and strengthening 
country-level capacity to reach targets outlined in the WHO roadmap.  
This aim of this thesis as a whole was to examine the concept and reality of integrating a package of NTD 
control interventions and to assess different facets of the MoH of Uganda’s transition from coordinating 
multiple SA control programmes into one NTD control programme delivering IPCT. At the time of this 
study’s design and application there was insufficient evidence on the implementation processes, costs 
and barriers to scaling-up of IPCT. There was a need for extensive evaluations of different models, in 
different settings, to guide practice on co-implementation and rapid scaling-up of efforts. Consequently, 
this thesis set out to: review the history of NTD control and the extent of integration in Uganda (Chapter 
1); estimate the full economic costs and cost per person treated of delivering IPCT and the effects of 
scaling up (Chapter 3); define the cost savings and elucidate efficiencies between SA programmes and 
IPCT (Chapter 4); determine the time and opportunity costs of CDD involvement in the NTDCP control 
programme and to infer programme sustainability (Chapter 5). Chapter 6 aims to bring all the findings 
together into a coherent whole and discuss implications and applications for future disease control 
programmes and operational research. 
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Summary of Empirical Findings 
The major research themes of this thesis are:  
 the affordability of integrated PCT for the control of NTDs and anticipated cost savings.  
 whether the NTDCP achieved at least as good as, if not better, effectiveness and efficiency when 
compared to the previous delivery of multiple SA programmes for NTDs, whilst still being an 
acceptable model to the individuals delivering the chemotherapy in their communities. 
 
This thesis has demonstrated that the NTDCP in Uganda was, overall, rolled out at low financial cost and, 
by integrating the SA programmes, cost savings were observed (Chapters 3 and 4). The cost savings were 
comparable to expected projections in the literature [166,207,356]. Neither the costs nor the savings 
were, however, constant over time or across settings, and were affected by the scaling up of the 
programme which began with a more expensive ‘start-up’ phase and progressed to increased numbers 
of individuals being targeted each year, with only marginal increases in expenditure and economies of 
scope being realised. In addition, cost savings were only witnessed when those delivering the IPCT, the 
CDDs, had to deliver two or three rounds of drugs in a treatment campaign. As could be anticipated, 
where only one delivery was performed, no cost savings were seen. When the opportunity costs of the 
CDD time were included in the valuations, the previous cost savings with multiple deliveries were no 
longer observed. This was clearly illustrated in Chapter 5 by the significantly increasing amount of time 
invested by the CDDs with each additional delivery that was required for IPCT. The time, and thus costs, 
awarded to programme activities were amplified even further with larger populations served and by the 
uncoordinated supply of drugs. What is most alarming is that even with greater financial and economic 
inputs and despite the scaling up of geographical coverage (i.e. the number of implementation units 
being treated), the WHO mandated treatment coverage (i.e. the number of eligible persons in an 
implementation unit of at least 75%) is not being achieved (Chapters 3 and 5) [24]. 
 
It is well documented that PCT for NTDs can prevent and control morbidity, and even in certain 
situations reduce transmission of infection, where people successfully access and ingest these safe and 
effective drugs [27,35,109,143]. Thus a programme which aims to control and/or eliminate NTDs will 
only be effective if it is obtains and sustains high treatment coverage. Chapters 3 and 5 documented less 
than desirable treatment coverage outcomes. Programme effectiveness, measured in this study in terms 
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of morbidity and DALYs averted (Chapter 4), could have been greater with higher treatment coverage. 
This is because not only would the NTDCP be treating more infected individuals, but it would be having a 
greater impact on transmission and thus preventing reinfections or new infections. It was also suggested 
in Chapter 4 that more of an effect could have been witnessed in Uganda by the NTDCP had prevalence 
of helminth infection been at pre-treatment levels and not reduced due to previous efforts of the SA 
programmes [50,80,86,160,189,190].  
For a health intervention to be a ‘better buy’ in sub-Saharan Africa [357,358], it should have a high 
impact on improving the health of the target population. This impact on health has to correlate to the 
cost of resources used, thereby increasing the chance of being cost-effective. The costs must also be 
below the willingness-to-pay threshold of health policy makers. Where resources are scarce, as in sub-
Saharan Africa, an intervention is competing not only with other health interventions, but also 
interventions in agriculture, water supply and energy. Despite the reduced effect of the Ugandan NTDCP 
due to, as previously discussed, sub-optimal programme coverage, the integrated strategy was still a 
highly cost-effective model for targeting multiple NTDs by WHO standards [281]. Not only that, it was 
shown in the ICER calculations, where the counterfactual SA programmes were assumed to achieve the 
same outcomes as the NTDCP but excluding trachoma outcomes, that IPCT was a more cost-effective 
intervention than the previous SA control programmes, with greater cost savings and DALYs averted 
(Chapter 4).  
 
When committing scarce resources towards a programme it is not just the financial expenditure that 
must be considered. Political support and a considerable human resource contribution are also critical.   
Using a novel method of PDs to quantify human resource input at the community level this study 
determined that time allocated by the CDDs towards their NTDCP duties was a significant factor 
affecting their performance (Chapter 5). The time invested by the CDDs, which averaged 2.1 weeks for 
one delivery, 2.8 weeks for two and 3.4 weeks for three deliveries, had a significant impact upon their 
time available for subsistence and income generating engagements. Subsequently, it was felt by the 
CDDs that there were not sufficient incentives to reward their efforts which, despite their intrinsic 
motivation had a fundamental impact on overall motivation to perform well. CDDs provide a critical 
input into NTD programmes and are at the same time dependence upon community distribution 
strategies is a significant risk if the willingness of these community members suddenly decreases.  
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The CDDs play a crucial role in galvanising communities to repeatedly seek annual treatment, a 
responsibility that becomes more challenging with increasing programme effectiveness and a reduction 
in individuals experiencing symptomatic morbidity. The evidence in this thesis suggest that, whilst there 
is universal acceptability of the NTDCP, programme sustainability at the community level will not be 
achieved unless the distribution methods are altered to those suggested in Chapter 5. A key potential 
example of this includes support of the VHT through non-financial rewards or changing to a kinship 
system [196,305], so that each CDD is expected to serve a smaller population. Without these changes 
technical inefficiencies shown in the integrated approach, that is, greater inputs with the same coverage 
or less as SA, will continue and escalate. Such inefficiency, at any programme layer, renders a 
programme unsustainable and unacceptable to the end users and a poor investment for governments 
and external donors.  
 
 
Thesis Contributions for Integrated PCT for NTDs 
Here the opportunity is taken to discuss the applications and implications of the results of this thesis and 
their importance in the wider context of NTD control and elimination, where evidence on best practice is 
still limited. Finally the priority areas for future operational research for the NTD community are 
suggested. 
 
Application for Integrated PCT for NTD  
The cost analyses in this thesis demonstrated that integrating a package of drugs to treat the NTDs was 
an affordable financial investment for donors. This agrees with other study findings [208,209,359]. The 
financial contribution in terms of in-country budget allocation by ministries of health towards overall 
programme costs is low, despite the costs being only a small fraction of government expenditure on 
health [360,361]. Nevertheless it is important to recognise and value the contribution of the 
government in terms of human resource, materials, and health system infrastructure [13]. This thesis is 
unique in articulating these significant contributions towards IPCT and valuing them in financial terms. It 
is imperative that the government, at all levels, is aware of what it is providing towards programme 
achievements and to demonstrate country ownership and buy in with the donors and implementing 
agencies. 
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It must also be made apparent to ministries of health and their international partners in NTD control 
that their investments will not remain constant over the lifetime of a programme [150,359,362]. As this 
thesis highlights economies of scale are likely to be achieved in the first 5 to 10 years of control, but as 
the focus moves towards elimination and there are greater human resource costs, and an extended 
administrative infrastructure, then diseconomies of scale are possible [224,363]. The economies of scale 
and scope will vary within a country, as we have seen in Uganda, and also between countries. These 
variations are due to stages in a programme cycle, treatment coverage being achieved and underlying 
epidemiology of the NTDs and the consequent number of drug deliveries required for treatment. Thus, 
any predictions and funding gap analysis that assume average costs will remain constant is likely to be 
will ultimately be inaccurate and result in financial projections that are inadequate [166,207,356,364]. 
Not only can the average unit cost per person treated over multiple time points from this thesis be used 
to feed into robust models for funding gap analyses being conducted by WHO, the Bill and Melinda 
Gates Foundation and others, but the detailed breakdowns of inputs and activities and the intra-country 
and drug package variations are all highly valuable for such projections. For such projections this study 
also provides insight into treatment coverage levels and what inputs are required to achieve the 
respective coverage. Treatment coverage is essential in such models as the lower the treatment 
coverage i.e. below 65% of the targeted population, the longer it will take to reach transmission 
breakpoints and the subsequent decision to reduce and/or stop PCT [142,365].   
Current single-disease control models which estimate the costs of elimination using semi-annual 
treatments for LF and onchocerciasis predict that cost savings will be achieved with small additional 
health gains [366,367]. These control models have taken into consideration that low treatment coverage 
and recurrent systematic non-compliance will make a programme take longer to achieve elimination 
goals. Under the Ugandan NTDCP during the time frame covered by this thesis, low treatment coverage 
was a pervading issue. Increasing frequency of MDA to twice a year for several of the NTDs may increase 
programme coverage as populations are more aware of it [366]. However increased frequency of MDA 
might also create a backlash from communities who could feel that they are being over-targeted and 
lead to treatment fatigue and diminishing treatment coverage. Before the promotion and introduction 
of semi-annual treatments to accelerate the progress towards elimination goals for NTDs, the context of 
where, how and whom will be distributing these increased rounds of treatment must be considered. As 
can be seen in this thesis, current annual treatment rounds of MDA must be increased in efficiency, in 
terms of the increased treatment coverage, before we begin overloading an already fragile system that 
requires distributors to spend significant amounts of time away from their economic activities. Future 
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modelling of the costs of elimination for NTDs need to take into account the context of multiple diseases 
being targeted through an integrated mechanism and use observed costs such as those demonstrated 
within this thesis. 
 
Demonstrating impact and cost-effectiveness of health interventions is gaining more importance to 
global health organisations as bilateral, multilateral and philanthropic donors increasingly want to see 
value for money investments [368,369]. Health metrics are used to measure such programme 
performances and provide quantifiable results. The health metrics are used by the wider global health 
community, which consists of policy makers, implementers, donors and academics, to inform 
discussions and map achievements and gaps in global health. As employed in this thesis, DALYs are one 
such metric that allow decision-making based on costs and effectiveness of health interventions with 
their benefit being that they are not disease specific.  
In measuring the cost-effectiveness of IPCT NTD programmes in comparison to other programmes, 
DALYs have only been used in theoretical studies and not from using empirical evidence to make 
programmatic decisions [9,370]. This has been in part due to an apprehension that this metric 
undervalues the disability contributed by NTDs [371], and because there are limited studies which 
simultaneously measure both programme impact on health and costs. The use of alternative metrics of 
health outcome such as quality-adjusted life years (QALYs) can be challenging where individuals suffer 
multiple health complications and are often unable to distinguish between the underlying conditions 
[372,373]. An alternative outcome metric for NTD helminth infection is the proportion of individuals 
harbouring a heavy infection, since morbidity is associated with prevalence of heavy infection [374]. 
However, using the proportion of heavily infected would be to ignore the health impact of moderate 
and subtle morbidity [123] and thus underestimate any achievements and make the calculation of a 
multiple-species impact impossible.  
This thesis is the first to develop a methodology for assessing the joint benefits and costs of NTDs and 
for calculating the cost-effectiveness between multiple SA programmes and IPCT using the DALY metric 
with actual programme data. Although several assumptions have been made, as there are in all models, 
this is a theoretical advance over the current cost-effectiveness analyses which estimate the burden of 
NTDs one condition at a time and do not allow for multiple co-infections. Although cost-effectiveness 
analyses using cost per DALY averted are commonly used to evaluate health interventions in low and 
middle income countries [375-378], their use by governments in such countries has been more limited 
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[379,380]. However one global health organisation, ‘Population Services International (PSI)’, is now 
using the DALY averted metric to measure health impact of its programmes. This has led PSI to a more 
targeted strategy based on burden of disease rather than product sales [381]. Further alignment of the 
DALY averted model for better informed decision-making is in progress and there is strong justification 
for DALYs averted to be used more by decision-makers at the district and national levels to allocate their 
scarce resources more effectively and efficiently. The estimates of DALYs averted and the methodology 
of a composite measure for co-infections established in this thesis can be used as a benchmark for 
country burden of disease calculations by governments and for the NTD community to further refine 
and conceivably use as a tool for measuring integrated NTD programme costs and benefits. 
 
Implications for Integrated PCT for NTD  
When referring to the integration of the PCT NTD control and elimination programmes it is from the 
disease control perspective ‘“Integration” means the creation of packages of healthcare which will be 
delivered vertically through campaigns or other channels’ which is theoretically and practically used in 
the NTD forum. The motivation behind integration is for organisational networks to achieve reduction in 
expenditure and optimal use of limited resources to gain efficiencies in delivery and to exploit 
economies of scope and scale [14,165,168]. The outcomes to be gained from these efficiencies are 
improved health in the targeted populations and ultimately improved school attendance and 
performance, and worker productivity [56,168].  
 
Integration came about because overlaps and synergies in the implementation of SA control 
programmes for NTDs were identified especially by those funding the programmes. There was then a 
strong global movement which brought about funding for integrating programmes because, at least at 
the policy-level, it made a lot of sense to integrate [7,14,356,382]. However, there wasn’t a lot of 
foresight put in to how integration would technically work in practice. For those first ‘fact-track’ 
countries – Uganda, Niger, Burkina Faso, Ghana - there was little or no guidance or recommendations 
from the WHO, or other technical bodies, on how it should be done. WHO did not print their ‘Preventive 
Chemotherapy in Human Helminthiasis’ guide until late 2006 [53] and these programmes were grappling 
with how to plan and implement integrated NTD programmes up to a year before. This left gaps for the 
implementing agencies and funding partners to influence, always well-meaning but often not in an 
educated way, what should happen on the ground. There was a naivety by all involved as to how it 
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would work and as illustrated by this study, not a great deal of thought was put into how the Ugandan 
NTDCP would strengthen existing systems. For example, the need to improve drug forecasting and 
logistics, ensuring minimum treatment coverage and the increasing expectations of community level 
implementation, to cope with the rapid scale-up and expansion were not addressed by the NTDCP. The 
national governments of the fast-track countries have had high expectations and pressure enforced by 
the outside world to achieve cost savings and efficiencies from delivering their complex new integrated 
programmes. Anecdotally, in Uganda this pressure led to tensions when the former head of VCD, and 
the PELF, was appointed the in-country manager for NTD control at RTI. Due to the traditional 
hierarchical nature of power in Ugandan society the SA programme managers at VCD continued to defer 
to the new RTI in-country manager for decisions on the integrated NTDCP. This deferral happened even 
if the SA programme managers were not comfortable with the choices being made, e.g. with the 
creation of a financing and reporting system outside the MoH structures where districts reported 
directly to RTI, and the influence being exerted from the RTI head office in the US which reported to its 
donor USAID. This meant that the initial ‘integration’ of SA programmes, which had previously benefited 
from close collaboration within the Ministry, was fraught with resentment, misunderstandings and poor 
communication. Fortunately, in spite of the challenges faced, this study has determined that the 
Ugandan NTDCP has been able to achieve cost-savings and efficiencies gained through integration. 
Nevertheless, there is the risk that if the integration processes and consequences highlighted earlier are 
not taken into consideration the economic costs of the programme will further increase. Also, if ultimate 
treatment coverage is not attained diseconomies of scope will be realised, whereby adding more 
treatments to the community distribution system results in less efficient treatment. 
 
Looking beyond integration as a package of drugs for NTDs, NTD control also has to be integrated into 
broader public health systems and include integration across sectors. To achieve the NTD control and 
elimination targets set out in the WHO Roadmap for NTDs [23] we not only need to prevent and treat 
infections with PCT, but to address the underlying causes of infection i.e. improve the provision of safe 
water, sanitation and hygiene facilities (WASH) and poverty reduction, and increase access to healthcare 
using a holistic approach. Decentralisation has the aim of improving population health by strengthening 
and facilitating the tailoring of health resources to local needs through primary health care (PHC) 
programmes and community health initiatives [383,384]. On top of this the expectation is that a 
decentralised system improves technical efficiency, allocative efficiency and the quality of service [385]. 
PHC in Uganda is delivered through such a decentralised health care system. The current NTDCP in 
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Uganda attempts to integrate selective programme activities such as training and supervision at the 
district level downwards into this PHC system previously described in this thesis. Further integration of 
the NTDCP activities into a decentralised system will not occur under the current system because, 
ultimately, the programme is still driven from the central level by the MoH, RTI and other 
implementation partners. To fully immerse the programme into the PHC system would likely prove more 
sustainable in the long run [386,387], nevertheless, there are clear challenges to such integration. The 
concern from the NTDCP perspective is that with decentralised PHC, achieving programme objectives 
might receive less focus and efforts may be hindered during the implementation of other health 
interventions which are perceived to be more important by health staff e.g. vaccination campaigns. 
Despite this study showing the affordability and effectiveness of the NTDCP, if the diseases are not 
perceived as a public health priority then focus will be diverted from them onto those that are. Indeed 
donors may also see the integration of the NTDCP into the PHC as a less attractive investment as the 
cost of doing so is considered to be greater, but achieving impact and outcomes potentially slower and 
harder to measure [157]. In contrast, the concern from the PHC perspective would be that an NTD PCT 
campaign could divert resources, such as person time, from other health activities and create extra costs 
for the health services, just as polio eradication efforts have done [388-390]. Although non-salaried MoH 
personnel, the CDDs involved in the NTDCP are part of the decentralised PHC system and, as seen 
throughout this thesis, the programme responsibilities use a significant amount of their time and for 
those MoH personnel supervising the CDDs a corresponding amount of time is invested. Indeed the 
current substantial economic contribution of the MoH towards the NTD control in Uganda, as it stands, 
is under recognised. If NTD control is fully integrated into PHC, the expected contribution of the 
Government of Uganda might well increase.  It is essential that the Government of Uganda commit to 
such a move and that the international NTD community provide time, support and motivation for doing 
so.  
In Mali, the integration of the NTDCP has been successfully integrated into the PHC system, and has now 
reportedly become a routine activity of the MoH salaried Community Health Care Workers (CHCW), 
based at HC [161]. The Mali paper experience suggests that, eventually, large-scale intervention would 
reduce the demand of the CHCW’s time on NTDs due to reduced patient care as a result of IPCT. 
Another successful model for which the Ugandan NTD control efforts could learn from is the integration 
of the PELF into PHC services in the Dominican Republic [162]. This resulted in increased PHC staff 
morale, increased capacity building, improved relationships between community and PHC staff, and the 
delivery of multiple health messages simultaneously.  
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As with the Dominican Republic example, a decentralised PHC system could be better for NTD 
programmes when they have shifted from a focus of control to that of interrupting transmission and 
elimination. When elimination programmes have progressed to a point of stopping PCT, the routine 
surveillance within the PHC structure could be used for effective case detection, treatment and 
subsequent care [391]. The history of NTD control in Uganda is an important contextual variable that is 
often ignored. Due to the number of PCT rounds administered each of the helminth infections, 
excepting the STH, are progressing, at least in some foci, towards elimination. Onchocerciasis control 
has its own committee the ‘Uganda Onchocerciasis Elimination Expert Advisory Committee’ and has 
achieved interruption of transmission in eight out of 18 foci, there have now been over eight rounds of 
treatment for lymphatic filariasis and therefore Transmission Assessment Surveys are being conducted 
[392], and in selected low schistosomiasis transmission regions, the frequency of PCT on transmission is 
being investigated. Therefore, although the NTDCP has been implemented at low cost with economies 
of scale being achieved, a reallocation of resources will be required in future years. In many areas of the 
country active surveillance models for NTDs will be more appropriate although, the costs of doing this 
have yet to be evaluated. However a projection by Seddoh et al. 2013 [369] of financial cost per capita 
to treat all five PCT NTDs between 2014 and 2040 is $0.40 per capita, expenditure after the introduction 
of post-treatment surveillance activities in relation to their $0.21 per capita expenditure during PCT 
only. This increase is a consequence of the inversion of the budget to population ratio. These figures do 
not take into account the increased opportunity or economic costs which would result from additional 
human resource efforts. Any future estimation which builds on the Seddoh et al. 2013 report could use 
the economic costs of CDD efforts, determined in this thesis, to model a more accurate estimate. There 
is also the fear if such active surveillance systems were not managed properly or closely supervised at 
the district or sub-district level this could lead to resurgence of infection and potentially drug resistance 
[393]. 
A more horizontal health systems approach to NTD control and elimination would also increase the 
prospect of intersectoral collaborations such as engineering projects and community-led initiatives in 
sub-Saharan Africa focusing on clean water and sanitation [157] for which there is a current disconnect 
with the NTD community [394,395]. Without such intersectoral collaborations not only will elimination 
of trachoma, schistosomiasis and the STH be unachievable, and poverty alleviation is not addressed 
[396].  
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Sustainability in this thesis focused on the sine qua non participation of the CDDs and community 
contributions. Without CDD volunteer time the delivery of IPCT would not be as affordable or 
achievable. Nonetheless the importance of community ownership, has received conflicting opinions with 
some declaring it as essential [323] and others determining that there is no direct relationship unless 
there is a cost recovery function in place [168,397-399]. Sustainability of NTD control programmes 
additionally requires political and economic contextual factors to ensure that activities and benefits 
accrued are maintained after external funding has ceased [399]. To ensure health benefits such as 
reduced disease morbidity are continued and gains maintained after further gained after donor support, 
programmes such as the NTDCP in Uganda need to move away from vertical structures. Vertical and 
top-down structures do not build up a wide net of health administrators who have invested time in the 
programme, so it has become part of their routine [323,399]. Thus the issue comes around again, as 
previously discussed, to that of integrating into existing health infrastructures to ensure sustainability 
and a holistic approach for NTD control.  
 
In rare exceptions where eradication is possible, for example small pox, sustainability is not a factor in 
programme success, because the reduction of infection prevalence to zero will ensure that health gains 
are permanently achieved for future generations [400]. With the targets for the PCT diseases being 
accelerated to elimination, or in the case of schistosomiasis to the vague notion of ‘elimination of a 
public health problem’, by 2020 [23] then it is debatable how much importance sustainability can play a 
role in NTD programme success. Sustainability cannot be achieved without continued external support 
as illustrated by the guinea worm and yaws eradication campaigns [401,402]. The London Declaration 
has led to significant increased commitment to new drug research and development, increased drug 
donations and increased financial support for NTD programmes, however there are currently only two 
bilateral donors (DFID and USAID) providing the support for implementation to get these drugs to the 
beneficiaries. If the international community itself is struggling to achieve the support required for 
elimination, then it is unrealistic to expect existing health systems in sub-Saharan Africa to deliver such 
targets with donor support, or on their own, in the same time-frame. If these elimination targets, or 
post-elimination surveillance, were placed on the shoulders of the existing health systems to ensure 
sustainability, there is the possibility that previous achievements would not be maintained and infection 
levels could increase to pre-treatment levels [403-405].  
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It is clear that elimination of the NTDs is not a long-term sustainable model if it works in parallel to 
existing health systems. Perhaps the global health community needs to accept the reality of NTD 
elimination being an unsustainable model and to not conflate elimination and sustainability, nor use the 
latter as a metric for the former. Or, at the very least the NTD community needs to be more realistic in 
terms of setting elimination goals with longer-time frames which take into account barriers to 
elimination such as drug resistance, lack of simultaneous clean water and improved sanitation 
interventions, community enthusiasm for delivering and taking drugs and allow for the integration of 
NTD programmes into existing PHC systems. Such an integrated model would require increased funds 
for supervision and potentially new health workers posts within the system, to enable countries to have 
the capacity to deal with achieving and sustaining elimination goals on their own.  
 
Recommendations for future operational research 
The following is a list of operations research priorities for the NTD community in terms of financing, 
costs and integration which are listed in order of priority.   
 
Scaling-up 
Further work is required to document the determinants and barriers (behavioural, operational, and 
technical) that limit treatment coverage, delivery and access to integrated NTD programmes in other 
settings and their effect on the scale-up of IPCT. This would include further investigations into improving 
the performance of CDDs and the system which supports and supervises them. Thresholds for technical 
efficiency need to be explored as well as identifying when programmes become too large and 
diseconomies of scope are being realised. Such figures would inform decision makers on which 
strategies were optimal and when it would be more cost-effective to change delivery strategies, 
interventions or target populations to ensure those at greatest risk are still benefitting from control 
and/or elimination efforts.  
Integration 
There is a need to identify which models are the best for cost-effective and sustainable integrated NTD 
control programmes. Possibilities are, but not limited to: 
(i) integration with each other and optimal delivery platform i.e. kinship systems, VHTs, school-based, 
community-based, CDTI;  (ii) other health programmes;  (iii) the primary healthcare system; (iv) non-
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health sectors 
Going beyond identifying the most favourable models, detailing best practice on how programmes for 
NTD control could move from their current status quo, to that of the recommended models would need 
to be described. 
Measuring success 
Research is required into what outcome metric(s) could be used which is easily measureable, accessible 
to all and can allow for comparisons across countries/ programmes/ different models of NTD control 
and elimination/ non-NTD health interventions e.g. DALYs, QALYs, or a potential new metric. This 
universal metric would be able to illustrate impact for different diseases with different outcomes and 
take into account co-infection of multiple diseases. If feasible a metric that could also incorporate a 
measure of equity, coverage of vulnerable populations (gender, ethnicity, socioeconomic) and 
sustainability would be an asset to health programming in general.  
 
Modelling costs of elimination 
Although single disease control models which factor in elimination of infection have been developed, 
further models which take into account the level of integration of an NTD control programme are 
required. These models would look at the costs of treating what population, in what system, at what 
frequency and for how long to achieve elimination of each NTD. The models would also need to take 
into account known barriers to programme success e.g. co-infection, drug resistance, drug availability 
and incorporate other interventions which are needed for elimination of transmission for each disease 
e.g. WATSAN, behaviour change, snail control, environmental modifications, active case-detection and 
surveillance  
 
 
Conclusion 
The key findings of this novel research were, when using the Ugandan NTDCP as an illustration of IPCT in 
practice, improvements in the efficiency of resource use are achieved through an integrated strategy 
over a combination of concurrently run SA programmes. In addition to the low cost and financial savings 
of IPCT for the NTDs, the strategy was also found to be an effective and highly cost-effective health 
intervention. However, this thesis also highlights potential areas of concern, such as the increased 
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demands expected of the volunteer workforce and the consequences for programme sustainability and 
effectiveness. Furthermore, I emphasise that the results given for Uganda are not necessarily 
transferable to all other integrated NTD control programmes. Finally I make specific recommendations 
in terms of policy for ongoing and future programmes. 
There is currently considerable discourse about accelerating NTD programmes to achieve unrealistic, 
externally-imposed, elimination goals. However, the reasons for the NTDCP to assimilate activities into 
the PHC system in Uganda and to take longer to achieve the control or elimination goals, appear to 
outweigh those against. A lot of careful planning, detailing of process flows and initial supervision, as 
well as, financial and human resources would be required to reach goals of control and elimination 
under a PHC system. To not tackle the NTDs under the existing PHC system undermines the current 
efforts of IPCT by not going to the root of what is making communities vulnerable to NTD infection. 
Perhaps it is time to invest in long-term holistic solutions to health, as ‘If you want to go fast, go alone. If 
you want to go far, go together.” —African Proverb. 
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a. Description of NTDCP Activities, their purpose and the level 
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co
rd
in
g,
 r
ep
or
tin
g 
an
d 
ho
w
 t
o 
co
nd
uc
t 
th
e 
di
st
ric
t 
Tr
ai
ni
ng
 o
f 
Tr
ai
ne
rs
 (
To
T)
 
w
or
ks
ho
ps
. 
 Di
st
ric
t L
ev
el
 –
 T
ra
in
in
g 
of
 T
ra
in
er
s  
Th
e 
tw
o 
da
y 
To
T 
w
or
ks
ho
ps
 w
er
e 
he
ld
 i
m
m
ed
ia
te
ly
 a
ft
er
 t
he
 D
ist
ric
t 
Ad
vo
ca
cy
 W
or
ks
ho
ps
 w
ith
 
pa
rt
ic
ip
an
ts
 f
ro
m
 t
he
 D
ist
ric
t 
He
al
th
, 
Ed
uc
at
io
n 
an
d 
Co
m
m
un
ity
 D
ev
el
op
m
en
t 
of
fic
es
. 
Th
e 
tr
ai
ni
ng
  
in
cl
ud
ed
: 

a 
ba
ck
gr
ou
nd
 o
f e
ac
h 
en
de
m
ic
 N
TD
 d
ise
as
e 
in
 th
e 
di
st
ric
t i
.e
. l
ife
 c
yc
le
s,
 tr
an
sm
iss
io
n,
 s
ig
ns
 a
nd
 
sy
m
pt
om
s,
 p
re
ve
nt
io
n,
 b
en
ef
its
 o
f t
re
at
m
en
t  

th
e 
st
ra
te
gi
es
 in
vo
lv
ed
 fo
r I
PC
T 
at
 th
e 
di
st
ric
t l
ev
el
 a
nd
,  

th
ei
r r
ol
es
 a
s b
ot
h 
tr
ai
ne
rs
 a
nd
 a
s s
up
er
vi
so
rs
 th
ro
ug
ho
ut
 th
e 
im
pl
em
en
ta
tio
n 
pr
oc
es
s.
  

Ea
ch
 p
ar
tic
ip
an
t w
as
 g
iv
en
 a
 tr
ai
ni
ng
 m
an
ua
l, 
re
gi
st
er
s 
an
d 
IE
C 
m
at
er
ia
ls 
fo
r 
di
st
rib
ut
io
n 
w
ith
in
 
th
ei
r d
ist
ric
ts
. 
 
Co
m
m
un
ity
 Le
ve
l –
 T
ra
in
in
g 
of
 S
up
er
vi
so
rs
 a
nd
 T
ea
ch
er
s 
Th
e 
tr
ai
ni
ng
 o
f 
su
pe
rv
iso
rs
 a
nd
 t
ea
ch
er
s 
w
as
 a
 o
ne
 d
ay
 w
or
ks
ho
p 
he
ld
 a
t 
th
e 
he
al
th
 s
ub
-d
ist
ric
t 
an
d 
co
nd
uc
te
d 
by
 t
w
o 
di
st
ric
t 
To
Ts
. T
he
 s
up
er
vi
so
rs
 in
cl
ud
ed
 h
ea
lth
-w
or
ke
rs
 fr
om
 H
C 
le
ve
ls 
II 
an
d 
III
. T
he
y 
w
er
e 
tr
ai
ne
d 
in
: 

ho
w
 to
 c
on
du
ct
 h
ea
lth
 e
du
ca
tio
n 
an
d 
so
ci
al
 m
ob
ili
sa
tio
n 

ba
ck
gr
ou
nd
 o
f e
ac
h 
en
de
m
ic
 N
TD
 d
ise
as
e 
in
 t
he
 d
ist
ric
t 
i.e
. l
ife
 c
yc
le
s,
 t
ra
ns
m
iss
io
n,
 s
ig
ns
 a
nd
 
sy
m
pt
om
s,
 p
re
ve
nt
io
n,
 b
en
ef
its
 o
f t
re
at
m
en
t  

ho
w
 to
 re
gi
st
er
 in
 sc
ho
ol
s a
nd
 c
om
m
un
iti
es
 

co
-a
dm
in
ist
ra
tio
n 
an
d 
tr
ea
tm
en
t i
nt
er
va
ls 
fo
r e
ac
h 
dr
ug
 p
ac
ka
ge
 

id
en
tif
ic
at
io
n 
an
d 
m
an
ag
em
en
t o
f s
id
e 
ef
fe
ct
s 

fo
r 
th
e 
Su
pe
rv
iso
rs
, t
he
ir 
ro
le
s 
as
 b
ot
h 
tr
ai
ne
rs
 t
o 
th
e 
CD
Ds
 a
nd
 a
s 
su
pe
rv
iso
rs
 t
hr
ou
gh
ou
t 
th
e 
im
pl
em
en
ta
tio
n 
pr
oc
es
s  
Th
e 
tr
ai
ni
ng
 
fo
r 
ea
ch
 
di
se
as
e-
sp
ec
ifi
c 
pr
og
ra
m
m
e 
w
as
 
in
te
gr
at
ed
 
at
 
ea
ch
 
of
 
th
e 
im
pl
em
en
ta
tio
n 
le
ve
ls 
un
de
r 
th
e 
um
br
el
la
 N
TD
CP
. 
 Co
m
m
un
ity
 Le
ve
l –
 T
ra
in
in
g 
of
 C
DD
s 
Th
e 
di
st
ric
t t
ra
in
er
s a
nd
 su
pe
rv
iso
rs
 w
er
e 
re
sp
on
sib
le
 fo
r t
ra
in
in
g 
th
e 
CD
Ds
. T
he
 c
om
m
un
ity
 e
le
ct
ed
 C
DD
s 
w
er
e 
in
di
vi
du
al
s w
ho
 w
er
e 
ex
pe
ct
ed
 to
 b
e 
pe
rm
an
en
t r
es
id
en
ts
 in
 th
ei
r c
om
m
un
iti
es
, w
ith
 a
 m
in
im
um
 o
f 
fiv
e 
ye
ar
s 
of
 p
rim
ar
y 
ed
uc
at
io
n 
an
d 
sh
ou
ld
 b
e 
ab
le
 t
o 
re
ad
 a
nd
 w
rit
e 
En
gl
ish
 a
nd
 p
er
fo
rm
 s
im
pl
e 
ca
lc
ul
at
io
ns
. A
pp
ro
xi
m
at
el
y 
tw
o 
to
 th
re
e 
CD
Ds
 w
er
e 
tr
ai
ne
d 
pe
r v
ill
ag
e 
at
 p
ar
ish
 le
ve
l w
or
ks
ho
ps
 la
st
in
g 
on
e 
or
 tw
o 
da
ys
. D
ur
in
g 
th
es
e 
w
or
ks
ho
ps
 th
e 
CD
Ds
 w
er
e 
tr
ai
ne
d 
in
 th
e 
sa
m
e 
to
pi
cs
 w
hi
ch
 w
er
e 
co
ve
re
d 
du
rin
g 
th
e 
tr
ai
ni
ng
 o
f s
up
er
vi
so
rs
 a
nd
 te
ac
he
rs
, b
ut
 a
t a
 m
or
e 
el
em
en
ta
ry
 le
ve
l. 
 
 
Re
gi
st
ra
tio
n 
 
To
 re
gi
st
er
 a
ll 
el
ig
ib
le
 
in
di
vi
du
al
s f
or
 IP
CT
 to
 
es
tim
at
e 
dr
ug
 n
ee
d 
an
d 
ca
lc
ul
at
in
g 
nu
m
be
rs
 tr
ea
te
d 
 
Co
m
m
un
ity
 Le
ve
l 
In
 e
ac
h 
sc
ho
ol
 a
nd
 c
om
m
un
ity
, r
eg
ist
ra
tio
n 
of
 a
ll 
el
ig
ib
le
 in
di
vi
du
al
s 
w
as
 c
ar
rie
d 
ou
t b
y 
th
e 
te
ac
he
rs
 a
nd
 
CD
Ds
, r
es
pe
ct
iv
el
y.
 In
 s
ch
oo
ls,
 t
he
 h
ea
d-
te
ac
he
rs
 a
ss
ig
ne
d 
ov
er
al
l r
es
po
ns
ib
ili
ty
 f
or
 r
eg
ist
ra
tio
n 
to
 t
he
 
N
TD
CP
 t
ra
in
ed
 t
ea
ch
er
s.
 In
 c
om
m
un
iti
es
, i
t 
in
vo
lv
ed
 d
oo
r 
to
 d
oo
r 
re
gi
st
ra
tio
n 
of
 e
ac
h 
ho
us
eh
ol
d.
 T
he
 
Su
pe
rv
iso
rs
 o
ve
rs
aw
 th
e 
re
gi
st
ra
tio
n 
pr
oc
es
s a
nd
 c
ol
la
te
d 
th
e 
da
ta
 w
hi
ch
 w
as
 p
as
se
d 
th
ro
ug
h 
th
e 
HC
III
 to
 
he
al
th
 s
ub
-d
ist
ric
t 
fo
r 
co
m
pi
la
tio
n 
an
d 
fo
rw
ar
di
ng
 t
o 
th
e 
Di
st
ric
t 
He
al
th
 O
ffi
ce
 (
us
ua
lly
 t
he
 D
VC
O
) 
fo
r 
us
in
g 
in
 e
st
im
at
in
g 
IP
CT
 tr
ea
tm
en
t n
um
be
rs
 a
nd
 e
ve
nt
ua
lly
 c
al
cu
la
tin
g 
th
er
ap
eu
tic
 c
ov
er
ag
e.
 
 
Th
e 
re
gi
st
ra
tio
n 
of
 
el
ig
ib
le
 
po
pu
la
tio
ns
 
ta
rg
et
ed
 
fo
r 
ea
ch
 
en
de
m
ic
 d
ise
as
e 
w
as
 d
on
e 
at
 th
e 
sa
m
e 
tim
e 
an
d 
en
te
re
d 
in
to
 o
ne
 
in
te
gr
at
ed
 
N
TD
CP
 
tr
ea
tm
en
t 
re
gi
st
er
 t
o 
be
 u
se
d 
by
 a
 t
ea
ch
er
 
or
 C
DD
. 
De
liv
er
y 
an
d 
di
st
rib
ut
io
n 
 To
 tr
ea
t a
ll 
el
ig
ib
le
 
po
pu
la
tio
ns
 w
ith
 IP
CT
 
fo
r t
he
 tr
ea
tm
en
t a
nd
 
pr
ev
en
tio
n 
of
 N
TD
s  
Dr
ug
 P
ro
cu
re
m
en
t 
O
nl
y 
PZ
Q
 fo
r s
ch
ist
os
om
ia
sis
 a
nd
 A
LB
 fo
r S
TH
 (w
he
re
 th
er
e 
is 
no
 a
ct
iv
e 
ly
m
ph
at
ic
 fi
la
ria
sis
 c
on
tr
ol
) w
er
e 
pu
rc
ha
se
d.
 C
al
cu
la
tio
n 
on
 th
e 
am
ou
nt
 o
f d
ru
gs
 re
qu
ire
d 
w
as
 d
on
e 
by
 th
e 
BW
CP
 st
af
f a
nd
 p
ur
ch
as
es
 d
on
e 
by
 R
TI
. 
Th
e 
N
O
CP
, P
EL
F 
an
d 
TT
F 
w
er
e 
re
sp
on
sib
le
 fo
r 
ca
lc
ul
at
in
g 
ea
ch
 o
f t
he
ir 
pr
og
ra
m
m
e 
dr
ug
 n
ee
ds
 a
nd
 t
he
 
N
TD
 S
ec
re
ta
ria
t 
w
as
 r
es
po
ns
ib
le
 f
or
 m
ak
in
g 
th
e 
do
na
te
d 
dr
ug
 o
rd
er
s 
fo
r 
on
ch
oc
er
ci
as
is,
 l
ym
ph
at
ic
 
fil
ar
ia
sis
 a
nd
 tr
ac
ho
m
a.
  
 Dr
ug
 D
el
iv
er
y 
W
he
n 
th
e 
dr
ug
s 
ar
riv
ed
 in
to
 th
e 
co
un
tr
y 
it 
w
as
 th
e 
N
TD
CP
 C
ou
nt
ry
 P
ro
gr
am
m
e 
M
an
ag
er
 a
nd
 L
og
ist
ic
ia
n 
w
ho
 w
er
e 
re
sp
on
sib
le
 f
or
 h
an
dl
in
g 
an
d 
cl
ea
rin
g 
of
 t
he
 d
ru
gs
 w
ith
 t
he
 N
at
io
na
l M
ed
ic
al
 S
to
re
s 
(N
M
S)
. 
Pr
io
r t
o 
th
e 
Ap
ril
 a
nd
 O
ct
ob
er
 IP
CT
 c
am
pa
ig
ns
, a
ll 
th
e 
dr
ug
s 
re
qu
ire
d 
in
 a
 d
ist
ric
t w
er
e 
th
en
 tr
an
sp
or
te
d 
to
 t
he
 d
ist
ric
t 
m
ed
ic
al
 s
to
re
s 
by
 t
he
 N
M
S.
 T
he
 I
PC
T 
dr
ug
s 
w
er
e 
th
en
 u
nd
er
 t
he
 r
es
po
ns
ib
ili
ty
 o
f 
th
e 
Es
tim
at
es
 o
f 
dr
ug
 r
eq
ui
re
m
en
ts
 
w
er
e 
do
ne
 
se
pa
ra
te
ly
 
by
 
th
e 
ea
ch
 
of
 
th
e 
di
se
as
e-
sp
ec
ifi
c 
pr
og
ra
m
m
es
. 
Ho
w
ev
er
, 
al
l 
or
de
rin
g 
w
as
 d
on
e 
by
 t
he
 R
TI
 
N
TD
CP
 s
ta
ff 
co
or
di
na
te
d 
w
ith
 th
e 
N
TD
 S
ec
re
ta
ria
t. 
 Fo
llo
w
in
g 
de
liv
er
y 
in
to
 
th
e 
co
un
tr
y 
an
d 
st
or
ag
e 
th
e 
de
liv
er
y 
of
 t
he
 d
ru
gs
 f
ro
m
 t
he
 c
en
tr
al
 
do
w
n 
to
 
th
e 
co
m
m
un
ity
 
le
ve
l 
w
er
e 
do
ne
 
in
 
an
 
in
te
gr
at
ed
 
Di
st
ric
t H
ea
lth
 O
ffi
ce
 w
ho
 c
oo
rd
in
at
ed
 th
e 
de
liv
er
y 
of
 th
e 
dr
ug
s 
to
 th
e 
he
al
th
 s
ub
-d
ist
ric
ts
 d
ur
in
g 
ro
ut
in
e 
he
al
th
 a
ct
iv
iti
es
. T
he
 d
ru
gs
 w
er
e 
th
en
 m
ov
ed
 t
hr
ou
gh
 t
he
 h
ea
lth
 s
ys
te
m
 (f
ro
m
 d
ist
ric
t 
st
or
es
) d
ow
n 
to
 
th
e 
HC
II 
Le
ve
l. 
Th
e 
su
pe
rv
iso
rs
 c
al
cu
la
te
d 
th
e 
ex
ac
t 
nu
m
be
r 
of
 t
ab
le
ts
 r
eq
ui
re
d 
fo
r 
ea
ch
 d
ise
as
e 
fr
om
 
sc
ho
ol
 a
nd
 c
om
m
un
ity
 r
eg
ist
er
s 
an
d 
co
m
m
un
ic
at
ed
 th
is 
in
fo
rm
at
io
n 
to
 th
e 
HC
 II
. T
he
 H
CI
I p
re
pa
re
d 
th
e 
dr
ug
 a
m
ou
nt
s 
fo
r 
ea
ch
 s
ch
oo
l a
nd
 c
om
m
un
ity
 a
nd
 t
he
 t
ea
ch
er
s 
an
d 
CD
Ds
 c
am
e 
to
 c
ol
le
ct
 t
he
 d
ru
g 
su
pp
lie
s f
ro
m
 th
e 
ne
ar
es
t H
C 
II 
pr
io
r t
o 
IP
CT
. 
 Dr
ug
 D
ist
rib
ut
io
n 
In
 U
ga
nd
a 
tr
ea
tm
en
t 
fo
r 
m
os
t 
of
 t
he
 S
A 
N
TD
 c
on
tr
ol
 p
ro
gr
am
m
es
 w
er
e 
co
nd
uc
te
d 
se
pa
ra
te
ly
, 
bu
t 
al
on
gs
id
e 
th
e 
Ch
ild
 D
ay
s 
Pl
us
 c
am
pa
ig
ns
 (
pe
rio
d 
of
 a
cc
el
er
at
ed
 r
ou
tin
e 
m
at
er
na
l 
an
d 
ch
ild
 h
ea
lth
 
in
te
rv
en
tio
ns
 e
.g
. m
ea
sle
s i
m
m
un
isa
tio
ns
, a
t a
ll 
st
at
ic
 h
ea
lth
 u
ni
ts
 a
nd
 o
ut
re
ac
he
s)
 in
 e
ith
er
 th
e 
m
on
th
 o
f 
Ap
ril
 o
r O
ct
ob
er
. T
hu
s 
it 
w
as
 d
et
er
m
in
ed
, t
ha
t t
he
 in
te
gr
at
ed
 N
TD
CP
 tr
ea
tm
en
t w
ou
ld
 ta
ke
 p
la
ce
 d
ur
in
g 
th
e 
sa
m
e 
m
on
th
s 
w
ith
 s
om
e 
di
st
ric
ts
 ro
lli
ng
 o
ut
 IP
CT
 in
 A
pr
il 
an
d 
ot
he
rs
 in
 O
ct
ob
er
. T
ab
le
 1
.6
 il
lu
st
ra
te
s 
th
e 
tim
in
g 
of
 th
e 
IP
CT
 in
 U
ga
nd
a 
in
 a
cc
or
da
nc
e 
w
ith
 W
HO
 r
ec
om
m
en
da
tio
ns
 [5
3]
. T
he
 o
rig
in
al
 p
la
nn
in
g 
w
as
 fo
r t
he
 IP
CT
 c
am
pa
ig
n 
to
 ta
ke
 p
la
ce
 o
ve
r, 
at
 th
e 
m
ax
im
um
, a
 p
er
io
d 
of
 e
ig
ht
 w
ee
ks
.  
 Th
e 
ta
bl
et
s 
w
er
e 
ad
m
in
ist
er
ed
, f
ol
lo
w
in
g 
W
HO
 g
ui
de
lin
es
 [5
3]
 to
 in
di
vi
du
al
s 
on
 th
e 
ba
sis
 o
f h
ei
gh
t, 
us
in
g 
lo
ca
lly
 m
ad
e 
he
ig
ht
 p
ol
es
 a
pp
ro
pr
ia
te
 f
or
 e
ac
h 
dr
ug
. 
Th
e 
dr
ug
s 
w
er
e 
ad
m
in
ist
er
ed
 o
ve
r 
th
e 
IP
CT
 
ca
m
pa
ig
n 
by
 e
ac
h 
tr
ai
ne
d 
te
ac
he
r t
o 
th
ei
r c
la
ss
 o
f p
up
ils
, o
r i
n 
co
m
m
un
iti
es
, i
nd
iv
id
ua
ls 
w
er
e 
re
ac
he
d 
by
 
th
e 
CD
Ds
 m
ov
in
g 
do
or
 t
o 
do
or
 w
ith
 t
he
 d
ru
gs
 f
or
 t
re
at
m
en
t, 
or
 f
ro
m
 a
 c
en
tr
al
 l
oc
at
io
n 
w
ith
in
 t
he
 
co
m
m
un
ity
 e
.g
. a
 m
ee
tin
g 
pl
ac
e,
 a
 h
ea
lth
 c
en
tr
e,
 a
 c
hu
rc
h,
 f
ro
m
 w
he
re
 t
re
at
m
en
t 
to
ok
 p
la
ce
. A
n 
IP
CT
 
ca
m
pa
ig
n 
fo
r e
ac
h 
dr
ug
 w
ou
ld
 ta
ke
 p
la
ce
 o
ve
r a
 ra
ng
e 
of
 d
ay
s,
 ty
pi
ca
lly
 fr
om
 o
ne
 to
 th
re
e 
da
ys
. I
n 
so
m
e 
lo
ca
tio
ns
 a
 c
om
bi
na
tio
n 
of
 b
ot
h 
m
et
ho
ds
 w
er
e 
us
ed
 b
y 
th
e 
CD
Ds
, w
he
re
by
 t
re
at
m
en
t 
w
as
 fi
rs
t 
fr
om
 a
 
ce
nt
ra
l l
oc
at
io
n 
an
d 
th
en
 d
oo
r t
o 
do
or
 ‘m
op
pi
ng
 u
p’
 w
as
 c
ar
rie
d 
ou
t b
y 
th
e 
CD
D 
w
he
n 
he
 id
en
tif
ie
d,
 fr
om
 
hi
s 
tr
ea
tm
en
t r
eg
ist
er
, w
ho
m
 h
ad
 n
ot
 b
ee
n 
tr
ea
te
d.
 T
he
 d
ist
rib
ut
io
n 
m
ec
ha
ni
sm
 u
se
d 
by
 t
he
 C
DD
s 
w
as
 
de
pe
nd
en
t o
n 
w
hi
ch
 p
la
tf
or
m
 fo
r M
DA
 th
ey
 h
ad
 h
ist
or
ic
al
ly
 u
se
d 
i.e
. c
om
m
un
ity
-b
as
ed
 - 
th
at
 o
f d
oo
r t
o 
do
or
 f
or
 t
re
at
m
en
t 
of
 l
ym
ph
at
ic
 f
ila
ria
sis
 o
r 
fr
om
 a
 c
en
tr
al
 p
la
ce
 f
or
 s
ch
ist
os
om
ia
sis
; 
or
 C
DT
I 
fo
r 
on
ch
oc
er
ci
as
is 
tr
ea
tm
en
t; 
an
d 
th
us
 it
 v
ar
ie
d 
fr
om
 d
ist
ric
t t
o 
di
st
ric
t. 
 
Al
l u
nu
se
d 
ta
bl
et
s w
er
e 
re
co
ve
re
d 
by
 D
VC
O
s w
ho
 a
lso
 c
om
pi
le
d 
a 
re
po
rt
 o
f a
ll 
tr
ea
tm
en
t a
ct
iv
iti
es
. 
 
m
an
ne
r u
nd
er
 th
e 
N
TD
CP
.  
      IP
CT
 
w
as
 
ca
rr
ie
d 
ou
t 
in
 
an
 
in
te
gr
at
ed
 m
an
ne
r 
in
 t
ha
t 
it 
w
as
 
do
ne
 
ov
er
 
on
e 
tr
ea
tm
en
t 
ca
m
pa
ig
n 
as
 o
pp
os
ed
 to
 s
ep
ar
at
e 
ca
m
pa
ig
ns
 
by
 
ea
ch
 
di
se
as
e-
sp
ec
ifi
c 
pr
og
ra
m
m
e.
 
Ho
w
ev
er
, 
no
t 
al
l t
he
 d
ru
gs
 w
er
e 
ph
ys
ic
al
ly
 
gi
ve
n 
to
 e
ac
h 
pe
rs
on
 a
t t
he
 s
am
e 
tim
e 
fo
r p
ha
rm
ac
ok
in
et
ic
 re
as
on
s 
[5
3]
 
Da
ta
 m
an
ag
em
en
t a
nd
 
re
po
rt
in
g 
 To
 ro
ut
in
el
y 
co
lle
ct
 
tr
ea
tm
en
t a
nd
 
pr
og
ra
m
m
at
ic
 d
at
a 
fo
r 
re
po
rt
 g
en
er
at
io
n,
 
di
st
rib
ut
io
n 
an
d 
di
ss
em
in
at
io
n 
to
 a
ll 
N
TD
CP
 p
ar
tn
er
s 
Co
m
m
un
ity
 Le
ve
l 
Al
l t
ea
ch
er
s 
an
d 
CD
Ds
 s
um
m
ar
ise
d 
th
e 
IP
CT
 d
at
a 
us
in
g 
fo
rm
s 
at
ta
ch
ed
 t
o 
th
e 
re
gi
st
er
s. 
Th
e 
su
m
m
ar
y 
sh
ow
ed
 t
he
 s
ch
oo
l/c
om
m
un
ity
 p
op
ul
at
io
n,
 t
he
 n
um
be
r 
of
 e
lig
ib
le
 i
nd
iv
id
ua
ls 
re
gi
st
er
ed
, 
th
e 
nu
m
be
r 
tr
ea
te
d,
 r
ea
so
ns
 f
or
 a
ny
 n
on
-c
om
pl
ia
nc
e,
 a
nd
 t
he
 n
um
be
r 
of
 t
ab
le
ts
 r
ec
ei
ve
d,
 c
on
su
m
ed
 a
nd
 d
ru
g 
ba
la
nc
es
. R
eg
ist
er
s 
w
er
e 
th
en
 c
ol
le
ct
ed
 w
ith
 t
he
 r
ep
or
ts
 b
y 
th
e 
Pa
ris
h 
Su
pe
rv
iso
rs
 a
nd
 d
el
iv
er
ed
 t
o 
th
e 
ne
ar
es
t 
he
al
th
 u
ni
t. 
Th
e 
Su
pe
rv
iso
rs
 w
er
e 
re
sp
on
sib
le
 f
or
 c
ol
le
ct
in
g 
al
l t
he
 t
re
at
m
en
t 
da
ta
 f
ro
m
 t
he
 
re
gi
st
er
s 
an
d 
re
po
rt
in
g 
th
e 
in
fo
rm
at
io
n 
to
 t
he
 h
ea
lth
 s
ub
-d
ist
ric
ts
, w
hi
ch
 in
 t
ur
n,
 r
ep
or
te
d 
ba
ck
 t
o 
th
e 
Di
st
ric
t H
ea
lth
 O
ffi
ce
.  
 Di
st
ric
t L
ev
el
 
It 
w
as
 th
en
 th
e 
re
sp
on
sib
ili
ty
 fo
r t
he
 D
VC
O
 to
 w
rit
e 
a 
fu
ll 
di
st
ric
t t
re
at
m
en
t r
ep
or
t d
es
cr
ib
in
g 
th
e 
tr
ai
ni
ng
 
ca
rr
ie
d 
ou
t, 
so
ci
al
 m
ob
ili
sa
tio
n 
ac
tiv
iti
es
, c
ov
er
ag
e 
of
 tr
ea
tm
en
t a
nd
 d
ru
g 
ba
la
nc
es
 a
nd
 re
tu
rn
 th
is 
to
 th
e 
N
TD
 S
ec
re
ta
ria
t. 
Sp
ec
ia
l 
fo
rm
s 
fo
r 
re
po
rt
in
g 
SA
Es
 w
er
e 
pr
ov
id
ed
 t
o 
al
l t
he
 d
ist
ric
ts
 a
nd
 h
ea
lth
 u
ni
ts
 
be
fo
re
 IP
CT
 c
om
m
en
ce
d 
to
 b
e 
fil
le
d 
by
 th
e 
M
ed
ic
al
 o
r C
lin
ic
al
 O
ffi
ce
r i
n 
Ch
ar
ge
 o
f t
he
 H
ea
lth
 U
ni
t w
he
re
 
an
y 
SA
E 
ev
en
t o
cc
ur
s 
an
d 
se
nt
 to
 th
e 
Di
st
ric
t H
ea
lth
 O
ffi
ce
 a
nd
 th
en
 to
 th
e 
N
TD
 S
ec
re
ta
ria
t. 
Th
e 
DV
CO
 in
 
co
lla
bo
ra
tio
n 
w
ith
 th
e 
Di
st
ric
t A
cc
ou
nt
an
t w
as
 a
lso
 r
es
po
ns
ib
le
 fo
r 
m
ak
in
g 
a 
fin
an
ci
al
 s
um
m
ar
y 
of
 fu
nd
s 
sp
en
t. 
 Ce
nt
ra
l L
ev
el
 
Th
e 
N
TD
 S
ec
re
ta
ria
t a
nd
 th
e 
N
TD
CP
 C
ou
nt
ry
 P
ro
gr
am
m
e 
M
an
ag
er
 w
er
e 
fin
al
ly
 re
sp
on
sib
le
 fo
r 
re
po
rt
in
g 
th
e 
da
ta
 b
ac
k 
to
 th
e 
N
TD
 p
ar
tn
er
s a
nd
 st
ak
eh
ol
de
rs
, t
he
 D
ire
ct
or
 G
en
er
al
 o
f H
ea
lth
 S
er
vi
ce
s,
 th
e 
N
at
io
na
l 
He
al
th
 D
at
a 
Ba
nk
 a
nd
 W
HO
.  
 
Al
l 
da
ta
 
w
er
e 
co
m
in
g 
fr
om
 
in
te
gr
at
ed
 
N
TD
CP
 
tr
ea
tm
en
t 
re
gi
st
er
s 
th
us
 a
ll 
th
e 
tr
ea
tm
en
t 
re
po
rt
in
g 
fo
r 
ea
ch
 d
ise
as
e 
w
as
 
in
te
gr
at
ed
 u
nd
er
 th
e 
N
TD
CP
.  
  
M
on
ito
rin
g 
an
d 
ev
al
ua
tio
n 
 To
 c
ol
le
ct
 d
at
a 
on
 th
e 
N
TD
CP
’s 
pr
og
re
ss
io
n 
to
w
ar
ds
 it
s a
im
s a
nd
 
ob
je
ct
iv
es
 a
nd
 to
 
Fi
el
d 
Su
pe
rv
isi
on
 
Su
pp
or
t s
up
er
vi
sio
n 
by
 th
e 
N
TD
 S
ec
re
ta
ria
t a
nd
 M
oH
/M
oE
 o
ffi
ci
al
s 
w
as
 d
on
e 
at
 v
ar
io
us
 ti
m
es
, c
ov
er
in
g 
ac
tiv
iti
es
 p
rio
r 
to
, d
ur
in
g 
an
d 
po
st
 IP
CT
 c
am
pa
ig
ns
. I
t 
w
as
 n
ec
es
sa
ry
 t
o 
su
pe
rv
ise
 d
ist
ric
ts
 p
ar
tic
ul
ar
ly
 
du
rin
g 
th
e 
tr
ai
ni
ng
 o
f s
up
er
vi
so
rs
, t
ea
ch
er
s C
DD
s a
nd
 d
ur
in
g 
IP
CT
 so
 a
s t
o 
se
e 
ho
w
 d
ist
ric
ts
 a
re
 o
rg
an
isi
ng
 
an
d 
co
nd
uc
tin
g 
th
em
se
lv
es
 a
nd
 t
o 
as
se
ss
 w
he
th
er
 lo
gi
st
ic
s 
an
d 
ot
he
r 
re
qu
ire
m
en
ts
 fo
r 
im
pl
em
en
ta
tio
n 
w
er
e 
ad
eq
ua
te
ly
 e
st
im
at
ed
.  
 
Th
es
e 
su
pe
rv
iso
ry
 a
ct
iv
iti
es
 w
er
e 
fu
lly
 
in
te
gr
at
ed
 
w
he
re
by
, 
fo
r 
ex
am
pl
e,
 N
O
CP
 s
ta
ff 
su
pe
rv
ise
d 
N
TD
CP
 a
ct
iv
iti
es
 i
n 
ar
ea
s 
w
he
re
 
IP
CT
 w
as
 f
or
 o
nc
ho
ce
rc
ia
sis
, S
TH
 
an
d 
sc
hi
st
os
om
ia
sis
.  
 
ev
al
ua
te
 w
he
re
 th
e 
pr
og
ra
m
m
e 
ca
n 
be
 
im
pr
ov
ed
 a
nd
 h
ow
 th
is 
ca
n 
be
 d
on
e.
 
An
nu
al
 re
vi
ew
s 
To
 e
ffe
ct
iv
el
y 
ev
al
ua
te
 a
nd
 to
 re
ce
iv
e 
es
se
nt
ia
l f
ee
db
ac
k 
fr
om
 th
e 
Di
st
ric
t H
ea
lth
 O
ffi
ce
r i
t w
as
 n
ec
es
sa
ry
 
to
 h
ol
d 
se
ve
ra
l a
nn
ua
l p
ro
gr
am
m
e 
re
vi
ew
s.
 In
vi
te
d 
to
 e
ac
h 
pr
og
ra
m
m
e 
re
vi
ew
 w
er
e 
th
e 
DH
O
, t
he
 D
VC
O
, 
th
e 
DH
E 
an
d 
th
re
e 
he
ad
s f
ro
m
 th
e 
he
al
th
 su
b-
di
st
ric
ts
. E
ac
h 
di
st
ric
t p
re
pa
re
d 
a 
po
w
er
 p
oi
nt
 p
re
se
nt
at
io
n 
w
hi
ch
 g
av
e 
a 
ba
ck
gr
ou
nd
 t
o 
N
TD
 c
on
tr
ol
 in
 t
he
ir 
di
st
ric
t, 
th
e 
su
cc
es
s 
an
d 
th
e 
ch
al
le
ng
es
 t
ha
t 
ha
d 
be
en
 
fa
ce
d 
in
 im
pl
em
en
tin
g 
IP
CT
 a
nd
 fu
tu
re
 re
co
m
m
en
da
tio
ns
. A
ny
 r
ec
ur
rin
g 
m
aj
or
 is
su
es
 w
er
e 
di
sc
us
se
d 
by
 
th
e 
pa
rt
ic
ip
an
ts
 a
s 
a 
w
ho
le
 w
ith
 p
ot
en
tia
l s
ol
ut
io
ns
 p
ro
po
se
d.
 T
he
 d
ist
ric
ts
 a
lso
 p
re
se
nt
ed
 th
ei
r p
la
ns
 fo
r 
IP
CT
 fo
r t
he
 fo
llo
w
in
g 
ye
ar
. 
 Pe
rfo
rm
an
ce
 M
on
ito
rin
g 
 
RT
I c
on
du
ct
ed
 t
w
o 
ho
us
eh
ol
d 
tr
ea
tm
en
t 
co
ve
ra
ge
 s
ur
ve
ys
 in
 2
00
8 
an
d 
20
09
. T
he
se
 s
ur
ve
ye
d 
al
lo
w
ed
 
da
ta
 to
 b
e 
co
lle
ct
ed
 to
: 1
.V
al
id
at
e 
re
po
rt
ed
 c
ov
er
ag
e 
ra
te
s 
fo
r e
ac
h 
N
TD
; 2
. D
et
er
m
in
e 
ag
e-
 a
nd
 g
en
de
r-
sp
ec
ifi
c 
co
ve
ra
ge
; a
nd
 3
. C
ol
le
ct
 im
po
rt
an
t i
nf
or
m
at
io
n 
on
 w
hy
 p
eo
pl
e 
do
 o
r d
o 
no
t t
ak
e 
pa
rt
 in
 M
DA
s 
 Im
pa
ct
 M
on
ito
rin
g 
SC
I 
co
nd
uc
te
d 
in
de
pe
nd
en
t 
im
pa
ct
 m
on
ito
rin
g 
to
 a
ss
es
s 
th
e 
im
pa
ct
 o
f 
th
e 
in
te
gr
at
ed
 N
TD
CP
 o
n 
th
e 
he
al
th
 o
f t
he
 ta
rg
et
 p
op
ul
at
io
ns
 b
y 
qu
an
tif
yi
ng
 c
ha
ng
e 
as
 a
 re
su
lt 
of
 IP
CT
 o
n:
 1
.P
re
va
le
nc
e 
an
d 
in
te
ns
ity
 
of
 in
fe
ct
io
n 
in
 c
om
m
un
iti
es
 a
ffe
ct
ed
 b
y 
on
e 
or
 m
or
e 
of
 th
e 
sp
ec
ifi
ed
 N
TD
s,
 2
. M
or
bi
di
ty
 a
ss
oc
ia
te
d 
w
ith
 
ea
ch
 o
f 
th
e 
N
TD
s 
an
d 
po
ly
pa
ra
sit
ise
d 
in
di
vi
du
al
s;
 3
. N
ut
rit
io
na
l s
ta
tu
s 
of
 in
di
vi
du
al
s;
 4
.T
ra
ns
m
iss
io
n 
of
 
th
e 
ea
ch
 N
TD
 
 Ec
on
om
ic 
Ev
al
ua
tio
n 
SC
I c
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du
ct
ed
 a
n 
in
de
pe
nd
en
t 
ec
on
om
ic
 e
va
lu
at
io
n 
w
hi
ch
 is
 r
ep
or
te
d 
in
 C
ha
pt
er
s 
2 
an
d 
3.
 W
ith
 t
he
 
ob
je
ct
iv
es
 o
f d
et
er
m
in
in
g 
1.
 T
he
 a
nn
ua
l c
os
ts
 o
f t
he
 N
TD
CP
, 2
. T
he
 a
nn
ua
l c
os
t p
er
 p
er
so
n 
tr
ea
te
d 
an
d 
3.
 
Th
e 
co
st
-e
ffe
ct
iv
en
es
s o
f t
he
 N
TD
CP
 a
s m
ea
su
re
d 
by
 D
AL
Ys
 a
ve
rt
ed
 
 Pr
oc
es
s M
on
ito
rin
g 
RT
I 
m
on
ito
re
d 
an
nu
al
 p
ro
ce
ss
 in
di
ca
to
rs
 s
uc
h 
as
 n
um
be
r 
of
 a
dd
iti
on
al
 d
ist
ric
ts
 m
ap
pe
d,
 n
um
be
rs
 o
f 
pe
op
le
 tr
ai
ne
d,
 n
um
be
r 
of
 a
dd
iti
on
al
 d
ist
ric
ts
 tr
ea
te
d 
an
d 
ad
di
tio
na
l n
um
be
r 
of
 p
er
so
n 
tr
ea
te
d 
fo
r 
ea
ch
 
N
TD
. 
Th
e 
an
nu
al
 r
ev
ie
w
s 
re
po
rt
ed
 t
he
 
IP
CT
, a
nd
 th
us
 a
ll 
di
se
as
es
 a
t o
ne
 
tim
e,
 t
o 
th
e 
N
TD
 S
ec
re
ta
ria
t 
an
d 
ot
he
r 
im
po
rt
an
t 
N
TD
CP
 
st
ak
eh
ol
de
rs
. 
    Th
is 
ac
tiv
ity
 w
as
 n
ot
 i
nt
eg
ra
te
d 
w
ith
 a
ny
 o
th
er
 a
ct
iv
iti
es
 b
ut
 w
as
 
co
nd
uc
te
d 
in
 c
ol
la
bo
ra
tio
n 
w
ith
 
th
e 
M
oH
. 
 Th
is 
ac
tiv
ity
 w
as
 n
ot
 i
nt
eg
ra
te
d 
w
ith
 a
ny
 o
th
er
 a
ct
iv
iti
es
 b
ut
 w
as
 
co
nd
uc
te
d 
in
 c
ol
la
bo
ra
tio
n 
w
ith
 
th
e 
M
oH
 
   Th
is 
ac
tiv
ity
 w
as
 n
ot
 i
nt
eg
ra
te
d 
w
ith
 a
ny
 o
th
er
 a
ct
iv
iti
es
 b
ut
 w
as
 
co
nd
uc
te
d 
in
 c
ol
la
bo
ra
tio
n 
w
ith
 
th
e 
M
oH
 
an
d 
M
ak
er
er
e 
U
ni
ve
rs
ity
 K
am
pa
la
 (M
U
K)
 
 Th
es
e 
ac
tiv
iti
es
 
w
er
e 
no
t 
in
te
gr
at
ed
 
w
ith
 
an
y 
ot
he
r 
ac
tiv
iti
es
 b
ut
 w
er
e 
co
nd
uc
te
d 
in
 
SC
I 
co
nd
uc
te
d 
in
de
pe
nd
en
t 
qu
an
tit
at
iv
e 
an
d 
qu
al
ita
tiv
e 
m
on
ito
rin
g 
to
 d
et
er
m
in
e 
fa
ct
or
s 
in
flu
en
ci
ng
 
ac
ce
ss
ib
ili
ty
 a
nd
 a
cc
ep
ta
bi
lit
y 
to
 IP
CT
 a
t d
iff
er
en
t l
ev
el
s o
f N
TD
CP
 im
pl
em
en
ta
tio
n.
  
 
co
lla
bo
ra
tio
n 
w
ith
 t
he
 M
oH
 a
nd
 
M
U
K 
 
Pl
an
ni
ng
 a
nd
 
bu
dg
et
in
g 
 To
 e
na
bl
e 
th
e 
N
TD
CP
 
to
 c
on
du
ct
 a
ct
iv
iti
es
 
ac
co
rd
in
g 
to
 sc
he
du
le
 
an
d 
bu
dg
et
 
  
Th
e 
N
TD
 S
ec
re
ta
ria
t w
ou
ld
 m
ee
t o
n 
a 
m
on
th
ly
, o
r m
or
e 
fr
eq
ue
nt
ly
 b
as
is 
to
 p
la
n 
an
d 
bu
dg
et
 fo
r u
pc
om
in
g 
N
TD
CP
 a
ct
iv
iti
es
 
 An
nu
al
 p
la
nn
in
g 
re
tr
ea
t 
Th
es
e 
re
tr
ea
ts
 w
er
e 
he
ld
 o
n 
an
 a
nn
ua
l b
as
is 
an
d 
in
vo
lv
ed
 t
he
 N
TD
 S
ec
re
ta
ria
t, 
ot
he
r 
M
oH
 a
nd
 M
oE
 
pe
rs
on
ne
l a
nd
 t
he
 N
TD
CP
 S
ta
ff 
tr
av
el
lin
g 
to
 a
 d
ist
ric
t 
w
he
re
 t
he
y 
w
ou
ld
 s
pe
nd
 t
hr
ee
 d
ay
s 
pl
an
ni
ng
 a
nd
 
bu
dg
et
in
g 
fo
r t
he
 y
ea
r a
he
ad
. 
 
Th
es
e 
pl
an
ni
ng
 
an
d 
bu
dg
et
in
g 
ac
tiv
iti
es
 w
er
e 
co
nd
uc
te
d 
by
 t
he
 
N
TD
 
Se
cr
et
ar
ia
t, 
N
TD
CP
 
st
ak
eh
ol
de
rs
 a
nd
 s
ev
er
al
 d
ist
ric
ts
 
in
 a
 c
oo
rd
in
at
ed
 m
an
ne
r. 
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A
pp
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W
H
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it
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m
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T
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RETROSPECTIVE QUESTIONNAIRES 
 
3DJHRI
Retrospective Questionnaire: Personnel 
To be completed by economist for each employee of the Ministry of Health and NGOs involved in 
the grant project.  This does not include those who complete a daily work log.  Please note that 
all questions refer to time spent during one year. 
 
 
Intervention Codes  Activity Codes 
(1)  Lymphatic Filariasis  (1)  Advocacy 
(2)  Onchocerciasis  (2)  Data Management & Reporting 
(3)  Schistosomiasis  (3)  Delivery and Distribution 
(4)  Soil-transmitted Helminthiasis  (4)  Field Supervision 
(5)  Trachoma  (5)  Health Education and Mobilisation 
(6)  Child Health Days  (6) Latrine Construction 
(7)  EPI  (7)  Mapping and Assessment  
(8)  Malaria  (8)  Monitoring & Evaluation 
(9) Vitamin A Supplementation  (9)  Morbidity Control 
(10) Maternal and Child Health  (10)  Planning and Budgeting 
(11) Family Planning  (11) Procurement 
(12) Clinical Patient Care  (12) Surgery 
(13) Other  (13) Training 
  (14) Vector Control 
  (15) Other 
 
 
1. Do you spend any time on Neglected Tropical Diseases (NTDs)?  (For the purposes of this 
study, NTDs include lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted 
helminthiasis, and trachoma) 
  Yes       No 
If yes, please proceed through the rest of the questions; if no, there is no need to 
complete this questionnaire. 
 
 
2. What proportion (%) of your time per year is spent on NTD interventions (as defined in 
Question 1 above)? 
      % 
 
 
3. A. What proportion (%) of your time is spent per year on a single-focus health intervention 
(i.e., interventions that are not a part of an integrated package of interventions)?   
      % 
 
B.  If the answer to 3.A is greater than 0%, which intervention(s)? 
 Intervention code(s):       
 
3DJHRI
C. Please allocate your time spent on single-focus health interventions across the following 
activities: (Note:  total must equal 100%) 
 
Activity  % 
(1)  Advocacy  
(2)  Data Management & Reporting  
(3)  Delivery and Distribution  
(4)  Field Supervision  
(5)  Health Education and Mobilisation  
(6) Latrine Construction  
(7)  Mapping and Assessment   
(8)  Monitoring & Evaluation  
(9)  Morbidity Control  
(10)  Planning and Budgeting  
(11) Procurement  
(12) Surgery  
(13) Training  
(14) Vector Control  
(15) Other  
 
 
4. A. What proportion (%) of your time is spent per year on an integrated package of health 
interventions including at least two health interventions? 
     % 
 
B.  If the answer to 4.A is greater than 0%, which interventions? 
 Intervention codes:       
 
C. Please allocate your time spent on an integrated package of health interventions across 
the following activities: (Note:  total must equal 100%) 
 
Activity  % 
(1)  Advocacy   
(2)  Data Management & Reporting  
(3)  Delivery and Distribution  
(4)  Field Supervision  
(5)  Health Education and Mobilisation  
(6) Latrine Construction  
(7)  Mapping and Assessment   
(8)  Monitoring & Evaluation  
(9)  Morbidity Control  
(10)  Planning and Budgeting  
(11) Procurement  
(12) Surgery  
(13) Training  
(14) Vector Control  
(15) Other  
 
3DJHRI
Data Collection Instrument for Drug Distributors 
 
Investigator Name 
 
Date (Month / Year) 
Project Name / Community Name 
 
Contact’s Name 
 
Position in the Project (e.g. community drug distributor, teacher, village leader, other?) 
 
In the last year, how many days did you spend on NTD control activities?  
 
Please indicate how you spent that time, by listing the number of days or part-days spent on each of the activities 
listed below and allowance received and transport used / money used for transport 
Attending training  
 
 
 
Health Education and 
Mobilisation  
 
Registration 
 
 
 
Collecting the drugs 
 
Giving out the drugs to 
the community 
 
 
 
Monitoring and 
Evaluation 
 
Reporting to NTDCP 
 
All other administration 
 
 
 
Other project activities 
(describe) 
 
 
 
3DJHRI
 
Did you provide anything to the project apart from time e.g. bicycle, chairs, cups etc?  
If yes, what and how often?  
What was the item(s) used for (referring to the same activity categories mentioned on page one)? 
                                                                                      
Item Cost    How often? (quantity/frequency) Activity used for 
    
    
    
    
    
Does the village provide anything else needed by the project? Who exactly provides it, and how often? What was 
the item(s) used for (referring to the same activity categories mentioned on the first page)? 
 
Item / Source Cost    How often? (quantity/frequency) Activity used for 
    
    
    
    
What do you do for a living / do you have another job?  (eg., Farmer, Teacher) 
 
 
 
 
How often do you work on each job? (e.g. during the school year, during the harvest?) 
 
 
 
 
Normally what do you earn for each job?  (daily /weekly/ monthly/ annually) 
 
 
 
 
 
Thank you for your time 
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APPENDIX III 
 
District Costs 
 
1.District Cost Table 
2.Kamuli District Cost Table 
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Introduction
Cost-effectiveness analysis has become a principal tool to
evaluate health interventions, guiding health policy in both
developed (McDaid et al. 2003) and developing countries
(World Bank 1993; Jamison et al. 2006). Estimates of cost-
effectiveness are typically taken from a single study or a few
small-scale studies in different countries (Walker and Fox-
Rushby 2000), with no attempt to review the possible variation
in estimates. However, because both intervention costs and
effectiveness differ among locations, a single estimate of cost-
effectiveness is unlikely to be universally applicable (Musgrove
and Fox-Rushby 2006). More probable is that costs and
cost-effectiveness will vary, even within a single country.
For instance, intra-country variation in costs has been demon-
strated in the delivery of routine immunization in Peru (Walker
et al. 2004), antenatal care in Cuba and Thailand (Hutton et al.
2004), a bednet distribution programme in Malawi (Stevens
et al. 2005) and a lymphatic filariasis elimination programme in
Egypt (Ramzy et al. 2005). Variations in average costs may arise
in the short run from differences in the relative costs of inputs,
differences in technical efficiency, or, in the long run, from
factors associated with economies of scale (Folland et al. 2004).
Differences may also reflect variation in respect to the
demography and epidemiology of disease, availability of
health care resources and system of health care delivery
(Drummond and Pang 2001). Understanding how and why
costs vary can help in assessing the degree to which cost and
cost-effectiveness estimates can be reliably extrapolated across
different settings, and can also enable health planners and
policy makers to discern what drives costs and to plan future
budgets (Drummond et al. 1992; O’Brien 1997; Bryan and
Brown 1998; Spath et al. 1999; Drummond and Pang 2001;
Walker et al. 2004). This understanding is particularly important
for global health programmes which implement a common
health package in a range of settings. For example, a number of
initiatives are now underway which seek to control a number of
tropical diseases, including those caused by parasitic helminth
(worm) infections (Albonico et al. 2006; Boatin and Richards
2006; Fenwick et al. 2006; Ottesen 2006).
The staff of these initiatives, together with national pro-
gramme staff, also need information on how costs change
as the programmes are gradually scaled-up. In economics,
changes in the level of output may change average costs;
as output increases, average costs either remain constant
(constant returns to scale), decrease (economies of scale)
or increase (diseconomies of scale) (Folland et al. 2004).
Many studies assume constant returns to scale, and take
average costs per recipient and multiply them by projected
output levels (e.g. Fenwick et al. 2005; Brady et al. 2006).
In practice, however, available studies demonstrate that
average costs vary at different levels of output (Over 1998;
Mansley et al. 2002; Valdmanis et al. 2003; Elbasha and
Messonnier 2004).
There is a clear need for empirical evidence to better
understand variations in cost and cost-effectiveness, particu-
larly in the context of large-scale control programmes. This
paper assesses the variation in costs and cost-effectiveness of a
nationwide helminth control programme, and the effect of
scaling-up on costs. The specific aims are to: (1) investigate the
intra-country variation in the cost and cost-effectiveness of a
national school-based schistosomiasis and soil-transmitted
helminth (STH) control programme in Uganda, (2) determine
the effects of scaling-up on costs and cost-effectiveness, and (3)
identify the main determinants of average costs.
Description of the control programme
In 2003, the Ugandan Ministry of Health (MoH) launched
its national schistosomiasis and STH control programme
(Kabatereine et al. 2006a,b). Implemented vertically through
the Vector Control Division (VCD) in Kampala, the programme
provides anthelmintic (deworming) treatment to schools and
communities at risk of morbidity due to helminth infection.
In brief, the programme comprises the following activities:
community sensitization, training of teachers and community
drug distributors (CDDs), and school-based delivery of two
anthelmintic drugs. Mass treatment with praziquantel to treat
schistosomiasis and with albendazole to treat soil-transmitted
helminths was given to all schools and communities in targeted
areas. Treatment in schools is carried out by teachers and in
communities by CDDs. The programme manager and VCD
headquarters staff have overall responsibility for the pro-
gramme and regularly visit districts to monitor progress.
Implementation of the programme at the district level is
undertaken by District Vector Control Officers (DVCOs) and
district health teams.
To help create awareness and political engagement, a series of
national workshops were held in Kampala between 2001 and
2005 (two in 2001, two in 2002 and one each in 2004 and
2005). The implementation of control began with a pilot
phase from April to October 2003 targeting 400 000 people,
with one sub-county selected for mass treatment in each
of the 18 most affected districts (Kabatereine et al. 2006a).
In 2004 the number of sub-counties targeted in each of the
KEY MESSAGES
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18 districts was increased, and in 2005 the programme was
expanded to include 23 districts, targeting 2.3 million people
(Kabatereine et al. 2006b). In each district, training workshops
provided teachers and CDDs with a basic understanding of
schistosomiasis and STH, and of how to complete record forms
and to administer tablets. The design of training and number
of participants varied between districts. Health education
messages were delivered through posters, booklets and audio
and film media. All information, education and communication
(IEC) material was translated into various local languages.
Imported drugs were cleared at Entebbe airport by the
Uganda National Medical Stores, who transported them to
VCD headquarters. Drugs and IEC material were either
transported to the districts by VCD or collected by the districts
during routine visits to Kampala. Drug registration and
treatment included compiling school enrolment data and
community census information to determine the target popula-
tion and drug needs. The number of tablets provided to each
school was calculated on the basis of treatment registers
completed by head teachers and CCDs. The drugs were
delivered to each school by the DVCOs and were received by
the head teacher. Tablets were then administered by teachers
on a specified day in all schools under the supervision of the
head teachers and community health workers. In communities,
treatment was provided by CCDs. Praziquantel (25mg/kg) was
administered to individuals on the basis of height, using locally
made height poles, and every individual was given a single dose
of albendazole (400mg). All unused tablets were recovered by
DVCOs who also compiled a report of activities.
Data and methods
Only costs associated with school-based treatment are con-
sidered here because of the global focus of helminth control on
the school-age child (Bundy et al. 2006) and the availability of
detailed effectiveness data for schoolchildren (Kabatereine et al.
2007).
Cost analysis
Cost data were collected retrospectively from the VCD team in
Kampala and from six of the 23 intervention districts
(Figure 1). Districts were chosen to reflect differences in
disease transmission (Kabatereine et al. 2004) and in socio-
economic and health service infrastructure. Data collection was
carried out between February and June 2006. A semi-structured
questionnaire was drafted and was revised and amended during
joint discussions with MoH officials. Data were collected by
interviews with district officials using the final questionnaire
and by consultation of the programme accounting system in
Kampala. Documentation related to expenditure had been
checked by each district accountant for accountability and
cross-checked by the research team for accuracy.
The perspective adopted in the evaluation was that of the
government, rather than society, since the costs of accessing
treatment were negligible as children were treated in their own
schools. Both financial and economic costs were estimated.
Financial costs represent cash expenditure paid for the
implementation of the intervention on an annual basis.
Economic costs include the opportunity cost of using existing
Ministry of Health staff and school teachers as well as
annuitized capital costs, and represent the true cost of any
intervention. Opportunity costs for staff were calculated from
salary costs, based on Ugandan civil service pay scales for 2005.
Capital costs were annuitized over the useful life of each item
using a discount rate of 3%, consistent with the recommenda-
tions of the World Bank (1993). Such annuitization enables an
equivalent annual cost to be estimated and reflects the value-
in-use of capital items, rather than reflecting when the item
was purchased. The assumed useful life of buildings was
30 years, vehicles 7.5 years, motorcycles 4 years and computers
3 years. Vehicle running costs also included maintenance and
insurance. The purchase, freight and insurance of drugs was
paid in foreign currency (US$). All other costs were paid in
Uganda Shillings (USh) and converted to US dollars using
official exchange rates, based on average yearly exchange rate:
1 US$¼ 1777 USh in 2003, 1807 USh in 2004 and 1844 USh in
2005 (http://www.oanda.com/convert/classic). Monetary costs
were adjusted for inflation over time using the Gross Domestic
Product (GDP) implicit price deflator (http://ifs.apdi.net/imf/
logon.aspx) and expressed in 2000 prices. Details on the
resources employed, their unit costs and quantities consumed
are provided in the appendix. All costs directly related to
research activities were excluded.
The cost data are organized into six main cost centres:
(1) programme running costs; (2) community awareness;
(3) training; (4) imported drugs; (5) drug registration and
distribution; and (6) IEC material. The different cost compo-
nents of the intervention were identified using an ingredients
approach, considering both the number of units and the prices
of units in local currency (Ugandan Shillings). The unit cost
data were combined with numbers treated to calculate, on a
district-by-district basis, the average cost per child treated.
The relationship between the cost per child treated and the
percentage of overall costs due to different cost centres and
other independent demographic and geographic variables was
assessed using a non-parametric Spearman rank correlation.
Figure 1 Map of Uganda showing districts selected for cost analysis
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Effectiveness
Evidence of the programme effectiveness was measured in
terms of anaemia cases averted. Epidemiological data were
collected prospectively through longitudinal surveys conducted
in 30 schools between 2003 and 2005. The details of the
sampling strategy, survey design and procedures are provided
elsewhere (Brooker et al. 2004; Kabatereine et al. 2007).
Population-based measures of programme impact included
parasitological and haematological data which were collected
from randomly selected schoolchildren who were followed up
over 3 years. Anaemia is defined as haemoglobin concentration
(Hb)<110 g/L. The current analysis focuses on those districts
where cost data were collected, thereby excluding effectiveness
data from Arua, Bugiri and Mayunde districts. The number of
cases of anaemia averted was calculated by multiplying the
absolute difference in proportion of anaemia cases averted
between 2003 and 2005 by the total number of children treated.
This was calculated on a district-by-district basis, as well as,
overall, assuming the mean difference in proportion of anaemia
cases averted among districts.
Cost-effectiveness analysis
The counterfactual is defined as ‘do-nothing’. This is justified
on the basis that prior to the current control programme, no
efforts were made to control helminth infection in the country,
with only passive detection of cases in health centres and
presumptive treatment, although in practice, anthelmintic
drugs were rarely available. Cost-effectiveness is defined
in terms of the cost per case of anaemia averted, and cost-
effectiveness ratios are based on annual economic costs.
Sensitivity analysis
Sensitivity analysis allows for uncertainty within the economic
evaluation. It shows how responsive the result is to changes in
key economic parameters but also gives an indication of the
robustness of the estimate to changes in unknown variables.
Sensitivity analysis was undertaken to investigate the effect on
the results of varying the discount rate (reduced to 1%
and increased to 10%), the prices of the drugs (reduced by
10% and 20% to reflect the use of cheaper drugs in the future)
and effectiveness of treatment in reducing the proportion of
anaemia cases (reduced by 33% and 50% to reflect differences
in the impact of treatment on anaemia in different transmis-
sion settings). One-way scenario sensitivity analysis was carried
out to assess the impact of key variables on estimates of the
cost per anaemia case averted.
Results
Total financial and economic costs
The total financial cost of the intervention in the six districts was
estimated at US$161 312. The financial costs per district ranged
from US$18 015 in Masindi district to US$33 809 in Hoima
district. The economic cost of the intervention was calculated by
valuing staff time and annuitizing capital costs to provide an
equivalent annual cost. The economic costs of the intervention in
each district are summarized by the major cost centres in Table 1.
The total economic cost was estimated at US$218 303: ranging
from US$25 624 in Masindi district to US$44 958 in Hoima
district. In each district, the largest individual cost item was the
purchase of drugs, ranging from 23.6% of total costs in Masindi
district in 2003 to 52.1% in Moyo district in 2005. Community
sensitization activities and IEC materials were the next largest
items (Table 1).
Costs per children treated
The overall financial cost per child treated in the six districts
was US$0.39. The total economic cost per child treated in the
six districts was US$0.54, which includes the imputed value of
labour as well as annuitized capital costs. Considerable
variation in the economic costs per child treated existed
between districts and between years, ranging from US$0.41 to
US$0.91 (Table 2). The economic delivery cost per child treated
(which excludes drug cost) also varied considerably: US$0.19–
0.69. The cost per child treated is highly sensitive to the total
number of children treated (Figure 2). Increasing the number
of children treated can significantly decrease the cost per child
treated (Figure 2a; Spearman’s rho: –0.93, P<0.001), sugges-
tive of economies of scale. Similar economies of scale were
observed in the delivery cost per child treated (Figure 2b;
Spearman’s rho: –0.93, P<0.001).
In order to investigate possible causes of observed variation
in costs, the relationship between delivery cost per child
treated and the percentage of overall costs due to different
cost centres was investigated. Cost per child treated was
significantly associated with the percentage of overall costs
due to sensitization and awareness (Spearman’s rho: 0.769,
P¼ 0.0002). The majority of the costs involved here are per
diem (allowances) rates paid to district officials, which ranged
from US$4.95–15.44, although the correlation between allow-
ance rates and cost per child treated was non-significant
(Spearman’s rho: 0.19, P¼ 0.444). Differences in demographic
and geographic factors, including distance of each district from
Kampala, geographical area and population density of the
district, and differences in epidemiological factors, such as
baseline intensity of infection and reduction in infection
following treatment, were not significantly associated with
costs per child treated.
Cost-effectiveness
Among the 1455 children monitored for the 3-year period in
the six districts, the percentage of children anaemic, defined as
Hb<110 g/L, fell from 35.2% in 2003 to 18.5% in 2005,
following three rounds of treatment. This translates to a
52.5% reduction in the proportion of anaemia cases within
the study population. Table 3 reports the proportion of anaemia
cases averted over the 3 year period by district. Overall, 0.4
million children were treated at an estimated cost of US$3.19
per case of anaemia averted. Cost-effectiveness ranged from
US$1.70 in Moyo district to US$9.51 in Masindi district. Cost-
effectiveness decreased with increasing cost per child treated
(Figure 3a; Spearman’s rho: 0.940.19, P¼ 0.005) and increased
with increasing difference in the proportion of anaemia averted
as a result of the intervention (Figure 3b; Spearman’s rho: 1.0,
P<0.0001). This suggests that neither costs nor effectiveness
are constant and therefore cost-effectiveness varies between
districts. Figure 3c indicates a negative association between
cost-effectiveness and the number of children receiving
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Table 1 Comparative economic costs (2005 US$ prices) of anthelmintic treatment by major cost centre and percentage of overall costs by district in
Uganda 2003-05
2003 2004 2005 Average % 2003–5
Costs % Costs % Costs %
Busia Programme running costs 526 4.0 526 4.3 526 5.3 4.5
Community sensitization 2349 17.8 1984 16.1 621 6.2 13.4
Training 2459 18.6 1897 15.4 688 6.9 13.6
Drug distribution and treatment 2531 19.1 2761 22.5 2594 26.0 22.5
Imported drugs 4701 35.5 4722 38.4 4815 48.3 40.7
IEC material 658 5.0 404 3.3 721 7.2 5.2
Total 13 224 12 294 9963
Mayuge Programme running costs 526 7.7 526 3.3 526 5.4 5.5
Community sensitization 2189 32.1 1269 8.1 455 4.6 14.9
Training 874 12.8 1553 9.9 3986 40.7 21.1
Drug distribution and treatment 1073 15.7 2910 18.5 2337 23.9 19.4
Imported drugs 1722 25.3 7602 48.3 2393 24.5 32.7
IEC material 435 6.4 1872 11.9 91 0.9 6.4
Total 6819 15 732 9789
Hoima Programme running costs 526 3.6 526 3.8 526 3.2 3.5
Community sensitization 2154 14.8 586 4.2 425 2.6 7.2
Training 2246 15.5 2796 20.1 4497 27.2 20.9
Drug distribution and treatment 2893 19.9 1906 13.7 3257 19.7 17.8
Imported drugs 6210 42.8 6612 47.6 6137 37.1 42.5
IEC material 479 3.3 1476 10.6 1706 10.3 8.1
Total 14 508 13 902 16 548
Masindi Programme running costs 526 8.1 526 6.4 526 4.8 6.4
Community sensitization 2340 36.0 1314 16.1 1117 10.2 20.8
Training 585 9.0 678 8.3 3100 28.3 15.2
Drug distribution and treatment 1249 19.2 1347 16.5 1892 17.3 17.7
Imported drugs 1533 23.6 2608 31.9 3072 28.0 27.8
IEC material 267 4.1 1694 20.7 1248 11.4 12.1
Total 6500 8167 10 955
Moyo Programme running costs 526 3.5 526 4.8 526 3.4 3.9
Community sensitization 1944 12.8 723 6.6 615 4.0 7.8
Training 2235 14.7 1445 13.1 2031 13.0 13.6
Drug distribution and treatment 2218 14.6 1443 13.1 5283 34.0 20.6
Imported drugs 7928 52.1 4627 42.0 6837 43.9 46.0
IEC material 352 2.3 2246 20.4 269 1.7 8.1
Total 15 203 11 010 15 561
Nebbi Programme running costs 526 6.8 526 3.2 526 3.0 4.3
Community sensitization 1771 23.1 750 4.6 802 4.5 10.7
Training 995 13.0 1015 6.2 4323 24.5 14.6
Drug distribution and treatment 1338 17.4 6291 38.7 4715 26.7 27.6
Imported drugs 2609 34.0 6873 42.3 6682 37.8 38.0
IEC material 438 5.7 781 4.8 616 3.5 4.7
Total 7677 16 236 17 664
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treatment (Spearman’s rho: –0.828, P¼ 0.04), suggesting that
there are increasing returns to scale in cost-effectiveness with
respect to the target population.
Sensitivity analysis
The sensitivity of cost-effectiveness (cost per anaemia case
averted) to variation in key parameters was explored (Table 4).
Varying the discount rate made little difference to the estimate
of cost-effectiveness. Reducing the prices of drugs by 10% and
20% reduced the cost per anaemia case averted to US$3.07 and
US$2.94, respectively.
Discussion
The cost of school-based control of helminth infection has been
widely documented in a number of pilot programmes (Guyatt
et al. 1993, 1994; Holland et al. 1996; Partnership for Child
Development 1998, 1999; Mascie-Taylor et al. 1999; Guyatt
2003). Few studies, however, have looked at costs of school-
based control under nationwide programmatic conditions
(Sinuon et al. 2005; Gabrielli et al. 2006). This current study is
the first to document both the costs and cost-effectiveness of a
national school-based control programme involving mass
treatment for schistosomiasis using praziquantel and for
intestinal nematodes using albendazole. The overall economic
cost per child treated in the six districts was US$0.54, the
overall financial cost per child treated was US$0.39, and the
cost-effectiveness was US$3.19 per case of anaemia averted.
These estimates fall below the range of estimates from the
experience of the Partnership for Child Development in Africa,
where the financial cost per child treated with praziquantel and
albendazole was estimated to be US$1.22 and US$0.24,
respectively, in Ghana and US$0.79 and US$0.23, respectively,
in Tanzania (Partnership for Child Development 1998, 1999).
The related economic costs were US$2.94 and US$0.27 in
Ghana and US$1.32 and US$0.26 in Tanzania. The programmes
in Ghana and Tanzania included prior screening of urinary
schistosomiasis at the school level using a questionnaire about
symptoms of urinary schistosomiasis, administered by teachers,
which added to overall costs. Such an approach is not
applicable for intestinal schistosomiasis—the species endemic
throughout Uganda—because of the non-specific nature of its
symptoms, and therefore mass treatment was provided to all
schools in target sub-counties in this study. Furthermore,
both the praziquantel and albendazole used in the Ghana and
Tanzania programmes were proprietary and not generic
products and therefore cost more than in the Uganda
programme, where the drugs used were generic products
(costing US$0.20 compared with US$0.68 in Ghana and
Tanzania). However, our estimates include start-up costs
and central running costs, which were excluded in the Ghana
and Tanzania estimates. In Burkina Faso, a crude macro-costing
of overall costs of a combined school-based and community-
based national control programme estimated the financial cost
per child of providing praziquantel and albendazole to be
US$0.32 (Gabrielli et al. 2006), although this is likely to be an
underestimate because of the methodology adopted.
Regarding cost-effectiveness, Guyatt et al. (2001) estimated
that the cost per anaemia (Hb<110 g/L) case prevented over
15 months as part of the Tanzania programme could be
US$7.43 using the existing school system to deliver
anthelmintics. This higher estimate is due to the higher costs
mentioned above and because the intervention only reduced
anaemia by 25% in Tanzania. In a study on the island of
Table 2 Estimated district-level economic costs (US$) per child treated
of nationwide helminth control by district in Uganda 2003-05, which
included valuation of staff time using full salary costs and annuitized
capital costs. Figures in parenthesis indicate the estimated delivery cost
per child treated (which excludes drug costs)
Area/District 2003 2004 2005
Lake Victoria
Busia 0.60 (0.38) 0.56 (0.34) 0.44 (0.22)
Mayuge 0.85 (0.63) 0.44 (0.22) 0.87 (0.66)
Lake Albert
Hoima 0.50 (0.28) 0.45 (0.23) 0.57 (0.36)
Masindi 0.91 (0.69) 0.67 (0.45) 0.76 (0.54)
Albert Nile
Moyo 0.41 (0.19) 0.51 (0.29) 0.48 (0.27)
Nebbi 0.63 (0.41) 0.51 (0.23) 0.56 (0.35)
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Figure 2 (a) The relationship between output (number of children
treated) and average costs (cost per child treated) and (b) the
relationship between output (number of children treated) and delivery
cost per child treated in six districts in Uganda, 2003–05
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Zanzibar, Stoltzfus et al. (1998) estimated that the cost per
moderate to severe anaemia case (Hb<90 g/L) averted over 1
year for thrice-yearly mebendazole treatment was US$3.57,
increasing to US$16.30 for a case of severe anaemia averted
(<70 g/L).
Our study showed that estimates of cost and cost-effective-
ness differ markedly with the total number of children treated.
Specifically, average costs per child treated ranged from
US$0.91 at an output of 7161 children treated to US$0.41 at
an output of 37 032 children treated. Over the same output
range, delivery costs ranged from US$0.69 to US$0.19. It is also
shown that cost-effectiveness increases with increasing output.
Various reasons might explain the occurrence of these
economies of scale. First, a number of the costs are fixed,
and therefore increasing output reduces average fixed costs per
child treated. Second, there is increasing ease, through better
organization, learning-by-doing and more efficient processes, in
implementation as the programme expands (Elbasha and
Messonnier 2004). It is possible that further expansion of the
programme into more remote areas may entail diseconomies of
scale due to greater transport costs and stretched administrative
structures and human resources (Johns and Torres 2005).
Economies of scale have previously been documented for cancer
detection programmes in the USA (Mansley et al. 2002), mass
polio immunization campaigns in China (Zhang et al. 1998),
vaccination sites in Bangladesh (Valdmanis et al. 2003), a
national insecticide-treated net programme in Malawi (Stevens
et al. 2005) and a shopkeeper training programme for improving
malaria home management in Kenya (Goodman et al. 2006).
In the Malawian bednet programme, the scale efficiency
savings were mostly related to lowering product or procurement
costs (Stevens et al. 2005). Together with these studies,
our findings confirm the assertion of Jacobs and Baladi
(1996) that assuming constant returns to scale is unlikely to
be reliable.
This study also highlights the substantial variation between
districts in the cost per individual treated with praziquantel and
albendazole and in cost-effectiveness. We found that the cost
per schoolchild treated was lowest (US$0.41) in Moyo district
and highest (US$0.91) in Masindi district. Cost-effectiveness
ranged from US$1.70–9.51 among districts. Because the same
costing methods were used in each district, we can exclude
methodological inconsistencies as a major source of variation.
The results represent a first initial analysis of why costs and
cost-effectiveness vary within a country. In economic terms,
differences in costs may reflect underlying differences in the
underlying production and cost frontiers and in the technical
efficiency in delivering the intervention (Folland et al. 2004).
We found that the percentage of total costs attributed to
community sensitization differed across districts and was
statistically associated with the delivery cost per child treated.
Differences in these costs were predominantly due to the higher
number of participants, especially supervisors from the district,
included in the sensitization, and their allowances and salary
costs. Because district officials are paid an allowance for such
supervision, there is an incentive for some district officials to
increase the amount of supervision, possibly leading to
inefficiency.
We did not observe that costs varied according to the
epidemiology, geography or demography of the district.
Hutton et al. (2004) found that the major determinants of the
costs of antenatal care in Cuba and Thailand were staffing
patterns and productivity, where productivity was assessed
using data envelopment analysis (DEA) (Charnes et al. 1995).
This analytical approach was employed by Valdmanis et al.
(2003) in evaluating vaccination sites in Bangladesh where they
identified levels of output which were inefficient in terms of
both technical and scale efficiency. Unfortunately, the small
number of implementation units (districts) included in the
present study precluded the use of DEA and so it was not
possible to identify the optimal average costs and scale of
operation to maximise technical efficiency. The current study
needs to be repeated using larger sample sizes to quantitatively
investigate the existence of technical inefficiencies. Further
investigation of why costs and effects vary within different
settings and between countries would also allow some
Table 3 The proportion of cases of anaemia averted and cost per anaemia case averted as a result of the nationwide helminth control programme of
six districts in Uganda, 2003-05
Area/District
Total no.
children
treated 2003–5
No.
examined
Prevalence (%)
of anaemia
at baseline
Prevalence (%)
of anaemia
follow-up
Proportion (%)
of anaemia cases
prevented
Financial cost (US$)
per anaemia
case preventedb
Lake Victoria
Busia 66 507 323 27.8 (90)a 11.5 (37) 41.1 3.27
Mayuge 54 733 173 27.2 (47) 11.6 (20) 42.6 3.79
Lake Albert
Hoima 88 556 210 32.9 (69) 15.7 (33) 47.8 2.95
Masindi 33 694 125 39.2 (49) 31.2 (39) 79.6 9.51
Albert Nile
Moyo 90 580 340 42.4 (144) 15.3 (52) 36.1 1.70
Nebbi 74 282 284 39.8 (113) 31.0 (88) 77.9 5.83
Overall 408 352 1455 35.2 (512) 18.5 (269) 52.5 3.19
aNumber in parenthesis indicates number of cases.
bThe effectiveness of treatment with PQZ and ABZ was assessed as the number of anaemia cases prevented over the 3-year period, and was calculated from the
difference between the proportion of children with anaemia at baseline and follow-up survey, multiplied by the number of children treated. The cost per
anaemia case prevented was then calculated for a threshold for defining anaemia as <110g/L.
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judgement to be made about the relative impact of independent
variables on programme costs and cost-effectiveness in a range
of settings, and the extent to which cost estimates can and
cannot be generalized to other settings. To guide this empirical
work there is a related requirement to develop a common
analytical framework for assessing cost variation (Hutton et al.
2004).
There are several qualifications in the present analysis which
justify attention. First, although we have inferred that the
reduction in the prevalence of anaemia was due to the
intervention, one could argue that external factors may be
responsible for the observed changes. Cluster-randomized trials
are the accepted gold standard for evaluating health interven-
tions delivered at the community level (Kirkwood et al. 1997).
In the Uganda programme, however, it was not possible to
study control cohorts of children because it was felt that a
randomized controlled design, a so-called probability design
(Habicht et al. 1999), would not bear relevance to the opera-
tional reality of the national programme and would be poli-
tically difficult to implement and ethically inappropriate. As a
result, there is an opportunity for chance and bias to contribute
to the differences observed compared with randomized con-
trolled trials. However, robust statistical analysis indicated that
improvements in haemoglobin were largest for children who
harboured the heaviest infections at baseline and that observed
changes in infection patterns were in accordance with predic-
tions arising from independently validated mathematical
models of transmission dynamics (Kabatereine et al. 2007).
A second limitation is that the number of anaemia cases
averted is an intermediate health outcome, which does not
translate into a universally comparable health outcome measure
such as deaths or disability-adjusted life years (DALYs).
However, the basis for converting observed changes in patterns
of helminth infection and nutrition into DALYs remains
controversial (King et al. 2005; Hotez et al. 2006). To date,
only one theoretical study has compared the cost-effectiveness
of helminth control in relation to other programmes on the
basis of DALYs (Warren et al. 1993), and this included a
number of assumptions which have been subsequently ques-
tioned (Evans and Guyatt 1995). Estimation of alternative
outcome measures such as quality-adjusted life years (QALYs)
remains problematic in a sub-Saharan African setting, where
individuals suffer multiple health insults and are typically
unable to distinguish between conditions (Kirigia 1998;
Nyandieka et al. 2002). A second alternative outcome measure
is the proportion of individuals harbouring a heavy infection
(Guyatt et al. 1994), since morbidity is associated with
prevalence of heavy infection. WHO (2002) provides definitions
of heavy infection based on the intensity of infection as
assessed by faecal egg counts. However, these units are specific
to individual helminth species, making the definition of a
single, multiple-species threshold impossible. Comparison of
the cost-effectiveness of school-based helminth control in
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Figure 3 (a) The relationship between economic cost per child treated
and cost-effectiveness (cost per anaemia case averted); (b) the
relationship between effectiveness (proportion of anaemia cases
averted) and cost-effectiveness (cost per anaemia case averted);
and (c) the relationship between total number of schoolchildren
treated in each district over the period 2003–05 and cost-effectiveness
(cost per anaemia case averted) in six districts in Uganda
Table 4 Results of one-way sensitivity analysis on the cost per case of
anaemia averted of a national school-based anthelmintic treatment
programme in Uganda, 2003-05
Variation tested
Economic cost per anaemia
case averted (US$)
Base case 3.19
Discount rate
1% 3.18
10% 3.25
Reduction in drug prices
10% 3.07
20% 2.94
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relation to other public health interventions requires a more
universal unit. The advantage of measuring cost-effectiveness in
terms of anaemia is that it is an easily assessed outcome, which
has been used to evaluate a number of tropical disease
interventions (Stoltzfus et al. 1998; Guyatt et al. 2001;
Wiseman et al. 2003; Baltussen et al. 2004). It is recognized,
however, that the use of anaemia may miss the more subtle
health benefits of deworming, such as improved growth and
education (King et al. 2005; Hotez et al. 2006).
There are a number of policy implications arising from this
study. First, the analysis presents costs that are likely to be
representative of a full-scale national programme and suggests
that the programme is affordable. In particular, the cost
estimates support the conclusions of earlier studies (PCD
1998, 1999; Guyatt 2003) which suggest that regular school-
based delivery of simple and safe health interventions is a
relatively low cost approach.
Second, the existence of intra-country variation in costs and
variable returns to scale clearly indicates that comparison of
costs and cost-effectiveness across programme settings and
time periods could be misleading unless the effect of differences
in input prices and output are taken into account. This is
especially important in relation to forecasting costs and cost-
effectiveness (Mansley et al. 2002). Many estimates of
hypothetical public health programmes assume average cost
will remain constant in relation to the population served
(Fenwick et al. 2005; Brady et al. 2006). This assumption is, as
indicated here, invalid and could lead to inaccurate cost
projections. A further implication of the existence of economies
of scale identified by Mansley et al. (2002) relates to comparing
different interventions. Given that the cost-effectiveness is
dependent on output, it is valid only to compare different
interventions with similar outputs, or undertake some form of
analytical adjustment to empirical estimates (Elbasha and
Messonnier 2004).
Third, the results indicate that substantial variation in
intervention costs exists within a single national programme.
As such, it is important to carefully consider which costs can be
reliably extrapolated across different programmes. Further
empirical studies, coupled with the development of modelling
techniques, can inform future extrapolations. Such studies can
also identify potential cost savings and technical efficiencies,
and thereby inform policy decisions and promote long-term
sustainability of national programmes.
Finally, there is recent interest in the possibility of simulta-
neously treating a number of parasitic diseases as part of an
integrated control package (Hotez et al. 2006; Lammie et al. 2006).
Adding more treatments to the current programme may yield
economies of scope resulting in lower average costs (Folland et al.
2004). However, this may also cause diseconomies of scope
(increasing average costs), whereby adding more treatments
overloads capacity and the current treatment is delivered less
efficiently (Johns and Torres 2005). This aspect deserves critical
attention as integrated programmes are rolled out.
Conclusion
Economic evaluation has become a key criterion relevant for
priority setting in health and in planning health care
interventions. The current analysis is the first to document
both the cost and cost-effectiveness of national school-based
helminth control and the first to document the intra-variation
in both costs and cost-effectiveness. We report the existence of
economies of scale and intra-country variation in costs and in
cost-effectiveness, and present an initial analysis of the causes
of observed variation. The findings highlight the potential bias
in transferring data across settings without understanding the
nature of observed variations. Failure to do so will ultimately
hinder the efficient allocation of health care resources.
However, the consistency in the findings suggests that it may
be possible to adjust for such variation in future analysis and
the challenge remains to develop an analytical framework for
understanding and assessing the extent and causes of cost
variation. More evidence is clearly necessary on the cost-
effectiveness of nationwide control under a range of program-
matic conditions and on the underlying causes of variation in
cost and cost-effectiveness.
Acknowledgements
In each district, we would like to thank the District Directors of
Health Services and the District Vector Control Officers who
assisted in data collection and provided access to financial
records. We would also like to thank Allen Magezi and Jackson
Rwaheru who provided invaluable assistance in data collection,
Matilda Temperley who helped calculate the economic costs,
and Catherine Goodman, Jan Kolaczinski, Kara Hanson and
Damian Walker for helpful advice. The Ugandan national
control programme is supported by the Schistosomiasis
Control Initiative, which receives funding from the Bill and
Melinda Gates Foundation. Data collection was supported by a
research grant from the Schistosomiasis Research Programme,
based at DBL-Institute for Health Research and Development.
The first author is supported by a Wellcome Trust Advanced
Training Fellowship (073656).
References
Albonico M, Montresor A, Crompton DW, Savioli L. 2006. Intervention
for the control of soil-transmitted helminthiasis in the community.
Advances in Parasitology 61: 311–48.
Baltussen R, Knai C, Sharan M. 2004. Iron fortification and iron
supplementation are cost-effective interventions to reduce iron
deficiency in four subregions of the world. Journal of Nutrition 134:
2678–84.
Boatin BA, Richards FO. 2006. Control of onchocerciasis. Advances in
Parasitology 61: 349–94.
Brady M, Hooper PJ, Ottensen EA. 2006. Projected benefits from
integrating NTD programs in sub-Saharan Africa. Trends in
Parasitology 22: 285–91.
Brooker S, Whawell S, Kabatereine NB et al. 2004. Evaluating the
epidemiological impact of national control programmes for
helminths. Trends in Parasitology 20: 537–45.
Brouwer W, Rutten F, Koopmanschap M. 2001. Costing in economic
evaluation. In: McGuire A, Drummond MF (eds). Economic
evaluation in health care: merging theory with practice. New York:
Oxford University Press, pp. 68–93.
32 HEALTH POLICY AND PLANNING
Bryan S, Brown J. 1998. Extrapolation of cost-effectiveness information
to local settings. Journal of Health Services Research and Policy 3:
108–12.
Bundy DAP, Shaeffer S, Jukes M et al. 2006. School based health and
nutrition programs. In: Jamison DT, Breman J, Measham AR et al.
(eds). Disease control priorities in developing countries, 2nd edn.
New York: Oxford University Press, pp. 1091–108.
Charnes A, Cooper WW, Lewin AY, Seiford LM. 1995. Data envelopment
analysis: theory, methodology and applications. Boston, MA: Kluwer
Academic Publishers.
Drummond MF, Pang F. 2001. Transferability of economic evaluation
results. In: McGuire A, Drummond MF (eds). Economic evaluation in
health care: merging theory with practice. New York: Oxford University
Press, pp. 256–76.
Drummond MF, Bloom BS, Carrin G et al. 1992. Issues in the cross-
national assessment of health technology. International Journal of
Technology Assessment in Health Care 8: 671–82.
Drummond MF, O’Brien B, Stoddart GL, Torrance GW. 1997. Methods for
the economic evaluation of health care programmes. Oxford: Oxford
University Press.
Elbasha EH, Messonnier ML. 2004. Cost-effectiveness analysis and
health care resource allocation: decision rules under variable
returns to scale. Health Economics 13: 21–35.
Evans DB, Guyatt HL. 1995. The cost effectiveness of mass drug therapy
for intestinal helminths. Pharmacoeconomics 8: 14–22.
Fenwick A, Molyneux D, Nantulya V. 2005. Achieving the Millennium
Development Goals. The Lancet 365: 1029–30.
Fenwick A, Rollinson D, Southgate V. 2006. Implementation of human
schistosomiasis control: challenges and prospects. Advances in
Parasitology 61: 567–622.
Folland S, Goodman AC, Stano M. 2004. The economics of health and
health care, 4th edn. Upper Saddle River, NJ: Pearson.
Gabrielli AF, Toure S, Sellin B et al. 2006. A combined school- and
community-based campaign targeting all school-age children of
Burkina Faso against schistosomiasis and soil-transmitted hel-
minthiasis: performance, financial costs and implications for
sustainability. Acta Tropica 99: 234–42.
Goodman CA, Mutemi WM, Baya EK et al. 2006. The cost-effectiveness
of improving malaria home management: shopkeeper training in
rural Kenya. Health Policy and Planning 21: 275–88.
Guyatt HL. 2003. The cost of delivering and sustaining a control
programme for schistosomiasis and soil-transmitted helminthiasis.
Acta Tropica 86: 267–74.
Guyatt HL, Bundy DA, Evans D. 1993. A population dynamic approach to
the cost-effectiveness analysis of mass anthelmintic treatment:
effects of treatment frequency on Ascaris infection. Transactions of
the Royal Society of Tropical Medicine and Hygiene 87: 570–5.
Guyatt HL, Evans DB, Lengeler C, Tanner M. 1994. Controlling
schistosomiasis: the cost-effectiveness of alternative treatment
strategies. Health Policy and Planning 9: 385–95.
Guyatt HL, Brooker S, Hall A et al. 2001. Evaluation of efficacy of
school-based anthelmintic treatments against anaemia in children
in the United Republic of Tanzania. Bulletin of the World Health
Organization 79: 695–703.
Habicht JP, Victora CG, Vaughan JP. 1999. Evaluation designs for ade-
quacy, plausibility and probability of public health programme
performance and impact. International Journal of Epidemiology 28:
10–18.
Holland CV, O’Shea E, Asaolu SO et al. 1996. A cost-effectiveness
analysis of anthelminthic intervention for community control of
soil-transmitted helminth infection: levamisole and Ascaris lumbri-
coides. Journal of Parasitology 82: 527–30.
Hotez PJ, Bundy DAP, Beegle K et al. 2006. Helminth Infections. In:
Jamison DT, Breman J, Measham AR et al. (eds). Disease control
priorities in developing countries, 2nd edn. New York: Oxford University
Press, pp. 467–97.
Hutton G, Fox-Rushby J, Mugford M et al. 2004. Examining within-
country variation of maternity costs in the context of a multi-
country, multicentre randomized controlled trial. Applied Health
Economics and Health Policy 3: 161–70.
Jacobs P, Baladi JF. 1996. Biases in cost measurement for economic
evaluation studies in health care. Health Economics 5: 525–9.
Jamison DJ, Breman J, Measham AR et al. (eds) Disease control priorities
in developing countries, 2nd edn. New York: Oxford University Press.
Johns B, Tan Torres T. 2005. Costs of scaling up health interventions: a
systematic review. Health Policy and Planning 20: 1–13.
Kabatereine NB, Brooker S, Tukahebwa EM et al. 2004. Epidemiology
and geography of Schistosoma mansoni in Uganda: implications for
planning control. Tropical Medicine and International Health 9: 372–80.
Kabatereine NB, Tukahebwa EM, Kazibwe F et al. 2006a. Progress
towards country-wide control of schistosomiasis and soil-trans-
mitted helminthiasis in Uganda. Transactions of the Royal Society of
Tropical Medicine and Hygiene 100: 208–15.
Kabatereine NB, Fleming FM, Nyandindi U et al. 2006b. The control of
schistosomiasis and soil-transmitted helminths in East Africa.
Trends in Parasitology 22: 332–9.
Kabatereine NB, Brooker S, Koukounari A et al. 2007. Impact of a
national schistosomiasis control programme on infection and
morbidity in Ugandan schoolchildren. Bulletin of the World Health
Organization 85: 91–99.
King CH, Dickman K, Tisch DJ. 2005. Reassessment of the cost of
chronic helmintic infection: a meta-analysis of disability-related
outcomes in endemic schistosomiasis. The Lancet 365: 1561–9.
Kirigia JM. 1998. Economic evaluation in schistosomiasis: valuation of
health states preferences. A research note.Health Economics 7: 551–56.
Kirkwood BR, Cousens SN, Victoria CG, de Zoysa I. 1997. Issues in the
design and interpretation of studies to evaluate the impact of
community-based interventions. Tropical Medicine and International
Health 2: 1022–9.
Lammie PJ, Fenwick A, Utzinger J. 2006. A blueprint for success:
integration of neglected tropical disease control programmes. Trends
in Parasitology 22: 313–21.
Mansley EC, Dunet DO, May DS et al. 2002. Variation in average costs
among federally sponsored state-organized cancer detection pro-
grams: economies of scale? Medical Decision Making 22: S67–79.
Mascie-Taylor CG, Alam M, Montanari RM et al. 1999. A study of the cost
effectiveness of selective health interventions for the control of
intestinal parasites in rural Bangladesh. Journal of Parasitology 85:
6–11.
McDaid D, Cookson R, ASTEC Group. 2003. Evaluating health care
interventions in the European Union. Health Policy 63: 133–9.
Montresor A, Zin TT, Padmasiri E et al. 2004. Soil-transmitted
helminthiasis in Myanmar and approximate costs for countrywide
control. Tropical Medicine and International Health 9: 1012–5.
Musgrove P, Fox-Rushby J. 2006. Cost-effectiveness analysis for priority
setting. In: Jamison DT, Breman J, Measham AR et al. (eds). Disease
control priorities in developing countries, 2nd edn. New York: Oxford
University Press, pp. 271–85.
Nyandieka LN, Bowden A, Wanjau J, Fox-Rushby JA. 2002. Managing a
household survey: a practical example from the KENQOL survey.
Kenya Quality of Life. Health Policy and Planning 17: 207–12.
O’Brein BJ. 1997. A tale of two or more cities: geographic transferability
of pharmacoeconomic data. American Journal of Managed Care 3:
S33–9.
VARIATION IN COSTS AND COST-EFFECTIVENESS OF HELMINTH CONTROL 33
Ottesen EA. 2006. Lymphatic filariasis: treatment, control and elimina-
tion. Advances in Parasitology 61: 395–441.
Over M. 1998. The effect of scale on cost projections for a primary
health care program in a developing country. Social Science and
Medicine 22: 351–60.
Partnership for Child Development. 1998. Cost of school-based drug
delivery in Tanzania. Health Policy and Planning 13: 384–96.
Partnership for Child Development. 1999. The cost of large-scale school
health programmes which deliver anthelmintics in Ghana and
Tanzania. Acta Tropica 73: 183–204.
Ramzy RMR, Goldman AS, Kamal HA. 2005. Defining the cost of the
Egyptian lymphatic filariasis elimination programme. Filaria Journal
4: 7.
Sinuon M, Tsuyuoka R, Socheat D et al. 2005. Financial costs
of deworming children in all primary schools in Cambodia.
Transactions of the Royal Society of Tropical Medicine and Hygiene 99:
664–8.
Spath HM, Carrere MO, Fervers B, Philip T. 1999. Analysis of the
eligibility of published economic evaluations for transfer to a given
health care system: methodological approach and application to
the French health care system. Health Policy 49: 161–77.
Stevens W, Wiseman V, Ortiz J, Chavasse D. 2005. The costs and effects
of a nationwide insecticide-treated net programme: the case of
Malawi. Malaria Journal 4: 22.
Stoltzfus R, Albonico M, Chwaya HM et al. 1998. Effects of the Zanzibar
school-based deworming program on iron status of children.
American Journal of Clinical Nutrition 68: 179–86.
Valdmanis V, Walker D, Fox-Rushby J. 2003. Are vaccination sites in
Bangladesh scale efficient? International Journal of Technology
Assessment in Health Care 19: 692–7.
Walker D, Fox-Rushby JA. 2000. Economic evaluation of communicable
disease interventions in developing countries: a critical review of
the published literature. Health Economics 9: 681–98.
Walker D, Mosqueira NR, Penny ME et al. 2004. Variation in the costs of
delivery routine immunization services in Peru. Bulletin of the World
Health Organization 82: 676–82.
Warren KS, Bundy DAP, Anderson RM et al. 1993. Helminth infections.
In: Jamison DT, Mosley WH, Measham AR et al. (eds). Disease
control priorities in developing countries, Oxford: Oxford University
Press, pp. 131–60.
Wiseman V, Hawley WA, ter Kuile FO et al. 2003. The cost-effectiveness
of permethrin-treated bed nets in an area of intense malaria
transmission in western Kenya. American Journal of Tropical Medicine
and Hygiene 68(4 Suppl.): 161–7.
WHO. 2002. Prevention and Control of Schistosomiasis and Soil-
Transmitted Helminthiasis. WHO Technical Series Report 912.
Geneva: World Health Organization.
World Bank. 1993. World Development Report 1993: Investing in Health.
Oxford: Oxford University Press.
Zhang J, Yu JJ, Zhang RZ et al. 1998. Costs of polio immunization days
in China: implications for mass immunization campaign strategies.
International Journal for Health Planning and Management 13: 5–25.
Appendix: Resources, quantities
and unit costs
The resources employed, the quantities consumed and unit costs
are described below under the different cost centres. Many of the
costs were divided equally between the school-based programme
and the community-based programme, although a cost analysis
is only presented for school-based treatment (see Table A1).
Programme running costs
The programme has a main office at the VCD headquarters in
Kampala, which incurred expenses such as telephone, station-
ary, computers and vehicles. The proportion of time staff at
Table A1 Unit costs (and where appropriate range) of delivering
anthelmintic treatment through schools in Uganda 2003–05
Category Input Units Unit cost (US$)
Capital items Building Per building 87 000
Project vehicle Per vehicle 25 000–44 304
Computer Per computer 1545
Fax machine Per machine 700
Salaries National coordinator Per month 409
National administrator Per month 341
Secretary Per month 157
Driver Per month 63
District VCD officer Per month 262
Health worker Per month 157
Teacher Per month 120
Local leader Per month 60
Allowances VCD (Kampala)
supervisor per diem
Per day 24.70
VCD (Kampala) driver
per diem
Per day 12.87–17.90
DVCO per diem Per day 4.95–15.44
Driver per diem Per day 1.98–8.44
Community health
worker per diem
Per day 2.48–5.63
Training workshop
participant
Per workshop 1.03–3.96
Vehicle running
costs
Diesel Per litre 0.77–1.18
Insurance Per day 3.97
Maintenance Per day 8.99
Consumables Training manual Per manual 10
IEC poster Per poster 0.45
IEC leaflet Per leaflet 0.14
IEC booklet Per booklet 0.37–0.42
Praziquantel Per dose 0.18
Albendazole Per dose 0.023
Treatment register Per register 1.64–2.53
Height pole Per pole 1.29
Modified height pole Per pole 0.34
Other National workshop Per workshop 11 285–26 000
Radio show Per show 30.68–378.45
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VCD in Kampala devoted to the programme was estimated. The
additional resources used in making the intervention available
were also estimated, including new capital costs such as
vehicles, building space and equipment.
The financial cost of a new building in Kampala used to store
drugs and other equipment and to house some of the programme
officers was estimated on the basis of the cost of constructing and
furnishing the building (US$87 000), annuitized using an
estimated useful life of 30 years. An estimated 10% to cover
annual utilities was included. The building is shared with the
onchocerciasis and filariasis control programmes and therefore it
was assumed that 45% of the building costs were attributable to
the current programme. Between 2002 and 2005, five vehicles
were purchased by the programme at a total cost of US$134 183.
The costs of these vehicles were annuitized over a useful life of 7.5
years and it was assumed that 70% of costs were attributable to
programme activities. Annual expenditure on services and repairs
was assumed to be 10% of annualized capital costs. Allowances of
drivers and staff from the headquarters visiting districts were
included in district-level cost estimates. Fuel costs to each district
were calculated using MoH guidelines for distance from Kampala
to specific district capitals. A computer and fax machine were also
purchased at a total cost of US$2245, assuming 100% allocation to
the programme and a 3-year useful life. Annuitized capital costs
were allocated equally across the 23 districts, attributing half the
cost to school-based treatment and half to community-based
treatment. Each of the districts was provided with a motorcycle at
a cost of US$2899 each, assumed to have a useful life of 4 years
and estimated to have an annuitized cost of US$633, and split
50:50 between school- and community-based treatment.
Community sensitization
Prior to treatment, a series of meetings were held with
community leaders and school committee members. The
format of these meetings and the number of participants
varied between districts. A mobile film team from MoH
headquarters visited each district and showed a film in several
communities to raise awareness about schistosomiasis and soil-
transmitted helminths. The opportunity cost for using existing
district health officials was estimated.
Training
The costs of the national training workshops were US$16 980 in
May 2001, US$11 285 in November 2001, US$13 500 in June 2002,
US$26 000 in December 2002, US$20 000 in April 2004 and
US$22 107 in April 2005. Attended by national staff and district
health staff, the workshops provided general information on
schistosomiasis and STH and the national programme, as well as
training on treatment registration and recording and drug
administration. The total cost of these workshops is divided
equally among the 26 districts, allocating half the cost to school-
based treatment and half to community-based treatment. The
opportunity cost for using existing district health officials for the
training and the time of teachers was estimated.
In 2003, a training manual was developed by staff from VCD
and SCI. The unit cost was US$10.00, and 10 copies were
provided to each district in 2003; this cost was shared 50:50
between school-based and community-based delivery. At the
district-level, the training of school teachers and community
drug distributors included public awareness, drug treatment
and treatment monitoring and record keeping. The expenditure
for this training included trainee transport and lunch allow-
ance, stationary (typically exercise books, pens, marking tape,
permanent markers and flipcharts), district training facilitators
per diem, district drivers per diem and fuel. The estimate of
costs also included the per diem and fuel costs of national staff
from Kampala attending the district-level training. The unit
cost and quantities of each cost element varied between
districts and had to be estimated separately.
Drug distribution and treatment
Praziquantel tablets were supplied by Shin Pong
Pharmaceutical Company (Kyonggi, South Korea) at a unit
price of US$0.072 per 600mg tablet. Assuming 2.5 tablets per
child, the drug cost per child treated was US$0.18. Albendazole
tablets (400mg) were supplied by International Dispensary
Association (Amsterdam, Netherlands) at a unit price of
US$0.023, including CIF. The Uganda National Medical Stores
cleared the imported drugs and transported them to VCD
headquarters in Kampala at a cost of 5% of the drug price. Drug
distribution and treatment included school, drug delivery,
supervision and recording of treatment, and collection of
treatment registers and unused drugs. Per diems or allowances
(which varied between districts) were paid to MoH staff within
a district and to community health workers to perform these
activities; however, teachers were not paid. Fuel and stationary
costs were also estimated. The initial cost of locally produced
registers to record treatment was US$2.53 but this was
subsequently reduced to US$1.64. In 2003 and 2004 the cost
of locally manufactured height poles was US$1.29; in 2005
modifications of the pole reduced this cost to US$0.34. The
mean treatment dose per child and adult was estimated from
treatment registers. Based on experience of other programmes
(PCD 1999) and local experience, the wastage rate of drugs was
assumed to be 1%. Where activities covered both school-based
and community-based delivery of treatment, the costs of the
activity were shared 50:50 between the two delivery systems.
Production and distribution of IEC material
Health education messages were delivered through posters,
booklets, films and radio shows. Information, education and
communication (IEC) material included posters, leaflets and
question and answer booklets. These were developed in English
and then translated into various local languages by the Health
Education department of the Ministry of Health at a cost of
US$26 000. This cost was again divided equally among the 26
districts. The distribution channel for the IEC material was the
same as the drugs. In addition, an 18minute educational video
film and a 5minute advocacy film was produced locally and
shown widely in each district. During the treatment period,
which extended from April to July, radio talk shows were aired
frequently on appropriate local FM stations encouraging people
to take their drugs. The cost of these shows ranged from
US$378.45 in Moyo district to US$30.68 in Masindi district. The
cost elements under this cost centre were shared in the
proportion 50:50 between school-based treatment and commu-
nity-based treatment.
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Appendix V – Sample size calculations for a longitudinal cohort of school 
children in Uganda 
1. Background for negative binomial distribution
In macroparasitic infections such as schistosomiasis, it is common for distributions of the 
number of parasites among hosts to be often strongly aggregated (overdispersed). The 
negative binomial distribution is a convenient overdispersed distribution and this is what 
has been used here in order to study in the first instance the distribution of the SCI 
Ugandan data.
In general, a negative binomial distribution is characterized by specifying its mean, ,
and aggregation (overdispersion) parameter, k.  To fit the distribution to the data, the 
observed arithmetic mean intensity by school, mˆ , as an estimate of was used while 
it was attempted to find a kˆ value that fitted the data best. In general, kĺFRUUHVSRQGV
to severe aggregation (in the extreme case, all worms would be harboured by a single 
host) while kĺf corresponds to a random (Poisson) distribution.  The value of k is 
inversely related to the degree of overdispersion and most k values for more parasites 
as in the case of schistosomiasis infection, lie generally below 1.The individual terms of 
the negative binomial distribution for the probability of hosts harbouring i parasites can 
be generated from:
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where the prevalence of infection (the proportion infected), P, is simply
kkmP  )/1(1                               (eqn A.2)                                                     k>=0
And where k has been estimated by maximum likelihood. In eqn A.1 we have also 
assumed that our observations are independent from each other (the probability of 
observing an uninfected host does not affect the probability of observing another 
uninfected host, etc.) [1]. 
2. Estimation of k’s (aggregation parameter) per transmission region in Uganda 
and time point i.e. baseline and follow-up year 3
In Uganda, intestinal schistosomiasis has long been known to be prevalent, being 
dominant in 38 out of 58 districts, within regions surrounding Lakes Victoria and Albert 
and the Albert Nile area. 
At the SCI baseline surveys (conducted in 2003), 37 primary schools were selected 
randomly and visited in 8 districts representing the three different aforementioned 
transmission regions; the Lake Albert region (Hoima and Masindi districts), the Lake 
Victoria region (Busia, Bugiri and Mayuge districts) and the Albert Nile region (Nebbi, 
Moyo and Arua districts), as well as three endemic categories according to WHO 
standards; low, medium and high category prevalence at the school level (n=4351 
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school children). Out of these 4351 children, only those with available ages at baseline 
of 6, 7, 8 and 11 years old were taken into account for the sample sizes calculations 
here (n=3945 schoolchildren). Approximately equal numbers of children in each age and 
gender were recruited at baseline.
The Ugandan SCI cohort represents the longest period of follow-up of a national control 
program (i.e. longitudinal data from 4 annual surveys) and this is the main reason why 
sample sizes calculations start first from this SCI supported African country.   
In 2006 (i.e follow-up year 3 and final time point of the study) no data from Arua district 
were collected because during the day that this school was visited, children were doing 
exams and immediately after were leaving for school holidays. Therefore, all subsequent 
calculations presented here exclude data from this specific school from all previous 
years also (i.e. baseline, follow-up year 1, follow-up year 2). Likewise, Ewafa school in 
Moyo district was not also visited during the fourth year of the study.  Also for Paminya 
school in Nebbi district raw data were not received for this school. So data from these 
two schools from all previous years are also excluded in the following analyses. In Biiso 
school in Masindi district there were not traced any children from baseline to follow-up 
year 3. Furthermore, there were no S. mansoni egg counts for children with longitudinal 
data from Ikulwe school in Mayuge district for the fourth year of the study (i.e. follow-up
year 3). For this particular school S. mansoni egg counts were only available for newly 
recruited children. Therefore, during the fourth year of the study (i.e. follow-up year 3) 
and taking all the above into account for Schistosoma mansoni infection, 991 children 
from 32 schools were successfully followed up since baseline. These children had also 
available data on all 4 time points (i.e. baseline, follow-up year 1, follow-up year 2 and 
follow-up year 3).  
In the next 3 pages, the negative binomial distribution was fitted to the observed data for 
each of the three afore mentioned transmission regions once at baseline and another 
time at follow-up year 3, trying in all cases k as constant and finally as a linear function 
of m (arithmetic mean intensity of schistosomiasis infection at the school level). Within 
each particular set of surveys (i.e. baseline and follow-up year 3) the trend in k was 
examined with likelihood ratio tests. More precisely, the difference of the log likelihood 
from each model (i.e. model with k linear and model with k constant) was calculated and 
then multiplied by 2. Finally, this last quantity was then compared to the X21 df critical 
value in order to acquire a p-value that would define the significance of the differences 
between the two likelihoods (CHIDIST function in excel was used in order to acquire 
this). 
For Lake Albert at baseline, k linear has a better fit (see Figure 1). Log likelihoods were 
estimated to be lc=-73.98 when k was constant and ll=-57.80 when k was linear.  Thus 
twice their absolute difference is more than 3.84, i.e., a Chi-square with one degree of 
freedom, suggesting that the model with k linear is significantly different and better from 
the second model with k constant. P-value was estimated to be less than 0.001 which 
also indicates that the difference between these two likelihoods is significant.
Similarly for Lake Albert at follow-up year 3, k linear has also a better fit (see Figure 2). 
Log likelihoods were estimated to be lc=-55.94 when k was constant and ll=-46.61 when 
k was linear.  Thus twice their absolute difference is more than 3.84, i.e., a Chi-square 
with one degree of freedom, suggesting that the model with k linear is significantly 
different and better from the model with k constant. P-value was estimated to be less 
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than 0.001 which also indicates that the difference between these two likelihoods is 
significant.
Then for Lake Victoria at baseline (see Figure 3), likelihood ratio test indicated that k 
linear had a better fit (P-value<0.001, with log likelihoods lc=-267.26 when k was 
constant and ll=-250.26 when k was linear). 
Again for Lake Victoria at follow-up year 3 (see Figure 4), likelihood ratio test indicated 
that k linear had a better fit (P-value<0.001, with log likelihoods lc=-373.99 when k was 
constant and ll=-178.89 when k was linear). 
Finally for the Albert Nile at baseline (see Figure 5), likelihood ratio test indicated that k 
linear had a better fit (P-value<0.001, with log likelihoods lc=-201.12 when k was 
constant and ll=-175.11 when k was linear). 
At follow-up year 3 for the Albert Nile region, likelihood ratio test indicated that k linear 
had a better fit (P-value<0.001 with log likelihoods lc=-58.35 when k was constant and 
ll=-54.27 was linear). 
To conclude, all the above observations call for the k to change over time and among 
the different transmission regions across the whole country and this should be taken into 
consideration also of course in the calculations of the sample sizes. Moreover, tests for 
the k changing over the years for each of the three different transmission regions, were 
performed and they have all yield p-values <0.001. Finally, due to different follow-up
rates per district at follow-up year 3 relatively to baseline and consequently per region 
(i.e. Lake Albert: 18.87 %, Lake Victoria: 25.43 % and Albert Nile: 30.88 %) it was 
decided after several SCI Monitoring and Evaluation (M&E) meetings that sample sizes 
are calculated separately for each transmission region.
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Figure 1
Prevalence vs. Mean intensity in Lake Albert at baseline
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Figure 2
Prevalence vs. Mean intensity in Lake Albert at follow-up year 3
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Figure 3
Prevalence vs. Mean intensity in Lake Victoria at baseline
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Figure 4
Prevalence vs. Mean intensity in Lake Victoria at follow-up year 3
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Figure 5
Prevalence vs. Mean intensity in Albert Nile at baseline
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Figure 6
Prevalence vs. Mean intensity in Albert Nile at follow-up year 3
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3. Mathematical models of expected impact per transmission region
The EpiSchisto modelling software was used in order to allow direct comparison 
between a mathematical model developed by Chan et al 1996 [2] and the SCI 
longitudinal monitoring data from 4 annual surveys. Furthermore, pre-intervention survey 
data (SCI baseline monitoring data in Uganda-i.e. first annual survey) on initial mean 
egg count, m, were used as input data in the model predictions. The mathematical 
model applied in this investigation has used the following partial differential equation:
),(),(),(),( )( taMeta
a
taM
t
taM aI PG / w
ww
w  (eqn A.3)
where:
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QRWH WKDW DQ H[SRQHQWLDO IXQFWLRQ LV
assumed to relate acquired immunity to the extent of protection offered while the exact 
formula for this is: ³  
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with R0 denoting the basic reproductive number, 
I0ĮWGHQRWLQJa density dependent establishment function, 
ʌĮUHSUHVHQWLQJWKHSURSRUWLRQRISHRSOHLQHDFKDJHJURXS
ȡĮUHSUHVHQWLQJWKHDJH-dependent contact function and 
țĮUHSUHVHQWLQJWKHFRQWDPLQDWLRQIXQFWLRQ
More details about the exact formulas of WKHODVWWZRIXQFWLRQVȡĮDQGțĮFDQEH
found also in Chan et al 1996 [2].
Children aged 6-15 years old were assumed to have been treated with drug coverage of 
75 % and drug efficacy of 90 % after agreement in M & E meetings between several 
members of SCI staff.
Default parameters in order to run all simulations (see Tables 1 and 2 for further details 
in Chan et al 1996 [2] for exact values of these parameters) were kept similar apart from 
changing only the coefficients of k. The coefficients of k were changed according to the 
findings of section 2 in this document. 
Comparison of observed and expected changes in the intensity of S. mansoni infection 
is displayed in the figures below (Figures 7-9): 
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Figure 7
Comparison  of observed (n=201) & expected (based on 
predictions arising from a deterministic mathematical model) 
changes in the intensity of S.mansoni  infection as part of a 
national schistosomiasis control programme in the Lake Albert 
2003-2006
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Figure 8
Comparison  of observed (n=463) & expected (based on 
predictions arising from a deterministic mathematical model) 
changes in the intensity of S.mansoni  infection as part of a 
national schistosomiasis control programme in the Lake 
Victoria  2003-2006
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Figure 9
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Comparison  of observed (n=327) & expected (based on 
predictions arising from a deterministic mathematical model) 
changes in the intensity of S.mansoni  infection as part of a 
national schistosomiasis control programme in Albert Nile  
2003-2006
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Figure 7 indicates that predictions of the deterministic mathematical model lie within the 
confidence intervals of the observed values in Lake Albert at all years of the study.
Figure 8 indicates that for Lake Victoria for all follow up years predictions from
EpiSchisto are quite conservative. 
Finally Figure 9 indicates that from follow-up year 1 to follow-up year 2 the deterministic 
mathematical model provides a quite conservative estimation for the change in the 
intensity of S.mansoni infection. The observed value for follow-up year 2 suggests that 
the intensity of S.mansoni infection was lower than this that EpiSchisto predicts. For all 
other years predictions of the deterministic mathematical model lie within the confidence 
intervals of the observed values of this region. 
In the absence of an alternative mathematical model and recognizing that the 
mathematical model described above for some particular years of the surveys, does not 
fit the observed data and therefore there is some uncertainty for the predictions it yields, 
we still employ EpiSchisto in order to get predictions within the integration era (i.e. post-
treatment environment) for a number of different scenarios, trying to use as starting point 
of the integrated programme the final year of the SCI data for each of the three 
transmission regions. In addition, the corresponding estimated negative binomial 
aggregation parameter k at follow-up year 3 for each of the three transmission regions 
(see Figures 2, 4 and 6) is also used as input data in the model predictions. 
Predicted values from Figures below (see Figures 10-12) show results for each of the 
three transmission regions when starting arithmetic mean intensity of S.mansoni
infection was attempted to be the final SCI observed value for follow-up year 3 in each of 
these three transmission areas. In EpiSchisto calculations it was also assumed that drug 
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coverage would be 75 %, the drug efficacy would be 90 % while 3 annual treatments
would be given during the period 2007-2009.
Finally for all 3 different attempted scenarios proportional expected changes as 
predicted from EpiSchisto were calculated to be almost 81 % for Lake Albert and 72 % 
for Lake Victoria and Albert Nile from baseline (i.e. 2007) to follow-up year 2 (i.e. 2009).
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Figure 10
Expected changes (arising from mathematical model) in the intensity 
of S. mansoni infection within the integration era (i.e. in a post 
treatment environment) in Lake Albert when starting arithmetic mean 
intensity was input as 115 epg
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Figure 11
Expected changes (arising from a deterministic mathematical 
model) in the intensity of S.mansoni  infection in Lake Victoria 
within the integration era (i.e. in a post tretament environment) 
when starting arithmetic mean intensity was input as 25 epg
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Figure 12
Expected changes (arising from a deterministic mathematical 
model) in the intensity of S.mansoni  infection in Albert Nile 
within the integration era (i.e. in a post treatment environment) 
when starting arithmetic mean intensity was input as 17 epg
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4. Sample size calculations
In order to detect a reduction in mean intensity of infection post integrated intervention 
relatively to baseline (i.e. pre integrated intervention), a two samples t-test was used. 
This test assumes that the raw data are a sample from an underlying normal distribution. 
As egg counts are highly overdispersed, a log(xi+k/2) transformation was used (where k 
is the aggregation parameter afore mentioned in sections 1 & 2 – see Figures 1-6 for 
estimates of k per transmission region and time point and where xi stands for the raw S. 
mansoni egg counts of i individual) in order to normalize the raw egg counts. As we are 
interested to perform longitudinal studies and the measurements are repeated on the 
same individual, the correlated nature of the data was accommodated using a paired 
two-samples t-WHVW7KHWHVWUHTXLUHVNQRZOHGJHRIWKHWZRPHDQVȝB DQGȝ f ZKHUHȝB
LVPHDQDULWKPHWLF LQWHQVLW\DWEDVHOLQHDQGȝ f is mean arithmetic intensity at follow-up 
year 3 WKHLU VWDQGDUG GHYLDWLRQ ıB DQG ı f, the correlation coefficient r between the 
PHDVXUHPHQWV WKH VLJQLILFDQFH OHYHO Į DW ZKLFK ZH ZDQW WR GHWHFW D GLIIHUHQFH DQG
finally the desired power (1-ȕ RI WKH WHVW ȝB DQG ȝ f were substituted by the log 
transformations of the sample estimators mB (i.e. observed arithmetic mean intensity of 
final year of SCI data) and mf (predicted arithmetic mean intensity from EpiSchisto-
where actually a variety of values were tested-see Figures 10-15 under section 3) plus 
the estimated k aggregation parameter divided by 2. The standard deviations (sds) were 
those of the log transformed mB and mf as given by PROC MEANS in SAS. 
Once these were acquired (i.e. sds) they were regressed on m+m2 by PROC GLM in 
SAS. 
Plots of observed versus predicted values were generated for each of the three 
transmission areas in order to check the linearity of the fitted models (see Figures 17, 19 
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and 21). For these particular plots in order that the assumption of linearity to be met, 
points should be symmetrically distributed around a diagonal line. This assumption is not 
particularly violated in all three transmission areas.
Furthermore, plots of residuals versus fitted values were generated for each of the three 
transmission areas in order to check that the assumption of homoscedasticity
(constant variance) of the errors was met (see Figures 16, 18 and 20). Any structure in 
these plots might yield evidence of some unexplained feature in the data. This 
assumption is violated  mostly in the regression model fitted in Lake Victoria and Albert 
Nile.
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Lake Albert
Figure 16: Plot of residuals vs fitted values 
RESID
-0.9
-0.8
-0.7
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
YHAT
0 1 2 3 4 5
Figure 17: Plot of fitted vs observed values 
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Lake Victoria
Figure 18: Plot of residuals vs fitted values 
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Figure 19: Plot of fitted vs observed values 
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Albert Nile
Figure 20: Plot of residuals vs fitted values 
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Figure 21: Plot of fitted vs observed values 
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Values of r, the Pearson correlation coefficient, were determined where possible from 
the available literature, but calculations have been made for various values since further 
verification is needed. Sample sizes were also calculated allowing power to take the 
values 80 %, 90 % and 95 %. All these calculations were performed using SAS V8 (SAS 
Institute, Cary, NC). 
Table 1. S. mansoni, Lake Albert
Starting mean 
intensity, epg
r necessary 
sample size, n, 
80% power
necessary 
sample size, n, 
90 % power
necessary 
sample size, n, 
95 % power
81% reduction 115 0.2 39 53 66
115 0.3 35 48 60
115 0.4 31 43 53
72% reduction 115 0.2 56 77 97
115 0.3 50 69 87
115 0.4 44 61 76
50% reduction 115 0.2 141 195 246
115 0.3 125 172 217
115 0.4 109 150 189
Table 2. S. mansoni, Lake Victoria
Starting mean 
intensity, epg
r necessary 
sample size, n, 
80% power
necessary 
sample size, n, 
90 % power
necessary 
sample size, n, 
95 % power
81% reduction 25 0.2 48 66 83
25 0.3 43 59 74
25 0.4 37 51 64
72% reduction 25 0.2 77 106 134
25 0.3 68 94 118
25 0.4 59 81 102
50% reduction 25 0.2 231 319 402
25 0.3 202 280 353
25 0.4 174 241 303
Table 3. S. mansoni, Albert Nile
Starting mean 
intensity, epg
r necessary 
sample size, n, 
80% power
necessary 
sample size, n, 
90 % power
necessary 
sample size, n, 
95 % power
81% reduction 17 0.2 31 43 54
17 0.3 28 39 48
17 0.4 25 34 43
72% reduction 17 0.2 46 63 79
17 0.3 41 56 71
17 0.4 36 50 62
50% reduction 17 0.2 117 161 203
17 0.3 103 142 179
17 0.4 90 124 156
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The above calculations are made and concern the sample size of the entire school. Drop
out rate should be factored in per each of the three transmission regions (i.e. for Lake 
Albert: 65.35 %, Lake Victoria: 56.62 % and Albert Nile: 49.01 % for three years) i.e. in 
the values displayed in Tables 1-3 to add these drop out rates.
5. Conclusions
x Select numbers displayed with power 80 %
x The r does not seem to affect greatly the values within the same starting mean 
intensity
x It does seem necessary to calculate sample sizes per region (incorporating 
different ks and drop out rates) but at the end we should select for all three 
regions the maximum sample size from Tables 1-3.
x Some observations concerning trends seen in Tables 1-3: The smaller the 
reduction (i.e. the more conservative we will decide to be) no matter what the 
size of the coefficient r and the starting mean intensity are, sample size required 
is bigger.
Finally given all the above and if we decide to select power of 80 %, we would need for 
Lake Albert 233 children per school (i.e. this number comes from the following 
calculation: 141+141*0.6535), for Lake Victoria 362 children per school (i.e. this number 
comes from the following calculation: 231+231*0.5662) and for Albert Nile 174 children 
per school (i.e. this number comes from the following calculation: 117+117*0.4901)  
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Appendix VI – Sample size calculations for a cross-sectional survey of 
adults in Uganda 
Calculation for required sample size for cross sectional surveys of adults for 
the integration project in Uganda
Table below illustrates descriptive measures for the arithmetic mean intensity of soil 
transmitted helminths of adults in the country for four years as estimated from SCI 
data.
These data for S. mansoni infection were used in order to help calculate sample sizes 
for the cross sectional surveys of adults for the integration project in Uganda. At 
baseline, data on adults concerned 9 communities while at follow-up year 3 data on 
adults were collected from 10 communities. Due to very low number of communities 
though in total and consequently when stratified by area, it was finally decided to 
analyze all these 10 communities together.
In order to estimate the relationship between the mean intensity and the prevalence of S. 
mansoni infection at both time points of interest i.e. baseline and follow-up year 3, the 
negative binomial distribution was employed. The aggregation parameter k was 
calculated once at baseline and another time at follow-up year. At both time points this 
was estimated to be linear and the exact parameters of this function of k were 
incorporated accordingly in the sample size calculations. 
In order to detect a reduction in mean intensity of infection post integrated intervention 
relatively to baseline (i.e. pre integrated intervention), a two samples t-test was used. 
Baseline Follow-up Year 1 Follow-up Year 2 Follow-up year 3
Schistosoma mansoni
Overall Mean EPG (95% CI) 251.61 [213.66-289.55] (n=903) 80.43 [61.11-99.74] (n=689) 19.64 [4.96-34.33] (n=397) 47.02 [24.61-69.44] (n=516)
0 epg (%) 42.64 [39.41-45.86] (n=385) 65.31 [61.76-68.87] (n=450) 90.18 [87.25-93.10] (n=358) 84.06 [80.90-87.21] (n=427)
1-99 epg (%) 23.70 [20.93-26.47] (n=214) 19.30 [16.36-22.25] (n=133) 6.80 [4.32-9.28] (n=27) 9.65 [7.10-12.19] (n=49)
100-399 epg (%) 16.83 [14.39-19.27] (n=152) 10.16 [7.90-12.42] (n=70) 2.02 [0.63-3.40] (n=8) 2.95 [1.49-4.41] (n=15)
>=400 epg (%) 16.83 [14.39-19.27] (n=152) 5.22 [3.56-6.89] (n=36) 1.01 [0.03-1.99] (n=4) 3.35 [1.79-4.90] (n=17)
Region
Lake Victoria 216.18 [169.74-262.62] (n=420) 78.70 [54.49-102.91] (n=384) 18.36 [5.94-30.79] (n=247) 71.82 [30.36-113.28] (n=272)
Albert Nile 67.62 [46.25-89.00] (n=181) 30.97 [9.38-52.54] (n=149) 2.48 [0.13-4.84] (n=116) 2.82 [0.00-6.43] (n=85)
Lake Albert 411.15 [321.64-500.65] (n=302) 131.92 [74.88-188.97] (n=156) 62.00 [0.00-167.62] (n=48) 28.23 [13.06-43.40] (n=159)
Sex
Male 346.88 [284.99-408.77] (n=441) 101.82 [65.77-137.88] (n=294) 19.55 [0.00-44.37] (n=205) 63.70 [23.66-103.75] (n=269)
Female 154.91 [107.62-202.21] (n=413) 69.22 [42.89-95.56] (n=288) 19.73 [4.57-34.89] (n=191) 29.62 [11.91-47.34] (n=239)
Hookworm
Mean EPG (95% CI) 121.85 [92.59-151.12] (n=903) 142.59 [101.50-183.67] (n=689) 34.27 [15.49-53.05] (n=397) 0.05 [0.00-0.16] (n=449)
Ascaris lumbricoides
Mean epg 2.42 [0.00-5.56] (n=903) 6.25 [0.58-11.93] (n=689) 3.57 [0.00-10.46] (n=397) 0.00 [NA] (n=516)
Trichuris trichura
Mean epg 0.61 [0.15-1.07] (n=903) 1.57 [0.00-3.40] (n=689) 0.66 [0.00-1.74] (n=397) 0.00 [NA] (n=513)
Table 7.  Schistosoma mansoni  and other soil-transmitted helminth infection intensity in the community adults before and after treatment (cross-sectional data)
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This test assumes that the raw data are a sample from an underlying normal distribution. 
As egg counts are highly overdispersed, a log(xi+k/2) transformation was used (where k 
is the aggregation parameter mentioned above and where xi stands for the raw S. 
mansoni egg counts of i individual) in order to normalize the raw egg counts. As we are 
interested to perform cross sectional studies an independent two-samples t-test was 
now used7KHWHVWUHTXLUHVNQRZOHGJHRIWKHWZRPHDQVȝB DQGȝ f ZKHUHȝB is mean 
DULWKPHWLF LQWHQVLW\DWEDVHOLQHDQGȝ f is mean arithmetic intensity at follow-up year 3), 
WKHVLJQLILFDQFH OHYHOĮDWZKLFKZHZDQW WRGHWHFWDGLIIHUHQFHDQGILQDOO\ WKHGHVLUHG
power (1-ȕ RI WKH WHVW ȝB DQG ȝ f were substituted by the log transformations of the 
sample estimators mB (i.e. observed arithmetic mean intensity of final year of SCI data) 
and mf (reductions of 50 % and 80 % were assumed) plus the estimated k aggregation 
parameter divided by 2. The standard deviations (sds) were those of the log transformed 
mB and mf as given by PROC MEANS in SAS. 
Once these were acquired (i.e. sds) they were regressed on m+m2 by PROC GLM in 
SAS. 
Taking all the above into consideration the following table illustrates some calculations 
for the sample sizes needed.
Conclusion-suggestion
The smaller the reduction (i.e. the more conservative we will decide to be) the sample 
size required is bigger. I suggest that we try to remain pragmatic and go for the number 
of 180 adults per community. Number of communities is not taken into account in these 
calculations and is only depending on logistical constraints. 
Starting mean 
intensity, epg
necessary sample 
size, n, 80% 
power
80% reduction                30.00 26
47.02 70
70.00 132
50% reduction                30.00 182
47.02 359
70.00 685
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Appendix VII Hour Pictorial Diary
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OLWEGGULO EKIRODate …..…/…….../……..
Name ………..………….
EKIRO KUMAKYA MUTTUNTU
Appendix VII Time Pictorial Diary
Date …..…/…….../……..
Name ………..………….
MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY SATURDAY SUNDAY
Bathing
Praying
Preparing Children 
for School
In the Garden
Cooking & Meal-time
Looking After Animals
Relaxing & Socialising 
Houshold Chores
Family Time
Business
Training
Community 
Mobilisation
Collection of Drugs 
& Materials
Registration
Treatment
Reporting
Other Health Activities
BATHING
PRAYING
PREPARING CHILDREN FOR SCHOOL
IN THE GARDEN
PREPARING AND EATING MEALS
TENDING TO ANIMALS
RELAXING AND SOCIALISING
HOUSEHOLD CHORES
FAMILY TIME
This picture represents tending to animals. This could be 
feeding them, giving the water, taking them to graze etc.
This picture represents relaxing and socialising. This 
could be visiting friends, drinking, playing sports, listening to 
the radio, playing games etc.
This picture represents household chores e.g. washing 
clothes, sweeping, cleaning, collecting water, collecting 
firewood, collecting food from garden etc.
This picture represents family time. This could be relaxing 
as a family listening to the radio together, helping children 
with their homework, playing with the children etc.
Appendix VII Aide Memoire for Pictorial Diaries
This picture represents bathing activities e.g. washing face 
in the morning, bathing in the morning and evening.
This picture represents the activity of praying e.g. praying 
at home in the morning or at night or going to the mosque 
or church to pray.
This picture represents preparing children for school and 
is generally done in the morning.
The picture represents work in the garden. This could be 
digging, ploughing, harvesting, weeding, planting or any 
other garden activities.
This picture represents the preparing and eating of 
meals. This could be breakfast, lunch or dinner or 
break/evening tea.
BUSINESS
NTD TRAINING
SENSITISATION ABOUT NTDs TO THE COMMUNITY
COLLECTING DRUGS AND MATERIALS
NTD REGISTRATION
NTD TREATMENT (MDA)
REPORTING
OTHER HEALTH ACTIVITIES
This picture represents the activity of reporting about the 
treatment of NTDs. When the MDA is finished CMDs must 
summarise the total number of people treated in their 
registers and take both the register and any remaining 
drugs to his supervisor at the health clinic/centre. 
This picture represents any of the other health activities 
(non-NTD) that the CMDs may be involved in e.g. bed net 
distribution; HIV/AIDS education, water & sanitation 
sensitisation, hygiene, HOMAPAK, TB, immunisations etc
This picture represents the CMDs sensitising and 
mobilising the community for the NTD control 
programme. This is either done in a central place e.g. a 
church, trading centre, school or it is done by the CMD 
moving from home to home. 
This picture represents the CMD collecting the drugs 
he/she needs for treating the community and materials 
such as the treatment register and dose poles. The drugs 
and materials are collected from the CMDs supervisor at 
the nearest health centre or clinic.
This picture represents the household registration of the 
communities for the NTD control programme. The CMD 
goes from house to house entering the information into 
his/her treatment register. This will be used to calculate how 
many people are eligible (of the right age etc) to receive 
treatment for each of the diseases. 
This picture represents the activity of treatment also 
called mass drug administration (MDA) of the NTDs. 
This is when CMDs treat all registered people by moving 
house to house or by treating them at a central place e.g. a 
school, health centre, etc. If there is more than one disease 
to treat in the community the CMD waits 2 weeks between 
each distribution. 
This picture represents business. This could be any activity 
that is termed as a business or is income generating. There 
is a Memory Aid - Business which gives more examples of 
what can be included.
This picture represents the CMDs receiving training for 
the NTD control programme. This training is normally 
held for 1 to 2 days at parish, sub-county or health sub-
district facilities. This is usually the only time CMDs receive 
an allowance.
MAIZE MILLING RETAIL SHOP
HOTEL BRICK LAYING
TRADING PREACHING
ROPE MAKING TAILORING
MEMORY AID FOR BUSINESS
These are some examples of types of Business:
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1Instrument 1: Research Assistant Checklist
First Visit
Pictorial Diary Explanation
1. Introduce yourselves to the CMD and explain who is carrying out the Pictorial Diary 
(PD) exercise and why.
The PD is being carried out by the Vector Control Division of the Ministry of Health and 
the Schistosomiasis Control Initiative. The purpose of the PD is to collect a record of 
how much time the CMDs spend on their routine daily activities and how much time they 
spend on the NTD programme when it is being implemented. This record of time will 
help us to value the CMD input into the programme and will help us to assess how much 
it costs to treat one person under the NTD control programme. This information will be 
communicated to the MoH and international donors to attract continued funding for the 
programme.
2. Next show the CMDs the PD and get them to interpret the pictures and those on the 
Aide Mémoire (Memory Aid). Ensure that there is no confusion about any of the pictures.
3. After the CMDs are comfortable with the pictures, explain to them how the PD works 
and follow on with a practice session where the CMDs fill in the PD for their previous 
days activities. Highlight that more than one activity can be entered in each hour
4. Finally answer any questions that the CMDs may have about the PD. Then ask them 
if they would be happy to keep and fill the diary for up to end of treatment. Explain that 
they are free to drop out of the PD study at any point with no consequences. If they are 
happy and agree ask them to sign a consent form.
Instrument 2: Background Questionnaire
Following the explanation of the PD, use the Instrument 2 to answer the questions about 
the CMDs socio-demographic details and background with the NTD programme and 
other health related activities.
2Arrange the next appointment e.g. date and time for your next visit. Take the 
mobile number of the CMD if they have one, or if a friend/neighbour of theirs does.
Second Visit
Instrument 3a: Pictorial Diary Check
See the Instrument 3a which has the questions that you need to ask the CMD and gives 
room to fill the answers for each CMD. The initial questions are focused on how the 
CMD found the PD to use and the later questions are looking at the entries in the PD 
and will require you to thoroughly look through each day of the PD and to ask for further 
details where necessary. 
Instrument 4: Semi-Structured Interview
If any NTD activities have been carried out then look at Instrument 4 which has a list of 
open-ended questions which ask about the CMDs perceptions of each NTD activity. Ask 
the appropriate questions for the NTD activities that have been completed during your 
visit i.e. when training has been completed ask the NTD training questions; when 
treatment has been completed ask the NTD treatment questions.
Third and Subsequent Visits
Follow the instructions for the 2nd visit ensuring that you carry out Instrument 3b:
Pictorial Diary Check and a Semi-Structured Interview with the appropriate 
questions.
Final Visit
For the final visit you will be required to do the last Instrument 3b: Pictorial Diary 
Check and then carry out Instrument 5: Performance Questionnaire.
Instrument 5: Performance Questionnaire
See Instrument 5, this asks questions regarding the CMDs performance during the NTD 
programme, their attitude to the programme and about their future participation in the 
programme. After the questionnaire has been completed you will then need to look at 
the CMDs treatment register and complete a short review of its condition and contents.
3DON’T FORGET TO THANK THE CMD AT THE END OF EVERY VISIT FOR THEIR 
TIME AND PARTICIPATION IN THE STUDY.
Potential Questions and Answers
How to do I benefit from doing this PD?
The benefit is not for you personally but for your family and the community as a whole to 
seek continued support for the control and elimination of the NTDs
Where should they enter the time that they are spending to fill the PDs?
They should not actually mark down when they are filling the PDs, this information will 
be collected every two weeks during the interviews.
Where should they enter time they spend on development programmes like the Heifer 
Project or keeping pigs etc. 
In these circumstances if the goal of the project is income generation then it should go 
under business.
What time should I be filling my PD?
When people fill the PD is up to them, whenever suits them best e.g. they may want to 
fill at the end of the day before bed or the next morning for the day before or some 
people may choose to fill after each activity but must fill after every day.
Where should I mark down sleeping?
This should not be marked down. The CMD should enter the activities that he/she 
spends time on up until they go to bed. 
1Instrument 2: CMD Background Questionnaire
Observer Initials Date
CMD Name Time of Interview
Village Sub-county
Parish District
Socio-demographic characteristics
1. Sex Male
Female
2. Age in years __________________
3. Marital status
• Single
• Married
• Divorced
• Widow
4. Educational level
• No formal education
• Primary level
• Secondary level
• Post secondary
5. Occupation
• Farmer
• Trader
• Housewife
• Civil servant
• Religious leader
• Unemployed
• Other (Specify) ………………………………………………………………………………………….
2CMD involvement
6. Which diseases do you treat under the Neglected Tropical Disease Control Programme 
in your community?
………………………………………………………………………………………………………………..
………………………………………………………………………………………………………………..
7. How do these diseases affect your community?
………………………………………………………………………………………………………………..
………………………………………………………………………………………………………………..
………………………………………………………………………………………………………………..
………………………………………………………………………………………………………………..
8. How were you selected as a CMD for the NTD Control Programme?
• At a village meeting
• By the health worker
• By the health committee
• By the traditional chief
• By the local council chairman
• Other (specify) ……………………………………………………………………………………………..
9. Why did you become a CMD for the NTD Control Programme?
………………………………………………………………………………………………………………..
………………………………………………………………………………………………………………..
………………………………………………………………………………………………………………..
………………………………………………………………………………………………………………..
10. When did you start as a CMD for the NTD Control Programme?
2007 2008
11. In the past which of these programmes were you involved in as a CMD?
Programme CMD (Yes/No) When (year)?
1. Bilharzia and Worm Control Programme
2. Programme for Lymphatic Filariasis Elimination
3. National Onchocerciasis Control Programme
4. Trachoma Control Programme
313. How many days do you spend on being a CMD for the NTD Control Programme in a 
year?
…………………………………………………………………………………………………………………
14. What kind of support or incentive do you receive from the community in your role as a 
CMD?
• Financial (if yes, specify) _______________________________________________________
___________________________________________________________________________
• Moral (if yes, specify) __________________________________________________________
___________________________________________________________________________
• Food (if yes, specify) ___________________________________________________________
___________________________________________________________________________
• Nothing
Other health-related activities
15. Are you involved in any other health-related activities other than the NTD Control 
Programme?
• Yes
• No = Then finish the questionnaire here
16. If yes, what are the different activities in which you are involved in this community?
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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417. How were you involved in these activities, and when?
Activities What role did you play? When (year)?
1.
2. 
3.
4.
5.
18. How motivated are you to carry out each of these activities as compared to your work 
as CMD for the NTD Control Programme?
Activities Level of motivation Give reason
1.
2. 
3.
4.
5.
1. Less motivated than NTD
2. Equally motivated as NTD
3. More motivated than NTD
519. How many days (in a year) do you spend on each of these activities?
Activities Days spent per year Period when activities are carried out*
1.
2. 
3.
4.
5.
*1= before NTD
2 = during NTD
3 = after NTD
20. Are financial incentives received for any of these activities?
Activities Financial incentive received?  How much? Source
1.
2. 
3.
4.
5.
621. Do you receive any non-financial incentives received for any of these activities? 
Activities Incentive received  How much? Source
1.
2. 
3.
4.
5.
22. Are there similarities between your functions in the other health-related activities 
you are involved in and your tasks as CMD for the NTD Control Programme?
• Yes
• No
23. If yes to Q20, what are the similarities?
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1Instrument 3a: Second Visit - Data Entry Form
Observer Initials Date
CMD Name Time of Interview
Village Sub-county
Parish District
1. How was the PD to use?
x very difficult
x difficult
x satisfactory
x easy
x very easy
2. What did you think of the pictures of the activities? 
x were they easy to understand?
x did they represent all your daily activities?
x did you remember what each one represented throughout the week?
3. How long did it take you to fill the diary 
4. What time of day did you complete it (e.g. after each activity or at end of day)?
5. Do you understand why the PD is being kept?
26. Then go over each days PD entries and ask the CMD to explain in more detail:
x Where Business has been marked, ask what type of business was involved?
x Where other health activities have been marked, ask what type of health activities they 
were?
7. Look for any inconsistencies in the PDs:
x Where an activity is ticked but should most likely not be there e.g. preparing children for 
school in the evening/night time; MDA treatment when no training has been received yet. 
x Where no activities have been marked down i.e. gaps in the day
x If there are any activities that are not marked down that did occur?
Date Business Other health activities Inconsistencies
1Instrument 3b: Third and Subsequent Visits - Data Entry Form
Observer Initials Date
CMD Name Time of Interview
Village Sub-county
Parish District
1. How was the PD to use?
x very difficult
x difficult
x satisfactory
x easy
x very easy
2. How long did it take you to fill the diary 
3. What time of day did you complete it (e.g. after each activity or at end of day)?
4. Then go over each days PD entries and ask the CMD to explain in more detail:
x Where Business has been marked, ask what type of business was involved?
x Where other health activities have been marked, ask what type of health activities they 
were?
5. Look for any inconsistencies in the PDs:
x Where an activity is wrongly marked i.e. ticked but should, most likely, not be there e.g. 
preparing children for school at night; treatment when no training has been received yet. 
x Where no activities have been marked down i.e. gaps in the day
x If there are any activities that are not marked down that did occur?
2# Date Business Other health activities InconsistenciesX=wrongly marked;    G=gap;    NM= not marked
1
2
3
4
5
6
7
3# Date Business Other health activities InconsistenciesX=wrongly marked;    G=gap;    NM= not marked
8
9
10
11
12
13
14
1Instrument 4: Semi-structured Interviews 
Please ask the following questions in Instruments 4a to 4f after you see, from the PD, that the 
activity has been carried out. If the activity has only just begun or is not yet finished, then please 
wait and, ask the questions when it has been completed.
For those districts where more than one round of drug delivery will be carried out you may, for 
some activities, need to ask the same set of questions several times. The table below (adapted 
from the protocol) illustrates where there will be multiple rounds of drug delivery.
District Diseases Drugs #Distributions
Pallisa Lymphatic Filariasis (elephantiasis & hydrocele)Soil Transmitted Helminths (intestinal worms)
Ivermectin (IVM) + 
Albendazole (ALB) 1
Mayuge
Schistosomiasis (bilharzia)
Soil Transmitted Helminths (intestinal worms)
Trachoma
Praziquantel (PZQ) + 
Albendazole (ALB)
Azithromycin (ZIT)
2
Yumbe
Lymphatic Filariasis (elephantiasis & hydrocele)
Soil Transmitted Helminths (intestinal worms)
Onchocerciasis (river blindness)
Schistosomiasis (bilharzia)
Ivermectin (IVM) + 
Albendazole (ALB)
Praziquantel (PZQ) 
2
Kamuli
Lymphatic Filariasis (elephantiasis & hydrocele)
Soil Transmitted Helminths (intestinal worms)
Schistosomiasis (bilharzia)
Trachoma
Ivermectin (IVM) + 
Albendazole (ALB)
Praziquantel (PZQ) 
Azithromycin (ZIT)
3
Pallisa district = each set of questions (4a to 4f) only needs to be carried out once
Mayuge and Yumbe districts = the following needs to be carried out:
4a NTD Training x 1
4b Mobilisation x 2 (if you see from the PD that the CMD has carried out more mobilisation after 
the 1st round of drug delivery) 
4c Registration x 1
4d Collecting Drugs x 2 (if you see from the PD that the CMD has spent more time collecting 
drugs after the 1st round of drug delivery)
24e Treatment (Mass Drug Administration) x 2 (after each round of drug delivery has been 
completed)
4f Reporting x 1 
Kamuli district = the following needs to be carried out:
4a NTD Training x 1
4b Mobilisation x 3 (if you see from the PD that the CMD has carried out more mobilisation after 
the 1st round of drug delivery and again after the 2nd round of delivery) 
4c Registration x 1 
4d Collecting Drugs x 3 (if you see from the PD that the CMD has spent more time collecting
drugs after the 1st round of drug delivery and again after the 2nd round of delivery)
4e Treatment (Mass Drug Administration) x 3 (after each round of drug delivery has been 
completed)
4f Reporting x 1 
1Instrument 4a: NTD Training
Observer Initials Date
CMD Name Time of Interview
Village Sub-county
Parish District
1. How and when did you hear about the training?
2. What topics did the training cover? N.B do not probe the CMD for this question
x Introduction to NTD Control in Uganda (how programme is managed and implemented)
x The Neglected Tropical Diseases (how you get infection; signs & symptoms; prevention)
x Role as the Community Medicine Distributor
x The Drugs (what diseases they treat; the doses; what they look like; how to handle them)
x The Register (how to register people; how to fill; how to make the summary report)
x How to treat – were they just instructed or did they actually get to practice how to treat?
x Adverse Drug Experiences (how to manage adverse reactions)
x Messages for the Non-Compliant (telling people about the importance & safety of drugs)
x Other (please specify)………………………………………………………………………………...
3. What is your opinion about the training? (probe about the following aspects)
x Time
x Content
x Level of understanding
x Meeting the CMD’s expectations
24. Which diseases are you expected to treat in your community this year?
5. What materials were you given during the training?
x Register 
x Exercise Book
x Pen
x Dose/Treatment Poles
x Field Guide (guidelines)
x Other guidelines (please specify)…………………………………………………….
x T-shirt
x Allowance
x Other (please specify)…………………………………………………………………
6. What are your responsibilities under the NTD control programme? (probe)
7a. During the training were you told about being a volunteer for the NTD control programme?
If no, you are finished asking questions.
If yes,
b. Was the meaning of being a volunteer explained to you?
If yes, what is meant by the term ‘volunteer’ for the NTD control programme?
1Instrument 4b: Mobilisation and Sensitisation
Observer Initials Date
CMD Name Time of Interview
Village Sub-county
Parish District
Interviewer
Under some circumstances mobilisation may be done at the same time as registration and/ or 
treatment, if this is the case then ensure that this is clearly marked on the PD.
Please note when this mobilisation took place:
x Before any treatment
x After 1st delivery of treatment
x After 2nd delivery of treatment
x After 3rd delivery of treatment
If it is after the 1st or 2nd deliveries of treatment please make sure the CMD is answering the
questions for this specific mobilisation only and not any previous times that they have mobilised.
1. How did you carry out mobilisation? (probe)
x to individuals or groups?
x where?
x why did you carry it out in this way?
2a. What messages did you give to the community during mobilisation?  
b. Where did you learn these messages that you used during mobilisation?
23a. What assisted you in providing mobilisation?
b. What constrained you from providing mobilisation?
4. What reactions did you get from the community when you mobilised about the NTD 
programme?
5. Were you supervised during the mobilisation?
If yes, (probe)
x by whom i.e. their position (parish, sub-county, health subdistrict, district, national) 
x for how long were they with you? 
1Instrument 4c: Registration
Observer Initials Date
CMD Name Time of Interview
Village Sub-county
Parish District
Interviewer – Under some circumstances registration may be done at the same time as 
mobilisation and/or treatment, if this is the case, ensure that it is clearly marked on the PD.
1. How did you carry out the registration? (probe)
x from home to home or at a central place or both of these?
x why did you carry it out in this/these way(s)?
Interviewer - If the CMD has carried out registration on the same day as treatment (as seen on 
the PD), ask them why they did it then and not before the day of treatment?
2a. Did you register children enrolled in school (day or boarding)?
b. Where will enrolled school-children receive treatment for the NTDs?
3a. How many homes in total did you have to register?
2b. How do you know that you have not missed registering any homes?
4. Were you supervised during the registration?
If yes, (probe)
x by whom i.e. their position (parish, sub-county, health subdistrict, district, national) 
x for how long were they with you? 
1Instrument 4d: Collecting Drugs
Observer Initials Date
CMD Name Time of Interview
Village Sub-county
Parish District
Interviewer - Please note when this collection of drugs took place:
x Before any treatment
x After 1st delivery of treatment
x After 2nd delivery of treatment
If it is after the 1st or 2nd deliveries of treatment please make sure the CMD is answering the 
questions for this specific collection of drugs only and not any previous times.  
1. How did you obtain the drugs for the NTD programme? (probe)
x Were there any constraints in obtaining the drugs?
2. What other materials did you collect at the same time as the drugs?
x Register 
x Dose/Treatment Poles
x Field Guide (guidelines)
x Other guidelines (please specify)…………………………………………………….
x T-shirt
x Other (please specify)…………………………………………………………………
23a. Which drug(s) did you collect?
b. Which disease(s) do this/these drug(s) treat?
4. How adequate are the number of drugs you got for treating your community?
1Instrument 4e: Treatment (Mass Drug Administration)
Observer Initials Date
CMD Name Time of Interview
Village Sub-county
Parish District
Interviewer - Please note which delivery of drugs for treatment this is:
x 1st delivery of drugs for treatment
x 2nd delivery of drugs for treatment
x 3rd delivery of drugs for treatment
If it is the 2nd or 3rd delivery of drugs for treatment please make sure the CMD is answering the 
questions for this specific delivery of drugs only and not any previous times that they did 
treatment.
1a. Which drug(s) did you distribute in this delivery?
b. which diseases does this or do these drugs treat?
2. How many people did you treat?
3. How did people get to know that the drugs for the treatment have arrived? 
(probe)
x Who told the people in the community about the arrival of the drugs?  
x How did you make sure that every member of the community was informed about the 
arrival of the NTD drugs? 
x Who helped you in the mobilisation of the community for the treatment?   
24. Where were the drug(s) distributed from? (probe) 
x Did the people come to you?  Where?
x Did you take the drugs to the households? 
x Why did you use this approach for distributing the drugs?
x What were the disadvantages of this approach?
x Did anyone help you to distribute the drugs? Who?
x Which people took long to get the treatment? Why?
x Which people did not receive treatment? Why?  
5a. Did you only treat people who were registered?
If yes, (probe)
x Did people who were not registered ask to be treated? 
x Who were these people and why had they not been registered?
If no, (probe)
x Which people did you treat that were not registered? 
x How did you reconcile this with the register and the available drugs?  
b. How did you follow-up those people who were on the register that did not get treated?
36. Why were you treating people at the times that you have indicated on the PD?
7. What were the procedures taken in distributing this/these drug(s)?
(probe)
x Which of the treatment procedures are you confident managing? Why?
x Which of the treatment procedures do you find difficult managing? Why? 
x What did you have to do during the drug distribution that had not been covered during 
your training?
8. How did you ensure that the drug was swallowed by the individual? 
9. How will people who missed the treatment obtain the drug? 
(probe)
x Are the drugs available in the health units?  Which health units? 
x Why did some people not take the free drug distributed under the NTD control 
programme?
10. What were the general attitudes of the community towards the treatment drug(s)? (N.B.
make sure the CMD answers what the community attitude is and not their own attitude)
(probe)
x Positive attitudes
x Negative attitudes
4x How do parents feel about their children taking this/these treatment drug(s)?
x What are the communities’ attitudes towards you?
11. Did any of the people you treated experience any side-effects?
If no, then move to Q.12.     
If yes, (probe)
x Who (age, gender, occupation)
x In what way did you manage side effects?  
x How confident did you feel about doing this?
x What makes some people more susceptible to side effects?
x What was the reaction of the parents of children who had side-effects?
12. Did you give any sensitisation during treatment?
If yes (probe)
x What did you sensitise about?
13. Did you treat any children that are enrolled in school? Where?
x Are the enrolled in primary or secondary schools or both?
14. Were you supervised during the treatment?
If yes, (probe)
x by whom i.e. their position (parish, sub-county, health subdistrict, district, national) 
x for how long were they with you?
5Instrument 4f: Reporting
Observer Initials Date
CMD Name Time of Interview
Village Sub-county
Parish District
1. How long after treatment did you write your treatment report?
2. What information did your report contain?
x Number of females treated
x Number of males treated
x Number of 0 to 4 years treated
x Number of 5 to 14 years treated 
x Number 15 years and above treated
x Total people treated 
x Other………………………………………………………………………………………….
3. What challenges did you have writing the report? 
4. How did you submit your report?
(probe)
x To whom?
x Where? 
5. Were you supervised during reporting?
If yes, (probe)
x by whom i.e. their position (parish, sub-county, health subdistrict, district, national) 
x for how long were they with you? 
1Instrument 5: CMD Performance and Attitude Questionnaire
Observer Initials Date
CMD Name Time of Interview
Village Sub-county
Parish District
Performance
1. What activities did you carry out during this last MDA as a CMD?
(These are not options – tick all that they mention)
x Treatment of eligible persons
x Management of side-effects
x Community mobilization and sensitisation
x Training
x Registering / register update
x Collection of drugs
x Reporting
x Others (specify) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
2. How many people were you supposed to treat in this community during this
treatment round?
Lymphatic Filariasis (elephantiasis and hydrocele)…………………………………………
Soil Transmitted Helminths (worms) …………………………………………………………
Bilharzia…………………………………………………………………………………………
Trachoma…………………………………………………………………………………………
Onchocerciasis ………………………………………………………………………………..
3. How many people received the drugs during this treatment round?
Lymphatic Filariasis (elephantiasis and hydrocele)…………………………………………
Soil Transmitted Helminths (worms) …………………………………………………………
Bilharzia…………………………………………………………………………………………
Trachoma…………………………………………………………………………………………
Onchocerciasis ……………………………………………………………………………….
2Sustainability
1. Will you continue as CMD for the next treatment round (MDA) of the NTD Control 
Programme (October 2009)?
• Yes
• No
Give reasons for your answer
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
2. Did you receive a per diem (allowance) for your role as a CMD for the NTD Control 
Programme? Yes / No
3a. If yes, what was it? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
3b. Was it satisfactory? Yes / No       
Give reasons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
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3c. Who did you receive the allowance from? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
4a. If you received no allowance, what reward (in cash or kind) do you think would be 
satisfactory?
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
4b. Give reasons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
35. What kind of support or incentive did you receive from the community for 
distributing the drugs under the NTD Control Programme?
• Financial (if yes, specify). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    
• Moral (if yes, specify) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     
• Food (if yes, specify) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . .     
• Nothing
6. How do you think your involvement in other health-related activities affects your 
work as a CMD for the NTD Control Programme?
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Benefits 
1. What health benefits have you seen in the community after treatment? 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2. What benefits do the community members see after treatment?
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
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4Attitude Scale
Indicate your strength of agreement/disagreement with the following statements:
Statements Strongly 
Agree Agree Indifferent Disagree
Strongly
Disagree
1. The performance of the NTD MDA in
this community was satisfactory
2. CMDs are able to distribute more than 
two drugs during the MDA period
3. CMDs find it confusing to give out more 
than two drugs during the MDA period
4. Giving out more than two drugs during 
one MDA period is confusing to the 
community without good health education
5. Communities dislike taking more than 
two drugs over one MDA period
6. The MDA period was too long
7. CMDs are not capable of handling 
several health activities at the same time
8. When a CMD is involved in other 
health-related activities, this helps in 
mobilizing the community for the NTD 
MDA
9. The work of the CMD has improved 
since they got involved in additional 
health activities (non-NTD activities)
10. To be effective, a CMD should not be 
involved in other health-related activities
(non-NTD activities)
11. Because there are few health
services in the communities, CMDs have 
to carry out health activities (NTD and 
non-NTD)
12. The involvement of CMDs in
health activities enhances health services 
in this community
5Statements Strongly 
Agree Agree Indifferent Disagree
Strongly
Disagree
13. The involvement of CMDs in NTD
activities requires frequent monitoring and
supervision by health staff
14. The type of support given by the 
community to CMDs is enough motivation
15. CMDs require more support from the 
Ministry of Health to motivate them
16. Comments and suggestions for the improvement of MDA under the NTD Control 
Programme
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6Review of village-based records: census records
1. Mark the type of record book (tick)
• Soft cover exercise book/notebook
• Hard cover register
• Other (specify) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
2. Condition of census records (tick)
• Clean or stained, smudged, dirty describe problems, ask for reasons?
• Intact or damaged, torn, missing pages describe problems, ask why?
3. Evidence of updating since last distribution (tick all that are found)
• Children born have been added
• New families who have moved in have been added
• People who have moved out have been crossed off
• No evidence of updating
• Other (specify) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4. Does the register distinguish between village members who are normally present
and those who are not usually around (e.g. work in the city, away at school, married 
and living elsewhere)?
• Yes
• No
5. Verify how many people were supposed to be treated in the community during the 
last distribution from treatment register?
Lymphatic Filariasis (elephantiasis and hydrocele)…………………………………………
Soil Transmitted Helminths (worms) …………………………………………………………
Bilharzia…………………………………………………………………………………………
Trachoma…………………………………………………………………………………………
76. Verify how many received the drugs during the last distribution from treatment 
register?
Lymphatic Filariasis (elephantiasis and hydrocele)…………………………………………
Soil Transmitted Helminths (worms) …………………………………………………………
Bilharzia…………………………………………………………………………………………
Trachoma…………………………………………………………………………………………
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Appendix IX 
 
GUIDE QUESTIONS FOR FOCUS GROUP DISCUSSIONS WITH COMMUNITY DRUG 
DISTRIBUTORS  
 
Particulars about the group participant 
x Name of group (e.g. Male FGD held in – village, parish, sub-county, district) 
x Name of person 
x Age, Sex 
x Village, parish and sub-county of residence  
x Married or single 
x Occupation 
x Duration of service on the NTD control programme 
 
A. Awareness and perceived magnitude of worms/lymphatic filariasis/bilharzia/trachoma  
1. What are the major health problems in this community?   
i) How big is the problem of worms/lymphatic filariasis/bilharzia/trachoma 
in relation to other problems?  (make them rank the problems) 
ii) Which diseases do you treat under the Neglected Tropical Disease 
Control (NTD) programme in your community? 
 
2. Are worms/lymphatic filariasis/bilharzia/trachoma a problem in this community?   
(probe) 
i) What makes them a problem?   
ii) Who is most affected?  Why?  
iii) Which families are most affected? How? Why?  (probe: whether the 
families like the single headed families, grand-parenting families, child 
headed families, poor families are affected more than others) 
 
3. What do you believe causes worms/lymphatic filariasis/bilharzia/trachoma and related 
illnesses?  
 
 
B. Responsibilities on the control program 
1. How were you selected as a CMD for the NTD Control Programme? 
i) What motivated you to become a CMD for the programme? 
 
2. What are your responsibilities for the NTD Control Programme? 
i) What are the responsibility of the individuals and community during the 
mass treatment days?   
ii) What are the responsibilities of the community leaders during the mass 
treatment days?   
iii) Are these responsibilities carried out well by the leaders and the 
community?  
 
C. Training 
1. How well did the training prepare you for the treatment process? 
i) Are there topics that were not taught that would have helped you in 
treating the community? 
ii) What is your opinion on the length of the training period? 
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2. What improvements could be made to the training? 
D. Health Education  
1. What health messages about worms/lymphatic filariasis/bilharzia/trachoma do you 
commonly give the community?   
 
2. How do you organize health education (probe):  
i) Do you give health education to individuals or groups?  
ii) When do you give health education? 
 
3. How comfortable do you feel giving health education on worms/lymphatic 
filariasis/bilharzia/trachoma? [probe] Why? 
 
 
E. Management of the mass treatment exercise 
1. Which drugs have you been distributing to treat worms/lymphatic 
filariasis/bilharzia/trachoma? 
 
2. How are the drugs for the treatment for worms/lymphatic filariasis/bilharzia/trachoma 
obtained?  (probe) 
i) Who collects the drug from where they are stored?  
ii) Who meets the transport costs? 
iii) What enables you to obtain the drugs easily? 
iv) What constrains from obtaining the drugs easily?  
v) Do you always have enough drugs to go around the registered people?  
vi) How do you handle people from other areas who may not be on your 
register?  
 
3. How do people get to know that the drugs for treatment of worms/lymphatic 
filariasis/bilharzia/trachoma have arrived? (Probe)  
i) Who tells the people in the villages about the arrival of the drug?   
ii) How do you make sure that every member of the village is informed 
about the arrival of worms/lymphatic filariasis/bilharzia/trachoma 
drugs in the village?   
iii) What could be done to improve mobilisation? 
iv) Who helps in the mobilization exercise of the people during treatment 
days?    
v) Which kind of people are commonly left out or not easily reached during 
the mobilization? Why? 
 
4. How are the drugs distributed? (Probe)  
i) Do the people come to you?   
ii) Do you take the drugs to the households?  
iii) Why? 
iv) What are the advantages of taking the drugs to individual households? 
v) What are the disadvantages of either approach? 
 
 
5. For how long, on average, did it take you to distribute the drug this year?   
i) Why did you take this amount of time? (probe) 
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ii) How do you combine distribution with your normal social and economic 
activities?  
iii) Does your spouse (wife or husband) or children help you to distribute 
the drugs in your absence? Why? 
iv) What would be the best length of time for the treatment period? Why? 
v) What time of year is best for treatment to take place? Why? 
 
6. What are the procedures or steps taken in giving albendazole, ivermectin (Mectizan), 
praziquantel, azithromycin (Zithromax) during the mass treatment days?  
i) Which treatment related activities do you feel confident handling? 
Why? 
ii) Which ones do you find difficult managing? Why?  
 
 
F. ACCESSIBILITY 
1. Which people miss getting the treatment? 
i) Why do these groups of people miss the treatment? 
ii) What would help to motivate these people to come for treatment? 
 
2. If people miss the mass treatment days, how do they obtain the drugs? [Probe]  
i) Is this drug always available in the health units?  Which health units?  
ii) Where else is this drug distributed in the community?   
iii) Why are some people not using the free drugs distributed under the 
NTD control programme? 
 
3. What could you do, as the CMD, to increase coverage of treatment and prevention of 
transmission?    
i) What needs to be put in place to do this?  
 
 
 
F. BENEFITS AND SIDE-EFFECTS 
1. What health benefits have you seen in the community after treatment?  
i) What benefits do the community members see after treatment? 
 
2. What are the common side-effects? 
i) Among children? 
ii) Among adults?  
 
3. What type of people experience side-effects? Why? 
 
4.  How do you handle side-effects?  (let them give you a example of a side effect. Let them 
narrate the effect, how long it took, the risk factors and what was done to help) 
 
5.  How do you feel when an individual gets such a side-effect? 
 
6.  How do people react to getting the side-effects? Why? 
i) Reaction of adults? 
ii) Reaction of parents of children if their child gets a side-effect after 
taking the drug? 
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7. What are the general attitudes of the people towards the treatment with albendazole, 
ivermectin (Mectizan), praziquantel, azithromycin (Zithromax)? (try to find out the 
responses for each drug) 
i) How do parents feel about their children taking the treatment drug? 
Why? 
 
8. What are the general attitudes towards the way the program is organized?   
i) What are the people’s attitudes towards your work as a CMD for the 
NTD control programme? 
 
 
G. SUSTAINABILITY 
1. Have you been able to build demand attitudes for the NTD treatment programme in the 
community?   
i) What does the program need to do to create demand for the NTD 
treatment among children and adults?  
 
2. How much of your time do you spend on the NTD treatment programme? 
i) How does this affect your normal activities 
ii) How does this affect the other health-related activities that you are 
involved in? 
iii) What could be done to reduce the time involved in the NTD treatment 
programme? 
iv) Would having more than two CMDs per village help in reducing your 
burden? How many CMDs per village would be best to carry out 
treatment? 
v) What other issues might hinder you from continuing as a CMD for the 
NTD control programme? 
 
3. What do you think are the major strengths of the NTD control programme?   
 
4. What are the major weaknesses of the NTD control programme?   
i) What could be done to improve these weaknesses? 
 
[probe] the CMDs are most likely to talk about incentives here please ask 
ii) Other than incentives what could be done to improve the weaknesses? 
 
 
DO YOU HAVE ANY QUESTIONS TO ASK ME?? 
 
 
THANK YOU VERY MUCH FOR YOUR TIME AND IDEAS. 
APPENDIX X 
 
 
 
 
Post MDA Survey Guidelines for validating treatment coverage 
of NTDs 
 
 
Appendix X 
Revised Post MDA Survey Design 
Monitoring treatment coverage of neglected disease control programs
A toolkit developed for USAID Neglected Tropical Disease Control Project
Updated March 2009
BACKGROUND
Why this toolkit? 
The U.S. Agency for International Development recently supported a program to control a number 
of Neglected Tropical Diseases (NTDs), including schistosomiasis, onchocerciasis (river 
blindness), intestinal worms, lymphatic filariasis (elephantiasis), and trachoma.  Interventions, 
which will begin initially in five fast-track countries - Burkina Faso, Ghana, Mali, Niger, and Uganda 
- will target countries that have a high prevalence of at least three NTDs, to allow cost-effective 
integrated treatment. 
The program provides support to countries to deliver regular, large-scale treatment for at-risk 
populations, usually given once a year. These treatments are distributed by community-based 
distributors through a method called mass drug administration (MDA). Regular monitoring of drug 
treatment coverage is essential to monitor progress towards program goals and to identify 
communities with poor or insufficient coverage in order to permit timely and appropriate actions to 
improve coverage. The higher the coverage of intervention, the greater the chance of achieving 
desired health gains. In areas of low coverage, appropriate corrective action can be taken to 
improve coverage. 
This report presents a simple, easy-to-use yet accurate population-based survey method to assess 
drug treatment coverage. The objectives of the presented survey are to:
1. Validate reported coverage rates;  
2. Determine age- and gender-specific coverage; and 
3. Collect important information on why people do or do not take part in MDAs; 
A generic tool is presented below. This tool can be used by country programs to develop their own 
coverage assessment tool, which includes country-specific information on drug package and 
sampling parameters. 
Who is this toolkit for? 
The monitoring treatment coverage toolkit aims to provide country managers, program staff and 
researchers with practical up-to-date information to monitor treatment coverage of NTD. Users will 
be able to use this toolkit to implement a cluster survey in order to assess treatment coverage.
What are its contents?
The toolkit presents information to help program staff develop and implement a survey to assess 
treatment coverage following community-based administration of several NTD drug packages, and 
will help users:  
x Understand definitions of coverage 
x Learn about alternative sampling designs
x Determine sample size of coverage surveys
x Know how to implement a population-based cluster survey
x Undertake data analysis of collected data
x Decide on appropriate corrective action following analysis of results
Estimating treatment coverage
Drug coverage is defined as the proportion of eligible individuals who actually ingested the drugs. It 
is calculated as (WHO, 2005): 
100
assessedbecouldingestiondrugonninformatioon whomhouseholdssurveyed theallinresidingsindividualofnumberTotal
drugs theingestedhavingassurveyshouseholdbyidentifiedsindividualofnumberTotal u
Population-based survey methods are the gold standard method to validate coverage and to 
provide grounds for evidence based decision making. 
Sampling methods to assess coverage
A number of different population-based survey methods have been developed to assess drug 
treatment coverage, with a trade-off between statistical accuracy and feasibility in the field. The 
design, advantages and limitations of alternative survey methodologies are presented in the 
Appendix.
1. The conventional multi-stage survey design is recommended here to assess surveyed coverage. 
Which drug packages should be investigated? 
For the purposes of this document the following definitions are used: 
Drug package is defined as drugs which are given out together in one point of contact. 
Mass Drug Administration (MDA) is defined as the coordinated co-administration of drug 
package(s) over a period of a few weeks.
For example: Scenario: Albendazole and Ivermectin given in the first week, praziquantel in week
three, and Zithromax or tetracycline in week five. Albendazole + Ivermectin is referred to as one 
drug package, praziquantel as another drug package and zithro/tetra as a third drug package. 
Together these three drug packages administered in a coordinated fashion are referred to as one 
NTD MDA.
The combination of drug packages used in any one NTD MDA varies between countries according 
to the presence and distribution of different diseases. Ideally, coverage should be assessed for 
each of the different MDA scenarios. Because of financial and human resource constraints this is 
impractical, and only a selection of different scenarios will be evaluated. For example, the following 
integrated MDA scenarios could be sampled: 
x Albendazole + praziquantel plus Zithromax / tetracycline 
x Albendazole + ivermection plus Zithromax / tetracycline 
x Praziquantel alone  plus Albendazole + ivermection plus Zithromax / tetracycline 
x Zithromax / tetracycline alone
A PROTOCOL FOR POPULATION-BASED SURVEYS
Implementation
When implementing the survey it is important to consider the following aspects: 
x The survey is done at the level of the implementation unit for which mass treatment is 
administrated to the population (typically the district)
x It is recommended that the survey is implemented as soon after the MDA as possible to 
minimize recall bias. 
x Keep implementation and evaluation separate such that:
o Interviewers should not be the same persons who implemented the MDA
o Where district levels implemented MDAs and sent in reported coverage rates, then 
national level should evaluate and vise versa.
PART ONE: SAMPLING METHODOLOGY
The sampling design is outlined in Figure 1. Each country can implement either national-level or 
regional-level surveys. Please note, that national coverage can be validated with a national level 
survey only.
The primary sampling units (PSUs) / clusters should be chosen within a region (or within a
country) as geographical areas equivalent to about 10-20 villages in size for which population data 
is available and which were targeted with the same drug package(s). Sub-districts or enumeration 
areas are the secondary sampling units, villages are the third stage sampling units and households 
are the fourth and final sampling units. 
Here are the steps that should be followed in conducting the survey for Uganda.
1) Sample Sizes. (See Appendix 1 for detail on how these sample sizes were derived)
First Stage: 10 Districts (PSUs)
Second Stage: 5 Sub-Districts
Third Stage: 3 Villages
Fourth Stage: 10 Households
Total Sample Size: 150 Villages per drug type
1,500 Households per drug type
2) Drug/Drug Package “Universes” and Number of Districts to be Selected
Treatment packages are defined as follows:
x IVM (this includes IVM alone and IVM/ALB)
x ALB (this includes IVM/ALB)
x PZQ
i) Start by listing all districts for the drug IVM. Select 10 Districts from this list. Make a note 
of how many also have ALB.
ii) Now make a list of all districts for ALB. Select a sufficient number of districts from this 
list to yield a total of 10. 
iii) Repeat this process for PZQ after noting how many PZQ Districts were selected in 
steps i and ii.
The total number of Districts to be selected is less than or equal to 30.
3) Sampling Design
a) Stage 1: Select the Districts
Select 10 PSUs stratified by geography and population size. Use population-proportionate 
sampling (PPS), with total population as the measure of size, to select 10 PSUs within each 
stratum (see appendix 1). First sort all districts by geography, size, and other relevant 
characteristics and then implement a systematic sample with a random start and a fixed interval.
b) Stage 2: Randomly select Sub-Districts within each District (PSU).
A list of all sub-districts within each selected district should be made, then sorted by geography, 
size, and other relevant characteristics. Using systematic sampling, five sub-districts should be
randomly selected using PPS sampling.
c) Stage 3: Select 3 Villages with each Sub-District
As in Stages 1 and 2, villages with each selected sub-district should be sorted and a sample of 
three villages should be selected using systematic PPS sampling.
d) Stage 4: Select 10 Households per Village
Once the villages have been selected make a list of all households in the selected villages. This 
was done in about 1 hour per village in Niger by sitting down with key informants such as village 
leaders and community health workers. Suggested steps: 
i) 1-Ask for the number of quarters/ sectors of the village,   
ii) 2-Divide up the audience by origin of quarter, 
iii) 3- Proceed to ask for name of chief of household.
Select a systematic sample of 10 households from the list of all households in the village.
In certain situations, a simpler approach, like random walk, can be used to implement the random 
sample. However, care must be exercised when using such short-cut strategies since they allow 
for interviewer flexibility and the risk of bias. The main goal in the process is to ensure that the 
selection is random and to avoid the introduction of systematic selection bias.
e) Conduct interviews in all of the households selected.
f) Make sure to enumerate all the members of the household, whether present or absent.
4) Interviews
a) All household members living in the selected households, who were living in the household 
during the drug distribution, should be interviewed. 
x Ask for the head of the household or an other person who can speak for the household
x Information for children aged 1-10 years will be collected from their primary caretakers
x Interviewer completes the coverage questionnaire.
b) Problems 
i) If nobody is at home or no adults are at home, go back later the same day. If again 
nobody is at home, drop this house, but DO count this houses as one of the houses 
visited (don’t replace the house with another house).  Make sure that a questionnaire is 
completed for this house, noting that nobody was present. 
ii) Refusal: insist by revisiting same day, but do not force.  DO count this houses as one of 
the houses visited (don’t replace the house with another house).  Make sure that a 
questionnaire is completed for this house, noting that survey participation was refused.
iii) If all the people moved in after the distribution, skip the house and don’t count it as a 
house.
iv) If nobody lives in the house (abandoned house), skip it and don’t count it as a house.
v) Several families who are living together: consider as 1 household.
PART TWO: DATA COLLECTION
Your final dataset should include the following two elements:
x Questionnaire data
x Survey design information
5) Questionnaire Data:
The questionnaire should be designed to include the following minimum set of information. 
Additional questions can be added by program managers as they see important (see attached 
example of questionnaire – Appendix 2).
x Interviewer
x Date of interview
x PSU
x Village
x Household ID
x Person ID
x Whether person participated in the survey (Yes/No). Make sure that ALL persons who 
resided in the household at the time of the MDA and who still live there are listed on the 
questionnaire, regardless of whether they participate in the survey. (Possible reasons for non-
participation in the survey include absence and refusal but it is not necessary to capture why
they did not participate).
x Age
x Sex
x Whether the drugs were taken (please make sure that the question is not whether they 
received the drugs but rather, did they actually swallow the drugs).
x Where 2 drugs are given in one drug package persons should be asked separately whether 
they took each drug. E.g. IVM+ALB package – did you take the ALB tablet? Did you take 
the IVM tablet? 
x Reasons for not taking the drug. Make sure to have a separate code for all possible exclusion 
criteria (e.g. pregnant, first week of breast feeding, too sick, too young). Record reasons for 
not taking the drugs separately for each drug, e.g. for ALB and for IVM.
6) Survey Design Information
In addition to the information recorded in the questionnaires the following information should be 
recorded:
x For the region:
a) List of drug package delivered
b) Total population
x For each drug package (stratum):
a) Total number of PSUs
b) Total population
x For each selected PSUs:
a) All drug packages delivered
b) Total number of villages
c) Total population in PSU
Appendix 1: Sample Size Calculation
1. To have the largest sample size possible drug treatment coverage is assumed to be 50% of the 
target population. In this case the target population is often the general population; however, 
the target population may vary depending on the drug package utilized. For example the target 
population may be school age children.
2. Desired precision of +/- 5% for drug treatment coverage. 
3. The confidence interval is 95%
4. To calculate the minimum required size to meet the precision requirement, use the formula
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5. Design effect is a co-efficient which reflects how sampling design affects the computation of 
significance levels compared to simple random sampling, and depends on the homogeneity 
within clusters and the number of observations per cluster. A design effect coefficient of 1.0 
means the sampling design is equivalent to simple random sampling. A design effect greater 
than 1.0 means the sampling design reduces precision of estimate compared to simple random 
sampling. From the 2007 survey we discovered that design effects differ mostly due to the 
number of clusters selected.  The more the number of clusters, and the more heterogeneous 
the clusters are, the lower is the sample size that is need to meet the precision requirements.
Inflate the sample size by the design effect.  For example, if the assumed design effect is 5, 
then multiply the number derived in step 4 by 5.
6. The nonresponse rate is assumed to be 10%.  Inflate the sample size derived in part 5 by 1.1.
7. Country-specific information on the mean household size is required, and can be derived from 
the country’s Demographic Health Surveys (http://www.statcompiler.com). 
Appendix 2: Population-proportionate sampling (WHO, 2005). 
PSU= Primary Sampling Unit. This should be a geographical areas about the size of 10-20 
villages which all received the same drug package(s) and for which estimations of population data 
are available.
Step 1: List all PSUs within the region to be surveyed. For each drug package given, make a complete 
list of all PSUs in the region. If one PSU received two different drug packages then it should appear on two 
different lists. The list does not need to be in any particular order, but must include all the PSUs within the 
region.
**Steps 2-7 should be carried out separately for each drug package (stratum)**
Step 2: List the population for each PSU. In a column next to the name of the PSU, list its estimated 
population. The source of the population figures is not critical as long as the same source is used for each 
area. Usually census figures (with appropriate correction if the census is old) are used.
Step 3: Calculate the cumulative population for the list of PSUs. In a third column, successively add the 
population for each PSU, providing a cumulative population figure of all PSUs receiving this drug package 
within the region. This can be done using a computer spreadsheet.
Step 4: Calculate the sampling interval. To calculate the sampling interval, divide the total population for 
all PSUs in your list by the total number of PSUs to be selected (10).
Step 5: Randomly select the starting point. Using a table of random numbers (or computer generated 
random numbers), select a number between 1 and the sampling interval; make a note of this number.
Step 6: Calculate populations from which to select the subsequent PSU. Add the sampling interval to 
the starting point; record this number below the starting point number. Continue to add the sampling interval 
successively until the total population for the area is reached. As you are selecting a total of 10 PSUs you will 
have 10 numbers in this list.
Step 7: Select remaining PSUs. Using the list of numbers that you have just generated, determine if a PSU
is to be included in the survey as follows. If the first random number (the starting point number) recorded 
includes the cumulative population of the first PSU listed (in the third column), then that PSU is selected as 
the first of the total number of PSU to be selected. If the random number is larger, then the first PSU for
which the cumulative population includes this random number is selected as the first PSU.
Using the next number in your list, determine the next PSU that is included in that number, and continue 
making selections until the total number of PSUs that you intend to survey are selected. In some instances, 
an area will have a large population, and it is possible that it will be selected more than once.
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